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Safety around the Plasmodium Vivax induced blood stage malaria model by 
Anand Odedra 
Experimental malaria infection studies entailing the infection of healthy volunteers 
using the induced blood stage malaria (IBSM) model where blood stage Plasmodium 
vivax parasites are injected intravenously provide valuable information on parasite 
biology and the development of drugs and vaccines. A single serious adverse event 
could threaten the ongoing use of this and other experimental malaria infection 
models. 
This thesis aimed to explore the safety of the P. vivax IBSM model, centring around 
an exploratory study using apheresis as a method to extract and concentrate all stages 
of P. vivax parasites from healthy volunteers infected with blood stage P. vivax. The 
absence of a method to culture P. vivax has hampered many aspects of P. vivax 
research. Apheresis harvested asexual parasites may be used to produce human 
malaria parasite banks, and gametocytes for cryopreservation as well as for mosquito 
feeding and subsequent attainment of sporozoites. The safety evaluation involved; a 
review of safety aspects across all malaria experimental infection models, a 
systematic review of the safety and efficacy of apheresis in the treatment of malaria 
and other infectious diseases, an assessment of the safety of apheresis for the 
harvesting of P. vivax parasites and analysis of post treatment transaminase 
elevations encountered in prior P. vivax IBSM.  
No safety concerns were identified during the review of malaria VIS or the use of 
apheresis in the treatment of infectious diseases that were concerning enough to 
interfere with the plan for the exploratory study. Publications identified in the 
systematic review were case reports, case series, and cohort studies, thus publication 
bias was considered to be high. Apheresis may be a potentially useful adjunct to 
chemotherapy in the treatment of patients hospitalised for babesia, and prior to 
chemotherapy in loiasis with microfilarial count >8000/mL. The data did not support 
the use of apheresis in critical pertussis infection or for patients with severe P. 
falciparum malaria. No serious safety concerns were encountered in the four subjects 
involved in the exploratory study. Apheresis achieved a modest level of parasite 





enrichment compared to whole blood sampling (4.9-fold and 1.45-fold per mL of 
sample for asexual parasites and gametocytes respectively) but was insufficient to 
meet the objectives for the collection of parasites for downstream research. 
Therefore apheresis should not be used as a method for harvesting P. vivax parasites. 
Post treatment transaminase elevations are transient, asymptomatic and appear to be 
more common in P. vivax IBSM than in natural infection. Evidence indicates that 
parasite clearance burden, haemolysis and systemic inflammation post anti-malarial 
treatment may be drivers for the observed transaminase elevations. However, the 
mechanisms underlying these abnormalities remain unclear and require further 
investigation. 
  





CHAPTER 1 INTRODUCTION  
In 2015 the World Health Organization (WHO) declared that the response to malaria 
is a global development priority and thus changed their recommendations from 
control to elimination1. This announcement came against a background of a decrease 
in malaria incidence and deaths over the last 17 years. However this parasitic disease 
still threatens almost half of the world’s population and evidence suggests that since 
2015 this downward trend in deaths has begun to plateau. In 2018, there were 228 
million cases of malaria and 405,000 deaths2. Most malaria cases occurred in sub-
Saharan Africa. However, Asia, Latin America, the Middle East and parts of Europe 
are also at risk.  
Plasmodium falciparum is the most prevalent malaria parasite in Africa and is 
responsible for the vast majority of deaths from malaria worldwide. However,  
Plasmodium vivax has a wider geographical distribution. In 2015, 41% of the malaria 
cases that occurred outside the African continent were caused by P. vivax, resulting 
in an estimated 3,100 deaths. Thus without control strategies that consider P. vivax, 
global eradication will undoubtedly be impeded. 
A mounting body of evidence opposes the traditional view that P. vivax is a benign 
disease. It has been estimated that 0.3% of cases are fatal, but mortality varies 
greatly between geographical areas, with seemingly higher numbers of severe cases 
in Papua New Guinea and India, and low numbers in the greater Mekong subregion, 
Afghanistan and Bangladesh3, 4. Individuals acquire immunity to P. vivax faster than 
with P. falciparum at any given transmission intensity4, 5. This is thought to explain 
why the majority of deaths occur in children from high transmission settings3, 4, 6. 
Deaths also occur in older patients with pre-existing co-morbidities from low 
transmission settings7. Careful consideration is required to quantify the contribution 
of  P. vivax in any death, particularly in elderly patients with co-morbidities as P. 
vivax may be a contributor and not necessarily a cause of death. The number of 
reports of severe P. vivax have increased in recent years4. This could simply 
represent an increase in awareness and reporting. However, some studies suggest this 
may be a genuine increase in severe cases. Studies involving adults conducted in 
India suggest that rates of severe malaria have increased from 0.4% in 19448 to 2.2% 





in 19829 to 14.8% in 201210. However thrombocytopenia was used as the sole 
marker of severity in the majority (68%) of the severe cases in the 2012 study; this 
was not used in the 1944 and 1982 studies, making comparison difficult. 
Chloroquine resistance could explain the findings in Papua New Guinea but not 
necessarily the increases in severe cases in India, where chloroquine resistance is not 
widespread11, 12, 13. 
The morbidity that results from P. vivax is well recognised. Infections during 
pregnancy worsen outcomes for both the mother and child. Maternal anaemia from 
P. vivax14 increases the likelihood of stillbirth, premature labour and low birth 
weight15, 16. This effect is compounded by the risk of repeated bouts of malaria in 
pregnancy from relapsing P. vivax, as primaquine is contraindicated due to the 
potential risk of haemolysis in a foetus whose glucose-6-phosphate dehydrogenase 
(G6PD) deficiency status is unknown14, 17, 18, 19. It is important to note that anaemia 
in the context of P. vivax is usually multifactorial with iron deficiency, pregnancy, 
primaquine therapy and hookworm infection all potentially contributing20. P. vivax is 
also responsible for severe anaemia in children21 and often accounts for the majority 
of severe disease in some areas22. Malnutrition from P. vivax is another complication 
that may have long lasting effects, especially in childhood infections resulting in 
underweight children with an increased risk of stunted growth23 and potentially 
lower IQ24.  
Undoubtedly malaria control and eradication efforts have been focused on P. 
falciparum with good reason. However, an argument could be made as to whether 
the level of attention and subsequent funding for P. vivax compared to other malaria 
species is appropriate. Between 2007 to 2009 it was estimated that only 3.1% of 
global malaria spending was on P. vivax25. A search exercise using the G finder 
public search tool database identified research and development funding on malaria 
of $624 million in 2017 compared with spending on P. vivax totalling $61 million or 
10.2% of overall malaria funding26. Moreover as the prevalence of P. falciparum 
decreases over time, P. vivax could become the dominant parasite in many areas. 
Thus it would be prudent to invest in developing and implementing strategies and 
interventions now in preparation for this. To maximise potential benefits, control 
measures should ideally target both P. falciparum and P. vivax. Indeed better control 





of P. falciparum may well reduce the number of P. vivax cases by decreasing the 
number of P. vivax relapses triggered by P. falciparum infection27.   
Perhaps the most striking example of the need for greater research and development 
in P. vivax is the reliance on primaquine for the eradication of liver stage 
hypnozoites, responsible for an estimated 70 to 80 million cases of relapsing malaria 
each year28. Primaquine has significant drawbacks including the need for 14 days of 
therapy to clear hypnozoites, often resulting in low adherence, and thus failure of 
hypnozoite eradication leading to ongoing relapses and transmission. Unobserved 
primaquine therapy has been documented as having success rates as low as 12%29. 
Whilst the recent introduction of tafenoquine is likely to dramatically improve 
adherence as eradication of hypnozoites only requires a single dose of 300mg, it is 
not a definitive answer. Like primaquine, tafenoquine can potentially cause life 
threating haemolysis in patients with certain forms of G6PD deficiency, which 
affects around 400 million people worldwide30. Furthermore, even in the setting of 
G6PD heterozygosity, females are at risk of significant haemolysis31 such that some 
authors advise primaquine only in those with G6PD activity >30% and tafenoquine 
in those with >70% activity32. The higher threshold for tafenoquine is because any 
haemolytic effects due to tafenoquine cannot be limited by halting treatment as 
occurs with primaquine as it is a single dose regime33. This could result in an 
estimated 8-19% of women being ineligible for primaquine and 50-70% of women 
being ineligible for tafenoquine34. Furthermore the limited availability of G6PD 
testing in endemic areas means that clinicians are reluctant to use primaquine. 
Current guidelines suggest those with confirmed G6PD deficiency may be 
considered for weekly treatment with primaquine 0.75mg/kg for 8 weeks, with close 
monitoring for haemolysis35. However this relies upon the presence of reliable G6PD 
testing as well as sufficient healthcare resources and the willingness of the patient to 
attend follow up; all of which are prohibitive factors in the endemic setting. 
Although funding is part of the issue, there are other reasons why no real acceptable 
replacement to primaquine has been developed in the more than 65 years since it was 
first licensed. One of these is the inability to reliably culture P. vivax in vitro. This is 
primarily due to P. vivax exclusively invading reticulocytes36. The result is a lack of 
parasite availability which hampers the ability of researchers to accumulate basic 





efficacy data on treatments against P. vivax. To address the need for reticulocytes in 
culture media, reticulocyte rich blood from haemochromatosis patients has been 
used37 with some success, but not sufficiently to provide the reliable supply of P. 
vivax parasites required by researchers38. In particular, a reliable source of 
gametocytes and sporozoites has remained elusive. As sporozoites are required to 
establish hypnozoites, this is a major restriction in the study of new hypnozoiticidal 
drugs. Alternatively parasites can be attained ex vivo. However, this entails an 
expensive, logistically complex and unreliable process where P. vivax-infected 
mosquitoes are sourced from endemic areas of Asia. In addition to the logistic issues, 
parasites obtained in this fashion are not genetically homogenous. Thus experiments 
must take into account the effects of strain variability. 
The definitive step with any potential intervention is establishing safety and efficacy 
in the target population via a randomised control trial, but earlier phase clinical 
evidence is needed before a new treatment can be tested against the current gold 
standard. In the absence of good in vitro models, volunteer infection studies (VIS) 
provide an important bridge between what can be achieved in the laboratory and 
studies involving subjects in the endemic setting. 
VIS involve the intentional infection of healthy volunteers with self-limiting or 
easily treatable infections. VIS has been used to collect data on pathogenicity and 
immune responses as well as to assess interventions in typhoid, influenza, respiratory 
syncytial virus and cholera to name a few39, 40, 41, 42, 43. The first ever cholera vaccine 
to be licensed by the Food and Drug administration (FDA) was approved based on 
evidence from VIS42. This circumvented the need to expose thousands of individuals 
in a large phase three trial, saving precious time and resources, as challenge studies 
can be carried out for a fraction of the cost of most large field studies43. 
VIS studies do have drawbacks. Findings in VIS may not necessarily be 
generalisable. For example malaria VIS often use a single clonal parasite such as the 
P. falciparum NF54 parasite or its derivative 3D7 to test new interventions44. The 
question arises as to whether the obtained results are translatable to the field, where 
many clones may be present in any given area45, 46. Another potential limitation is 





that challenge studies looking at vaccine efficacy can only really be designed to 
assess short term protection47. 
VIS in malaria involves the introduction of malaria parasites into healthy volunteers 
either by mosquito bite, injection of sporozoites or by injection of parasitised red 
blood cells (RBCs). The latter is referred to as the induced blood stage malaria 
model (IBSM) and is the method used at QIMR Berghofer. P. falciparum VIS has 
been successfully employed in the investigation of new antimalarial drugs both for 
prophylaxis48, 49 and treatment50, 51, vaccine candidates52, 53 and diagnostic tests54, 55, 
in addition to facilitating research on parasite biology56, 57 and host responses58, 59. 
IBSM studies have been established for P. falciparum and P. vivax60. The 
availability of the IBSM model offers a robust pathway to test the efficacy of 
vaccines and drugs using a small number of non-immune subjects, in a rapid and 
cost-effective manner61, 62. One of the advantages of the IBSM model is its ability to 
allow analysis of antimalarial efficacy, by providing opportunities to monitor 
parasite growth after challenge and decay after treatment. Moreover validation 
studies have shown a high correlation between endemic studies involving natural 
infection and malaria VIS when assessing the efficacy of new malaria vaccines or 
drugs63, 64, 65.  
The safety and utility of this approach for assessment of antimalarial efficacy has 
been augmented by the implementation of a rapid, and robust real-time quantitative 
polymerase chain reaction (qPCR) assay for the quantification of parasitemia66. 
More sensitive than thick blood smear, qPCR is able to detect and monitor malaria 
infection earlier and more accurately than blood film67, 68. Subjects undergo close 
monitoring and frequent sampling, only possible in a high-resource setting. QPCR 
testing allows for early detection and treatment of recrudescence in the event of 
vaccine or antimalarial drug treatment failure. 
In addition, calculation of pharmacokinetic (PK) and pharmacodynamic (PD) 
parameters such as the parasite reduction rate (PRR) are possible, at much lower 
parasitemias than in natural infection in the field69, 70. Modelling of qPCR data can 
determine the timing of the qPCR nadir. This can be related to PK modelling to 
determine the concentration of test drug at the timepoint of nadir parasitemia 





determined by qPCR which corresponds to the minimum inhibitory concentration 
(MIC). Thus IBSM is a valuable tool to help ensure that large, expensive and time-
consuming phase II/III studies conducted in the endemic setting which expose 
subjects with potentially life threating infection to treatments other than the gold-
standard, involve only the most promising candidates. If data collected during IBSM 
suggests a drug candidate is unsafe, or lacks the appropriate level of efficacy, 
development can be abandoned early and at a fraction of the cost of large phase II/III 
studies. The time and resources saved can be re-invested into other promising 
candidates. Currently there are more than a dozen potential antimalarial candidates 
under development71. Most of these compounds will eventually need to be placed 
into combination therapies, meaning that the number of potential combinations that 
require assessment is significantly higher. Hence IBSM is an ideal approach to meet 
demand for quick, efficient and reliable testing. 
As well as testing drug treatment and vaccines, the IBSM model facilitates a number 
of basic science activities focusing on understanding parasite biology, genetics and 
immunology44. QIMR Berghofer is also developing the IBSM model to assess 
transmission of malaria72. This is on the back of recent successes in transmitting 
malaria from human volunteers to laboratory reared mosquitos73, potentially offering 
an opportunity to assess transmission blocking interventions. However, all of these 
potentially beneficial outcomes are heavily dependent on the safety of the P. vivax 
IBSM model. A single death or even serious adverse event, such as a seizure or 
persisting renal impairment, would not only threaten the IBSM model but have 
implications for the use of all VIS models. 
This thesis explores the safety of the P. vivax IBSM model, centering around an 
exploratory study aimed at using apheresis to harvest all stages of P. vivax. The 
exploratory study was intended to provide a potential solution to the current issue of 
poor availability of P. vivax parasites for pre-clinical and clinical research. 
Ultimately the aim was to generate asexual parasites to produce a human malaria 
parasite (HMP) bank, and gametocytes for cryopreservation as well as for mosquito 
feeding and subsequent attainment of sporozoites from mosquito salivary glands. 
The specific aims of the study were to:  





a) Explore the utility of apheresis to safely harvest all life cycle stages of P. 
vivax parasites from healthy volunteers infected with blood stage P. 
vivax. 
b) Review the safety and efficacy of apheresis in malaria and other 
infectious diseases. 
c) Review of safety concerns specific to malaria VIS. 
d) Assess the cause of liver function test (LFT) abnormalities encountered in 
prior P. vivax IBSM studies. 
  





CHAPTER 2 SAFETY IN MALARIA VOLUNTEER INFECTION 
STUDY 
INTRODUCTION 
In malaria volunteer infection studies (VIS) healthy volunteers are infected with 
Plasmodium parasites through bites from infected mosquitos, injection of 
cryopreserved sporozoites or injection of blood stage parasites. I reviewed the safety 
risks and the techniques used to protect study subjects, staff and the wider 
community from these risks. Safety concerns and mitigation strategies from all 
methods of malaria VIS are discussed as they were thought relevant to the safe 
conduct of future P. vivax induced blood stage malaria (IBSM) studies. The safe use 
and containment of infectious material and the mitigation of other potentially 
hazardous biological risks was of relevance to the plans for the apheresis exploratory 
study. In addition, specific safety concerns surrounding the conduct of malaria VIS 
in endemic settings were also included. 
TYPES OF MALARIA VOLUNTEER INFECTION STUDIES 
Of the three forms of malaria VIS, bite from an infected mosquito (mosquito 
challenge) represents the most natural method. Anopheles mosquitos, typically 
laboratory reared An. stephensi are rendered infectious by feeding on in vitro 
cultured P. falciparum, or in the case of P. vivax by feeding on infected patients 
because in vitro culture is not possible74. A less natural mode of infection is needle-
based intravenous inoculation with aseptic purified cryopreserved sporozoites. 
Currently, only P. falciparum cryopreserved sporozoites are available but it is 
possible cryopreserved sporozoites could become available for other plasmodium 
species in the future. Finally, IBSM involves the intravenous injection of malaria-
infected red blood cells (RBCs). Each method has specific safety risks and 
mitigation strategies shown in Table 1 below.  
  





Table 1. Summary of safety risks and mitigation strategies in malaria VIS  
Safety risk  Type of VIS in which 
risk occurs 
Mitigation strategies for risk 
Transfusion-related 
infections  
IBSM Screening and microbial 
contamination testing of HMP 
bank and challenge agent  
Leukodepletion of HMP bank  
Co-infection with other 
malaria species  
Mosquito, sporozoite, 
IBSM 
Donors screened to exclude 
mixed malaria infection 
Co-infection with 
filariasis 
Mosquito P. vivax Donor screened for filariasis 
Transfusion reaction  IBSM Subject RBC antibody 
negative at screening  
Inoculation of subjects with 
compatible blood group and 
rhesus type  
Small numbers of RBCs in 
challenge agent 
Alloimmunisation IBSM Inoculation of subjects with 
compatible blood group and 
rhesus type 
RBC antibody negative at end 
of study 
Higher malaria 





controls for consistent 
inoculation dose (sporozoite75 
and IBSM) 
Myocarditis Mosquito, sporozoite, 
IBSM 
Exclusion of subjects at 
increased risk of 






Relapse from P. vivax 
hypnozoites 
Mosquito, P. vivax Exclusion of subjects with low 
CYP2D6 and G6PD activity at 
screening 






G6PD testing at screening 
 
Exposure of study staff 
to infectious materials 






Confinement of subject 
Travel restriction 
Antimalarial drug treatment 
that eradicates gametocytes 
PCR negative at end of study 
Blood donation restrictions  
Standard personal protection 
equipment 
Escape of infected 
mosquitos 
Mosquito, sporozoite, 
IBSM (with transmission 
studies) 
Insectary controls 
HMP; human malaria parasite, IBSM; induced blood stage malaria, PCR; 
polymerase chain reaction, RBC; red blood cell, CYP2D6; Cytochrome P450 2D6.  
Table summarising the safety risks identified and mitigation techniques utilised in 
malaria VIS.  
RISKS TO SUBJECT 
CROSS INFECTION 
Human malaria parasite (HMP) banks are collections of malaria parasites contained 
within human blood products76 and can be used as the ultimate source of parasites 





for all three methods of malaria VIS. Currently in vitro culture is only possible for P. 
falciparum77 and P. knowlesi78, 79 with the latter having not been used for VIS in the 
modern era. In vitro culture permits the production of P. falciparum HMP banks in 
good manufacturing practice (GMP) conditions, thereby permitting the selection of 
parasite strain for all types of P. falciparum VIS, and donor blood type for IBSM76, 
80.   
HMP banks can be produced from donors (ex vivo from parasitemic volunteers 
infected via mosquito bite or from IBSM from existing banks, or by collection of 
parasitemic blood from naturally infected subjects [returned travelers with malaria]), 
providing donors are adequately screened. Donors should complete a lifestyle 
questionnaire to identify risk factors for transfusion-transmitted diseases (e.g. blood 
borne viruses, prion diseases, Q-fever, leptospirosis, brucellosis, and Chagas 
disease). At QIMR Berghofer, this questionnaire is based on eligibility criteria for 
blood donation in Australia. Donors for HMP banks are screened, using sensitive 
PCR and serology assays, for a wide range of blood borne viruses (Human 
immunodeficiency virus [HIV] 1 and 2, human T-lymphotropic virus, Epstein–Barr 
virus [EBV], cytomegalovirus [CMV], hepatitis C, hepatitis B, parvovirus B19, West 
Nile virus, Ross River virus, Barmah Forest virus, dengue fever, and human herpes 
virus 6 and 7). Leukodepletion of collected blood is routinely practiced and provides 
an additional level of security by removing cell-associated herpes viruses such as 
CMV and EBV that are carried by leukocytes81. This obviates the need to match the 
serostatus of the donor and recipient for CMV and EBV. Because P. vivax cannot be 
cultured in vitro, mosquito bite inoculation can only occur if the mosquitos have 
been fed on infected donors. Therefore, these infected donors may require screening 
for other diseases transmitted by An. stephensi mosquitos including lymphatic 
filariasis. Although filarial parasites could theoretically be transmitted by blood 
transfusion, when microfilariae are transmitted through blood transfusion they 
cannot develop into adult worms and thus the risk of harm is very unlikely82, 83.  
HMP banks produced through continuous in vitro culture must be tested for 
adventitious agents using validated assays as required by regulatory agencies. At 
QIMR Berghofer, HMP banks are tested prior to release using a process that has 





been subject to regulatory review. This includes testing for microbial contamination 
and endotoxin. Whole genome sequencing of HMP banks can identify contaminants 
as well as parasite genotype, clonality and parasite polymorphisms associated with 
antimalarial sensitivity84, 85. 
TRANSFUSION REACTION 
A transfusion reaction is a risk specific to IBSM studies. The IBSM process 
inevitably results in transfusion of a small number of RBCs (up to 1.5 × 109 in the 
case of P. vivax IBSM at our center), which is equivalent to less than 1 mL of whole 
blood. Subjects are only inoculated if they have an ABO compatible blood group 
(and compatible rhesus group in the case of females of childbearing potential). It is 
remotely possible that the presence of a donor’s RBCs could precipitate a transfusion 
reaction, or cause development of alloantibodies that may make future blood 
transfusion more difficult or result in hemolytic disease of the newborn if a woman 
develops alloantibodies due to this process before becoming pregnant. Acute 
transfusion reactions are judged to be extremely unlikely because of the very small 
volume of blood that is administered with the challenge agent, and because white 
cells are removed by leukodepletion during processing. No acute transfusion 
reactions have been reported in the more than 380 subjects who have been infected 
through IBSM86. Nevertheless, subjects are monitored for transfusion reactions after 
receiving the challenge agent. Subjects are screened before inoculation and at the 
end of the study for RBC alloantibodies. Two subjects have been reported to develop 
RBC alloantibodies in the context of IBSM. One was injected with P. falciparum 
3D7 infected blood group O (RhD) negative RBCs and developed an anti-E antibody 
at the end of study blood sampling (Australian and New Zealand Clinical Trial 
Registry [ANZCTR] ID: ACTRN12614000781640). Adsorption studies confirmed 
the presence of a true anti-E alloantibody. No irregular anti-RBC antibodies were 
detected in a sample taken 6 weeks earlier. In addition, the RBCs in the HMP bank 
were documented to lack the E antigen. Although anti-E antibodies have been 
implicated in hemolytic transfusion reactions87, 88, it is well established that natural 
anti-E antibodies may occur without transfusion89, 90. A transfusion medicine expert 
concluded it was most likely that this subject had naturally occurring low level anti-
E alloantibodies and that it was unlikely that these alloantibodies were induced in the 





study. The second subject participated in a vaccine study in which they were injected 
with 3 × 107 chemically attenuated asexual whole P. falciparum parasites contained 
within blood group O (RhD) negative RBCs86. Parasites were derived from cultures 
with 5% parasitemia, making the total number of injected RBCs 6 × 108. This 
subject was the only one of six subjects, who developed antibodies to the minor Rh 
antigen c. Whether this was related in some other way to preparation of the vaccine 
is unknown. It is not clear why the vaccine induced an antibody response while there 
have been no such cases within IBSM studies with P. vivax (44 subjects)60, 72 or P. 
malariae (two subjects)55 where a mean 6.5 × 108 and 6.8 × 108 RBCs were 
administered per challenge agent syringe, respectively.  
DOSE OF PARASITES 
The number of parasites injected, i.e. the dose, is a determinant of the starting blood 
stage parasitemia. When infection is induced by sporozoite inoculation, the number 
of infected hepatocytes will determine the starting blood stage parasitemia91, 92, while 
in IBSM it is the actual number of parasites injected. Mosquito bite VIS typically 
involves five bites by infectious mosquitos. However, this entails uncertainty 
regarding the dose a subject receives, which can vary by several thousand 
sporozoites93, 94, 95. Each sporozoite that successfully establishes liver stage infection 
results in the production of 25,000-30,000 merozoites destined to invade RBCs. 
Thus, this variation can significantly impact the ultimate blood stage inoculum and 
the time to patency (detectable parasitemia). For studies using cryopreserved 
sporozoites and IBSM, it is possible to vary the dose of the challenge agent and 
ensure a reproducible process with reduced variation between study subjects70, 91. 
This results in a well characterised and uniform pattern of growth of parasitemia in 
vivo. The concentration of parasites in the HMP bank imposes practical limitations 
on the number of parasites inoculated. In theory, a single viable parasite is all that is 
needed, with the duration of the prepatent period depending on the challenge agent 
dose.  
SERIOUS ADVERSE EVENTS 
No serious adverse events have been reported, apart from an episode of myocarditis 
in one volunteer and abnormal blood tests suggesting cardiac inflammation in two 





volunteers, all infected by mosquitoes in the Netherlands. It is not clear if these 
events were related to the malaria infection96, 97, 98. As a precaution, subjects with 
significant cardiovascular disease risk factors are excluded at screening in VIS. At 
QIMR this involves the exclusion of subjects with a 5-year cardiovascular disease 
risk >10%99.  
RELAPSE OF PLASMODIUM VIVAX 
For P. vivax mosquito bite VIS, researchers must ensure no liver stage hypnozoites 
remain at the end of the study. Although radical cure with primaquine had been 
considered satisfactory for this purpose, two subjects experienced multiple relapses 
of P. vivax following challenge via mosquito bite despite chloroquine and 
primaquine treatment100. These relapses were discovered to be caused by a 
previously unrecognised pharmacogenetic effect of polymorphism in the human 
cytochrome P450 isoenzyme 2D6 (CYP2D6)101. Both subjects were shown to have 
low activity of CYP2D6 resulting in them not transforming primaquine into its 
active metabolite. Therefore, individuals who are poor or intermediate metabolizers 
of CYP2D6 should not be enrolled in such studies. In addition, individuals with 
glucose-6-phosphate dehydrogenase (G6PD) deficiency should be excluded from 
sporozoite-induced P. vivax VIS as they cannot receive primaquine because of the 
risk of haemolysis. Female heterozygotes may also experience clinically significant 
haemolysis if moderate deficiency is not excluded by a quantitative assay31. 
Currently, it is not clear whether poor CYP2D6 activity also affects the activity of 
primaquine against gametocytes102. Although the recently registered 8-
aminoquinoline, tafenoquine may provide an alternative, like primaquine, 
tafenoquine can potentially cause life threating haemolysis in G6PD deficient 
subjects. Furthermore, because of its long half-life the haemolytic effects of 
tafenoquine cannot be limited by halting treatment as can be practiced with 
primaquine as tafenoquine is a single dose regime33. Thus, a higher threshold of 
G6PD activity in female heterozygotes for use of tafenoquine (>70%) is required 
compared to primaquine (>30%)31. 





RISKS TO STAFF 
Risks to staff performing VIS include bites from an infected mosquito, or inadvertent 
exposure to infectious material such as a needle stick injury in cryopreserved 
sporozoite studies and IBSM studies. Staff should use appropriate personal 
protective equipment and have clear guidelines on how to access an infectious 
disease physician for advice regarding malaria-specific treatment. If the apheresis 
exploratory study is successful in concentrating asexual malaria parasites this may 
theoretically increase the likelihood of malaria transmission to staff following 
exposure, increasing the case for antimalarial treatment post exposure.    
RISKS TO THE COMMUNITY 
MALARIA TRANSMISSION  
Preventing onward transmission of malaria is vital. Malaria VIS has historically been 
conducted at a small number of research centers in developed countries with high 
levels of physical containment and health infrastructure (Australia, the Netherlands, 
the UK, and USA). At QIMR in Brisbane, Australia, subjects are inoculated at least 
8 days before receiving any therapeutic intervention. P. vivax produces gametocytes 
earlier in infection103 than P. falciparum, where gametocytes typically appear in the 
circulation 10 days after inoculation, and are therefore infectious from an earlier 
stage73. Subjects potentially infectious to mosquitos may be confined indoors to 
ensure they are not bitten by vector competent Anopheles mosquitos. More 
commonly, subjects are monitored as outpatients104 and required to adhere to travel 
restrictions. At our center, subjects are required to not travel in the period between 
inoculation and curative treatment, to malaria-endemic countries or to northern 
Australia where An. farauti (the Australian malaria vector) is present105. In 
Queensland, An. farauti mosquitos are not found south of Mackay, 950 km north of 
Brisbane. No vector-competent Anopheles mosquitos are found in Oxford, UK or 
Nijmegen, Netherlands, although these mosquitos were once endemic in both 
cities106, 107. The vector-competent species An. quadrimaculatus is endemic to the 
east coast of North America108, 109, and could conceivably result in local transmission 
in the context of VIS undertaken at centers in Maryland. Climate change models 
have predicted the expansion of malaria transmission zones in Australia, Europe and 





North America110, so researchers must remain vigilant of such changes and alter their 
practices accordingly.  
Mitigation strategies to prevent onward transmission may need to be applied at the 
end of malaria VIS if infection has resulted in the development of gametocytemia. 
Subjects may require treatment with an appropriate anti-gametocidal agent (e.g. 
primaquine) prior to exiting the trial. Parasite-negative status can be confirmed using 
a qPCR assay that detects both asexual parasites and gametocytes111, 112 and which is 
being increasingly used to confirm parasite clearance. Additional gametocyte-
specific qRT-PCR assays, such as one that targets pfs25 the abundant female 
gametocyte-specific mRNA present in female gametocytes, can also be used to 
confirm the absence of gametocytes113. The 18S qPCR used at QIMR Berghofer has 
a limit of quantitation of 111 parasites/mL. To transmit malaria in a 1 μL mosquito 
blood meal, the female Anopheles mosquito needs to take up one male and one 
female gametocyte. Thus, it is extremely unlikely that a subject would transmit 
malaria with a negative 18S qPCR. Strict enforcement of travel restrictions and 
qPCR negativity prior to the end of study is essential, particularly if the study entails 
the deliberate induction of higher gametocyte levels to test transmission blocking 
interventions73. Study subjects are not permitted to donate blood until 6 months after 
the end of the study in Australia, or 3 years in the USA. 
MOSQUITO ESCAPE  
Escape of a malaria-infected mosquito could result in difficult-to-diagnose and 
potentially fatal local malaria. Further, the local establishment of an exotic malaria 
vector would represent a serious breach of biocontainment. Recently updated 
guidelines from the American Society of Tropical Medicine and Hygiene provide 
strategies to mitigate risk of arthropod escape114. The primary method is the use of 
an appropriately secure insectary. 
GENETICALLY MODIFIED PARASITES 
Additional regulations, specific for each national jurisdiction apply to the use and 
potential release of genetically modified pathogens. This includes genetically 
modified malaria parasites that have been used in clinical trials ANZCTR Trial ID: 
12617000824369115, 116. The inadvertent release of genetically modified parasites 





into local malaria vectors could lead to unforeseen or additional negative effects 
beyond that caused by release of a wild type organism.  
RISKS OF VOLUNTEER INFECTION STUDIES IN THE ENDEMIC SETTING 
The development of malaria VIS in the endemic setting represents an important 
advance in the study of malaria infection in naturally-exposed populations117, 118 but 
its introduction also poses additional logistic and ethical concerns. Of particular 
concern is the unintentional release of a genetically modified parasite or a strain not 
endemic in the area, such as the K13 artemisinin-resistant strain P. falciparum 
recently used in an IBSM study in Brisbane (ANZCTR Trial ID: 
ACTRN12617000244303 and ACTRN12617001394336). Measures to mitigate the 
risk of onward transmission from gametocytemic subjects, with any species of 
malaria, and the escape of infectious or non-infectious exotic mosquitos are still 
required119. For example malaria VIS conducted in the endemic setting have been 
known to confine subjects from initial infection to clearance of parasitemia to 
mitigate the risk of transmission117. Going forward, it is essential to ensure the 
availability of equivalent containment measures and qPCR to ensure comparable 
volunteer safety and biocontainment to existing malaria VIS models65, 120. 
CONCLUSION 
In the context of malaria VIS, it is not enough to react to safety concerns as they 
occur. Researchers must remain vigilant to potential risks including new ones 
induced by climate change, changes in regulations and new genetically modified 
parasites to ensure the high safety standards vital to the safe conduct of such studies. 
Further, maintaining an intact reputation of malaria VIS is essential for ongoing 
support from the scientific community, regulators, the community, and, most 
importantly, the subjects. No new mitigation techniques are required to protect staff 
or the community during the apheresis exploratory study. Subject specific concerns 
around the apheresis procedure are discussed in the following chapter. 
  





CHAPTER 3 SAFETY AND EFFECTIVENESS OF APHERESIS 
IN THE TREATMENT OF INFECTIOUS DISEASES: A 
SYSTEMATIC REVIEW 
INTRODUCTION 
Whereas mitigation strategies against safety concerns are generally well established, 
the safety of apheresis in healthy volunteers infected with P. vivax is relatively 
unknown. However, there are data on the safety of apheresis in the treatment of 
severe P. falciparum. I reviewed this data and in light of the similarities between 
babesiosis and malaria121, 122 I also examined the safety concerns encountered during 
apheresis in patients with babesiosis which were thought to be relevant to malaria. 
Furthermore, I conducted an assessment of efficacy, in addition to safety of apheresis 
in malaria and babesiosis, as well as collating data on loiasis and severe pertussis 
infection.  
APHERESIS 
Apheresis is the removal of a specific component of an individual’s blood, with the 
remainder being returned to the individual. Apheresis may involve the removal of 
red blood cells (RBCs) (erythrocytapheresis), white blood cells (WBCs) 
(leukocytapheresis), plasma (plasmapheresis), or platelets (thrombocytapheresis). 
Currently, centrifugal apheresis is the preferred method whereby blood components 
are separated based on buoyancy. Modern automated apheresis systems are 
computer-controlled devices that undertake continuous removal, separation of the 
target component, and then return blood123. Advantages of apheresis over exchange 
transfusion include greater haemodynamic stability, lower risk of electrolyte 
imbalances, less chance of transfusion related complications including fluid 
overload, transfusion reactions and blood borne infections124, and speed such that a 
whole blood volume can be exchanged in 1.5 hours125 compared to 5 hours with an 
exchange transfusion124. The primary drawback of apheresis is its limited 
availability, predominantly in specialist centres, typically in high income settings. 
Apheresis is generally considered to be a safe and well tolerated method of treatment 
as well as a method for collecting blood component donations from healthy 





volunteers. Apheresis is an isovolaemic procedure hence there is thought to be little 
if any physiological challenge to the donor as a result of the procedure126 therefore 
syncope and presyncope is less common than in exchange transfusion. The 
Australian haemovigilance report noted that in 2013-2014 (12 month interval), over 
518,000 apheresis donations were undertaken with the total rate of adverse events of 
212 per 10,000 plasmapheresis and thrombocytapheresis procedures127. There were 
no associated deaths. The most common adverse events associated with 
plasmapheresis were vasovagal (65/10,000), haematoma and bruising (13/10,000). 
Adverse events requiring hospitalisation were 2/10,000 and 4/10,000 for 
plasmapheresis and thrombocytapheresis respectively127. Most hospital attendances 
were brief and uneventful requiring no treatment. Except for citrate reactions which 
are known to be more common in continuous mononuclear cell procedures (CMNC), 
other adverse events are thought to be similar in frequency to other forms of 
apheresis. Citrate reactions are probably the most likely adverse events that may 
occur during an apheresis procedure. They are a result of low blood calcium levels 
caused by the anticoagulant citrate which is commonly used instead of heparin for 
apheresis due to its lower tendency to cause bleeding and its short half-life. Most 
patients present with mild tingling around the mouth, nose, ears and extremities128. 
Very rarely citrate reactions may be severe and can manifest with seizures and 
abnormal heart rhythms.  
APHERESIS IN MALARIA 
In the case of malaria, automated erythrocytapheresis, also known as red cell 
exchange (RCE), has been used with the rationale of reducing the parasitised RBC 
concentration by replacing Plasmodium-infected red cells with normal donor red 
cells. RCE, as well as exchange blood transfusion, were historically used as adjuncts 
to intravenous quinine therapy for severe P. falciparum malaria with 
hyperparasitemia (parasitemia >5%), as per World health organisation (WHO) 
recommendations prior to the availability of intravenous artesunate129. The rapid 
parasite clearance resulting from artesunate therapy has resulted in exchange 
transfusion and RCE falling out of favor as a treatment for malaria130, 131. The 
question arises as to whether apheresis should be reconsidered as an adjunct to 





treatment for severe falciparum malaria in cases of hyperparasitemia with coexisting 
artemisinin resistance as it was during the pre-artemisinin era. 
APHERESIS IN BABESIOSIS 
Babesiosis is a rare potentially lethal vector-borne protozoan infection. The illness 
resembles malaria and, like malaria, babesia parasites infect red cells and can 
sequester132. Immunodeficient patients, particularly patients who are HIV infected, 
>50 years old, or with a history of malignancy and/or asplenia may develop severe 
babesiosis, which is a more serious illness, complicated by disseminated 
intravascular coagulopathy (DIC), acute renal failure and haemolytic anaemia. Most 
patients respond well to atovaquone and azithromycin or clindamycin and quinine 
(for severe cases)133. It is thought that RCE acts by physically removing infected red 
cells, thus lowering the parasite burden to a level where the immune system and 
antimicrobials can control the infection. 
APHERESIS IN LOIASIS 
Loiasis is a parasitic infection spread by vectors including the deerfly (Chrysops) and 
is endemic to west and central Africa. Clinical manifestations include Calabar 
swellings (non-tender swellings around joints in arms and legs) and eye worm 
(visualisation of adult worm passing across the conjunctivae). Rare complications 
include renal impairment, pneumonitis, painful lymphadenopathy, scrotal swellings 
and pleural effusions134. Apheresis can be used to reduce the parasite burden in 
loiasis prior to chemotherapy with diethylcarbamazine (DEC), with the aim to reduce 
the likelihood of treatment-induced side effects, particularly encephalopathy which 
can be fatal with high microfilarial loads (>30,000/mL)135. 
APHERESIS IN PERTUSSIS 
Bordetella pertussis is spread by droplet transmission resulting in a respiratory 
illness. It can affect all age groups but is particularly problematic to infants. Severe 
pertussis is characterised by a prominent leucocytosis secondary to lymphocyte 
proliferation stimulated by pertussis toxin production136. This often leads to 
occlusion of the pulmonary vascular tree by abnormal leukocytes, and acute 
vasoconstriction mediated by endothelial dysfunction and/or toxin effects. This 
manifests clinically as pulmonary hypertension137, 138, 139. This condition has a high 





mortality, even when managed with antibiotics, mechanical ventilation, inhaled nitric 
oxide and extracorporeal membrane oxygenation (ECMO)140, 141. In the acute setting 
it has been proposed that this occlusion could be rapidly resolved by the removal of 
excess WBCs. Leukapheresis, plasmapheresis and whole blood exchange transfusion 
have all been employed to alleviate the life threating manifestations of pertussis 
infection142.  
AIM OF REVIEW 
The purpose of this systematic review is to investigate the safety and effectiveness of 
apheresis as adjuvant treatment for malaria, loiasis, babesiosis, and severe pertussis. 
Although in each of these conditions there is a biologically plausible rationale for the 
use of apheresis, ethical and logistical issues mean there is a low likelihood that 
randomised control trials will be undertaken to assess the safety and efficacy of 
apheresis in the treatment of these conditions. Thus, this systematic review of the 
existing literature is aimed at providing as much guidance as possible. 
METHODS 
The complete protocol for this systematic review can be found in appendix 1, the 
methodology is summarised below. 
SEARCH STRATEGY AND SELECTION CRITERIA 
The search strategy aimed to find both published and unpublished studies in which 
male or female patients of any age were treated using apheresis for the following 
infectious diseases: severe falciparum malaria (including artemisinin-resistant P. 
falciparum), loiasis, babesiosis, or severe pertussis. 
Only studies in which automated apheresis (erythrocytapheresis, leukocytapheresis, 
and plasmapheresis) was used were included. Studies that evaluated whole blood 
exchange transfusion were excluded. However, in reports where exchange 
transfusion and apheresis outcomes were combined without any way to separate the 
data, the data were included. 
A two-step search strategy was utilised. An initial limited search of MEDLINE, 
PUBMED, EMBASE and CINAHL was undertaken as follows (searches #1 and #2 
were combined using AND). 






Blood Component Removal [MeSH] OR Cytapheresis [MeSH] OR Leukapheresis 
[MeSH] OR Plasma Exchange [MeSH] OR Plasmapheresis [MeSH] OR 
Plateletpheresis [MeSH] OR apheres* [ti.ab.kw] OR cytapheres* [ti.ab.kw] OR 
leukapheres* [ti.ab.kw] OR leukopheres* [ti.ab.kw] OR leukocytapheres* [ti.ab.kw] 
OR lymphopheres* [ti.ab.kw] OR lymphapheres* [ti.ab.kw] OR 
lymphocytapheres*[ti.ab.kw] OR lymphocytopheres* [ti.ab.kw] OR 
plateletpheris*[ti.ab.kw] OR thrombocytapheres*[ti.ab.kw] OR 
thrombocytophares*[ti.ab.kw] OR “red cell exchange” [ti.ab.kw] 
Search #2 
Malaria, Falciparum [MeSH] OR Loiasis [MeSH] OR Babesiosis [MeSH] OR 
Bordetella Pertussis [MeSH] OR “falciparum malaria”[ti.ab.kw] OR “plasmodium 
falciparum” [ti.ab.kw] OR loias* [ti.ab.kw] OR “Loa” [ti.ab.kw]  OR babesi* 
[ti.ab.kw]  OR pertussis [ti.ab.kw] 
The indices of the following journals were hand searched: Journal of Clinical 
Apheresis, Transfusion and Apheresis Science, Therapeutic Apheresis and Dialysis. 
An analysis of the title, abstract, and keywords of all retrieved articles was 
undertaken to ensure the article fit inclusion criteria. 
Secondly, the reference list of all identified reports and articles was searched for 
additional studies. Studies published in all languages were considered for inclusion 
in this review. Papers not written in English and identified as potentially relevant 
(based on their title and/or abstract) were translated as required. Because apheresis 
was introduced in the 1970s, searches were restricted to studies published from 1 
January 1969 to 16 March 2018. Literature searches were not restricted to a type of 
study. Animal studies were excluded. 
DATA EXTRACTION AND SYNTHESIS 
The data extracted included specific details about the apheresis intervention, 
populations, study methods and outcomes of relevance to the review questions and 
objectives. 





The characteristics of apheresis were recorded where documented including the 
apheresis protocol (e.g. number of cycles), apheresis equipment (e.g. Hemonetics™ 
model, COBE™ Spectra™, etc), and continuous or discontinuous removal and 
replacement of blood cells. 
The effectiveness endpoints recorded were specific to each disease and were based 
upon previous studies of disease. For malaria, the endpoints were the reduction in 
percentage parasitemia, the clinical outcome (survival vs death), and complete 
recovery from severe malaria without lasting complications. For loiasis, the 
endpoints were the percentage reduction in microfilariae, reduction of microfilariae 
<8000/mL, and absence of adverse events from DEC treatment post apheresis. For 
babesiosis, the endpoints were the percentage reduction in parasitemia and clinical 
outcome (survival vs death). For pertussis, the endpoints were the percentage 
reduction in leukocyte count, and clinical outcome (survival vs death). The safety 
endpoints recorded were the number and type of adverse events and complications 
due to apheresis. If a range was given for parasitemia, the middle of the range was 
selected as the value.  
All data were entered in duplicate. Effect sizes expressed as weighted mean or 
median differences (for continuous data) and their 95% confidence intervals [95% 
CI] or interquartile range [IQR] were calculated for analysis. Heterogeneity was 
explored using subgroup analyses based on the different study designs included in 
this review. Where statistical pooling was not possible, the findings were presented 
in narrative form including tables and figures to aid in data presentation where 
appropriate. 
RESULTS 
DESCRIPTION OF INCLUDED STUDIES 
A flowchart indicating the systematic selection of publications for inclusion in this 
review is presented in Figure 1.  
Malaria-related articles consisted of 19 case reports, 15 case series and 2 cohort 
studies. There were 5 studies that involved plasmapheresis only, 5 studies with 
plasmapheresis and RCE, and the remaining 23 studies involved RCE only.  





Babesiosis related articles consisted of 14 case reports and 3 case series. Pertussis-
related articles consisted of 4 case reports and 1 case series. Loiasis-related articles 
consisted of 10 case reports and 4 case series. Additionally, personal correspondence 
from Dr. Thomas Nutman from the National Institutes of Health outlining his 
experience with the use of apheresis in treatment of loiasis was included.  
RISK OF BIAS 
Apheresis is predominantly undertaken in high-resource settings, and also in 
institutions with sophisticated facilities and trained staff that improve the likelihood 
of survival (such as access to an intensive care unit and renal replacement therapy).  
There are no randomised control trials assessing the use of apheresis in the treatment 
of any of the four diseases under study. This is primarily a reflection of the relatively 
low number of cases of severe falciparum malaria, severe babesiosis, severe 
pertussis and loiasis in locations, where apheresis is available. Thus, the potential 
bias is large as only case reports, case series and cohort studies have been published. 
Publication bias will likely play a large part as studies that demonstrate perceived 
improvement and tolerance of apheresis, and survival, are more likely to be 
published. Although I included studies published in languages other than English 
(following translation), there may be a bias towards articles published in English as 
the journals where index searching was used published in English only. However, 
only one additional article was identified using the index searches of journals. 
  





Figure 1. PRISMA flowchart indicating the systematic selection of publications 



















PRISMA flowchart indicating the systematic selection of publications for inclusion 
in this review. 
Records identified through 
database searching
(n=177) 
Records after duplicates removed
(n=140) 
Additional records identified through review 




Full-text articles excluded, 
(n=68)  
• did not involve apheresis in 
the treatment of malaria, 
babesiosis, loiasis or pertussis 
(n=66) 
• apheresis machine was used 
to extract whole blood as the 
process bypassed the 
centrifuge (n=1) 
• not clear which patient 
received apheresis and which 
received exchange transfusion 
(n=1) 




• Malaria (n=36) 
• Babesiosis (n=17) 
• Loiasis (n=14) 
• Pertussis (n=5) 





APHERESIS IN THE TREATMENT OF MALARIA 
A total of 36 suitable publications were identified that included data on 70 patients, 
with a total of 87 apheresis procedures. Individual data were available on 73 
procedures and grouped data on 14 procedures. An additional 7 patients only 
underwent plasmapheresis, with a total of 14 procedures. The remainder of patients 
either underwent RCE alone or RCE and plasmapheresis. Of the 70 patients, 19 were 
from case reports, 42 were from case series and 9 were from cohort studies. All 
patients had confirmed severe malaria as per WHO criteria28. Table 2 summarises 






















Table 2. Apheresis in treatment of malaria  
Demographics 
Number of patients 70 
Number of male patients 44 (62.9%) 
Median age (IQR) in years 40 (26-49) 
Number of apheresis procedures 87 
Blood tests 
Median pre-apheresis haemoglobin (IQR) g/dL 9.80 (6.7-12) 
Median platelet nadir (IQR) ×109/L 27 (16-44) 
Parasitemia 
Median (IQR) peak parasitemia 28% (14.5-46.5) 
Median % reduction (IQR) in parasitemia for all apheresis 
procedures 
80% (68.4-90) 
Median % reduction (IQR) in parasitemia for 1st apheresis 
procedure per patient (n=50) 
80% (68.4-90.9) 
Median % reduction (IQR) in parasitemia for 2nd apheresis 
procedures per patient (n=44) 
76.8% (42.9-90) 
Log10 reduction (IQR) in parasitemia for all apheresis procedures 1.61 (1.2-2.3) 
Log10 reduction (IQR) in parasitemia for 1
st apheresis procedure 
per patient (n=50) 
1.60 (1.2-2.4) 
Log10 reduction (IQR) in parasitemia for 2
nd apheresis procedure 
per patient (n=44)  
1.46 (0.56-2.30) 
Safety of apheresis 
Number of patients with AEs related to apheresis 3 (4.3%)* 
Number of patients with AEs possibly related to apheresis 3 (4.3%)* 
Clinical outcome 
Number of patients who made a full recovery 65 (92.9%) 
Number of patients who died  2 (2.9%) 
Number of patients who experienced complications 3 (4.3%) 
IQR; interquartile range, AEs; adverse events 





*The presence or absence of AEs was only specified for 35 patients; the percentage 
is based on the assumption that if AEs were not specified than none occurred. 
Table detailing demographic, safety and efficacy data identified for the use of 
apheresis in the treatment of severe P. falciparum malaria. 
In several studies, parasitemia estimates were not explicit (e.g. >70% or <1%); in 
these cases, parasitemia levels were designated as 70% and 1% respectively. There 
were seven patients where the peak parasitemia was described as greater than a 
specific value. In such cases this may be an underestimate of peak parasitemia. For a 
similar reason, it is possible that the level of parasitemia reduction may also have 
been underestimated. Of the five (7.1%) patients who were reported to not have 
completely recovered, two (2.9%) died. One patient had what the authors described 
as “minimal organ damage”, one had persistent memory impairment and one 
developed persistent renal impairment (creatinine 165 µmol/L), peripheral 
neuropathy and retinopathy all thought to be secondary to malaria. One of the 
patients who died had a Glasgow Coma Scale (GCS) 3/15, and pinpoint pupils at 
presentation, suggesting that this patient’s condition was unsalvageable. The patient 
who was reported to have persisting memory impairment, had a GCS of five prior to 
RCE, and required intensive supportive treatment, including mechanical ventilation, 
vasopressor support with norepinephrine, and dialysis. 
A significant number of studies did not record (NR) whether their patients had 
cerebral malaria, pulmonary oedema or renal failure. Although it could be argued 
that these were not reported because they were absent, this cannot be stated with 
certainty. Hence, for cerebral malaria, pulmonary oedema and acute kidney injury, I 
carried out an additional analysis where NR is interpreted as not present (see Table 
3). However, it must be emphasised that this additional analysis is likely to mean 
that I underestimate the frequency of these conditions.  
The reporting of other complications, such as hyperbilirubinaemia, hyperlactataemia, 
hypoglycaemia and coagulopathy may have also been incomplete; they require blood 
testing for diagnosis. However, as the absence of reporting is less likely to represent 
true absence, they are not included in the additional analysis (Table 3). 
  





Table 3. Characteristics of malaria patients treated using apheresis  
 
NR excluded NR interpreted as not 
present  
Cerebral malaria  33/62 (53.2%) 33/70 (47.1%) 
Pulmonary oedema 24/58 (41.4%) 24/70 (34.3%) 
Renal failure 39/64 (60.9%) 39/70 (55.7%) 
Hyperbilirubinaemia 31/44 (70.5%) N/A 
DIC 16/39 (41.0%) N/A 
Hyperlactaemia* 12/16 (75.0%) N/A 
Hypoglycaemia 5/27 (18.5%) N/A 
NR; not recorded, DIC; disseminated intravascular coagulopathy. 
*Included a cohort study with 5 patients with a median lactate of 5.1 mmol/L.  
Table summarising the frequency of selected criteria for severe P. falciparum 
malaria in patients treated with apheresis. Frequency data is demonstrated both for 
when a severity characteristic is not recorded (NR) and is subsequently excluded and 
for when a severity characteristic is not recorded (NR) and is interpreted as not being 
present.  
There were only three adverse events thought to be related to apheresis. These events 
were all transient hypotension; in one patient this was treated by fluid resuscitation 
and two others were simply monitored until resolution. Pulmonary oedema was later 
seen in two of these patients, although the reports suggest this was unlikely to have 
been related to apheresis125, 143. Of note, all 3 patients who had adverse events related 
to apheresis survived without any complications. Acute respiratory distress 
syndrome (ARDS) occurred post RCE in 3 of the 6 patients in a case report by Molla 
et al144. The authors comment that it is not clear if the ARDS was related to RCE or 
malaria; all had hyperparasitemia (23%, 58% and 80%), and drug treatment began 
shortly before apheresis.  





It is notable that there were no adverse events reported in patients with anaemia or 
thrombocytopenia: Hb levels were not reported to be reduced in the 3 patients who 
developed hypotension (12.0 g/dL, 13.7 g/dL and NR). 
APHERESIS IN THE TREATMENT OF BABESIOSIS 
A total of 17 suitable publications were identified that included data on 22 patients 
who underwent a total of 29 RCE and 4 plasmapheresis procedures. Table 4 
summarises the main findings. 
Table 4. Apheresis in treatment of babesiosis 
Demographics 
Number of patients 22 
Number of male patients 16 (72.7%) 
Median age (IQR) in years 64.5 (47-67) 
Number of apheresis procedures 33 
Parasitemia 




Median % Reduction (IQR) in parasitemia for 1st apheresis 
procedure per patient (n=15) 
83.3% (57.6-
96.7) 
% Reduction in parasitemia for 2nd apheresis procedure per patient 
(n=2) 
50%, 95% 
Safety of apheresis 
Number of patients with AEs related to apheresis 0* 
Clinical outcome 
Number of patients who died  4 (18.2%) 
IQR; interquartile range, AEs; adverse events. 
*The presence or absence of AEs was only specified for four patients. 
Table detailing demographic, safety and efficacy data identified for the use of 
apheresis in the treatment of babesia. 
 





No adverse events were reported although this was only specified for 4 out of 33 
(12.1%) procedures. There were 4 deaths; one of the deaths occurred five days, and 
another six days after the blood film became negative for babesia. One patient had a 
background of chronic relapsing pancreatitis secondary to acute fulminant alcoholic 
pancreatitis and was due to have a total pancreatectomy or a biliary diverting 
procedure, but due to intra-operative complications a gastrojejunostomy was 
performed instead and the patient contracted transfusion related babesiosis. Babesia 
parasitemia improved from 30% to 6.6% following initiation of quinine and 
clindamycin and two RCE procedures. However, the patient’s bilirubin continued to 
increase despite the insertion of a biliary drain and the decision was made to 
withdraw active treatment. In the final case the authors believed that the cause of 
death was myocardial infarction. In this case, babesiosis was thought to be a 
contributing factor. It is not possible to ascertain the true effect that babesiosis had in 
each of these deaths.  
APHERESIS IN THE TREATMENT OF LOIASIS 
A total of 14 identified publications included data on 34 patients with a total of 61 
apheresis procedures. Table 5 summarises the main findings.  
  





Table 5. Apheresis in treatment of loiasis 
Demographics 
Number of patients 34 
Number of male patients 25 (74%) 
Median age (IQR) in years 32 (27-41) 
Number of apheresis procedures 61 
Microfilaraemia 
Median % reduction (IQR) in microfilaraemia per apheresis 
procedure for all apheresis procedures 
51.7% (28.9-70.8) 
Median % reduction (IQR) in microfilaraemia for 1st apheresis 
procedure (n=24) 
60.3% (27.4-82.5) 
Median % reduction (IQR) in microfilaraemia for 2nd apheresis 
procedure (n=9) 
38.2% (32.6-50.4) 
Median % reduction (IQR) in microfilaraemia for 3rd apheresis 
procedure (n=10) 
52.2% (36.7-64.7) 
Median absolute reduction (IQR) in microfilaraemia per 
apheresis procedure for all apheresis procedures  
2400 (1250-6750) 
microfilariae/mL 
Median absolute reduction (IQR) in microfilaraemia for 1st 
apheresis procedure (n=24) 
2450 (1110-7100)  
microfilariae/mL 
Median absolute reduction (IQR) in microfilaraemia for 2nd 
apheresis procedure (n=9) 
6600 (2370-7200) 
microfilariae/mL 
Median absolute reduction (IQR) in microfilaraemia for 3rd 
apheresis procedure (n=10) 
1515 (1200-4900) 
microfilariae/mL 
Number of patients with pre-apheresis microfilariae count 
>8000/mL with successful reduction to <8000/mL by apheresis 
9/12 (75%)* 
Safety of apheresis 
Number of patients with AEs related to apheresis 12 (35.3%)# 
Clinical outcome 
Number of patients with DEC related AEs post apheresis 3 (8.8%) 
IQR; interquartile range, AEs; adverse events, DEC; diethylcarbamazine. 





*Only assessable in 12 patients; in the remaining patients it was not possible to 
confirm that this target was met as the patients either had microfilaremia <8000/mL 
prior to apheresis, or data on microfilaremia were incomplete.  
#The presence or absence of AEs was only specified for 28 patients; the percentage is 
based on the assumption that if AEs were not specified than none occurred. 
Table detailing demographic, safety and efficacy data identified  for the use of 
apheresis in the treatment of loiasis. 
 
The generally accepted aim of apheresis in loiasis is to reduce the microfilariae level 
to as low as possible prior to anti-filarial therapy with efforts made to target 
<8000/mL (although this level has been chosen relatively arbitrarily)135, 145. In 22 
patients it was not possible to confirm that this target was met, as the patients either 
had microfilaremia <8000/mL prior to apheresis, or data on microfilaremia were 
incomplete. In the 12 patients that could be assessed, 9/12 (75%) reached this target. 
In the other three patients, there was a substantial reduction in parasitemia (15,000 to 
10,666, 37,500 to 20,000 and 21,900 to 8,900).  
A total of 12 patients were reported to have experienced adverse events related to 
apheresis. The most common adverse event was a reduction in platelet count. Other 
adverse events include reductions in lymphocyte count, haemoglobin and 
haematocrit. Lastly, difficultly in venous access was experienced in an obese woman 
(body mass index 40.1) and short-lived generalised weakness occurred following the 
procedure.  
Personal communication from Dr Thomas Nutman from the National Institutes of 
Health was also received. Since 1987, 72 apheresis procedures have been carried out 
in 50 patients, most of whom had microfilariae levels >1000/mL. No adverse events 
related to apheresis have been reported. The team typically aims for a 7 L apheresis 
procedure focused at the monocyte interface (Buffy coat) for maximal microfilarial 
yield. No reliable data on reduction in parasitemia are available, given that multiple 
types of apheresis equipment were used over this 30-year period and standardised 
assessment of microfilarial counts were not performed on all individuals. It was also 
noted that carrying out procedures at midday and re-checking the microfilarial level 





24 hours post apheresis is the only real way to provide accurate results about 
microfilarial clearance through apheresis because of the natural diurnal periodicity of 
microfilaremia. 
APHERESIS IN THE TREATMENT OF PERTUSSIS 
A total of 5 studies reporting patients who had undergone leukapheresis as part of 
treatment for severe pertussis were identified. All data were published relatively 
recently (from 2006 onwards). Table 6 summarises the main findings. 
Table 6. Apheresis in treatment of pertussis 
Demographics 
Number of patients 6 
Number of male patients 0 
Median age (IQR) in months 2.0 (1.3-3.0) 
Number of apheresis procedures 8 
Lymphocytes 
Median % Reduction (SD) in lymphocytes per apheresis 
procedure 
61.3% (19.4) 
Safety of apheresis 
Number of patients with AEs related to apheresis 2 (33.3%)* 
Clinical outcome 
Number of patients who died  2 (33.3%)# 
IQR; interquartile range, SD; standard deviation. 
*The presence or absence of AEs was only specified for 4 patients; the percentage is 
based on the assumption that if AEs were not specified than none occurred. 
#Survival was only specified for 5 patients; the percentage is based on the 
assumption that if survival was not specified than the subject did not die. 
Table detailing demographic, safety and efficacy data identified  for the use of 
apheresis in the treatment of pertussis. 
 





All 6 patients were female, in contrast to the usual male predominance in severe 
pertussis disease. Two patients died; one case report did not record survival or death. 
The first death was due to intraventricular and respiratory hemorrhage and the 
second was a result of respiratory failure as a direct result of pertussis infection. 
Adverse events secondary to apheresis were reported in 2 patients. One patient 
experienced a fall in fibrinogen (270 mg/dL to 238 mg/dL) and platelet count (576 × 
109/L to 163 × 109/L) and an increase in prothombin time (74 s to 85 s) and partial 
thromboplastin time (29.8 s to non-clotting). The other patient experienced a large 
drop in platelet count 706 × 109/L to 34 × 109/L. It may be inferred that these 
changes in clotting and bleeding tendency may have contributed to the 
intraventricular and respiratory hemorrhage and death.  
DISCUSSION 
The aim of the review was to analyse the safety and efficacy of apheresis in the 
treatment of severe P. falciparum malaria, severe babesiosis, severe pertussis and 
loiasis. The review highlights the relative lack of high quality, prospective studies for 
all four diseases. 
MALARIA 
Assessing the effectiveness of parasite reduction was difficult because many studies 
did not report parasite counts immediately before or after RCE; in some cases they 
were taken more than 24 hours after the procedure. This is compounded by 
sequestration of infected RBCs during the second half of the P. falciparum lifecycle, 
making the relative contribution of apheresis, sequestration or drug effect difficult to 
determine146, 147, 148, 149, 150. The median 80% (IQR 68.4-90) reduction in parasitemia 
per apheresis procedure may therefore overestimate the true reduction151. It should 
be noted that, independent of parasite clearance, other potential benefits of apheresis 
such as removal of toxins or cytokines152, 153 could help improve overall prognosis; 
this could explain the clinical improvements experienced following 
plasmapheresis153, 154, 155.   
Complete recovery in 65/70 (92.9%) of patients in this analysis, was an interesting 
finding given that, the literature suggests, malaria patients treated with apheresis are 
typically more unwell than the general population with severe malaria156, 157. 





Specifically, this is evidenced by a higher Acute Physiologic Assessment and 
Chronic Health Evaluation (APACHE) 2 score (26 versus 17)156 and a higher initial 
median parasitemia (46.5% vs 7.3%) in specific cohort studies. Anecdotally, several 
cases describe RCE as rescuing patients who were rapidly deteriorating 158, or 
clinical improvement soon after RCE or plasmapheresis154, 155. Plasmapheresis has 
also been used as an adjunct to antimalarial therapy154, 155, 159, with or without RCE 
and as a potential treatment for thrombotic microangiography154 and associated renal 
failure154, 159. However, the numbers are relatively small making interpretation of 
therapeutic benefit very difficult. 
Adverse events were rare, even in patients with thrombocytopaenia or anaemia. 
Some RCE procedures were complicated by transient hypotension143, 160, with most 
cases resolving without intervention or following fluid resuscitation160, all patients 
made a full recovery from malaria. Molla et al144 reported a case series involving 6 
patients with severe P. falciparum treated with RCE. Three patients developed 
ARDS post RCE requiring mechanical ventilation. The authors could not determine 
if the ARDS was due to malaria or RCE but all three were at high risk of ARDS as 
they had hyperparasitemia (23%, 58% and 80%) and multiple features of severe 
malaria including cerebral (2/3), renal (3/3) and DIC (2/3). All patients who 
experienced possible adverse events from apheresis completely recovered. 
This review specifically focused on the use of apheresis and not whole blood 
exchange transfusion. The WHO and Centers for Disease Control and Prevention 
(CDC) changed their guidelines regarding the use of exchange transfusion in severe 
malaria cases with parasitemia >5% following the introduction of artesunate with its 
rapid parasite clearance and superior efficacy over quinine130, 131. Tan et al161 
completed the most extensive review to date on the use of exchange transfusion in 
severe malaria. The overall mortality rate from the review was 17.8% and 15.9% for 
exchange transfusion and non-exchange transfusion respectively (OR 0.84; 95% CI 
0.44-1.60). The review assessed exchange transfusion as a whole and did not 
distinguish between manual and automated exchange or the relative proportions of 
either mechanism of exchange transfusion161. The inference was that the majority of 
cases if not all were manual exchange. The commentary regarding apheresis largely 
focused on the rate of adverse events reported from a study by McLeod et al162 with 





an overall complication rate of 10.3% based on a total of only 78 procedures. The 
review article was published in 1999, it is likely that practices have improved greatly 
over the last 20 years resulting in fewer adverse events. This is a large study in terms 
of overall numbers, but it is relatively small in terms of RCE numbers, and although 
important to consider it, the data does not allow for any strong decisions to be made 
on the safety, or efficacy of therapeutic RCE. 
The only randomised control trial assessing exchange transfusion in severe malaria 
occurred in Harare between 1986 to 1987. 8 patients with severe malaria were 
randomly assigned to receive antimalarials or antimalarials and exchange 
transfusion. All 4 patients who received exchange transfusion survived compared to 
only 1/4 who did not receive exchange transfusion. The authors reported that the 
result was not significant on Fischer’s exact testing but did not provide any statistical 
measures. Mean parasitemia was 4.2% and 2.5% for exchange transfusion treated 
and non-exchange transfusion treated patients. The authors commented this could 
represent the non-parasite reduction related effects of exchange transfusion such as 
removal of toxic metabolites or deficient clotting factors. 
In the context of increasing spread of artemisinin resistance, the question arises as to 
whether apheresis should be used as an adjunct to antimalarial drugs in those severe 
malaria patients at risk of having an artemisinin resistant parasite (e.g. returned 
traveller from Cambodia). In a multivariate logistic-regression model completed by 
Ashley et al163 demonstrated an infection associated with a kelch13 (K13) propeller 
mutation was substantially more likely to have a parasite clearance half-life longer 
than 5 hours (odds ratio, 94.7; 95% CI, 54.6 to 164.0; P<0.001)163. The parasite 
clearance half-life for quinine is 5.15 (IQR; range) (3.83-6.68; 0.86-105.5) compared 
to artesunate (non-resistant parasites) which is 3.11 (2.33-4.24; 0.59-34.28) hours164. 
This suggests that even in the presence of K13 mutations artemisinin therapy may 
still have a similar rate of parasite killing to quinine. However, given the increase in 
parasite clearance half-life where there is concern over the possibility of K13 
mutation infections as well as starting artesunate therapy apheresis may also be 
considered, especially given its good safety profile. It is important to note that 
different K13 mutations infer different degrees of artemisinin resistance and 
therefore slowed clearance, although as time has progressed the dominant form of 





K13 mutation has been the variant C580Y which has relatively moderate increases in 
parasite clearance time compared to other mutations165, 166.  
A clinician may be faced with a patient with severe P. falciparum from an area of 
high prevalence for artemisinin resistance and a high parasitemia, or alternatively 
they may not have access to artesunate in a timely manner or be unable to use 
artesunate, for example in the case of allergy (very rare167, 168). Given the low rate 
and short-lived nature of adverse events experienced during apheresis (4.3%), in 
such circumstances it may be considered as adjunctive treatment. If apheresis is 
undertaken and hypotension occurs, it would be more appropriate to stop the 
procedure given the data supporting the conservative use of intravenous fluid 
treatment in the management of severe malaria infection169. RCE should be carried 
out at least 3-4 hours post artesunate dosing to avoid removal of artesunate and its 
metabolite dihydroartemisinin157, 170, 171. Apheresis should only be used where there 
is local expertise and should not delay artesunate treatment. 
Overall, the published data indicate that the use of apheresis in the context of severe 
P. falciparum is safe and may have some therapeutic benefit. However, given the 
lack of randomised control studies, there is insufficient evidence to support the 
general application of apheresis as an adjunct, use of apheresis as routine treatment, 
or its establishment in resource limited settings solely for the treatment of severe 
malaria.  
BABESIOSIS 
The use of RCE and apheresis in babesiosis have mainly been extrapolated from 
evidence in malaria. Babesia-infected patients with high parasite loads have been 
treated with adjunctive whole blood exchange transfusion, or apheresis-mediated 
RCE, to reduce parasite burden. Patients hospitalised with babesiosis have a 
mortality of 6-9%, with case fatality rates of up to 21% in immunocompromised 
patients132, 172, 173. However, the patients in this review appear to reflect the severe 
end of the spectrum, with a median parasitemia pre-apheresis of 20.25% compared to 
median parasitemia levels of 7.6% to 15.1% in most studies132, 172, 173. All but one of 
the patients identified during this review had identifiable risk factors for 
immunosuppression, and 4/22 patients died.  





In terms of the safety of RCE in severe babesiosis, no adverse events related to RCE 
were reported. Furthermore, the low mean (SD) haemoglobin level pre-apheresis 7.6 
g/dl (2.2 g/dl) suggests the procedure is safe and well tolerated even at low 
haemoglobin levels. 
Guidelines from the Infectious Diseases Society of America suggest that RCE should 
be carried out in anyone with renal, liver, respiratory failure, significant haemolysis 
or high parasitemia174. They advise that one RCE volume is sufficient, as it replaces 
85-90% of the patient’s RBCs; this is the same advice given by the American 
Society for Apheresis (ASFA)175. ASFA suggests RCE for babesia infected patients 
with parasitemia >10%, or with significant comorbidities such as significant 
haemolysis, DIC, pulmonary, renal or hepatic compromise. In babesia-infected 
patients who are asplenic, RCE is recommended even in asymptomatic patients. In 
addition, plasmapheresis is recommended for critically ill asplenic patients not 
responding to chemotherapy or RCE, or with severe coagulopathy175. The data these 
recommendations are based on is considered weak.  
With the high reliance on case reports and lack of randomised control trials, the 
available data are not of sufficient quality to support the routine use of RCE in 
babesiosis. However, given the high mortality rate in immunosuppressed 
hospitalised patients, the lack of adverse events from the apheresis procedure, and 
the low number of babesia-related deaths identified in this review, the data suggests 
RCE may be considered by clinicians as a useful adjunct to standard chemotherapy 
in hospitalised patients with babesia infection (especially those with 
immunosuppression). Plasmapheresis may be considered if there is evidence of 
haemolytic anaemia, or if there are specific concerns regarding renal failure (e.g. in 
the context of renal transplant).  
LOIASIS 
Apheresis is aimed at reducing the microfilarial load prior to treatment with DEC, 
reducing the likelihood of treatment related encephalopathy135, 145. This review 
demonstrated a median (IQR) parasitemia reduction of 51.7% (28.9-70.8%) across 
all apheresis procedures where both pre- and post-procedure data are available. 
Given the diurnal variation and potential for microfilariae to migrate from the 





periphery176, it cannot be assumed that this reduction is solely due to apheresis, but it 
is highly likely to be contributing. 
Safety data suggests apheresis is an acceptable intervention as long as subjects have 
relatively normal platelet and haemoglobin counts. Given the clinical benefits of 
reducing the parasite count prior to anti-filarial treatment, and the good safety 
profile, the data support apheresis for the treatment of loiasis infected patients with 
high microfilarial counts.  
PERTUSSIS 
Severe pertussis cases make up only a small minority of the overall number of 
pertussis cases (3.2% in the United States)177. Severe cases can be complicated by a 
prominent leukocytosis136 which leads to occlusion of the pulmonary vascular tree 
manifesting clinically as pulmonary hypertension137, 138, 139. Pulmonary hypertension 
is associated with high mortality, even when managed with mechanical ventilation, 
inhaled nitric oxide, and extracorporeal membrane oxygenation (ECMO)140, 141.  
I identified published reports on only six patients, of which two died. At least one 
death appears to have been related to apheresis178. The combination of uncertain 
efficacy and serious safety concerns therefore suggest that apheresis should not be 
used in the treatment of severe pertussis infection.  
GENERAL CONSIDERATIONS 
The study endpoint was parasite clearance for malaria and babesiosis, microfilarial 
clearance for loiasis and lymphocyte clearance for pertussis. This does not allow any 
firm conclusion for other biological benefits of RCE or plasmapheresis, or indeed 
clinical outcome. Indeed any observed clinical improvement post apheresis could 
also be due to a delayed effect from the curative chemotherapy. Of course it is 
important to remember that non-circulating parasites (malaria, babesia and loa loa) 
will not be removed during apheresis, and hence return to the circulation. Thus, 
increases in parasite burden following apheresis may not necessarily signify failure 
of apheresis, and repeat apheresis should not be ruled out.  
This study assessed all the original published data on the use of apheresis in the 
treatment of malaria, babesiosis, loiasis and pertussis. No randomised trials were 
identified and only cohort studies, case series and case reports were available, 





reflecting the fact that most of these conditions are rare in resource rich settings 
where apheresis is available. Overall, the small sample sizes, lack of hard clinical 
endpoints and limitations of study design issues make it extremely difficult to clearly 
identify beneficial or harmful effects of adjunctive apheresis on clinical outcome in 
any of the four conditions.  
Where there is the potential for apheresis to be used to treat other conditions such as 
sickle cell disease, and where the health and financial incentives are present, 
apheresis may be able to establish itself in a resource limited setting. A randomised 
controlled trial initiated to study the use of apheresis in severe P. falciparum 
infection or loiasis may also be warranted. However, this may not be possible due to 
ethical concerns given the risk of potentially fatal encephalopathy and the relative 
lack of loiasis infected patients in areas where apheresis is available. In the case of 
severe pertussis and severe babesiosis, the issue is not one of mismatch between 
apheresis availability and disease endemicity but rather a lack of cases making a 
randomised control trial logistically difficult. A more realistic option would be to 
establish a managed database with voluntary reporting of all apheresis procedures 
carried out in the treatment of severe pertussis and severe babesia. There is no doubt 
that standardised recording and publication of data for any patients treated with 
apheresis would be valuable. In particular, accurate recordings of the parasitemia pre 
and post apheresis, safety data and clinical outcome data should be prioritised. 
CONCLUSION 
Existing data suggests that apheresis may be a useful adjunct to chemotherapy in the 
treatment of patients hospitalised for babesia, and prior to chemotherapy in loiasis 
with microfilarial count >8000/mL on the basis of reduction of parasite counts, but 
there are no clear clinical benefits. This review does not support the use of apheresis 
in critical pertussis infection or currently for patients with severe P. falciparum 
malaria. No safety concerns were identified during the review that were concerning 
enough to interfere with the plan to use apheresis as a method of harvesting all life 
cycle stages from subjects with induced blood stage P. vivax malaria. However, 
based on the findings in chapters 2 and 3 it was anticipated that the combination of 
apheresis and P. vivax IBSM may increase the likelihood and severity of  existing 
safety concerns commonly observed in both apheresis and IBSM studies including 





citrate reactions,  bruising and haematoma, syncope and anaemia. Techniques aimed 
at mitigating these risks are discussed in the next chapter.  
  





CHAPTER 4 APHERESIS OF SUBJECTS WITH INDUCED 
BLOOD STAGE PLASMODIUM VIVAX 
INTRODUCTION 
In the absence of a method of in vitro culture for P. vivax, the only way to source 
parasites is ex vivo from infected humans. This hampers all aspects of the 
development of tools to study this parasite and of tools to eliminate it. For example, 
to test and develop new hypnozoiticidal drugs that do not have the risk of significant 
haemolysis33, a reliable source of P. vivax sporozoites is required. Currently this 
entails an expensive, logistically complex and unreliable process of sourcing P. vivax 
infected mosquitoes from endemic areas. In addition to the inherent logistic issues, 
parasites sourced in this way are not genetically homogenous. Thus experiments 
must take into account the effects of strain variability. 
QIMR have successfully transmitted P. vivax parasites from healthy volunteers to 
An. stephensi mosquitoes and subsequently harvested sporozoites179. In one study 75 
mL of blood was pooled from 6 subjects, parasites were concentrated by density 
gradient centrifugation and the concentrate was fed to 6 pots of 100 An. Stephensi 
mosquitoes179.  
Based on this study, an exploratory study was designed to assess the use of apheresis 
as a means to harvest and concentrate all stages of P. vivax including gametocytes 
from up to 8 human subjects infected with blood stage P. vivax malaria. Venesection 
cannot be used to select a specific haematocrit and therefore purified parasites cannot 
be sourced as efficiently as through apheresis. The harvested parasites could then be 
cryopreserved; the asexual parasites could then be used to produce a human malaria 
parasite (HMP) bank for use in future IBSM studies, while gametocytes may be used 
to infect An. stephensi mosquitoes. Previous work has established that cryopreserved 
P. vivax gametocytes are infectious to mosquitoes180. These infected mosquitoes, or 
sporozoites derived from them, could be used to infect healthy subjects in radical 
cure challenge models. Additionally, these sporozoites could be used in in vitro 
microfluidic devices that sustain human hepatocyte culture181, as well as in 
humanised mouse models such as the severe combined immunodeficiency (SCID) 
mouse model which has shown potential to act as a model for the hepatic stage of 





malaria infection182. Furthermore, apheresis could transform P. vivax mosquito 
membrane feeding assays, obviating the need for a gametocytemic test subject. 
This chapter reports, for the first time, how apheresis was used as a method of 
acquiring purified P. vivax parasites from healthy human subjects infected with 
IBSM.  
HYPOTHESES 
• Apheresis can be used to extract and concentrate all stages of P. vivax 
parasites to a greater extent to that which can be attained by simple blood 
draws.  
• Parasites harvested via apheresis can be cryopreserved. 
• Asexual parasites extracted by apheresis can be used to produce a P. vivax 
HMP bank for future IBSM studies.  
OBJECTIVES 
PRIMARY OBJECTIVES 
• To further assess the safety of the P. vivax IBSM model following 
inoculation of healthy subjects with P. vivax isolate HMPBS02-Pv. 
• To assess the safety of apheresis in the P. vivax IBSM model following 
inoculation of healthy subjects with P. vivax isolate HMPBS02-Pv. 
SECONDARY OBJECTIVES 
• To assess the feasibility of apheresis as a method of extracting and 
concentrating all stages of malaria parasites following inoculation of healthy 
subjects with P. vivax isolate HMPBS02-Pv. 
• To evaluate the success of cryopreservation of all stages of P. vivax parasites 
from blood products extracted via apheresis from healthy subjects inoculated 
with. P. vivax isolate HMPBS02-Pv. 






• To explore the potential for apheresis to be used as a method for producing a 
P. vivax human malaria parasite (HMP) bank to be used for future IBSM 
studies.  
• To evaluate the transmission of P. vivax gametocytes to mosquitoes. 
MATERIALS AND METHODS 
A complete version of the study plan and specific safety concerns, and mitigation 
techniques regarding the use of apheresis in healthy volunteers infected with blood 
stage P. vivax including citrate reactions, syncope, bruising and haematoma, and 
anaemia can be found in the study protocol contained in appendix 2. Below is a 
summary of the main considerations. 
RISK MANAGEMENT OF CITRATE REACTIONS  
Citrate reactions are the most likely adverse events that may occur during the 
apheresis procedure. They are due to low blood calcium levels (hypocalcaemia) 
caused by the anticoagulant citrate. To reduce the chances of citrate reactions only 
subjects without a history of hypocalcaemia and with normal calcium levels on 
screening blood tests were included. If a subject developed signs or symptoms of 
hypocalcaemia during apheresis they would be advised verbally to commence a high 
calcium diet for 24 hours post-apheresis.  
RISK MANAGEMENT OF PRE-SYNCOPE AND SYNCOPE  
Subjects were most likely to experience syncope and pre-syncope during venous 
cannulation, often exacerbated by difficult venous access. To mitigate against this, 
only subjects with no previous history of syncope as a result of venous cannulation 
or venesection, and good venous access were included. Furthermore, blood draws 
from veins located in the ante-cubital fossa in the lead up to apheresis were avoided 
in order to preserve the veins.  





RISK MANAGEMENT OF BRUISING AND HAEMATOMA DURING 
VENOUS CANNULATION  
To counter the risk of bruising and haematoma only subjects with good venous 
access were included and blood draws from the veins in the ante-cubital fossa in the 
lead up to apheresis in order to preserve the veins.  
RISK MANAGEMENT OF ANAEMIA  
Statistical analysis of the trends in haemoglobin during P. vivax IBSM studies at 
QIMR Berghofer demonstrated a mean haemoglobin drop 10 days post-
inoculation of 3 g/L and the mean maximum fall in haemoglobin at any point 
during previous P. vivax IBSM studies was 13 g/L with a standard deviation of 7 
g/L. A double red cell collection apheresis procedure was estimated to cause a 
maximum drop in haemoglobin of 20%, approximating to 30 g/L. All subjects 
included in the study had normal haemoglobin levels at screening ( ≥135 g/L) 
thus, the maximum anticipated fall of around 43 g/L would leave a haemoglobin 
of 92 g/L, well above the cut-off for blood transfusion (70 g/L).  STUDY 
DESIGN 
I conducted a phase 1, exploratory study designed to determine the safety and 
feasibility of using apheresis as a method for extracting all lifecycle stages of malaria 
parasites from the blood of healthy subjects experimentally infected with blood stage 
P. vivax. This study was conducted in four sequential cohorts of one subject each 
(ANZCTR Trial ID: ACTRN12617001502325). The study was conducted at Q-
Pharm Pty Ltd, Brisbane, Australia and the apheresis unit of the Royal Brisbane and 
Women’s Hospital (RBWH), Australia between October 2017 and May 2019. 
It was anticipated during planning that modifications specific of the apheresis 
procedure would likely be required during the study in order to meet the objectives. 
The changes made in the apheresis procedure between cohorts were based on the 
findings of previous cohorts. A number of laboratory based experiments were 
conducted during the study to aid with study planning and interpretation of study 
results. 
See appendix 2 for full study protocol. 






The study was conducted in accordance with the protocol approved by QIMR 
Berghofer human research ethics committee (HREC) and the RBWH HREC, the 
principles of the Declaration of Helsinki (recommendations guiding medical doctors 
in biomedical research involving human subjects, Fortaleza, Brazil 2013), the 
NHMRC National Statement on Ethical Conduct in Human Research (2007) and the 
Notes for Guidance on Good Clinical Practice (GCP) (CPMP/ICH/135/95), as 
adopted by the Australian Therapeutic Goods Administration (2000). All 
amendments and addenda to the protocol were similarly submitted to the QIMR 
Berghofer HREC and the RBWH HREC for approval prior to their implementation. 
All subjects gave written informed consent before being included in the study. 
STUDY SUBJECTS 
Healthy adult males and females aged between 18 and 55 years who met all 
inclusion criteria and none of the exclusion criteria were eligible for participation. 
Subjects were required to be malaria naïve, Duffy Blood group positive and have 
blood type O; females had to be Rh(D) positive, and available for a safety follow up 
period of three months. A full list of the inclusion/exclusion criteria for this study are 
included in the study protocol located in appendix 2.  
STUDY CONDUCT 
PRE-CLINICAL COMPONENT 
A pre-clinical experiment was conducted prior to the inoculation of subjects in order 
to confirm the feasibility of harvesting Plasmodium parasites using apheresis. 
The P. falciparum NF54 clone was used in these experiments183 due to limited 
availability of P. vivax parasites. P. falciparum infected red blood cells (RBCs) (17.6 
mL; 16 mL blood with 0.1% asexual parasitemia and 1.67 mL blood with 0.01% 
gametocytemia) was added to 450 mL of fresh venous whole blood and subjected to 
ex vivo apheresis. Samples were collected from the 1%, 2%, 3%, 5% and 7% 
haematocrit (HCT) layers as determined by visualising the colour saturation of the 
apheresis product. An automated haematology analyser (Sysmex XN-3000; Sysmex 





UK) was used to confirm the HCT of samples collected during apheresis. Presence 
of parasites was assessed in each layer by 18S qPCR66 and microscopy.  
CLINICAL COMPONENT 
Following intravenous injection of P. vivax parasites (day 0), subjects were 
monitored by daily telephone calls until day 4, when subjects visited the clinical unit 
daily until the day of apheresis. Subjects were monitored for adverse events (AEs), 
signs and symptoms of malaria infection, and blood collected for 18S qPCR 
measurement of parasitemia.  
The threshold for commencement of apheresis and treatment with artemether-
lumefantrine was within 24 hours of a parasitemia >20,000 parasites/mL or the 
malaria clinical score reaching >6 (appendix 3) or at the Investigator’s discretion. 
The morning that this threshold was reached (anticipated based on previous studies 
to be Day 10 or 11179, subjects were admitted to the clinical unit (Q-Pharm) for 
initial safety assessments before being escorted to the Apheresis Unit at RBWH by 
Q-Pharm staff. The Apheresis Unit is located in the Haematology Department at 
RBWH where patients are subject to donor or therapeutic apheresis. At the 
Apheresis Unit the subjects underwent the apheresis procedure as per the Standard 
operating procedure (SOP) (appendix files 4 to 7) whilst being supervised by the 
apheresis specialist nurse and under the supervision of the responsible clinical 
haematologist. The apheresis specialist nurse was responsible for writing all SOPs. 
The same apheresis nurse performed the apheresis procedure for all four subjects. 
The apheresis procedure lasted 1-4 hours. Subjects were then escorted back to the 
clinical unit and began treatment with artemether-lumefantrine (Riamet®, Novartis 
Pharmaceuticals Australia Pty Ltd). Treatment consisted of six doses of 4 tablets at 
12 hourly intervals (each tablet contains 20 mg artemether and 120 mg of 
lumefantrine). Subjects remained confined within the clinical unit for 48-72 hours 
for safety monitoring. Following release from confinement, subjects attended 
protocol specified visits until three months post treatment to monitor for signs of 
parasite recrudescence and to assess late safety signals. A schematic of the study 
design is shown in Figure 2. 
  





Figure 2. Schematic of Apheresis study 
 
Schematic illustrating the main study activities. 
This study used an iterative adaptive design approach where subject safety and 
outcome data were analysed after each subject and modifications made to improve 
the chances of meeting the study objectives in the subsequent subject. A summary of 
the changes instituted is shown in Table 7. 





Table 7. Summary of main study design differences between subjects 
 Subject 1 Subject 2 Subject 3 Subject 4 
Apheresis procedure  CMNC CMNC CMNC Red cell depletion followed by CMNC on red cell 
depletion product 
HCT layers sampled 1%, 2%, 3%, 5%, 7% 1%, 2%, 3%, 
5%, 7% 
0.5 %, 1%, 2%, 3%, 
5%, 7%, 11%, 2-3%, 
5-7%, 1-7% 
From the primary apheresis (HCT):  Intermediate (64%) 
From the secondary apheresis (HCT): Final (3%) Spare 
(5%) Waste (42%) 
Apheresis timepoint 10 10 11 PM 11 AM 
Mosquito feeding assay 
samples 
Pre-apheresis (with-
percoll enrichment), 1%, 







Pre-apheresis (without-percoll enrichment), 
Intermediate, Final, Waste 
Whole blood:citrate 
ratio during apheresis 
15:1 8:1 8:1 13:1 
Citrate added to 
apheresis collection bags 
No Yes Yes Yes 
Biological duplicates* No No Yes Yes 
CMNC; continuous mononuclear cell collection, HCT; haematocrit. Protocols for subjects 1 to 4 and all experiments can be found in appendix 4 
to 11. *Biological duplicates involved repeat 18S qPCR testing from two separate blood samples from each HCT layer collected using apheresis. 
Table summarising the key differences in planning across each of the four subject cohorts during the clinical component of the study.  





Clinical and laboratory SOPs for cohorts 1 to 4 and all experiments can be found in 
appendix 4 to 11. Results for cohorts 1 to 4 and all experiments are located in the 
results chapter. The below table outlines the contributions provided by QIMR 
Berghofer researchers during the laboratory components of the study: 
Table 8. Summary of contributions provided by QIMR Berghofer researchers 
Researcher Apheresis cohort laboratory activities 
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Table outlining the contributions provided by QIMR Berghofer researchers during 
the laboratory components of the study. 
MALARIA INOCULUM 
The P. falciparum NF54 clone was used in the pre-clinical stage183. The P. vivax 
HMP013 was derived from blood group O rhesus positive blood donated from a 





returned traveller from India who presented with clinical manifestations of 
malaria179. The inoculum was prepared as previously described184. 
MEASUREMENT OF PARASITEMIA 
Parasitemia was quantified using 18S qPCR targeting a highly conserved 
Plasmodium 18S ribosomal RNA gene66, 185. Quantitative reverse transcriptase PCR 
(qRT-PCR) assays were used to measure gametocytemia with assays targeting the P. 
falciparum pfS25 and pfMGET, male and female gametocyte mRNA transcripts186 
respectively and P. vivax pvS25 gametocyte mRNA transcripts187. 
MICROSCOPY 
Slides were produced using Giemsa stain and examined by microscope under 100× 
oil immersion objective. Thick and thin slides were examined by level 1 or 2 World 
Health Organisation (WHO) certified microscopists. Apheresis samples were 
expected to have a significantly different composition in terms of proportions of red 
blood cells (RBCs) and white blood cells (WBCs) when compared to whole blood 
(e.g. RBCs make up 1% and approximately 46% of 1% HCT and whole blood 
samples respectively). As such traditional parasitemia measures were not feasible. 
FLOW CYTOMETRY 
Flow cytometry, using the CD71-APC antibody, was performed to characterise 
reticulocytes present in samples collected during the apheresis process in subject 4. 
MOSQUITO FEEDING ASSAYS 
Transmissibility of pre-apheresis samples and post-apheresis samples to Anopheles 
stephensi mosquitoes was evaluated using membrane feeding assays (MFA)73, 179. 
For enriched MFA (eMFA), gametocytes present in 80 mL of whole blood (pre-
apheresis) were enriched in 70% percoll gradient. For direct MFA (DMFA), 650 μL 
of pellet from whole blood (pre-apheresis) or from each apheresis sample was 
reconstituted to 50% HCT with AB+ serum. Infection in midguts was assessed by 
qPCR188 8 days after the feeding assays. For logistic reasons, eMFA was not carried 
out in subject 4. Following consideration of gametocyte levels, DMFA was not 
carried out in subject 2.   






Apheresis was carried out using a Spectra Optia v11.3 apheresis system (Terumo 
BCT, Inc Tokyo Japan). 
STATISTICAL ANALYSIS 
All measured variables and derived values were listed. Continuous data was 
summarised using descriptive statistics (mean and SD, or median and IQR). 
Categorical data was presented using N and % (using the number of subjects without 
missing data in the calculation). Unless otherwise stated, Microsoft Excel® version 




The feasibility of extracting Plasmodium parasites from blood using apheresis was 
initially assessed using cultured P. falciparum parasites. The 1% HCT layer 
contained the greatest concentration of all parasites as determined by 18S qPCR, 
with a 1.3-fold concentration of all parasites and a 3.7 and 8-fold concentration for 
female and male gametocytes, compared to pre-apheresis (whole blood)(Figure 3). 
The 2% HCT layer contained the greatest concentration of asexual parasites by 
microscopy (2.7-fold concentration; Figure 4A). The highest concentration of 
gametocytes detected by microscopy was seen in the 1% HCT layer (76-fold ; Figure 
4B). Both asexual parasites and gametocytes were also visualised by microscopy in 
the 1%, 3% and 5% HCT layers (Figure 4B). These results demonstrated the 
technical feasibility of the approach and the experiment was allowed to proceed to 
the clinical stage. 
  













































































































































HCT; haematocrit. Fold enrichment of qPCR seen in samples taken during apheresis 
compared to the pre-apheresis sample. 3A 18S qPCR/mL for asexual P. falciparum 
parasites, 3B pfS25 qPCR/mL for female P. falciparum gametocytes and 3C 
pfMGET qPCR/mL for male P. falciparum gametocytes. 
  





















































































































HCT; haematocrit. 4A microscopy of samples taken during apheresis showing levels 
of asexual parasites and gametocytes compared to the pre-apheresis sample. 4B 
staging of gametocytes identified during microscopy of samples taken during 
apheresis. Pre-apheresis sample did not contain any gametocytes. 
CLINICAL EXPERIMENT 
All subjects became PCR negative for parasites within 72 hours of treatment 
initiation.  
In order to meet the study objectives an iterative approach to study design was 
implemented. A summary of the key differences in the planning of the clinical trial 
in each of the four subject cohorts is shown in Table 7. Changes to study design for 
the subsequent subject cohort were made following review of previous subject data. 
To prevent sample clotting observed in apheresis collection bags from subject 1, 
subjects 2, 3 and 4 received higher concentrations of citrate during apheresis and 
citrate was directly added to apheresis collection bags pre-apheresis. Subjects 1 and 
2 were treated with artemether-lumefantrine 10 days post malaria inoculation. In an 
attempt to augment pre-apheresis parasitemia, treatment of subjects 3 and 4 was 
delayed to day 11. Biological duplicates were employed in subject cohorts 3 and 4 to 
improve the validity of results based on low level parasitemia findings in subjects 1 
and 2. Sampling below 1% HCT and above 7% HCT layer occurred in subject 3 as 
these layers had not been sampled previously. A red cell collection stage was added 





to the apheresis procedure in subject 4. During cohort 4 a RBC depletion was carried 
out in an attempt to target greater reticulocyte concentration, producing an 
intermediate bag sample, followed by a second apheresis procedure on the red cell 
depletion product. The second apheresis procedure involved sampling of ~100 mL of 
the lowest HCT layers of the sample (final bag) followed by ~100 mL of the 
subsequent lowest HCT layers (spare bag) and then the remainder (waste bag) 
(Figure 5). A schematic of the sampling that occurred during cohort 4 is shown 
below.  
  





Figure 5. Schematic of cohort 4 sampling 
 
PMN; polymorphonuclear. Schematic illustrating the origins of the pre-apheresis, 
intermediate, final, spare and waste samples collected during cohort 4. Cohort 4 
involved two consecutive apheresis procedures. The first was a RBC collection 
conducted on the human subject. A continuous mononuclear cell collection (CMNC) 
was then conducted on the RBC collection bag.





Figure 6. Parasite growth curves 

















Subject 1 (apheresis day 10)
Subject 2 (apheresis day 10)
Subject 3 (apheresis day 11)
Subject 4 (apheresis day 11)
 
Parasitemia as measured by 18S qPCR in all four subjects presented using a 
logarithmic scale. Day 0 represents the day of inoculation. Apheresis occurred on 
day 10 for subjects 1 and 2, and day 11 for subjects 3 and 4.  
SAFETY FINDINGS 
A total of 68 AEs occurred in the 4 subjects (Table 9). No Serious AEs were 
reported. The majority of AEs were mild or moderate. Five severe AEs occurred in 4 
subjects: one episode of neutropenia (0.68 × 109/L [0.45 × LLN]; duration 8 days), 
two of lymphopenia (0.43 × 109/L [0.43 × LLN] and 0.33 × 109/L [0.33 × LLN]; 
both lasting 3 days), and two of fever (both 40.2°C; duration 30 minutes and 25 
minutes). All severe AEs were transient and resolved by the end of the study. The 
majority of AEs (54/68; 79.4%) were attributed to malaria, while 9/68 (13.2%) were 
attributed to apheresis. These included neutropenia (one subject nadir 0.68 × 109/L) 
which was recorded as three separate AEs due to changes in the common 
terminology criteria for adverse events (CTCAE) grading, two cases of lymphopenia 
(nadir 0.33 × 109/L and 0.75 × 109/L) and two cases of leukopenia (nadir 2.2 × 109/L 
and 2.4 × 109/L). One subject had an episode of herpes labialis (herpes simplex 





virus-1 PCR positive). One subject experienced mild hypophosphatemia (0.70 
mmol/L) of two days duration.  
  





Table 9. Summary of the main safety findings  
 Subject 1 Subject 2 Subject 3 Subject 4 Total AEs 
SAEs 0 0 0 0 0 
AEs 20 13 15 20 68 
AEs related to 
malaria 
13 8 14 19 54 
AEs related to 
apheresis 
2 3 0 4 9 
Max temp °C 40.2 38.8 40.2 39.6 N/A 
Max malaria 
clinical score 
8 1 2 7 N/A 
Ibuprofen use 400 mg × 5 400 mg × 
5 
400 mg × 
5 
nil N/A 
Acetaminophen use 1 g × 4; 500 
mg × 1 
1 g × 2 1 g × 4 500 mg × 
2; 1 g × 2 
N/A 
Peak ALT (IU/L) 111 118 47 80 N/A 
Peak AST (IU/L) 83 57 42 44 N/A 
Platelet Nadir (× 
109/L) 
119 98 99 75 N/A 
Maximum drop in 
haemoglobin from 
baseline (g/L) 
17 9 25 20 N/A 
Lymphocyte Nadir 
(× 109/L) 
0.33 0.43 0.58 0.75 N/A 
Peak parasitemia 
(parasites/mL) 
15,943 35,156 64,243 44,431 N/A 
SAE; serious adverse event, AE; adverse event, ALT; alanine transaminase, AST; 
aspartate transaminase.  
Summary of the main safety findings encountered during the study. 






The RBC counts of the various HCT layers were generally in alignment with what 
would be expected (Table 10), except in two subjects. In subject 2 the RBC counts of 
the 2% HCT layer were closer to what would be expected from a 3% HCT layer and 
vice versa, and the 8% HCT sample in subject 3 had a HCT of 11%. The cell 
composition of samples collected using apheresis in subjects 1 to 3 (Figure 7A) 
showed an ~60 to 170-fold decrease in the RBC:WBC ratio from pre-apheresis 
samples compared to apheresis samples. Among samples collected by apheresis from 
subject 4, where a double apheresis process was undertaken, the RBC:WBC ratio 
was close to that of the pre-apheresis sample (Figure 7B), with the exception of the 
final bag sample (3% HCT). Reticulocyte counts measured on the Sysmex analyser 
were highest in subject 2: 0.23 × 109/L (reference range for whole blood: 25-120 × 
109/L). 
  





Table 10. HCT and RBC counts 
Subject Sample Type HCT RBC Count (× 106/L)  
1 Pre-apheresis 0.38 4.35 × 103 
1% HCT 0.01 1.40 × 102 
2% HCT 0.02 1.90 × 102 
3% HCT 0.03 3.00 × 102 
5% HCT 0.04 4.30 × 102 
7% HCT 0.05 5.90 × 102 
2 Pre-apheresis 0.41 4.81 × 103 
1% HCT 0.01 2.00 × 102 
2% HCT 0.03 3.50 × 102 
3%HCT 0.03 2.60 × 102 
5% HCT 0.03 4.30 × 102 
7% HCT 0.05 5.00 × 102 
3 Pre-apheresis 0.44 5.34 × 103 
0.5% HCT 0.01 7.00 × 10 
1% HCT 0.01 1.40 × 102 
2% HCT 0.01 1.50 × 102 
3% HCT 0.03 3.50 × 102 
5% HCT 0.04 4.40 × 102 
7% HCT 0.07 7.70 × 102 
*8% HCT 0.11 1.23 × 103 
2-3% HCT 0.02 2.60 × 102 
5-7% HCT 0.05 6.10 × 102 
0.5-8%* HCT 0.04 4.50 × 102 
4 Pre-apheresis 0.46 5.22 × 103 
Intermediate sample 0.64 7.18 × 103 
Final sample 0.03 2.90 × 102 
Spare sample 0.05 4.80 × 102 
Waste sample 0.42 3.94 × 103 
HCT; haematocrit, RBC; red blood cell 





*8% HCT was subsequently renamed as 11% HCT given the Sysmex HCT result. 
HCT and RBC count results for samples taken pre-apheresis and during apheresis in 
subjects 1 to 4. 



























































































































HCT; haematocrit, RBC; red blood cell, WBC; white blood cell. RBC/WBC ratio 
results for samples taken pre-apheresis and from the 1% HCT, 2% HCT, 3% HCT, 
5% HCT and 7% HCT layers during apheresis from subjects 1 to 3 (7A). The 
apheresis samples selected for the figure were those that were sampled across all 3 
subjects. Subject 4 was not included as the composition of samples differed 
significantly from subjects 1 to 3. RBC/WBC ratio results for samples taken pre-
apheresis and during apheresis from subject 4 (7B).  
CONCENTRATION OF ASEXUAL PARASITES 
No single HCT layer contained >40% of all the recovered P. vivax asexual parasites 
(Figure 8). An increase in parasite concentration occurred as HCT increased in 
subjects 1 to 3 (Figure 8A), with some variation in relative enrichment of parasites in 
apheresis samples compared to pre-apheresis samples at any given HCT (Figure 8A). 
The highest concentration achieved was a 4.9-fold increase in parasite density in the 
7% HCT layer in subject 1 (Figure 8A and appendix 12 Table 1). There was no 
apparent concentration of parasites when the procedure was modified to include a 
second apheresis process (subject 4; Figure 8B and appendix 12 Table 1).  














































































































































HCT; haematocrit. Fold enrichment of parasites as determined by 18S qPCR in 
samples collected using apheresis compared to the pre-apheresis samples in subjects 
1 to 3 (8A) and subject 4 (8B). 
When parasite concentration was adjusted for RBC count, all apheresis samples 
collected from subjects 1 to 3 demonstrated enrichment for asexual parasites 
compared to pre-apheresis (Figure 9A). In general, when parasite counts were 
corrected for RBC count, parasite enrichment was highest in the low HCT samples 
with the highest enrichment detected in the 0.5% HCT sample in subject 3 (138-fold 
compared to pre-apheresis; Figure 9A and appendix 12 Table 1). The relative 
concentration of parasites from subject 4, where the second apheresis procedure was 
performed, was observed in the lowest HCT samples. In particular, the final bag (3% 
HCT) and the spare bag (5% HCT) samples had relative enrichment levels of 20 and 
8-fold respectively compared to pre-apheresis (Figure 5B and appendix 12 Table 1). 
  




























































































































































HCT; haematocrit, RBC; red blood cell. Fold enrichment of parasites corrected for 
RBC counts as determined by 18S qPCR in samples collected using apheresis 
compared to the pre-apheresis sample in subjects 1, 2 and 3 (9A) and subject 4 (9B). 
CONCENTRATION OF GAMETOCYTES 
Analysis of the apheresis samples from subject 4, where the double apheresis process 
was undertaken, demonstrated an increase in the level of female gametocytes of 
1.45-fold compared to pre-apheresis, as determined by levels of the gametocyte-
specific transcript pvS25 qRT PCR (Figure 10B and appendix 12 Table 2). 
Subjects 1, 2 and 3 demonstrated a reduction in the level of female gametocytes 
compared to pre-apheresis (Figure 10A and appendix 12 Table 2). In most cases the 
reduction was >10-fold. Percoll concentration of whole blood taken pre-apheresis 
resulted in a significant (up to 45-fold in subject 3) enrichment of pvS25 compared to 
pre-apheresis samples not treated with percoll (Figure 10C and appendix 12 table 2).  
  
































































































































































































































HCT; haematocrit. Fold enrichment of female P. vivax gametocytes determined by 
pvS25/mL in samples collected using apheresis compared to the pre-apheresis 
sample in subjects 1, 2 and 3 (10A) and subject 4 (10B). Fold enrichment of female 
P. vivax gametocytes determined by pvS25/mL in samples collected using apheresis 
compared to the pre-apheresis sample and pre-apheresis samples treated with percoll 
in subjects 1, 2 and 3 (10C).  
When gametocyte concentrations were corrected for RBC counts, enrichment levels 
were generally higher in the lower HCT samples (Figure 11A and 11B and appendix 
12 Table 2). Relative enrichment of gametocytes in subjects 1, 2 and 3 was lower 
than for total parasites, with a maximum enrichment of 6.2-fold in the 0.5% HCT 
layer (appendix 12 Table 2). In subjects 3 and 4 enrichment relative to RBC count 
was observed (Figure 11A and 11B). In subject 4, the greatest enrichment of 
gametocyte transcripts in the double apheresis process was observed in the spare bag 
(5% HCT) with an enrichment of 6.1-fold (Figure 11B and appendix 12 Table 2). 
































































































































































HCT; haematocrit, RBC; red blood cell. Fold enrichment of female P. vivax 
gametocytes corrected for RBC counts determined by pvS25 of samples collected 
using apheresis compared to the pre-apheresis sample in Subjects 1 , 2 and 3 (11A) 
and subject 4 (11B). 
Asexual parasites and gametocytes were increased in whole blood samples taken 
post apheresis compared to pre-apheresis across all cohorts (Figure 12). 
  





Figure 12. asexual parasites/mL and gametocytes/mL pre and post apheresis 

















































































Change in 18S qPCR/mL (12A) and pvS25 qPCR/mL (12B) from whole blood 
samples taken pre- and post-apheresis. 
All subjects experienced an increase in asexual parasitemia and gametocytemia 
between samples taken pre- and post-apheresis. 
FLOW CYTOMETRY 
In subject 4, where CD71 antibody staining was used to identify reticulocytes, the 
highest levels of reticulocytes (CD71+ cells) were observed in the final bag (3% 
HCT) and the spare bag (5% HCT) (Figure 13). Microscopic analysis of these 
samples suggested that the reticulocyte population detected by flow cytometry 
consisted of uninfected reticulocytes. No parasitised RBCs or reticulocytes could be 
detected by flow cytometry. 
  

































































































HCT; haematocrit, RBC; red blood cell. The percentage of (CD71+) reticulocytes 
from subject 4.  
MICROSCOPY 
The high concentration of WBCs in apheresis samples meant many of the thick and 
thin blood smears were extremely difficult to read (Tables 11 and 12). Among 
samples where it was possible to read the films, parasite counts were low, and in 
alignment with the counts obtained by qPCR (Tables 11 and 12). Notwithstanding 
the technical difficulties in reading the slides and the low parasite counts, no 
apparent concentration of parasites was observed in any of the apheresis samples 
compared to pre-apheresis. The 3% HCT sample in subject 3 contained 7 parasitised 
cells compared to 0 in the pre-apheresis sample and the 1% HCT sample in subject 1 
demonstrated a 4-fold increase in the number of visualised parasites compared to 
pre-apheresis. In general, higher parasite numbers were seen in the lower HCT 
layers. The vast majority of parasitised RBCs contained ring form parasites, with 
trophozoites and gametocytes observed in samples from subjects 3 and 4 only 
(Tables 11 and 12). 





Table 11. Microscopy findings for subjects 1 to 3 
Sample Subject 1 Subject 2 *Subject 3 
 













film Thick film 
Thin film 




0 17 0 
Percoll Feed unreadable 1 ring n/a 0 n/a 0 70 unreadable 
0.5% HCT unreadable n/a n/a n/a n/a n/a unreadable  unreadable 




1 ring unreadable  unreadable 
2% HCT unreadable 1 ring 1 ring 1 ring 2 
rings 
0 unreadable  1 
3% HCT unreadable 0 0 1 ring 0 0 unreadable  7 
5% HCT unreadable 0 1 ring 0 1 ring 0 unreadable  4 
7% HCT unreadable 0 1 ring 0 1 ring 0 unreadable  1 
11% HCT unreadable n/a n/a n/a n/a n/a unreadable  0 
2-3% HCT unreadable n/a n/a n/a n/a n/a unreadable  12 
5-7% HCT unreadable n/a n/a n/a n/a n/a unreadable  6 
0.5-11% HCT unreadable n/a n/a n/a n/a n/a unreadable  0 
HCT; haematocrit. Two microscopists reviewed thick and thin films from subject 2. 
Subjects 1 and 3 involved only one microscopist who reviewed both thick and thin 
films. 
*Microscopist did not specifically document the type of parasites in each sample but 
simply commented there were “rings and trophozoites and a single gametocyte”.  
Table summarising microscopy findings from samples taken pre- and during 
apheresis in subjects 1, 2 and 3. 
  





Table 12. Microscopy findings for subject 4 
Sample (HCT) Reader 1 thick film Reader 2 thick film Reader 3 thin film 
Pre-apheresis (46%) 7 rings 6 trophozoites  
2 female gametocytes 
1 trophozoite 
Intermediate (64%) 3 trophozoites 6 trophozoites n/a 
Final (3%) n/a 4 trophozoites n/a 
Spare (5%) n/a n/a n/a 
Waste (42%) 3 trophozoites 2 rings 8 trophozoites 1 trophozoite 
HCT; haematocrit. Two microscopists reviewed the thick films and one the thin 
films from subject 4.  
Table summarising microscopy findings from samples taken pre- and during 
apheresis in subject 4. 
 
MOSQUITO TRANSMISSION 
Membrane feeding of pre-apheresis or post percoll enrichment samples were 
undertaken in all 4 subjects, but for logistical reasons membrane feeding on 
apheresis samples could only be undertaken in subjects 1 and 4 (Table 13).  
None of the samples from subject 1 or 2 resulted in successful mosquito transmission 
(Table 13). In subject 3, the infection rate from the percoll-enriched sample was 5.8-
fold higher than the infection rate from pre-apheresis sample (99% vs 17.2% [Table 
13]). Likewise, in subject 4, the infection rate from the final bag (3% HCT) was 5.5-
fold higher than the infection rate from either the pre-apheresis sample or the 
intermediate bag (64%HCT) (pre-apheresis: 3.6%, intermediate bag: 4%, final bag: 
20% [Table 13]).  
The final sample bag (3% HCT) in subject 4 was the only sample obtained using 
apheresis that demonstrated an increase in transmission over samples obtained pre-
apheresis. Due to logistic issues the spare bag (5% HCT), which contained the 
greatest enrichment for gametocytes compared to pre-apheresis when adjusted for 
RBC counts in subject 4 (Figure 11B) was not subject to membrane feeding. 











Table 13. Mosquito infection rates following membrane feeding assays 



























Feeding rate (No. 
mosquitos fed/No. 








[98.3%] 75/77 [97.4%] 102/103 [99%] 
107/107 





Mortality rate (No. 
dead mosquitos/No. 




























HCT; haematocrit. Only subjects 1 and 4 involved the testing of samples collected using apheresis. For logistic reasons, eMFA was not carried 
out in subject 4. Following consideration of gametocyte levels, DMFA was not carried out in subject 2. Reported parameters include feeding rate 
of mosquitoes, adult mosquito mortality rate after feeding and mosquito infection rate.  
*MFA without percoll enrichment to save on blood volume draw for safety reasons.  






Table summarising membrane feeding assay findings from samples taken pre-apheresis both with and without percoll enrichment and during 
apheresis across all subjects. 





ADDITIONAL 18S QPCR TESTING OUTSIDE OF APHERESIS SAMPLES 
To investigate for possible accumulation of parasites in the magnets and tubing 
structures in the apheresis cassette, qPCR testing was carried out on three blood clots 
with diameters of up to 1 cm found near two magnets, and a silo like structure that 
formed part of the single use apheresis tubing and processing cassette from subject 3 
(Figure 14). Clots were thoroughly homogenised and tested by 18S qPCR. The 
greatest enrichment observed relative to pre-apheresis was 1.4-fold in the apheresis 
cassette magnet 2 sample (Figure 15). 
To investigate whether haemolysis may be taking place in the apheresed blood 
resulting in release of parasite DNA into the extracellular fluid, plasma from 
apheresis samples in subject 3 was collected by centrifugation of the sample, with 
the plasma subject to 18S qPCR testing. However, no significant accumulation of 
parasite DNA was detected in the plasma compared to pre-apheresis (Figure 15). 
  




Figure 14. Apheresis single use cassette 
 
Example of an intermediate density layer apheresis single use casette used during 
apheresis. The 2 magnets and silo structure, where blood clots were found following 
subject 3’s apheresis procedure, are identified. Blood clots subsequently underwent 









Figure 15. Subject 3 additional testing for enrichment of parasites/mL 
































































































































































































Fold enrichment of 18S qPCR/mL, compared to pre-apheresis, of blood clots around 
magnet 1, magnet 2, and silo within the apheresis cassette and of post-centrifugation 
plasma originating from the collection bag during subject cohort 3. 
DISCUSSION 
SUMMARY 
Using apheresis it was possible to achieve modest concentration of both asexual and 
gametocyte stages of P. vivax. However, the modest level of parasite enrichment 
(4.9-fold and 1.45-fold per mL of sample for asexual parasites and gametocytes 
respectively) was insufficient to meet the objectives for the collection of parasites for 
downstream research. 
PRE-CLINICAL EXPERIMENT 
Apheresis successfully extracted malaria parasites from venesected blood infected 
with P. falciparum. RBCs in the 1% HCT layer were more likely to be infected with 




asexual parasites than in any other HCT layer that was sampled. Analysis of the P. 
falciparum gametocyte markers pfMGET qPCR and pfS25 qPCR suggest male and 
female gametocytes concentrate greatest in the 1% HCT layer, with an increase of 8 
and 2.7-fold per mL of sample respectively when compared to pre-apheresis. 
Interestingly gametocytes were only visualised in the 1%, 3% and 5% HCT layers, 
although gametocyte qPCR markers were positive in all samples. This could be 
explained by different gametocyte stages preferentially depositing at different HCT 
layers as can be seen in figure 4B. Alternatively this could simply be due to chance 
as the % parasitemia in all samples were relatively low.  
This preliminary experiment provided a guide for the location of asexual parasites 
and gametocytes for the clinical experiments. However, it was anticipated that RBCs 
infected with P. vivax, being larger than P. falciparum infected RBCs, would 
concentrate at different HCT layers compared to P. falciparum189. Moreover, blood 
from an infected subject may behave differently to uninfected whole blood, used 
during the pre-clinical experiment, as a result of malaria related inflammation and 
effects on blood coagulation190. Hence, during cohort 1 of the clinical experiment 
samples were again obtained from 1%, 2%, 3%, 5% and 7% HCT layers. 
SAFETY FINDINGS 
Safety data suggest that apheresis in healthy subjects infected with blood stage P. 
vivax parasites is safe (Table 9). No serious adverse events were encountered, with 
all adverse events having resolved by the end of study. The majority of adverse 
events were malaria related, and in line with previous P. vivax IBSM studies60, 72. 
Adverse events related to apheresis were largely asymptomatic transient reductions 
in haematology parameters. Safety data must be interpreted with caution given the 
low numbers of subjects. Going forward, in the context of P. vivax IBSM, it would 
be advised that this procedure should ideally only be carried out in subjects with 
normal haemoglobin, lymphocyte and platelet counts at screening to avoid potential 
complications or the need for blood transfusion. 





HAEMATOCRIT AND RED BLOOOD CELL COUNT 
Sysmex haemocytometer reports HCT to an accuracy of 0.01 (with 1% HCT = 0.01) 
thus there is a potential for a rounding error. The effects of any potential rounding 
error would be magnified at lower HCT layers. However in general RBC count data 
supported the accuracy of the samples selected during the experiments by the 
apheresis nurse (Table 10). 
RED BLOOD CELL TO WHITE BLOOD CELL RATIO  
Figures 7A and 7B demonstrate the RBC/WBC composition of samples collected 
using apheresis from subjects 1 to 3 and subject 4 respectively. The most striking 
finding is the difference in RBC/WBC ratio seen in pre-apheresis samples compared 
to samples obtained via apheresis in subjects 1 to 3 (Figure 7A). This is due to a 
combination of the reduction in RBC count and increase in WBC count compared to 
whole blood obtained pre-apheresis. In general as the HCT increases the RBC/WBC 
ratio increases (Figure 7A).  
CONCENTRATION OF ASEXUAL PARASITES 
No single HCT layer was seen to concentrate all or even a majority of P. vivax 
asexual parasites. The greatest concentration of parasite/mL of sample was seen in 
the 7% HCT layer in subject 1. Subject 3 was the only subject where direct apheresis 
sampling occurred above the 7% HCT layer. In this subject the greatest enrichment 
was observed in 11% HCT layer which is the highest HCT layer that was sampled, 
but the increase in enrichment between 7% HCT and 11% HCT layers was relatively 
moderate from 3.1 to 4.0-fold.  
In line with the existing literature, when adjusted for RBC count, asexual parasites 
were found in higher numbers in the lower HCT level191. The greatest enrichment 
compared to whole blood obtained pre-apheresis was an increase of 138-fold and 
occurred in the 0.5% HCT sample. Therefore a RBC from the 0.5% HCT sample 
was 138 times more likely to be parasitised than a RBC from the pre-apheresis 
sample. The level of enrichment observed in the 0.5% HCT sample should be 
interpreted with caution as this is based on a single sample. The 1% and 2% HCT 
layers were sampled from subjects 1 to 3. The level of enrichment between cohorts 




varied from 21 to 74-fold and 15 to 74-fold for the 1% and 2% HCT samples 
respectively. The level of variation calls into question the reproducibility of results in 
future experiments.  
The total number of RBCs in the apheresis samples were much lower than in pre-
apheresis samples (Table 10). Hence the total numbers of infected RBCs in any one 
apheresis sample were only moderately increased compared to whole blood obtained 
pre-apheresis. 
The findings in subject 4 were consistent with subjects 1 to 3 with the greatest 
concentration of asexual parasites/RBC occurring in the samples with the lowest 
HCT, namely the final bag (3% HCT) and the spare bag (5% HCT) samples, which 
experienced enrichments of 20 and 8-fold respectively compared to pre-apheresis 
(Figure 9B). The level of enrichment for the 3% HCT layer (final bag) from subject 
4 was lower but still comparable to the level of enrichment seen in the 3% HCT 
samples obtained from subjects 1 to 3. Whereas the level of enrichment for the 5% 
HCT layer (spare bag) from subject 4 was less than the level of enrichment seen in 
the 5% HCT samples obtained from subjects 1 to 3. Therefore, the addition of a RBC 
collection stage did not improve the yield of asexual parasites/RBC.   
CONCENTRATION OF GAMETOCYTES 
Subject 4 was the only subject where there was an increase in gametocytes/mL 
compared to pre-apheresis (Figure 10B). An increase of 1.45-fold was observed in 
the intermediate bag. The intermediate bag had a RBC count of 7.18 × 1012/L 
compared to 5.22 × 1012/L for pre-apheresis. 7.18 × 1012/ 5.22 × 1012 = 1.38. Hence, 
the 1.45-fold enrichment seen in the intermediate bag may simply represent an 
overall increase in the number of RBCs in the intermediate bag compared to pre-
apheresis whole blood. Percoll enrichment of gametocytes is far greater than 
enrichment seen during apheresis.   
As with asexual parasites, when corrected for RBC count gametocytes were 
generally higher in the lower HCT samples (Figure 11A and 11B) again in line with 
the existing literature191. From subjects 1 to 3 it was only subject 3 that saw 
significant enrichment of gametocytes (Figure 11A). This may be explained by the 
apheresis procedure taking place 11 days post inoculation in subject 3 as opposed to 




10 days post inoculation for subjects 1 and 2, thus resulting in more time for 
gametocyte maturation and a higher pre-apheresis parasitemia relative to subjects 1 
and 2. Conversely subject 2 actually had a higher post-apheresis gametocytes/mL 
count than subject 3. However this could represent a higher proportion of schizonts, 
containing greater copy numbers of pvS25 qPCR in subject 2 than subject 3, 
therefore pvS25 qPCR/mL results do not represent increased numbers of 
gametocytes but rather increased copy numbers of pvS25 qPCR192. The enrichment 
of gametocytes/RBC in subjects 1 to 3 was much more modest than with asexual 
parasites/RBC (up to 6-fold in 0.5% HCT layer).  
In contrast to asexual parasites/RBC, the greatest enrichment of gametocytes/RBC 
was observed in the spare bag (5% HCT) in subject 4 with an enrichment of 6.1-fold 
(Figure 11B). This contrasts with the low level or negative enrichment seen in 
subjects 1 to 3 at the 5% HCT layer. Suggesting that carrying out an initial RBC 
collection stage does enhance the enrichment of gametocytes/RBC compared to 
direct sampling from subjects using apheresis.  
In all four subjects, whole blood samples taken post-apheresis via venesection 
contained greater asexual parasite and gametocyte numbers per mL compared to pre-
apheresis whole blood samples taken via venesection. If apheresis was successful in 
capturing and concentrating P. vivax parasites, we would have expected to see a 
decrease. The increase could be explained by parasite maturation with an increased 
proportion of schizonts192, 193. However this explanation seems unlikely as apheresis 
occurred on different days depending on the subject (day 10; subject 1 and 2, and 
day 11; subject 3 and 4) and therefore the parasite stage would also be expected to 
differ. Moreover apheresis procedure only took 1 to 4 hours giving only a small 
window for parasite maturation.   
MICROSCOPY 
Samples that were of sufficient quality and composition to be able to be read 
demonstrated only small numbers of parasitised RBCs. In general there was a spread 
of parasitised RBCs across the various samples. Apheresis samples did not 
demonstrate significant parasite concentration compared to pre-apheresis. 
Microscopy findings mirrored those seen with qPCR. Most of the parasites seen 
using microscopy were ring forms, with trophozoites and gametocytes observed in 




subjects 3 and 4. Both of these cohorts took place on day 11 compared to day 10 for 
subjects 1 and 2, thus explaining the presence of more mature life cycle stage 
parasites. Microscopy results suggest any enrichment of parasites from apheresis is, 
at best, modest which again supports the findings observed with qPCR. 
MOSQUITO FEEDING 
An enhanced level of transmission to mosquitoes compared to whole blood samples 
collected pre-apheresis was only observed on one occasion (final sample bag [3% 
HCT] in subject 4), corresponding to the higher gametocyte concentration in this 
sample compared to the pre-apheresis whole blood (Figure 11B). A possible 
explanation of the low success in the transmission studies was the difficulty in 
maintaining tight temperature control to prevent exflagellation of male 
gametocytes194, thereby negatively impacting gametocyte infectivity195. Blood was 
most vulnerable to a temperature drop whilst in the apheresis equipment itself. It was 
not possible to heat the apheresis equipment, and it was deemed impractical to heat 
the room where apheresis took place to >35°C. Temperature monitoring was not 
possible during the experiments. However, the demonstration of transmission 
success in the final bag (3% HCT) indicates that at least some gametocytes were 
maintained within a temperature range that did not trigger exflagellation. Regardless 
of the underlying cause, recent reports of success in improving concentration of 
gametocytes and enhanced transmission by either percoll196 or magnetic bead197 
enrichment suggests that such methods are superior to apheresis for concentration of 
gametocytes for mosquito transmission experiments. 
ADDITIONAL 18S QPCR TESTING OUTSIDE OF APHERESIS SAMPLES 
It was hypothesised that the magnets within the apheresis equipment (Figure 15) 
may have concentrated parasitised RBCs containing hemozoin198. This greatest level 
of enrichment observed (1.4-fold in the magnet 2 sample) was insufficient to explain 
the low levels of parasite concentration in apheresis samples. pvS25 qPCR was not 
carried out as gametocytes are detected by the 18S qPCR assay and for reasons of 
cost193. 




Haemolysis within the apheresis blood collection bags is not the reason behind the 
poor enrichment of parasites compared to pre-apheresis (Figure 15). There was no 
way to test for the occurrence of haemolysis within the apheresis equipment. 
RETICULOCYTE ANALYSIS 
Following analysis of the data collated from subjects 1 to 3, it was hypothesised that 
the moderate enrichment of parasitised RBCs was due to absence of reticulocyte 
enrichment (P. vivax exclusively invades reticulocytes36). Instead of enriching for 
reticulocytes by selecting the layer in which they are commonly found (2% and 3% 
HCT191), the apheresis procedure resulted in replacement of uninfected RBCs, 
responsible for diluting reticulocytes (approximately 1% of whole blood199) in whole 
blood, with WBCs. Hence, in order to enrich for reticulocytes the experimental plan 
for subject 4 was altered. A RBC collection from the infected subject took place in 
the first instance. This ensured the subsequent product contained very little WBC 
component. Once this procedure was complete the material extracted via RBC 
collection underwent apheresis aimed at concentrating reticulocytes and therefore 
parasitised RBCs. Flow cytometry in subject 4 involved the use of the CD71 marker 
specific for reticulocytes. Apheresis samples collected post RBC collection 
demonstrated evidence of reticulocyte enrichment, most marked in the final and 
spare collection bag (Figure 13). Despite this the addition of the RBC collection did 
not result in an increase in asexual parasite enrichment by qPCR (Figure 8B). 
USE OF APHERESIS IN THE HARVESTING OF PLASMODIUM VIVAX 
PARASITES  
Several hypotheses were formed to explain the relative lack of parasite concentration 
in samples obtained using apheresis. Firstly, as gametocyte concentrations in 
apheresis samples were around the level of detection of the pvS25 qPCR assay any 
variation in concentration may have been difficult to identify192. In response, 
biological repeats were conducted but did not alter the outcome. Secondly altered 
RBC/WBC ratio in apheresis samples compared to whole blood affecting the 18S 
qPCR and pvS25 qPCR assays. Microscopy did not support this explanation. 
Thirdly, it is possible that infected RBCs may have attached to ferromagnetic 
components of the apheresis apparatus, this was not supported by qPCR. Finally, it is 




possible that lysis of asexual parasites and gametocyte, occurred during the apheresis 
procedure. This hypothesis is supported by recent evidence suggesting parasite 
maturation results in increasing osmotic fragility of P. vivax infected RBCs200. 
Although it may have been possible to assess for haemolysis during the procedure, 
for example by measuring haptoglobins, controlling for a range of other variables 
would have been difficult. 
Regardless of the underlying cause, enrichment suggests that other methods are 
superior to apheresis for the concentration of gametocytes for mosquito transmission 
experiments. 
Conversely instead of focusing on measuring gametocyte concentration via qPCR 
and microscopy the focus should be shifted to successful mosquito transmission and 
harvesting of sporozoites for downstream experimentation. Greater transmission in 
apheresis samples compared to pre-apheresis samples would suggest apheresis is 
capable of substantial gametocyte concentration. High levels of transmission can be 
achieved using percoll. However, apheresis may be used to increase the level of 
transmission in any given mosquito, potentially increasing the numbers of oocysts in 
mosquito midguts and subsequently the number of sporozoites in mosquito salivary 
glands. Given the increase in transmission was relatively modest and only occurred 
in one sample any future plans should be made with caution.   
However, if future apheresis transmission experiments occur and do not demonstrate 
successful transmission to mosquitos, it would not necessarily be informative. As the 
absence of transmission may be due to a failure to concentrate gametocytes, or 
failure to maintain the appropriate temperature required to prevent gametocyte 
exflagellation194.  
Although these would have been useful avenues to explore given the significant 
ethical, financial and logistical considerations for IBSM studies, it was decided that 
this was inappropriate during this study. Furthermore in order to produce a viable 
outcome which would provide benefit to the wider community, several issues would 
need to be overcome, of which there is no guarantee. For example currently there is 
no way to control the temperature of blood within the apheresis apparatus. Blood 
takes several minutes to go from the subject through the apparatus to the apheresis 
collection bag during which time the blood may cool to below 37°C, or experience a 




drop in temperature of 5°C and thus potentially trigger gametocyte exflagellation194 
and prevent transmission201. However the fact that transmission occurred in the final 
bag (3% HCT) sample from subject 4 would go against this and support the idea that 
gametocytes were maintained within a temperature range that did not trigger 
exflagellation. 
HUMAN MALARIA PARASITE BANK FORMATION 
Theoretically apheresis and percoll may be able to concentrate parasites enough to 
create HMP bank vials containing 2.51 × 105 parasites (calculations in appendix 12). 
The HMP013 P. vivax parasite bank used to infect the volunteers in the study 
produces vials each of which contains 2.08 × 106 parasites. In order to produce an 
equivalent bank to the HMP013 P. vivax parasite bank, it would require an 8.3-fold 
greater pre-apheresis parasitemia to that seen in subject 3 if apheresis and percoll 
was used. 
The HMP013 P. vivax bank is not the ideal bank for IBSM studies because of the 
relatively low parasitemia. The TS P. falciparum bank contains 15-fold higher 
parasites/vial than the HMP013 P. vivax bank. In order to produce a parasite bank 
equivalent to the TS P. falciparum bank it would require 120-fold greater enrichment 
with apheresis and percoll. This equates to subject parasitemias of 1.1 × 107 
parasites/mL. Until now the maximum parasite count in P. vivax observed across 37 
subjects was approximately 310,000 parasites/mL. This particular subject had a high 
number of AEs and under current standards it would be unethical to allow the 
parasitemia to increase to the levels needed to make apheresis a viable method for 
creating a HMP bank. Therefore, unless significant improvements in enrichment can 
be attained, apheresis should not be used to create HMP banks, and the current 
practice of collecting blood by venesection is preferable. 
Although the level of concentration is not sufficient to produce a viable HMP bank. 
It may be sufficient to produce material that could be used in other experiments 
including the assessment of a P. vivax stage specific assay by providing parasites for 
the production of a standard curve. 




STRENGTHS AND LIMITATIONS 
Strengths of the study include the wide sampling across HCT layers (1%, 2%, 3%, 
5% and 7%) and the use of microscopy and qPCR to enumerate parasites.  
Limitations included the low number of subjects involved, of which only one 
underwent a RBC collection. IBSM studies come with significant ethical and 
funding restrictions, as such low numbers of subjects for studies, particularly 
exploratory studies, are common. The study was only able to use the female 
gametocyte marker for P. vivax as a reliable male marker is not currently available. It 
is important to note the limitations in the accuracy of the pvS25 qPCR assay as a 
measure for female P. vivax gametocytemia. A single pvS25 genome is not always 
equivalent to a single gametocyte. For example a schizont may contain more than 20 
copies of the PvS25 genome thus overestimating the true number of gametocytes192. 
Moreover, the absence of in vitro culture for P. vivax means the standard curves for 
the assay are extrapolated from P. falciparum, resulting in even greater uncertainty 
with regards to the true gametocyte density. However for the purposes of quantifying 
the concentrating effect of apheresis compared to pre-apheresis this is not anticipated 
to have a large effect.  
Several issues, both quality related and operational, compromised the reliability of 
microscopy data. Selection of the HCT layer for sampling during apheresis occurred 
by visual inspection of the colour saturation of blood. Although this is a subjective 
process, it is routinely practiced by the clinical apheresis staff, and HCT and RBC 
count data supports the accuracy of sampling (Table 10).  
Temperature control of pre-apheresis and apheresis samples was attempted during 
the study to maintain gametocyte infectivity195. Blood was most vulnerable to a 
temperature drop whilst in the apheresis equipment itself. It was not possible to heat 
apheresis equipment itself and it was deemed impractical to heat the room where 
apheresis took place to >35°C. Temperature monitoring was not possible during the 
experiments. 
CONCLUSION 
Apheresis can be used safely in human volunteers infected with blood stage P. vivax 
and can achieve moderate enrichment of asexual parasites and to a lesser extent 




gametocytes. Currently the level of enrichment is not sufficient to produce a HMP 
bank or significantly improve transmission experiments above venesection and 
percoll. Given the significant ethical, financial and logistical concerns surrounding 
P. vivax IBSM studies, this work makes is clear that further apheresis studies are not 
warranted at this point. If apheresis were to be used again in the context of malaria 
VIS, it should ideally only be carried out in subjects with normal haematological 
parameters at screening to avoid potential complications or the need for blood 
transfusion.  
  




CHAPTER 5 LIVER FUNCTION TEST ABNORMALITIES IN 
INDUCED BLOOD STAGE PLASMODIUM VIVAX MALARIA 
INTRODUCTION 
Post treatment liver function test (LFT) abnormalities encountered in P. 
falciparum202 and P. vivax60 malaria volunteer infection studies (VIS), were observed 
in three of the four subjects involved in the apheresis exploratory study. This 
emphasised the importance of this safety issue, particularly as it occurs in healthy 
volunteers purposefully infected with malaria for research purposes. These 
abnormalities have become an important safety concern and have the potential to 
threaten the future role of malaria VIS as a tool in antimalarial drug development.  
Drug induced liver injury (DILI) remains the single most common cause for safety 
related drug withdrawal during drug research203. DILI usually resolves upon ceasing 
the offending drug without sequelae204, 205, but instances of chronic liver 
impairment206 and even death207 have been described. DILI is divided into intrinsic 
injury which is related to a specific drug and is typically dose dependant, and 
idiosyncratic injury which occurs in specific susceptible individuals and is typically 
not dose related and more difficult to predict.  
Hy’s law is predictive of acute liver failure208 and hepatocellular damage204, 209, need 
for transplantation209 and death209 from DILI. Hy’s law is met when transaminases 
are elevated >3 × ULN together with rises in total bilirubin >2 × ULN but in the 
absence of cholestasis (alkaline phosphatase [ALP] <2 × ULN) and an alternative 
cause. Hy’s law is often utilised as a stopping criteria in the study of new clinical 
entities (NCE). However, most drugs that cause severe DILI do so infrequently so it 
typical requires at least a few thousand subjects to demonstrate this abnormality, and 
therefore severe DILI may not be observed in small drug studies203. Hence, close 
attention must be paid to lesser degrees of DILI during pre-clinical and clinical 
studies. LFT abnormalities encountered during induced blood stage malaria (IBSM) 
studies are important safety signals for the safety of healthy volunteers as well as any 
NCE under investigation. Incorrect assignment of causality of these important 
adverse events to the NCE has serious implications. Moreover the failure to correctly 
assign LFT abnormalities to a NCE has even greater implications. Currently there is 
no reliable biomarker to distinguish DILI from other causes of liver injury. Therefore 




comprehensive evaluation of LFT abnormalities observed during human 
experimental challenge is important. 
LFT abnormalities in IBSM were first observed in P. falciparum studies. In total 
8/197 (4%) non-immune subjects in 4/16 (25%) studies reported severe transaminase 
elevations >5.1 × ULN, with a further 4 subjects with moderate elevations 2.6-5 × 
ULN210. The 4 studies involved 3 NCE (ferroquine50, KAE609 [NIH 
NCT02543086], SJ733 [NIH NCT02867059]) and the registered antimalarial 
piperaquine186. Transaminase elevations were characterised by alanine transaminase 
(ALT)/aspartate transaminase (AST) ratio >1, ALT peaking 2 to 4 days post 
treatment and returning to normal 18 to 35 days post treatment. The maximum ALT 
elevation was 24 × ULN. Elevations in lactate dehydrogenase (LDH) were observed 
without a rise in bilirubin. Subjects were typically asymptomatic during the time of 
LFT elevations210. 
Transaminase elevations of >5 × ULN were observed in 4/6 (66%) subjects in a 
subsequent P. vivax IBSM study60. The pattern of the elevations mirrored those 
observed in P. falciparum IBSM. It is plausible that transaminase elevations in P. 
vivax and P. falciparum IBSM are caused by the same process. Several possible 
causes have been suggested, including the blood stage malaria infection dose 
(inoculum), acetaminophen use, and oxidative stress secondary to haemolysis 
leading to hepatocyte injury60, 210.  
Malaria hepatopathy, defined as bilirubin >2.5 × ULN and rise in transaminase >3 × 
ULN211, 212, 213, 214, 215, is a well-recognised phenomenon in both experimentally 
induced and natural infection across all malaria species210, 211, 212, 216, 217, 218, 219. 
Malaria hepatopathy differs from LFT abnormalities in P. falciparum202 and P. vivax 
VIS60 in timing and the prominence of bilirubin elevations50, 220, 221, suggesting that 
malaria hepatopathy and post treatment LFT changes in VIS may be mediated by 
different mechanisms.  
My analysis aimed to describe in detail and investigate the cause of the LFT 
abnormalities observed in two P. vivax IBSM studies. One of these studies entailed 
treatment with the investigational antimalarial artefenomel and the other with the 
licensed drug chloroquine. Neither artefenomel222 nor chloroquine223, 224, 225 have 




been associated with hepatotoxicity when used in standard dose regimens in healthy 
subjects. However, LFT changes have previously been reported in clinical studies of 
artefenomel in malaria endemic settings226.  
I hypothesised that a range of factors may be associated with elevations in liver 
transaminase levels. These include C-reactive protein (CRP), and temperature, both 
markers of systemic inflammation, LDH, a potential marker of haemolysis, and the 
level of parasitemia at the time of treatment. I hypothesised that the rate of parasite 
clearance and the burden of parasite biomass cleared post treatment were potential 
contributors to the observed abnormalities. These parameters have not been assessed 
previously. In addition all of the variables identified above as potential causes of the 
observed LFT abnormalities were also assessed.  
HYPOTHESIS 
• Abnormalities in LFTs observed in the P. vivax IBSM model are mediated by 
rapid release of hepatotoxic products by rupture of infected red blood cells 
that overwhelms the intravascular capacity to detoxify them. 
• Abnormalities in LFTs observed in the P. vivax IBSM model are mediated by 
the inflammatory response in non-immune patients. 
AIM 
• Determine the cause of LFT abnormalities seen in P. vivax IBSM.  
OBJECTIVES 
• Assess the relationship between the rate of malaria parasite clearance and 
LFT abnormalities following treatment with investigational product.  
• Assess the relationship between the burden of parasites cleared following 
treatment with investigational product and LFT abnormalities. 
• Assess the relationship between systemic inflammation and LFT 
abnormalities.  
• Assess the relationship between haemolysis and LFT abnormalities.  
• Assess whether LFT abnormalities similar to those observed in P. vivax 
IBSM studies occur in studies from the field. 




MATERIAL AND METHODS 
CLINICAL METHODS 
INDUCED BLOOD STAGE MALARIA STUDIES 
Data for the two P. vivax IBSM studies were obtained, these included 32 malaria-
naive subjects who participated in two clinical trials at QIMR Berghofer between 
March 2016 and April 2017. Details are reported elsewhere179 (NCT02573857) and 
included in Table 14. Subjects were all healthy adults aged between 18 and 55 years. 
Subjects with a history of, or clinical signs of, liver disease were excluded from the 
studies. Subjects who tested positive for hepatitis BsAg or core antibody, hepatitis C 
antibody or HIV, were excluded. All subjects had ALT, AST and total bilirubin 
levels within the normal range one to three days prior to malaria inoculation. 
Subjects taking prescription medication, over the counter medication, vitamin, 
mineral, herbal remedy, or supplements likely to cause abnormal LFTs were 
excluded. All subjects had consented to the alcohol limitations. 
Subjects were inoculated intravenously with the P. vivax isolate HMP013. In the 
artefenomel study 8 subjects were treated with a single 200 mg dose of the drug on 
day 10. Based on previous studies the 200 mg dose was predicted to be sub-
efficacious51, and as expected 7/8 subjects had recrudescent parasitemia and received 
a standard course of artemether-lumefantrine on day 21-28. In the chloroquine study, 
a total of 24 subjects were treated with a standard three-day course of chloroquine, 
totalling 25 mg/kg, beginning on day 8 (n=8 subjects), day 9 (n=1 subject), or day 10 
(n=8 subjects). 




Table 14. Clinical trials details  
Drug  Artefenomel Chloroquine Chloroquine   Chloroquine  Chloroquine 
Cohort (n)  Artefenomel (8) Chloroquine C1 (8) Chloroquine C2a (6)** Chloroquine C2b 
(2)** 
Chloroquine C3 (8) 
Inoculation dose 
size (parasites) 
524,000 720,000 722,000 740,000 782,000 
Treatment regimen single dose 200 mg *3 days 
 
Day of treatment 
post inoculation 
day 10 day 8 day 10 (one subject 
treated on day 9) 




allowed both allowed both, 
encouraged ibuprofen 
only and only reported 
ibuprofen use 
ibuprofen ibuprofen acetaminophen 
*3-day standard oral curative treatment regimen dosed on a weight basis to a total of ~25 mg/kg. **Cohorts 2a and 2b were combined into 
Chloroquine cohort C2 for the statistical analysis as the conduct and characteristics of the cohorts were identical apart from the inoculum dose.  
Table summarising key differences in study design, inoculation dose and symptom relief across IBSM study cohorts. 






Data were made available from a previously published phase IIa open label study226 
which enrolled patients at the Hospital for Tropical Diseases in Bangkok and Shoklo 
Malaria Research Unit (SMRU) located on the north western border of Thailand 
between October 2010 to May 2012. Febrile adult male and non-pregnant female 
patients aged 18-60 years presenting with symptomatic, microscopically confirmed, 
P. falciparum or P. vivax (parasite counts 5000-50,000 /µl) were included. Patients 
were excluded if they had clinical or laboratory evidence of severe malaria227, were 
unable to tolerate oral therapy or had received any other antimalarials within the last 
14 days. Individual biochemistry data from 41 patients with microscopically 
confirmed P. vivax mono or mixed infection were analysed. LFTs were measured at 
screening prior to artefenomel treatment (day 0 pre-treatment), 4 hours post 
treatment (day 0 post treatment), day 1, day 2 and day 7. Investigators were 
permitted to conduct additional testing at their discretion.  
In the Malaysian study patients were enrolled from July 2013 to November 2015 as 
part of a randomised controlled trial228 or a prospective observational study229, both 
conducted at Kota Marudu, Kudat, and Pitas District Hospitals. Patients were 
included if they had PCR-confirmed P. vivax monoinfection, were aged >1 year of 
age, were non-pregnant, had no major comorbidities or concurrent illness, and had 
not started antimalarial treatment. Parasitemia was calculated by thin blood film 
microscopy. LFT testing of samples collected from 85 subjects between day 0 and 
day 7 was undertaken. All had ALT levels tested on days 0 and 7, while 19/85 and 
85/85 subjects had AST tested on day 0 and day 7 respectively. Total bilirubin levels 
were tested in 76/85 subjects on day 0, and 85/85 subjects on day 7.   
LABORATORY PARAMETERS 
LIVER FUNCTION TEST MEASUREMENTS  
LFT parameters measured during the analysis include ALT, AST, bilirubin, gamma-
glutamyl transferase (GGT), ALP and albumin. LDH was primarily assessed as a 
marker of haemolysis as discussed in more detail below. Although serum LDH is a 
less specific biomarker of haemolysis than haptoglobin, it was routinely measured as 




part of the biochemistry panel, and therefore for this analysis it was included as it 
was the only potential marker of haemolysis230 available. LFTs were taken at 
screening, pre-inoculation, pre-treatment with chloroquine or artefenomel, 72 hours 
post treatment, 5-8 days post treatment and at the end of study (EOS). Additional 
samples were taken at investigators’ discretion. Testing of markers of clotting factor 
synthesis were not taken during the studies. 
Peak ALT level was assessed as the primary LFT biomarker of interest for both the 
IBSM and endemic studies. ALT is predominantly found in the liver compared to 
AST which is also found in the brain, kidney, and muscle as well as the liver231. 
Therefore ALT was selected over AST as it is more liver specific231.  
ALT was categorised into ≥2 × ULN and <2 × ULN (ULN=40 IU/L for males and 
30 IU/L for females). The cut off  of ≥2 times × ULN was used as this was deemed 
by local liver experts and investigators familiar with phase I studies in healthy 
volunteers and IBSM studies as significant and unlikely to occur by chance.  
Common terminology criteria for adverse events (CTCAE)232 guidelines use >3 × 
ULN as significant, but this is specific to investigation of cancer trials. Excluding 
subjects with ALT rises ≥2 × ULN but <3 × ULN would have reduced the number of 
subjects considered to have significant ALT changes and thus weaken the ability to 
identify associations.  
  




Table. 15 Sensitivity analysis for the ALT cut off in IBSM studies 
Identifier Peak ALT (n%) 
Drug Cohort ≥2 × ULN  ≥2.5 × ULN  ≥3 × ULN  
















14 (43.75%) 11 (34.38%) 10 (31.25%) 
ALT; Alanine transaminase, ULN; Upper limit of normal.  
Table summarising the effect of altering the cut off for a significant peak ALT 
measurement from ≥2 × ULN to ≥2.5 × ULN to ≥3 × ULN across IBSM study 
cohorts and for all subjects treated with artefenomel and chloroquine.  
Instead of peak ALT × ULN, peak ALT × baseline was considered as the outcome of 
interest, but given the significant variations in ALT measurements observed in 
healthy individuals over time, it was thought to be inferior233, 234. Another strategy 
could be to select patients who were considered to have significant LFT changes 
based on the timing of peak ALT × ULN and compare this group of subjects against 
the remaining subjects (those without significant LFT changes). However this was 
considered too subjective and difficult to replicate in any future analysis. 
Alternative measures of liver damage were also considered including MicroRNA-
122 (MiR-122). MiR-122 is the single most abundant MiRNA expressed by liver 
tissue (up to 70% of adult miRNA)235. MiR-122 has been identified as a marker of 
hepatocyte injury in clinical studies involving NCE. MiR-122 elevations occur in 
mouse studies and clinical cases of acetaminophen overdose235, 236. MiR122 usually 
rises in acetaminophen overdose before ALT and typically by 100 to 10,000-fold. 
MiRNA is believed to be more specific than ALT for hepatocyte injury versus 
exercise induced muscular injury where ALT is often raised237.  




Following discussion with a local gastroenterologist familiar with the LFT 
abnormalities seen in IBSM studies it was decided that MiR122 should not be used 
during this analysis. This decision was based on a number of considerations; firstly 
the effects of malaria infection on MiR122 are unknown, secondly the relative lack 
of experience in interpretation of MiR122 compared to ALT, thirdly greater 
sensitivity to acetaminophen use may produce a false positive association and finally 
the logistics, cost of testing and ethical approval for testing were prohibitive. 
PARASITE RELATED MEASUREMENTS 
Parasitemia was measured prior to treatment and at multiple time-points throughout 
the study by 18S qPCR66 and analysed on the log10 scale. Overall peak parasitemia 
was thought to be relevant as a potential causative factor for LFT abnormalities, 
whereas pre-treatment peak parasitemia was included in the analysis to determine 
whether parasitemia could be used to predict which subjects develop transaminase 
elevations. The parasite clearance rate was reported using the parasite clearance half-
life (PCt1/2) in hours, calculated using the following equation as previously 
reported238. 
PCt1/2 = log10(2)/ -slope   
For the artefenomel study, the PCt1/2 was censored at parasitemia nadir, ~36 hours 
post treatment when rescue treatment with artemether-lumefantrine treatment was 
required. Although chloroquine was administered over three days, the initial parasite 
PCt1/2 was assumed to represent a continuous pharmacodynamic effect
179. 
It was hypothesised that there may be a saturable detoxification process for clearance 
of dead parasites and/or damaged RBCs. Therefore, a surrogate marker capturing the 
biomass of parasites cleared in the first 24 hours after treatment was calculated. This 
parasite clearance burden (PCB) was calculated by subtracting the parasitemia, at 24 
hours post treatment initiation from the peak parasitemia on the log10 scale and 
reported as a log-fold change. The 24-hour cut off was selected as the majority of 
parasite clearance occurred over this time interval, although parasitemia remained 
measurable at a low level beyond this timepoint. Peak parasitemia alone could not be 
used as it does not necessarily capture the burden of cleared parasites which is a 
function of peak parasitemia and rate of clearance. Likewise parasitemia at treatment 
or peak parasitemia determined by extrapolation and y-intercept from the parasite 




clearance curve may provide more appropriate measures of parasitemia before the 
effect of drug induced killing, but neither would incorporate the parasite clearance 
rate. These measures represent the starting point of drug induced killing, but it is the 
total reduction of parasites shortly after treatment that is the measure of interest. For 
example the same starting parasitemia with a very rapid parasite clearance will have 
a much greater reduction in parasite burden over 24 hours than the same starting 
parasitemia with a slow rate of parasite clearance. 
Another potential measure was the area under the 18S qPCR curve. But again this 
measure does not capture the total reduction of parasites shortly after treatment. For 
example a high area under the curve could simply be due to a high starting 
parasitemia and rapid parasite clearance, or a low starting parasitemia with slow 
clearance.  
The PCB measure does have limitations. It is produced using only two points of 
measurement increasing the likelihood of producing an unrepresentative value. The 
24h post treatment parasitemia measure is especially prone to variation as the value 
may be around the limit of quantification for the 18S qPCR assay. 
The endemic studies did not carry out serial qPCR measures, therefore peak 
parasitemia and parasite clearance half-life were not reported, as they would not be 
comparable to the peak parasitemia, parasite clearance half-life or parasite clearance 
burden in the IBSM studies. Instead median parasitemia levels at study enrolment 
were reported for the clinical studies.  
HAEMATOLOGY PARAMETERS 
White cell count (WCC), lymphocyte count, neutrophil count and platelet counts 
were selected for analysis, as these parameters are commonly altered in IBSM 
studies. The frequency and timing of WCC, lymphocyte, neutrophil and platelet 
counts testing in the endemic studies was not considered sufficient for analysis. 
MARKERS OF HOST RESPONSE  
CRP and temperature were measured as markers of host response. 




Retrospective CRP testing was carried out to quantify the level of inflammation 
experienced by each subject. CRP is a well-recognised measure of inflammation 
with an established assay and clinicians are familiar with its interpretation.  
CRP is produced by hepatocytes predominantly under control of interleukin-6 (IL-
6)239 but can be stimulated by interleukin-1 (IL-1) and Tumour necrosis factor α 
(TNFα)240. Hepatic synthesis occurs rapidly after stimulus and rises above 5 mg/L at 
about 6 hours after the inflammatory insult before peaking at around 48 hours post 
stimulus241. It has a plasma half-life of 19 hours which is constant under all 
conditions of health or disease. Thus synthesis rate is the sole determinant of CRP 
concentration which reflects the intensity of the pathological process242. CRP data 
collected from young healthy adult volunteer blood donors demonstrated a median 
CRP 0.8 mg/L, 90th centile 3.0 mg/L, 99th centile 10.0 mg/L)243. Normal ranges are 
relatable to study subjects who are young healthy adults.  
CRP was selected as published data has indicated that CRP levels are associated with 
parasitemia244, 245, 246, 247, 248 and disease severity246, 249, and generally peaks 1-2 days 
after initiation of antimalarial treatment247, 248. Hence the decision was made to check 
CRP at baseline (Day of inoculation or 1 to 3 days pre-inoculation), pre-treatment, 
24hrs post treatment, 48hrs post treatment, peak ALT (generally 5-8 days post 
treatment), 24hrs post peak ALT and 48hrs post peak ALT. 
Testing was carried out from stored PCR samples at QIMR Berghofer. Some of the 
desired timepoints did not have corresponding stored PCR samples. Therefore where 
possible the next available sample was tested instead. This was not an issue for 
baseline, pre-treatment or 24 hours post treatment samples as PCR samples were 
taken at this time routinely. However there were several occasions where samples 
were not present for peak ALT, 24 hours and 48 hours post peak ALT results as 
subjects were often PCR negative at this point, thus repeat testing was not always 
necessary as per study protocol.  
Both CRP × ULN and × baseline was measured. CRP × ULN was used as an inter-
subject measure of inflammation whereas CRP × baseline was considered a superior 
intra-subject measure of inflammation.  




CRP testing did not take place in the endemic studies. Following internal discussions 
at QIMR Berghofer, for reasons of logistical ease, sample preservation, ethical 
approval and cost it was decided not to test for CRP. 
In IBSM subjects the maximum temperature was recorded within 3 days pre- and 
post treatment, in order to ensure the measurements reflected malaria infection and 
treatment. Temperature <37.5°C were considered normal. The frequency and timing 
of temperature recordings in the endemic studies was not considered sufficient for 
analysis. 
Other markers of inflammation such as TNFα were also considered for analysis. 
Several studies have attempted to assess the role of TNFα in malaria. TNFα has been 
shown to be closely related to fever, paroxysms and anaemia in P. vivax infected 
patients250.TNFα is found in higher levels in acute P. falciparum malaria than 
convalescent malaria and healthy controls251. Elevated TNFα has also been shown to 
have a role in cerebral malaria and fever during P. falciparum malaria252, 253. TNFα 
testing did not take place in either IBSM studies under analysis or in the endemic 
studies. Following internal discussions at QIMR Berghofer, for reasons of logistical 
ease, sample preservation, ethical approval and cost it was decided not to use TNFα 
in this analysis. Of note TNFα induces a dose dependant secretion of CRP254. Hence 
it was believed that CRP could potentially act as a proxy measure for TNFα.  
CLINICAL REVIEW OF SUBJECTS 
The source documents of all 32 subjects involved in the P. vivax IBSM studies were 
reviewed to exclude an alternative diagnosis such as alcohol consumption or 
concomitant medication use such as acetaminophen. Clinical review of the source 
documents for patients in the endemic setting was not carried out for logistic reasons. 
STATISTICAL ANALYSIS 
All data are analysed using Stata v.15, Microsoft Excel® (version 1903) and figures 
were produced using PRISM v.8. Lachlan Webb statistician at QIMR Berghofer was 
involved in the production of the statistical analysis plan and data analysis using 
Stata®. Continuous variables are presented as mean and SD, median and IQR. For 
each participant maximum and minimum values for all parameters (LFTs, 




inflammatory, LDH and parasitemia) were identified from inoculation to drug 
treatment and from inoculation to EOS.  
Logistic regression analysis was used to test for associations between the continuous 
explanatory parameters and peak ALT × ULN (males=40 IU/L, females=30 IU/L). A 
fixed cohort effect was added to the regression models to account for any 
confounding effects due to the inherent differences between cohorts. Correlations 
between two continuous variables were assessed by Pearson’s correlation. 
A backwards stepwise regression was used to create two multivariable models for 
associations to the peak ALT≥2 × ULN outcome. Any variable that was significant 
(p<0.05) in the univariate logistic regression was included in the backwards stepwise 
regression. In the first multivariable model, parasite clearance rate was forcibly 
retained into the final model; in the second multivariable model, PCB was included. 
For the Thailand artefenomel and Sabah dataset, descriptive statistics of frequency 
and percentage were given for categorical measures. Continuous measures were 
described using median (IQR) and range. Paired t-tests on the log10 were used to test 
the differences in LFT results between day 0 (pre-treatment for Thailand artefenomel 
study) and day 7 as data was skewed and differences non-symmetric.  
RESULTS  
INDUCED BLOOD STAGE MALARIA 
DESCRIPTIVE ANALYSIS BY SUBJECT 
All 8 subjects recruited to the artefenomel study were male compared to 13/24 (54%) 
of subjects in the chloroquine group. The median (IQR) age of subjects recruited to 
the artefenomel and chloroquine studies were 23.5 (22-25.8) years and 24.5 (20-30) 
years respectively. 
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ALT; alanine transaminase, ULN; upper limit of normal. 
Changes in ALT levels (IU/L) over time for all 32 subjects. Each of the 32 subjects 
are represented by a single trace. Day 0 represents the day of inoculation. Those 
subjects represented by dotted lines were from chloroquine cohort C1 (n=8), all of 
which were treated 8 days post inoculation. The dashed line represents subject R013 
from chloroquine cohort C2 who was the only subject to be treated on day 9 post 
inoculation. The ULN for ALT in male subjects (40 IU/L) has been included for 
reference. 
  




Figure 17. Peak ALT × ULN vs AST × ULN 






















ALT; alanine transaminase, AST; aspartate transaminase, ULN; upper limit of 
normal. 
Peak ALT × ULN plotted against peak AST × ULN for all 32 study IBSM subjects. 
Peak ALT × ULN plotted against peak AST × ULN are strongly correlated. In 
general peak ALT is greater than peak AST.  
Following antimalarial treatment 14/32 (44%) subjects had an ALT≥2 × ULN. ALT 
elevations generally exceeded AST (Figure 17). Levels began to rise 3 days after 
treatment, peaking between days 5 and 8, and resolved between day 11 and day 32 
(Figure 16). The highest ALT observed was 632 IU/L (15.8 × ULN), occurring 6 
days post treatment. There was no relationship between age or sex and LFT 
elevations. Nine (64%) of the 14 subjects with peak ALT≥2 × ULN were male, 
compared to 12/18 (67%) subjects with peak ALT<2 × ULN. Median age (IQR) of 
subjects with peak ALT≥2 × ULN and ALT<2 × ULN were 25.5 (22-33) and 22 (20-
25) respectively. 
No volunteer had significant elevations in ALP or bilirubin. GGT was measured in 
the artefenomel treated subjects only; all results were within the normal range. 
Creatinine kinase (CK) was measured in three artefenomel treated subjects and one 
chloroquine treated subject at, or within 3 days, of the peak ALT; all were within 
normal range. 




There were no features in the past medical history of any of the subjects that 
suggested impairment of liver function. All subjects had normal examination 
findings and no suggestion of pre-existing liver pathology. Subject R206 took 
optimen (a multi-vitamin) but stopped 2 weeks before inoculation and this subject 
went on to develop moderate transaminase elevation (peak ALT 1.9 × ULN). 
Otherwise there was no use of prescription medication, over the counter medication, 
vitamin, mineral, herbal remedy, or supplements likely to cause LFT abnormalities. 
DESCRIPTIVE SUBJECT GRAPHS 
Graphical representations for each subject were created to provide an overview of 
how relevant parameters, thought to be related to the causation of LFT abnormalities, 
behaved during the IBSM studies and in order to produce a visual representation for 
each subject.  
Subjects with significant ALT abnormalities tended to have a greater number and 
severity of other malaria related measures and vice versa (appendix 12 Figure 1). 
DESCRIPTIVE ANALYSIS BY COHORT 
  




Figure 18. Peak ALT × ULN  per IBSM cohort 



















ALT; alanine transaminase, ULN; upper limit of normal. 
Peak ALT of all subjects split by IBSM study cohort with median (IQR) values. 
Kruskal Wallis P=0.0052. 
Median (IQR) peak ALT was greatest in the artefenomel cohort followed by 
Chloroquine cohort C2, Chloroquine Cohort C3 with subjects in Chloroquine cohort 
C1 experiencing the smallest elevations. 
PARASITEMIA MEASUREMENTS BY COHORT 
  




Table 16. Summary of parasitemia related outcomes per cohort 



































































PCt1/2; parasite clearance half-life, PCB; parasite clearance burden, IQR; 
interquartile range. 
*Artefenomel was only used in one cohort, thus the overall values for artefenomel 
are the same as for the cohort itself.  
Table 16 demonstrates the median (IQR) values for peak parasitemia overall, peak 








Table 17. Univariate analysis 
Investigative parameter Peak ALT Chi square Logistic regression Logistic regression with fixed cohort effect 
<2 × ULN 
n=18 
≥2 × ULN 
n=14 OR (95% CI) p OR (95% CI) p 
Parasitemia measurements 
 PCt1/2 (hours) 
 
Median (IQR) 4.57 (4.12-5.69) 4.36 (3.16-5.40) 
 
0.71 (0.36-1.38) 0.31 1.12 (0.472-.66) 0.79 
pre-treatment Peak parasitemia 
(log parasites/mL) 
Median (IQR) 4.19 (3.80-4.65) 4.88 (4.54-4.93) 
 
7.15 (1.35-38.02) 0.021 4.46 (0.41-48.45) 0.22 
Overall Peak parasitemia (log 
parasites/mL) 
Median (IQR) 4.52 (4.09-4.89) 4.94 (4.78-5.25) 
 
5.86 (1.17-29.43) 0.032 2.64 (0.25-28.15) 0.42 
PCB Median (IQR) 0.92 (0.70-1.20) 1.81 (1.15-2.20) 
 
5.09 (1.40-18.48) 0.013 3.95 (0.31-49.84) 0.29 











3.13 (1.14-8.61) 0.027 2.28 (0.65-7.97) 0.20 
CRP × ULN To EOS (mg/L) Median (IQR)  5.20 (2.40-7.60) 11.90 (9.40-14.20) 
 
1.81 (1.21-2.71) 0.004 1.98 (1.18-3.33) 0.010 
CRP × ULN Pre-treatment (mg/L) Median (IQR) 0.20 (0.20-0.60) 2.60 (0.60-7.00) 
 
2.20 (0.85-5.65) 0.1 bad fit# 
 
CRP Relative to Baseline (mg/L) Median (IQR) 18.50 (6.00-37.00) 58.00 (36.00-66.00) 
 
1.12 (1.04-1.20) 0.004 1.13 (1.04-1.24) 0.006 
Marker of haemolysis 
LDH × ULN To EOS (U/L) Median (IQR) 0.92 (0.84-1.08) 1.25 (1.05-1.36) 
 
1.89 (1.21-2.95) 0.005 1.78 (1.05-3.02) 0.034 
LDH × ULN Pre-treatment (U/L) Median (IQR) 0.68 (0.60-0.75) 0.80 (0.69-0.87) 
 
2.01 (1.06-3.82) 0.034 1.51 (0.74-3.06) 0.26 
Haematological parameters 
Neutrophils To EOS Median (IQR) 1.14 (1.07-1.36) 0.97 (0.83-1.25) 
0.14^ 
0.07 (0.004-1.22) 0.068 0.07 (0.003-1.75) 0.10 
<1 × LLN (109/L) n (%) 4 (22.2%) 7 (50.0%) 
Neutrophils Pre-treatment  Median (IQR) 2.17 (2.04-2.56)  1.58 (1.3-1.85) 
 
0.09 (0.01-0.59) 0.012 0.04 (0.002-0.56) 0.018 
<1 × LLN (109/L) n (%) 0 1 (7.1%) 
Platelets To EOS Median (IQR) 0.98 (0.85-1.17) 0.84 (0.76-0.85) 
0.068 
0.0003 (<0.001-0.34) 0.023 <0.001 (<0.001-0.33) 0.029 
<1 × LLN (109/L) n (%) 10 (55.6%) 12 (85.7%) 
Platelets Pre-treatment  Median (IQR) 1.2 (0.99-1.37) 1.01 (0.93-1.23) 0.37 0.03 (0.0008-1.03) 0.052 0.01 (<0.001-2.99) 0.12 




    
<1 × LLN (109/L) n (%) 5 (6.2%) 6 (4.8%) 
    
Lymphocytes To EOS Median (IQR) 0.92 (0.61-1.0) 0.59 (0.54-0.71) 
0.024^ 
0.003 (<0.001-0.29) 0.013 0.007 (<0.001-2.20) 0.09 
<1 × LLN (109/L) n (%) 12 (66.7%) 14 (100%) 
Lymphocytes Pre-treatment  Median (IQR) 0.98 (0.61-1.52) 0.59 (0.54-0.71) 
 
0.02 (<0.001-0.60) 0.023 0.003 (<0.001-0.86) 0.044 
<1 × LLN (109/L) n (%) 10 (55.6%) 13 (92.9%) 0.02 
    
White cell count To EOS Median (IQR) 1.04 (1.00-1.20) 0.87 (0.74-1.09) 
0.005 
0.013 (<0.001-0.73) 0.035 <0.001 (<0.001-0.97) 0.009 
<1 × LLN (109/L) n (%) 4 (22.2%) 10 (71.4%) 
White cell count Pre-treatment  Median (IQR) 1.44 (1.20-1.66) 0.96 (0.83-1.17) 
 
0.01 (<0.001-0.25) 0.005 <0.001 (<0.001-0.21) 0.012 
<1 × LLN (109/L) n (%) 2 (11.1%) 8 (57.1%) 0.005 
    
Antimalarial treatment  
Chloroquine 
AUC96 (μg/mL*h) 





0.95 (0.89-1.02) 0.17 0.97 (0.90-1.05) 0.48 
Chloroquine Cmax (μg/mL) Median (IQR) 1.05 (0.90-1.31) 0.93 (0.74-1.13) 
 
0.09 (0.003-3.19) 0.19 0.32 (0.01-20.0) 0.59 
Artefenomel 
AUC96 (μg/mL*h) 





0.60 (0.04-2.64) 0.5 
  
Artefenomel Cmax (μg/mL) Median (IQR) 0.70 (0.66-0.75) 0.51 (0.37-0.69) 
 
0.03 (<0.001-148.0) 0.42 
  
ALT; alanine transaminase, PCt1/2; parasite clearance half-life, PCB; parasite clearance burden, CRP; C-reactive protein, LDH; lactate 
dehydrogenase, ULN; upper limit of normal, LLN; lower limit of normal, OR; odds ratio, AUC96; area under curve 96 hours,  Cmax; maximum 
concentration of drug, EOS; end of study. OR refer to a 1-unit change in the measure of the explanatory parameter (e.g. 1°C for maximum 
temperature). 
^Fisher’s exact test. #Insufficient data for good model fit. Imbalance of data by cohort, and singularity in chloroquine cohort C2, make this 
model a bad fit. Univariate analysis assessing the effect of explanatory variables on peak ALT. Significant effects and associations (p<0.05) are 
in bold. Continuous measures are described with mean (SD), and categorical measures are described with frequency (%). Results from simple 
binary logistic regression are presented for the continuous measures. That logistic regression is then repeated with a fixed cohort effect included. 




The PK antimalarial measures could only be compared separately by drug, as the drug effect that would have to be included would confound 
with the cohort effect.  




PARASITEMIA MEASURES BY SUBJECT  
Figure 19. Parasitemia measures  
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ALT; alanine transaminase, ULN; upper limit of normal, PCB; parasite clearance 
burden. 
Relationship between peak parasitemia overall (19A), PCB (19B) and PCt1/2 (19C),  
and peak ALT. Peak ALT is split into 2 groups; peak ALT≥2 × ULN and peak 
ALT<2 × ULN. 19D linear regression between peak ALT (log10) and PCB (log10) 
with Pearson’s correlation values. Peak ALT (log10) was used to reduce skew from 
low level peak ALT measures. 
Overall peak parasitemia was significantly associated with peak ALT≥2 × ULN 
OR=5.86 (95% CI; 1.17-29.43 p=0.032; Figure 19A). The correlation coefficient 
between peak ALT and peak parasitemia was 0.39 (p=0.027) (appendix 12 Table 3). 
A one log increase in overall peak parasitemia increased the odds of a subject 
developing peak ALT≥2 × ULN by 5.86 (log10) fold respectively.  




Both the univariate and multivariable analysis for PCB do not show any statistically 
significant relationship between PCt1/2 and ALT abnormalities.  
The PCB (Figure 19B) was found to be a significant risk factor for developing a 
peak ALT≥2 × ULN, with an OR of 5.06 (95% CI 1.40-18.48, p=0.014) for a one 
log increase in PCB. The relationship between peak ALT log10 and PCB is supported 
by an analysis that shows a significant correlation between peak ALT log10 and PCB 
(0.48; p=0.005; Figure 19D). PCB for the artefenomel treated cohort (mean 2.25 
[95% CI; (2.1-2.4)] is greater than for the chloroquine cohorts overall (mean 0.95 
[95% CI; 0.71-1.22]) and chloroquine cohorts C2 (mean 1.16 [95% CI; 0.7-1.88]) 
and C3 (mean 1.18 [95% CI; 0.96-1.41]), the two cohorts where chloroquine 
treatment occurred on day 10 (Table 16). Multivariable analysis using PCB as the 
key parameter did not result in it emerging as a statistically significant variable. 
MARKERS OF HOST RESPONSE 
Figure 20. Markers of host response 
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 ALT; alanine transaminase; ULN; upper limit of normal, CRP; C-reactive protein. 
Relationship between maximum temperature °C (20A), and CRP × ULN (20B) with 
peak ALT. Peak ALT is split into 2 groups; ≥2 × ULN and peak ALT<2 × ULN. 
The maximum temperature (Figure 20A) was associated with an increased risk of 
having a peak ALT≥2 ×ULN, with an OR of 3.13 (95% CI 1.14-8.61, p=0.027) for a 
one degree increase in temperature. All subjects with a peak ALT>2 × ULN 
experienced a maximum temperature ≥38.3°C.  




An increase in the maximum CRP of 4 mg/L (ULN=4 mg/L) increased the odds of a 
subject developing peak ALT≥2 × ULN by 1.81-fold (95% CI 1.21-2.71 p=0.004), 
whereas a 1-fold increase in maximum CRP relative to baseline increases the odds of 
developing peak ALT≥2 × ULN by 1.12-fold (95% CI 1.04-1.24 p=0.004). CRP 
levels when tested pre-treatment were typically much lower than peak CRP level 
occurring post treatment regardless of the day of treatment (8 or 10). On 
multivariable analysis, the CRP was a statistically significant factor when PCB was 
the explanatory variable, both before and after cohort effect was accounted for. The 
correlation coefficients between peak ALT and peak CRP × ULN and CRP relative 
to baseline were 0.44 (p=0.012) and 0.47 (p=0.007) respectively (appendix 12 Table 
3). 
Temperature was no longer significant in the logistic regression model when the 
cohort effect was included, whereas CRP remained significant (p=0.010 for CRP × 
ULN; p=0.006 for CRP relative to baseline) (Table 17). 
MARKER OF HAEMOLYSIS 
Figure 21. Maximum LDH × ULN split by ALT outcome 

















p = 0.005 Chloroquine
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LDH; lactate dehydrogenase, ALT; alanine transaminase, ULN; upper limit of 
normal. 




Relationship between LDH × ULN and peak ALT. Peak ALT is split into 2 groups; 
peak ALT≥2 × ULN and peak ALT<2 × ULN. 
Maximum LDH has a significant association with peak ALT≥2 × ULN OR=1.89 
(95% CI 1.21-2.95 p=0.005). An increase in the maximum LDH of 250 U/L 
(ULN=250 U/L) was associated with an increase in the odds of a subject developing 
peak ALT ≥2 × ULN by 1.89-fold. Peak LDH retained its significance when cohort 
effect was included (Table 19) . The correlation coefficient between peak ALT and 
peak LDH was 0.58 (p<0.001) (appendix 12 Table 3). 
HAEMATOLOGICAL PARAMETERS 
Most of the changes in laboratory haematology values were significantly associated 
with ALT elevations ≥2 × ULN (Table 17). These effects remained significant when 
the cohort effect was included. No pre-treatment cut off for any of these parameters 
was predictive of the development of significant ALT elevations later in the study. 
Platelet count was the only significant parameter on multivariable regression with 
PCt1/2 as the fixed explanatory variable. A 0.1 decrease in the pre-treatment platelet 
count × LLN (e.g. from 0.7 × LLN to 0.6 × LLN) results in an increase in the odds of 
peak ALT being ≥2 × ULN by 2.79 (95% CI 1.12-6.93, p=0.027) (appendix 12 table 
4. The association remained significant when cohort effect was added.  
  
























ALT; alanine transaminase, ULN; upper limit of normal. 
Peak ALT × ULN for subjects treated with artefenomel (n=8) and chloroquine 
(n=24). All subjects treated with artefenomel were from the same cohort. Subjects 
treated with chloroquine came from three cohorts (chloroquine C1, n=8; chloroquine 
C2, n=8; chloroquine C3, n=8). The Mann-Whitney test was used to assess for 
difference in ALT values between the two drug treatments. Median Peak ALT was 
greater for subjects treated with artefenomel compared to those treated with 
chloroquine.  
  




Table 18. Logistic regression with antimalarial drug type 
OR; odds ratio, PCB; parasite clearance burden. 
Logistic regression demonstrating the effect of drug and the day of treatment on the 
likelihood of ALT≥2 × ULN and the effect of drug on ALT≥2 × ULN after being 
corrected for PCB. 
The median peak ALT × ULN level was greater among the 8 subjects administered 
artefenomel (5.3 IQR; 2.2-9.1), compared to the 24 subjects given chloroquine (1.0 
IQR; 0.8-2.5) p=0.002 (figure 22), and a greater proportion of patients in the 
artefenomel group had a peak ALT≥2 × ULN (6/8 [75%] vs 8/24 [33%]).Thus the 
OR (95% CI) for developing ALT≥2 × ULN with artefenomel compared to 
chloroquine was 6.0 (0.98-36.71), but the difference did not quite reach statistical 
significance (p=0.053). When PCB was incorporated into bivariate model with drug 
effect this effect disappeared: OR 0.69 (95% CI; 0.03-17.81 p=0.82).  
The peak concentration of artefenomel (Cmax) the bloodstream varied from 319 
ng/mL to 981 ng/mL. The bloodstream Cmax for chloroquine varied from 563 ng/mL 
to 1606 ng/mL. The active metabolite N-desethylchloroquine (DCQ) bloodstream 
Cmax varied from 80 ng/mL to 238 ng/mL. There was no link between peak 
artefenomel, chloroquine or DCQ concentration (Cmax) or AUC96 and transaminase 
Model Measure OR (95% CI) p 
Drug  
(n=32) 
Drug type   
Chloroquine Reference  




Drug type  
Chloroquine Reference  
Artefenomel 4.50 (0.67-30.23) 0.12 
Treatment Day  
Treatment day 8 Reference  
Treatment day 10 4.67 (0.45-48.26) 0.20 
Drug and PCB 
(n=32) 
Drug type  
Chloroquine Reference  
Artefenomel 0.69 (0.03-17.81) 0.82 
PCB (log10 scale) 6.29 (0.64-61.80) 0.12 




elevations (Table 17 and appendix 12 table 6). The time until peak concentration 
(Tmax) of artefenomel, chloroquine and DCQ was 3 to 6 hours, 2 to 5.45 hours and 2 
to 5.73 hours respectively. All Tmax time frames were well before the peak of the 
transaminase increases which typically occur between 120 to 192 hours post dose. 
Peak ALT occurred before any recrudescence in subjects treated with artefenomel. 
ACETAMINOPHEN AND IBUPROFEN   





Total ibuprofen (g) 
Artefenomel median (IQR) 3.0 (2.5-5.5) 2.0 (1.8-3.2) 
 n (%) positive 8 (100%) 8 (100%) 
Chloroquine C1 median (IQR) - 1.0 (0-2.0) 
 n (%) positive - 5 (62.5%) 
Chloroquine C2 median (IQR) - 2.4 (1.5-4.6) 
 n (%) positive - 8 (100%) 
Chloroquine C3 median (IQR) 8.8 (5.0-10.0) - 
 n (%) positive 8 (100%) - 
IQR; interquartile range. Table summarising acetaminophen and ibuprofen use 
across IBSM cohorts. 
  




Figure 23. Peak ALT chloroquine cohort C2 (no acetaminophen) vs chloroquine 























































ALT; alanine transaminase, ULN; upper limit of normal. 
Peak ALT × ULN of subjects in chloroquine cohort C2 where acetaminophen (no 
ibuprofen) was used for analgesia/apyretic compared to chloroquine cohort C3 where 
ibuprofen (no acetaminophen) was used for analgesia/apyretic. 
There was no statistically significant difference in median peak ALT between cohort 
C2 (no acetaminophen use, ibuprofen use [1.6 g IQR; 0.8-3.5]) and cohort C3 
(acetaminophen use, no ibuprofen use [1.7 g IQR; 1-2.5]) (p=0.74).  
BLOOD STAGE MALARIA DOSE 
The total number of parasites inoculated per subject across all 32 subjects ranged 
from 8.5 × 105 to 1.27 × 106 parasites. The lowest inoculation dose occurred in the 




artefenomel cohort, which saw the greatest LFT changes. Chloroquine cohort C2 to 
C4 had a narrow inoculation dose range (1.17 × 106 to 1.27 × 106 parasites) despite 
significant differences in LFT abnormalities between the cohorts.  
ALTERNATIVE MEDICAL DIAGNOSIS 
No alternative medical diagnoses were found that would account for the observed 
transaminase elevations (e.g. viral hepatitis, alcohol). All subjects had tested 
negative for hepatitis BsAg and core antibody, hepatitis C antibody and HIV at day 
28 following completion of the active malaria infection component of the studies. 
One subject had a mildly raised bilirubin at day -1 having had a result within the 
normal range at screening. Study protocol allows for a single repeat of a raised ALT, 
AST or bilirubin at screening and for all subjects to have normal ALT, AST and 
bilirubin at day -3 to day -1. All subjects had BMI<30 with acceptable lipid profiles. 
Thus, in the context of largely normal pre-study LFTs and no significant medical 
history (e.g. diabetes), undiagnosed non-alcoholic steatohepatitis was thought to be 
unlikely. The pattern of LFT changes and clinical presentation was not in line with 
hepatitis A or E. 
Liver ultrasound was not carried out as it was felt that it would not yield anything 
significant in the context of asymptomatic transient transaminase elevations that 
resolved within days. The gold standard investigation to confirm or rule out DILI 
would be liver biopsy, but this was not carried out for ethical reasons. 
ENDEMIC STUDIES 
THAI STUDY 
41 patients had day 0 and day 7 ALT measures available and were included in the 
analysis (Figure 24). The median (IQR) age of 41 patients was 26 years (21-30); 32 
(78%) were male. Mean (range) parasite count for P. vivax infected patients was 
15,905/μL (5,010-53,400)226. 
  




Figure 24. Thai study ALT over time  


















ALT; alanine transaminase, ULN; upper limit of normal. 
Changes in ALT levels (U/L) over time for all 41 subjects. Day -1 represents the day 
0 pre-treatment value and day 0 represents the first ALT value post treatment. This 
was done to improve the graphical representation of the data. For ease of 
interpretation subjects 02-19 and 01-22 are represented by dotted and dashed lines 
respectively. The ULN for ALT in male and female subjects (40 U/L) from the assay 
used in the study has been included for reference. 
  




Table 20. Liver function test measurements in Thai study 
Measure (n=41) Day 0 pre-treatment 
mean (95% CI) 
Day 7 mean (95% CI) p 
ALT (U/L) 21.3 (17.9-25.3) 30.0 (24.7-36.5) p<0.001 
AST (U/L) 21.4 (19.1-23.9) 21.7 (19.2-24.5) p=0.81 
Total bilirubin (µmol/L) 16.6 (13.8-20.2) 7.2 (6.2-8.4) p<0.001 
ALT; alanine transaminase, AST; aspartate transaminase. 
Mean (95% CI) and results of paired t-tests for LFTs between day 0 pre-treatment 
and day 7 measurements in patients from Thailand artefenomel phase IIa study. 
Only one patient had a significant ALT elevation, with a maximum absolute increase 
of 156 U/L (20 U/L on day 0, 176 U/L on day 7, improving to 50 U/L on day 15) 
(Figure 24). This patient was treated with a 200 mg dose of artefenomel, the lowest 
dose used in the study. 
MALAYSIAN STUDY  
85 patients had day 0 and day 7 ALT measures available and were included in the 
analysis (Figure 25). The median (IQR) age was 16 years (11-64), and 63/85 (74%) 
were male. Median (IQR) parasite count was 4048 /μL (1523-8120). Not all subjects 
had day 0 AST or total bilirubin data (Table 21). 44 (51.8%) of the 85 subjects were 
treated with artesunate-mefloquine, 32 (37.7%) with chloroquine, 7 (8.2%) with 
artemether-lumefantrine & primaquine and 2 (2.4%) with chloroquine & primaquine.  
  




Figure 25. Malaysian study ALT over time 












ALT Day 0 to Day 7
Increase ALT Day 0
to Day 7
 
ALT; alanine transaminase, ULN; upper limit of normal.  
Day 0 and Day 7 ALT results for all subjects split into those who experienced an 
increase in ALT and those who experienced a decrease or no change in ALT. 
  




Table 21. Liver function test measurements in Malaysian study. 
Measure n Day 0 mean (95% CI) Day 7 mean (95% CI) p 
ALT (IU/L) 85 18.1 (15.1-21.7) 9.6 (8.4-10.8) p<0.001 
AST (IU/L) 19 14.9 (11.3-19.8) 16.7 (13.7-20.3) p=0.25 
Total bilirubin (µmol/L) 76 9.8 (7.9-12.2) 5.7 (5.3-6.1) p<0.001 
ALT; alanine transaminase, AST; aspartate transaminase. 
Mean (95% CI) and results of paired t-tests for LFTs between day 0 pre-treatment 
and day 7 measurements in patients from Sabah Malaysia dataset. 
No significant changes in ALT (≥2 × ULN) from day 0 to day 7 occurred in any 
patient in any of the treatment groups .The maximum absolute increase observed was 
22 IU/L, in a patient whose ALT increased from 8 IU/L on day 0 to 30 IU/L on day 
7. No subjects developed ALT abnormalities like those observed in the P. vivax 
IBSM dataset. 
DISCUSSION 
INDUCED BLOOD STAGE MALARIA 
DESCRIPTIVE SUMMARY 
Asymptomatic elevations in transaminases equal to or greater than 2 times the ULN 
without concomitant increases in bilirubin occurred in 14/32 (44%) subjects 
involved in the P. vivax IBSM studies. Levels generally rose above the ULN 3 days 
post treatment, peaking 5-8 days post treatment with resolution by 32 days post 
treatment. Peak ALT was typically greater than peak AST. Transaminase elevations 
mirroring those seen in the P. vivax IBSM studies were rare in the endemic P. vivax 
studies occurring in only 1/41 (2.4%) Thai patients treated with artefenomel, and 
none of the 85 Malaysian patients. 
In this analysis I was unable to identify a single factor that accounted for all the 
observed transaminase elevations in the P. vivax IBSM studies. However, 
statistically significant associations were observed between significant elevations in 
transaminase levels and PCB, inflammation and LDH. The abnormalities were not 




thought to be related to an alternative medical illness, direct effect of artefenomel or 
chloroquine, malaria inoculum dose or concomitant medication use including 
analgesia. No pre-treatment parameter was able to accurately predict which subjects 
would go on to develop significant transaminase elevations. 
ALT elevations were more common and severe in subjects with greater symptoms, 
and laboratory abnormalities. This may simply reflect that ALT elevations are more 
common and more severe in sicker patients.  
PARASITEMIA RELATED MEASUREMENTS  
PCt1/2 was not associated with elevations of ALT≥2 × ULN, whereas both peak 
parasitemia and PCB were significantly associated with ALT≥2 × ULN, with PCB 
having a mildly stronger association than peak parasitemia (both pre-treatment and 
overall). PCB is a composite of the rapidity of antimalarial effect and peak 
parasitemia, and thus encompasses the biomass of parasites cleared immediately post 
treatment. PCB is the more significant determinant of whether a subject is likely to 
experience an ALT elevation ALT≥2 × ULN, than PCt1/2, as it remained significant 
on univariate analysis. This could be explained by peak parasitemia being the 
stronger determinant of PCB, as the variation in peak parasitemia between subjects 
(3,980 parasites/mL to 331,130 parasites/mL) was greater than the variation in PCt1/2 
(2.83 to 6.72 hours). Furthermore PCB was more closely correlated to peak ALT 
than peak parasitemia and PCt1/2; correlation coefficient of 0.58 (p<0.001), 0.39 
(p=0.027) and -0.26 (p=0.16) respectively.  
PCB was significantly higher in subjects treated with artefenomel than in those who 
received chloroquine. This may explain why ALT elevations occurred more 
commonly in subjects treated with artefenomel. 
MARKERS OF HOST RESPONSE 
CRP levels peaked post antimalarial therapy regardless of whether subjects were 
treated on day 8 or 10, implying that CRP increases are primarily a result of post 
treatment effects rather than due to malaria infection alone.  
Higher maximum CRP and maximum temperature were associated with an increased 
risk of a peak ALT≥2 × ULN. All subjects with ALT≥2 × ULN had temp >38.3°C. 




CRP was the only parameter that remained significant following multivariable 
analysis with both chosen explanatory variables; PCt1/2 and PCB. This might suggest 
that systemic inflammation contributes to LFT abnormalities. This is in line with 
findings reported by Reuling et al220 who described a positive correlation between 
LFT abnormalities in 16 subjects from a single VIS study and interferon (IFN), IL-6 
and interleukin-8 (IL-8) levels 1 day post treatment and a strong correlation between 
cumulative inflammatory responses (IFNγ, MCP-1, IL-6, IL-8, IL-10, IL12p70, IL-
17a, IL-18) and LFT abnormalities (r=0.65 p=0.008)255. 
MARKER OF HAEMOLYSIS 
LDH was the only marker of haemolysis assessed during this analysis. A raised LDH 
was significantly associated with ALT≥2 × ULN (OR 1.89 × ULN [95% CI 1.21-
2.95]; p=0.005) and, alongside PCB, had the strongest correlation with peak ALT 
(r=0.58; p<0.001) aside from AST, suggesting a possible association with 
haemolysis and LFT abnormalities. However LDH is also elevated in ischaemic liver 
injury256, lymphomas257 and EBV infection258, none of which were thought to be 
contributing to the observed LFT abnormalities. This supports the hypothesis that 
elevated LDH was caused by haemolysis and increases RBC turnover259. However it 
is difficult to separate the effect of haemolysis on LDH from the effect of transient 
liver injury on LDH. Furthermore the difference in median peak LDH between those 
subjects with ALT≥2 × ULN (1.24 × ULN [IQR 1.05-1.36]) and ALT<2 × ULN 
(0.92 × ULN [IQR 0.84-1.08]) was relatively small suggesting it may not be 
clinically relevant.  
HAEMATOLOGICAL PARAMETERS 
Platelet count and neutrophil count were significantly associated with ALT 
elevation: these effects remained significant when the cohort effect was included. 
This may be explained by the fact that these parameters are not directly related to 
TNFα or the effects of haemolysis, but rather intrinsic host regulation of malaria and 
thus not as strongly affected by cohort as other parameters (PCB). None of the 
haematology parameters examined turned out to be reliable predictors of future ALT 
elevation.  





Subjects in the IBSM studies and treated with artefenomel generally experienced 
greater elevations in ALT than those treated with chloroquine (Figure 22). Drug 
related hepatotoxicity alone would not explain why LFT changes occurred in both 
chloroquine and artefenomel treated subjects, particularly as both possess different 
mechanisms of action. Chloroquine is a 4-aminoquinolone that acts against large ring 
form and mature trophozoite stages of malaria260. Artefenomel is a novel synthetic 
trioxolane226 closely related to artemisinins, it contains the peroxidic pharmacophore 
believed to be responsible for potent antimalarial activity of artemisinins261. 
Transaminase elevations were not reported in a phase I study with artefenomel 
undertaken in 26 healthy volunteers without malaria222. Moreover the only patient 
with P. vivax infection in the phase IIa Thai study who experienced a transaminase 
elevation similar to those observed in P. vivax IBSM was treated with the lowest 
dose of artefenomel (200 mg, maximum dose 1200 mg) used in the study, again 
suggesting a direct drug effect from artefenomel is less likely to be the underlying 
cause of the LFT abnormalities. Only 1/448 (0.2%) subjects experienced a grade 3 
(5.1-10 × ULN) transaminase elevation in a double-blind phase II study of single 
dose artefenomel (800 mg) in combination with piperaquine (640 mg, 960 mg or 
1440 mg) for treatment of P. falciparum malaria262. The authors did not comment on 
the dose of piperaquine this subject received or on the presence of lesser 
transaminase elevations. Although the odds of developing elevations of ALT≥2 × 
ULN with artefenomel compared to chloroquine were higher, when corrected for 
PCB, the strength of association with artefenomel disappeared (Table 18).  
I focused on PCB because it is a composite of the rapidity of antimalarial effect and 
peak parasitemia, and thus encompasses the biomass of parasites cleared 
immediately post treatment. In this way it distinguishes between artefenomel (a fast 
killing drug) and chloroquine, a drug with a slower effect on parasite clearance. PCB 
for the artefenomel treated cohort is greater than for the chloroquine cohorts overall 
and the two cohorts where chloroquine treatment occurred on day 10 (artefenomel 
subjects were all treated on day 10). Differences in PCB may account for why ALT 
elevations were greater in magnitude and frequency in subjects treated with 
artefenomel than with chloroquine.  




ACETAMINOPHEN AND IBUPROFEN 
The data suggest acetaminophen and ibuprofen are unlikely to have caused the ALT 
elevations during the P. vivax IBSM studies (Figure 23). Acetaminophen when 
consumed in excessive doses is known to produce ALT elevations in healthy 
subjects263. These elevations are much smaller than the elevations seen in IBSM and 
typically the total acetaminophen dose received by subjects was much smaller in the 
P. vivax IBSM studies. It is possible that malaria infection may lower the toxic 
threshold for acetaminophen264. However there are a lack of data to support this. 
Ibuprofen is not known to cause LFT abnormalities similar to those observed in P. 
vivax IBSM.  
CROSS INFECTION 
The HMP013 P. vivax was used to infect the volunteers. It has been screened 
extensively for blood borne pathogens and inoculum are produced under sterile 
conditions and undergo sterility testing after each inoculation. Hence unintentional 
transmission of infection during malaria inoculation is unlikely to have caused the 
observed LFT abnormalities. Moreover based on the relatively small variation in P. 
vivax inoculation dose across cohorts and the fact that the greatest number and 
severity of transaminase elevations occurred in the cohort with the lowest inoculum 
dose (artefenomel cohort), it appears that the inoculum is not responsible for ALT 
elevations. 
MALARIA PARASITE STRAIN 
Whole genome sequencing of HMP013 P. vivax HMP bank did not reveal any 
significant changes compared to the reference strain P. vivax Sal 1265, 266. Similar 
LFT abnormalities to those described in the P. vivax IBSM studies have been 
observed in IBSM studies using P. falciparum 3D750 and P. falciparum K13 R539T 
variant (ANZCTR Trial ID: ACTRN12617000244303 and 
ACTRN12617001394336), as well as in P. falciparum studies where the infection 
was induced by sporozoites220. Therefore, the observed abnormalities are unlikely to 
be due to a specific effect from any species or strain used during these studies. 





A fixed cohort effect was added to the regression models to account for any 
confounding effects from different cohort differences (e.g. treatment day, drug, pain 
relief protocol). A number of parameters went from statistically significance to non-
statistically significant once the cohort effect was added (Table 17). These included 
parasitemia related parameters and temperature. This was expected given the impact 
factors such as the day of treatment possess over peak parasitemia, or similarly the 
impact of antimalarial treatment over PCt1/2 both of which are determinants of PCB.  
ENDEMIC STUDIES 
In the Thai study only a single patient (1/41, 2.4%) had LFT changes similar to those 
observed in P. vivax IBSM, which was in line with the rates observed in endemic P. 
falciparum studies267. No LFT abnormalities were observed in patients from the 
Sabah Malaysia study.  
COMPARISON WITH OTHER INDUCED BLOOD STAGE MALARIA 
STUDIES 
Although absent from the original P. vivax IBSM pilot study72 transaminase 
elevations of >5 × ULN were reported in 4/6 (66%) subjects in a P. vivax IBSM 
study that used a different parasite isolate and donor RBCs to infect subjects60. The 
high proportion of subjects with LFT abnormalities in this study, in the context of 
rapid parasite clearance, and therefore likely high PCB, post artemether-
lumefantrine, are consistent with the findings reported here. Furthermore 5/6 
(83.3%) subjects in this study experienced temperature >39.0°C, suggesting subjects 
experienced significant inflammation (authors did not report individual temperature 
data). CRP was not measured. 
Similar transaminase elevations have been observed in P. falciparum IBSM50, 264 
suggesting that transaminase elevations in P. vivax and P. falciparum are caused by 
the same underlying mechanism. Abnormalities were observed following treatment 
with ferroquine50, KAE609 [NIH NCT02543086], SJ733 [NIH NCT02867059])  and 
piperaquine186 all of which are considered moderate or fast acting antimalarials and 




thus would be expected to have relatively high PCBs50, 186, 221, 268, 269, 270 in line the P. 
vivax findings. 
COMARISON WITH LIVER FUNCTION TEST ABNORMALITIES IN 
NATURAL MALARIA INFECTION 
In this analysis the focus was P. vivax related LFT abnormalities. However, studies 
involving other malaria species were included as the number of studies with P. vivax 
specific data is limited.  
Malaria hepatopathy is defined as bilirubin >2.5 × ULN and rise in transaminases >3 
× ULN211, 212, 213, 214, 215. Rates of malaria hepatopathy varied between 2.6% and 45% 
across all malaria species211, 212, 216, 217, 218, 219. Compared to malaria hepatopathy, LFT 
changes observed in malaria VIS differ significantly. LFT abnormalities in VIS are 
characterised by elevations in transaminases but not bilirubin and peak 
approximately 5-8 days post treatment compared to malaria hepatopathy which 
typically peaks around the time of treatment211, 212, 216, 217, 218. This suggests that 
malaria hepatopathy and LFT abnormalities in VIS are mediated by different 
mechanisms. 
To date the most comprehensive review of serial LFT testing in naturally acquired 
infection has been conducted by Woodford et al271. 130/861 (15.1%) of returned 
travellers to Queensland Australia experienced ALT>3 × ULN with moderate (3-5 × 
ULN), severe (5.1-10 × ULN) and very severe (>10 × ULN) cases totalling 73 
(56.2%), 41 (31.5%) and 13 (10%) respectively. 64.6% of these patients experienced 
their peak within 4 days of admission with the remaining 35.4% experiencing their 
peak between day 4 and day 11, the latter corresponds to the timing of abnormalities 
described in the P. vivax IBSM study. Woodford et al did not report any data on 
inflammation, such as temperature or CRP.  
In a recent randomised clinical trial in West Africa where four different artemisinin 
combination therapies were evaluated in 4710 patients with 8640 malaria episodes 
(7119 P. falciparum, 146 P. malariae, 31 P. ovale and 17 mixed infections), LFT 
testing occurred on day 0 (pre-dose), 3, 7 and 28. LFT changes mimicking those 
reported here were observed after treatment with all 4 drug combinations in 0.9% to 




3.9% of the 8640 treatment encounters, and were more commonly seen in children 
<5 years of age267. The majority of the significant ALT elevations that were 
observed, across all four arms, were >3 × ULN (range across four arms: 0.5-3%) 
with a smaller number of these subjects experiencing ALT>5 × ULN (range across 
four arms: 0.5-2.3%) and a minority with elevation >10 × ULN (range across four 
arms: 0-0.5%). The authors were not able to provide a unifying hypothesis for the 
transaminase elevations that were observed. 
Artemisinins, quinine and chloroquine are the most common current and historical 
treatments for severe malaria. Parasite clearance in P. vivax is fastest with artesunate 
followed by artemether, then chloroquine, with quinine possessing a slower 
clearance; parasite reduction rate over 24hrs (range) of 844 (110-2613), 508 (57-
3,869), 36 (1-1,184) and 4 (1-54) respectively272. If drug treatment has no effect on 
post treatment LFT changes, we would expect to see a similar pattern across all 
drugs. Alternatively, if PCB is a determinant of transaminase elevations it would be 
expected that LFT abnormalities occur more commonly in artemisinin-based therapy 
compared to chloroquine and fewer if any abnormalities in quinine based regimes.  
Most studies involving artesunate, chloroquine and quinine that attempted to assess 
LFT changes did not carry out testing at timepoints equivalent to when abnormalities 
were observed in IBSM studies224, 273, 274, 275, 276, 277, 278, 279 or did not comment on 
LFT findings taken at relevant timepoints280, 281, 282.  
Studies that reported LFT testing at corresponding timepoints to the IBSM 
abnormalities, persistently identified small numbers of patients with transaminase 
elevations that mirrored those seen in P. vivax IBSM in those treated with 
artemisinins267, 283, 284, 285. LFT abnormalities were much less common, if present at 
all, in patients treated with chloroquine and quinine compared to those treated with 
artemisinins283, 285.  
Absence of testing at time points of interest was an issue in many studies assessing 
the efficacy of antimalarials. Authors would not necessarily have been looking for 
post treatment LFT abnormalities as artemisinins did not demonstrate LFT 
abnormalities in phase I studies223, 286, 287. Similarly chloroquine and quinine are not 




commonly associated with the development of LFT abnormalities that require 
routine monitoring.  
POTENTIAL IMPLICATIONS 
Physicians should become familiar with this phenomenon and remain vigilant for 
evidence of severe liver injury. Although, it is important to recognise that this 
observation represents a transient and asymptomatic finding. Typically patients 
would have completed their antimalarial treatment before any significant change in 
their transaminases. Therefore it should not affect antimalarial treatment. However 
other drugs, including antibiotics that are commonly prescribed alongside 
antimalarials for suspected or confirmed bacterial infection (e.g. typhoid), may be 
incorrectly implicated and stopped or changed unnecessarily. Furthermore it may 
result in unnecessary investigation, which may prove costly (ultrasound) or even 
dangerous (liver biopsy). When monitoring for resolution, where possible, is 
sufficient. Moreover transaminase elevations may be incorrectly assigned as a direct 
drug effect of antimalarial treatment (e.g. artesunate). In addition, incorrect 
assignment to a NCE could affect ongoing drug development resulting in delays or 
even cancellation of the drugs’ development. Drugs with rapid parasite clearance are 
associated with improved prognosis288. LFT abnormalities are seemingly linked to 
PCB, which in turn is partly dependant on parasite clearance rate. Therefore drugs 
with rapid parasite clearance rates may end up becoming victims of their own 
success as they are more likely to be associated with transaminase elevations. 
This issue is likely to occur in future IBSM studies. IBSM studies are often 
considered the most appropriate pre-endemic testing medium where such 
abnormalities can be identified in advance, documented and separated from true drug 
effect. If encountered in the endemic setting, transaminase elevations would be more 
difficult to untangle as monitoring, subject review and investigation is much more 
challenging. Furthermore, if there was to be an incidental rise in bilirubin (e.g. from 
a concomitant illness or medication) this may result in a technical case of Hy’s law. 
During a large trial this may occur several times, which may result in the trial being 
stopped. Hence it is important that pharmaceutical sponsors are aware of, and 
understand, transaminase elevations in malaria, so that the IBSM model is not 




avoided for fear of abnormal LFTs affecting drug development. Indeed, the presence 
of these transaminase elevations could be seen as a “badge of honour” as they are a 
surrogate marker of rapid parasite clearance.  
In light of the findings it could be questioned whether the search for drugs with 
faster and faster parasite clearance is a necessary and appropriate goal. In theory, if 
the observed transaminase elevations were to occur in individuals with existing liver 
impairment it could be problematic. For example it could result in a patient with 
compensated liver failure becoming decompensated. Reassuringly artesunate has 
been established in many countries as the 1st line treatment for severe malaria for 
more than a decade and yet review of the literature did not reveal a single case report 
of mortality or long-lasting liver impairment associated with transaminase elevations 
similar to those seen in IBSM studies. However, it is important to note that 
physicians may not be looking for such abnormalities and thus would not necessarily 
report them. In retrospect, the absence of LFT testing at timepoints that correspond 
to transaminase elevations in IBSM studies during the seminal artesunate efficacy 
trials130, 131 appears fortunate. As if LFT testing had occurred and led to the 
identification of transaminase elevations it may conceivably have led to the stalling 
or even abandonment of artesunate drug development.   
POTENTIAL BIOLOGICAL MECHANISM 
My analysis suggests PCB and inflammation appear to be factors in determining 
which subjects develop ALT elevations. A possible explanation may be the response 
to the demands of rapid haemolysis. Haemolysis is a universal consequence of 
malaria, affecting both parasitised and unparasitised RBC. Haemolysis leads to the 
release of free haemoglobin to plasma which is subsequently removed from the 
circulation by haptoglobin, hemopexin and heme oxygenase 1 (HO-1)289, 290, 291. In 
severe haemolysis haptoglobin, hemopexin and HO-1 capacity is overwhelmed 
leaving free heme to concentrate in serum. This process is summarised in the below 
figure.  
  




Figure 26. Haemolysis in malaria 
 
Figure 26 taken from Mendonça et al292 demonstrating the primary mechanisms 
underlying haemoglobin metabolism in malaria.  
Extracellular free haemoglobin and free heme are both agents that can induce 
significant oxidative stress230, 293, 294 resulting in cell death via oxidative stress 
mediated necrosis and apoptosis295, 296. Heme is thought to sensitise cells to TNFα 
mediated apoptosis296, 297, 298, 299 manifesting clinically as ALT/AST elevations from 
hepatocyte leakage300, 301, 302.  
LFT abnormalities similar to those in P. vivax IBSM studies have been observed in 
malaria mouse studies297, 303. The addition of zinc protoporphyrin, which inhibits 
HO-1, resulted in greater LFT abnormalities and hepatocyte apoptosis. Mouse 
hepatocyte studies demonstrated that at concentrations encountered in vivo during 
malaria infection, neither free heme nor TNFα were enough to induce cell death 
independently, but together they produced significant hepatocyte cell death (>25% of 
total hepatocytes)296, 297, 298, 299. Mouse studies suggest that LFT abnormalities are a 
result of free heme, produced by the saturation of intrinsic mechanisms designed to 
protect against damage from heme, released through post treatment haemolysis, 
acting synergistically with malaria induced TNFα. 
This may explain why PCB, LDH, temperature and CRP were all associated with an 
increased risk of developing significant elevations in ALT. TNFα triggers CRP 
production240, and has also been shown to be closely related to fever in P. vivax 
infection250. CRP and temperature may represent proxy measures of TNFα in this 
analysis. 
Free heme and TNFα mediated hepatocyte apoptosis may explain the LFT 
abnormalities observed in the West African network study267 discussed earlier. This 




study involved high numbers of subjects all treated with artemisinin-based regimes 
with fast parasite clearance and thus high PCB. Furthermore there was a relatively 
large number of children <5 years of age in each arm, who are more likely to mount 
a vigorous TNFα response than the adult population from the same area304, 305. 
Moreover, LFT testing occurred on day 3 and day 7 increasing the chances that 
significant elevations in transaminases are identified.  
Furthermore this hypothesis could explain the lack of LFT abnormalities in malaria 
patients treated with chloroquine and quinine compared to artemisinin. The slower 
onset of action of chloroquine and quinine would be expected to result in less 
haemolysis and TNFα generation, through hemozoin phagocytosis, and hence more 
modest transaminase elevations. 
This may also explain why significant ALT elevations were not observed in the 
Sabah Malaysia study. Chloroquine was used in 34/85 (40.1%) of subjects, only one 
subject was <5 years of age and LFTs occurred on day 0 and 7 only, resulting in 
lower PCB, greater levels of malaria immunity304 and fewer datapoints to detect 
transaminase elevations respectively. It should be noted that in general immunity to 
P. vivax malaria is significantly lower in Sabah than malaria endemic areas in West 
Africa28, 304, and thus patients are likely to produce higher amounts of TNFα which 
may play a key role in the development of transaminase elevations. Such 
characteristics may reduce the likelihood of detecting transaminase elevations, but 
the absence of any elevations suggests an alternate explanation. One possibility is 
that patients in Sabah could possess a genetic polymorphism that limit the formation 
of toxic free heme306 a potential factor in the causality of the LFT abnormalities. 
However genetic predisposition alone does not explain why transaminase elevations 
occur across several VIS sites around the world, are more common and severe in 
artefenomel treated subjects compared to chloroquine treated subjects, nor the 
relatively recent recognition of this phenomenon, or the association with PCB. 
Alternatively the high prevalence of iron deficiency307, 308, 309 in the population may 
protect against the formation of free heme306. Iron deficiency anaemia is common in 
Sabah with levels varying from 20% in adolescents307, 40% in pregnant females308, 
309 and up to 55% children310. Data on the prevalence of iron deficiency specifically 
in Bangkok and north west311 Thailand is limited.  




Although there is evidence to support the hypothesis that post treatment LFT 
abnormalities in malaria are secondary to free heme and TNFα, this remains 
unproven and requires further investigation.  
UNIFYING HYPOTHESIS ADDRESSING PLASMODIUM VIVAX 
INDUCED BLOOD STAGE MALARIA 
I hypothesise that transaminase elevations in IBSM P. vivax studies are thought to be 
due to a combination of; the use of drugs with fast parasite clearance overwhelming 
pathways designed to protect against haemolysis resulting in free heme. Free heme 
together with TNFα, produced in greater amounts by non-immune human volunteers 
compared to individuals infected in the endemic setting253, 312, result in hepatocyte 
apoptosis manifesting as transaminase elevations. Furthermore, ascertainment bias 
meant LFT testing in IBSM studies occurred at timepoints corresponding to peak 
transaminase elevations in contrast to studies in the endemic setting. 
STRENGTHS AND LIMITATIONS 
Rich data sampling in IBSM studies allowed for the investigation of parasite 
clearance rate, PCB, haemolysis and inflammation as potential explanations of LFT 
abnormalities. Despite being the largest dataset of LFT abnormalities in P. vivax 
IBSM, the relatively small number of subjects mean any conclusions should be made 
with caution, and a larger dataset would be required for a more robust multivariable 
analysis.  
Differences between cohorts, meant comparisons across cohorts was difficult and 
could have the outcome of removing the power of certain associations e.g. in the 
case of PCB which is strongly affected by both day of treatment and the antimalarial 
used.  
Additional testing for markers of haemolysis, free heme, and TNFα was not 
undertaken. Instead PCB, LDH and markers of inflammation were considered as 
potential proxy measures for free heme and TNFα246, 247, 249, 250. PCB has not been 
described before, as such there is no existing literature regarding its association with 
haemolysis. An advantage of PCB is that it can easily be applied to other studies as it 
uses existing data and does not require any additional sampling. Conversely, as it is 




calculated solely from two data points it may be susceptible to bias. Moreover during 
this analysis LDH was interpreted primarily as a marker of haemolysis. However it is 
difficult to exclude a direct effect from the liver. 
RECOMMENDATIONS 
Physicians must be made aware of transaminase elevations post antimalarial 
treatment and remain vigilant for evidence of severe liver injury. Although, it is 
important to recognize that these observations represent a transient and 
asymptomatic finding and monitoring for resolution is all that is required currently. 
Researchers and pharmaceutical companies should become familiar with this 
phenomenon so that alternate explanations for the causation of LFT changes can be 
considered in the course of clinical development of antimalarials. 
Prospective testing for TNFα and free heme during the time of malaria infection and 
subsequent transaminase elevation in a P. vivax IBSM study would provide definite 
evidence for the proposed hypothesis. Furthermore if possible, samples should be 
taken during the study that allow for retrospective testing of haptoglobin, 
hemopexin, ferritin and HO-1. In addition routine testing for CRP and calculation of 
PCB is being considered in future IBSM study designs.  
Retrospective testing of existing patient samples from IBSM studies, other VISs or 
endemic studies for markers of haemolysis and inflammation would provide a more 
rapid source of data to corroborate the findings observed during this analysis. 
Testing for inflammatory markers other than CRP and TNFα, as have occurred in 
other studies, would be useful220.     
Extending the analysis to the remaining P. vivax, and larger, P. falciparum IBSM 
datasets may provide additional information. Specifically maximum temperature, 
laboratory markers for inflammation and haemolysis, and parasitemia related factors 
including peak parasitemia, PCt1/2 and PCB should be compared against peak ALT.  
Ideally this should be implemented across a range of IBSM studies involving NCEs 
and existing antimalarial treatments, including any that have been implicated as 
possible causes of transaminase elevations. Studies lacking transaminase elevations 
should be included as relevant controls. In order to better understand the effects of 




PCt1/2 and PCB on post-treatment transaminase elevations, it would be desirable to 
include studies assessing antimalarials with a range of parasite clearance rates.    
Going forward it may be prudent to re-evaluate the conventional study cut-off of 
ALT≥2.5 × ULN, originating from cancer treatment trials313, to a cut off that may 
more accurately capture the observed phenomenon in healthy volunteers thus 
allowing for a more accurate assessment of causality and risk factors, namely 
ALT≥2 × ULN. A reduction in the cut off could only be implemented following 
assessment of individualised data to ensure ALT elevations peak post treatment in 
asymptomatic subjects with elevations in ALT being greater than AST and occurring 
without significant elevations in bilirubin and with no alternative cause. 
It would be valuable to retrospectively review existing data from natural malaria 
infection studies for evidence of transaminase elevations, beginning with studies 
involving returned travellers with malaria treated with artemisinin-based therapies, 
as such patients are more likely to yield positive findings. 
Prospective LFT testing during a large randomised control trial comparing a fast and 
slow acting antimalarial in the treatment of P. vivax malaria in the endemic setting 
and returned travellers would provide the ideal way of assessing for this 
phenomenon in natural infection. Conversely routinely incorporating LFT testing on 
days 3, 5 and 7 post treatment into antimalarial trial study design would be easier to 
implement. 
CONCLUSION 
Post treatment LFT changes are transient, asymptomatic and appear to be more 
common in P. vivax IBSM than in natural infection. Evidence indicates that PCB, 
haemolysis and systemic inflammation post antimalarial treatment may be drivers for 
the transaminase elevations observed in P. vivax IBSM studies. However, the 
mechanisms underlying these abnormalities remain unclear and require further 
investigation. Going forward it would be appropriate to conduct a similar analysis on 
LFT abnormalities seen in P. falciparum VIS studies and incorporate LFT testing on 
days 3, 5 and 7 post treatment initiation, where possible, into the study design of 
antimalarial clinical trials. Researchers and pharmaceutical companies should 




become familiar with these findings so that this phenomenon can be better 
understood, and alternate explanations of the causation of LFT changes can be 
considered in the development of antimalarials. 
  




CHAPTER 6 DISCUSSION 
Volunteer infection studies (VIS) have become valuable tools for basic research and 
the development of new interventions against a number of infectious diseases39, 40, 41, 
42, 43. Safety is critical to the future success of VIS. A single serious adverse event 
could risk the future of VIS models worldwide. Moreover the media and political 
fallout in the event of a serious breach of safety could have wide ramifications. 
In the absence of long-term culture and the resulting limitations on assessments of 
drug efficacy, P. vivax IBSM offers the potential to link pre-clinical research and 
expensive field studies. The aim of this thesis was to explore safety concerns around 
the P. vivax IBSM model, by centring around an exploratory study using apheresis as 
a method to extract and concentrate all stages of P. vivax parasites from healthy 
volunteers infected with blood stage P. vivax. Specific safety concerns for P. vivax 
IBSM include transfusion related infection, transfusion reactions, alloimmunisation, 
exposure to infectious materials and onward malaria transmission. These concerns 
were addressed prior to initiation of the P. vivax apheresis exploratory study. 
Mitigation strategies against existing safety concerns in malaria VIS have been well 
established. To prepare for the apheresis study, I conducted a review of the safety of 
apheresis in the treatment of P. falciparum infection. To provide a comprehensive 
analysis the review was extended to include the use of apheresis in babesiosis, as 
babesiosis shares many similarities with malaria121, 122. Furthermore to maximise the 
benefit to the scientific and clinical community the scope of the review was 
increased to include an analysis of apheresis in the treatment of loiasis and severe 
pertussis infections. 
The quality of the published data retrievable for the review was low, consisting of 
case studies, case series and cohort studies with no randomised control trials. With 
the exception of apheresis in severe pertussis, no serious safety concerns were 
identified. The aim of apheresis treatment in severe pertussis (reduction of leukocyte 
burden), differ considerably from malaria and thus the safety concerns were 
considered sufficiently distinct to be excluded. Efficacy data supported the use of 
apheresis as adjuvant treatment in patients hospitalised for babesia, and prior to 
chemotherapy in loiasis with microfilarial count >8000/mL.  




The data did not support the routine use of apheresis in severe P. falciparum malaria. 
However adjunctive treatment with apheresis tended to be initiated in the sickest 
patients with severe P. falciparum (higher parasitemias and APACHE-2 scores)132, 
172, 173 which may account for the lack of demonstratable benefit when compared to 
chemotherapy alone157, 161. The available data support the safety of apheresis in 
severe P. falciparum. Thus, apheresis could be utilised in the treatment of severe P. 
falciparum with poor prognosis, particularly when there is no access to intravenous 
artesunate314, the patient is allergic to artemisinin167, 168 or at risk of infection with an 
artemisinin resistant P. falciparum315. If used, apheresis should not delay initiation of 
antimalarial treatment, it should take place at least 4 hours post artesunate dosing, 
and should be discontinued if the patient develops hypotension during the procedure, 
to avoid any adverse events from the use of intravenous fluids169. Although the focus 
should remain on improving access to intravenous artesunate and the development of 
new clinical entities (NCE) active against artemisinin resistant parasites, in the 
meantime apheresis may be considered on a case by case basis. 
A mismatch exists between the location of most loiasis316, 317 and severe P. 
falciparum28 cases and the location of most apheresis units. This together with the 
low numbers of severe pertussis140, 318 and babesia133, 172, 173 cases mean that 
randomised control trials assessing the use of apheresis in any of these conditions are 
unlikely to occur. Therefore the data compiled during the review is the best currently 
available and unlikely to be greatly improved in the near future.  
The phase 1 exploratory study, aimed at assessing the use of apheresis in healthy 
volunteers infected with blood stage P. vivax in order to harvest all life cycle stages 
of P. vivax, did not identify any serious safety concerns. However it failed to 
produce sufficient concentration of P. vivax parasites to meet its study objectives. At 
the end of each cohort an analysis was conducted, and hypotheses were formed as to 
why the desired outcomes were not met. The study plan was subsequently adjusted 
in light of these hypotheses but still failed to produce results that supported the use 
of apheresis as a method for harvesting parasites for downstream experimentation. 
The data accrued were in agreement with previous data that suggested that P. vivax 
and P. falciparum gametocytes and asexual parasites preferentially concentrate 
around the Buffy coat, and that concentrating for reticulocytes does not necessarily 




improve the yield of P. vivax parasitised RBCs191. This information may be used in 
future attempts to concentrate and preserve P. vivax parasites outside of the setting of 
apheresis, or in the future use of adjuvant apheresis for the treatment of P. 
falciparum. However, with the exception of cohort 4 the procedure employed during 
the apheresis exploratory study is likely to differ substantially to that used for 
treatment.  
Increased transmission to mosquitos in membrane feeding using apheresis samples 
compared to pre-apheresis was only identified on one occasion. Although an 
interesting finding, the magnitude of improvement was insufficient to support the 
use of apheresis in this context. As percoll enrichment results in a higher rate of 
transmission73 this is preferred. Given the expense and safety concerns in IBSM 
studies, conducting such a study based on a single result would be inappropriate. 
The level of parasite concentration seen was not sufficient to warrant further 
investigation, given the significant ethical and resource concerns in IBSM studies. It 
is important that funding and political support for P. vivax research continues. 
Without this support it is unlikely that an effective, reliable and logistically 
acceptable source of P. vivax parasites necessary for basic and translational research 
will be discovered. This limitation remains a major impediment to the discovery of 
new hypnozoiticidal therapies.   
No new safety issues were identified during the apheresis exploratory study. 
However, an existing safety concern, namely transaminase elevations, were seen in 
three out of the four subjects who took part in the study.  
LFT abnormalities observed in P. vivax IBSM are thought to result from 
antimalarials inducing rapid parasite clearance overwhelming pathways designed to 
protect against haemolysis resulting in the release of free heme. I hypothesise that 
free heme together with TNFα, produced in greater amounts by non-immune human 
volunteers compared to individuals infected in the endemic setting253, 312, induce 
hepatocyte apoptosis resulting in transaminase elevation. 
The associations between peak ALT and parasite clearance burden (PCB), LDH, 
CRP and temperature are in line with this hypothesis. In my study I described a new 
metric, namely PCB. PCB was designed to represent the level of saturation of 




intrinsic pathways designed to protect against the potentially damaging by-products 
of haemolysis post antimalarial treatment230, 289, 293, 294, 319, 320. PCB was calculated 
without the need for further sampling and can be readily applied to other malaria VIS 
where qPCR has been used to monitor parasite clearance post treatment. Furthermore 
the abnormalities seen in P. vivax IBSM have been identified in field studies267. 
Understandably these abnormalities have been met with concern from clinicians, 
researchers, ethics committees and pharmaceutical collaborators.  
Several hypotheses have attempted to explain transaminase elevations220, none of 
which fully explain why the observed abnormalities occurred across different VIS 
methodologies, different parasite species and strains, multiple antimalarial 
candidates and were not prominent in the history of clinical research in malaria. Free 
heme and TNFα induced hepatocyte apoptosis is a possible explanation for the 
observed abnormalities. Clinicians who manage naturally acquired malaria should 
become familiar with these observations to avoid unnecessary investigation or 
treatment. 
In retrospect adverse events caused by rapid clearance of large malarial parasite 
loads would be in line with post treatment findings in other blood borne parasitic 
infections, namely loiasis321, lymphatic filariasis322 and onchocerciasis323. It could be 
considered fortuitous that such problems were not anticipated during the era of 
artemisinin development. Had they been anticipated, additional LFT testing during 
investigational studies may have been the result. The subsequent identification of 
LFT abnormalities may have led to the discontinuation of artemisinin drug 
development.  
Available data on the use of apheresis in the treatment of severe P. falciparum 
infection do not support its implementation for this indication. While the conduct of 
an appropriately powered randomised control trial would provide a definite answer, 
the logistic challenges of undertaking such a study represent important barriers. 
Establishment of apheresis in resource limited settings for the treatment of other 
conditions, such as sickle cell disease324, 325, 326, could allow for future randomised 
control trials comparing standard therapy and adjunctive apheresis to standard 
therapy alone. Until the necessary infrastructure and financial support are in place 
for a randomised control trial, it would be sensible to establish a clinical registry, 




with standardised reporting of apheresis procedures carried out in the treatment of 
severe P. falciparum. Important measures would include recording of pre and post 
apheresis parasitemia, safety data and clinical outcomes. 
The apheresis exploratory study was terminated when it became apparent that the 
procedure was not sufficiently concentrating parasites. It is possible that technical 
advances or improvement in processes may facilitate future experiments for example 
increasing the level of gametocytes to permit more efficient transmission in 
mosquito feeding assays, and potentially increasing the number of sporozoites 
harvested from mosquito salivary glands. Such experiments may also define the 
buoyancy of P. vivax parasites across haematocrit (HCT) layers, potentially 
informing any future apheresis studies. 
Going forward research should include extending the LFT analysis to P. vivax, and 
larger, P. falciparum IBSM datasets. It would be prudent to use ALT≥2 × ULN cut 
off to allow for a more accurate assessment of causality and risk factors for post 
treatment LFT abnormalities. Moreover, prospective testing for free heme and TNFα 
during an IBSM study would provide definitive evidence of free heme and TNFα 
induced hepatocyte apoptosis. Furthermore, mechanistic studies in pre-clinical 
models, such as the establishment of a malaria mouse model with testing of LFTs, 
free heme, markers of haemolysis and TNFα post antimalarial treatment, will allow 
for greater understanding of the processes underlying the observed LFT 
abnormalities. 
A large multi-arm randomised control trial comparing fast and slow acting 
antimalarials, including those associated with transaminase elevations in IBSM, for 
the treatment of P. vivax infection, both in endemic settings and returned travellers, 
with prospective LFT testing would advance understanding of post treatment LFT 
abnormalities in natural infection. Given the expense and resources required for such 
a study, incorporating LFT testing on days 3, 5 and 7 post treatment into the design 
of antimalarial drug trials would be more readily implemented. Finally, it would be 
prudent to conduct a more comprehensive review of existing data from natural 
malaria infection studies for evidence of transaminase elevations.  




P. vivax IBSM studies are a safe and acceptable model for the study of P. vivax 
parasite biology, immunology and transmission, and the development of new 
interventions against this parasite. However, the precise execution of existing safety 
controls, risk assessment of new safety concerns and the thorough and prompt 
assessment of genuine safety signals are necessary to maintain the acceptability of P. 
vivax IBSM. 
  




SUMMARY OF KEY FINDINGS 
Apheresis may be a useful adjunct to chemotherapy in the treatment of patients 
hospitalised for babesia, and prior to chemotherapy in loiasis with microfilarial count 
>8000/mL. The data did not support the use of apheresis in critical pertussis 
infection or for patients with severe P. falciparum malaria.  
Apheresis can be carried out safely in healthy volunteers infected with P. vivax and 
is able to achieve a modest level of parasite enrichment compared to whole blood 
sampling (4.9-fold and 1.45-fold per mL of sample for asexual parasites and 
gametocytes respectively) but the level of enrichment was not sufficient to 
recommend apheresis as a method for harvesting P. vivax parasites. 
Post treatment transaminase elevations are transient, asymptomatic and appear to be 
more common in P. vivax IBSM than in natural infection. Evidence indicates that 
parasite clearance burden, haemolysis and systemic inflammation post anti-malarial 
treatment may be drivers for the observed transaminase elevations. 
 
  






APPENDIX 1. SAFETY AND EFFECTIVENESS OF APHERESIS IN THE 
TREATMENT OF INFECTIOUS DISEASES: A SYSTEMATIC REVIEW 
PROTOCOL. 
Keywords 
apheresis; erythrocytapheresis; falciparum, leukocytapheresis; red cell exchange; 
malaria; babesia; babesiosis; loa; loiasis; pertussis, cytapheresis, plasmapheresis  
Inclusion criteria 
Types of participants 
This review will consider studies that include: 
• Male or Female patients of any age with severe falciparum malaria treated 
using apheresis 
• Male or Female patients of any age with loiasis infection treated using 
apheresis 
• Male or Female patients of any age with babesiosis infection treated using 
apheresis 
• Male or Female patients of any age with severe pertussis infection treated 
using apheresis 
Types of intervention(s)/phenomena of interest 
This review will consider studies that evaluate automated apheresis Types of 
automated apheresis to be evaluated are removal of: 
• red cells (erythrocytapheresis) 
• white cells (leukocytapheresis) 
• plasma (plasmapheresis) 
In addition to type, the following characteristics of apheresis will be abstracted from 
papers (where documented): 
• apheresis protocol (e.g. number of cycles) 




• apheresis equipment (e.g., Hemonetics model, COBE Spectra, etc) 
• continuous or discontinuous removal and replacement of blood cells 
This review will not consider studies that evaluate whole blood exchange 
transfusion.  
Types of outcomes 
This review will consider studies that include the following outcomes relating to 
effectiveness and safety of apheresis. In case of any uncertainty of 
inclusion/exclusion of a study other clinical authors will be asked to review and 
clarify.  
Outcomes relating to effectiveness are: 
Malaria  
• Reduction in percentage parasitaemia   
• Clinical outcome (survival vs death) 
Loiasis 
• Percentage reduction microfilariae 
• Successful reduction of microfilariae <8000/mL 
• Resolution of symptoms  
Babesiosis 
• Percentage reduction parasitaemia 
• Clinical outcome (survival vs death) 
Pertussis 
• Percentage reduction in leukocyte count 
• Clinical outcome (survival vs death) 
Outcomes relating to safety are: 
Malaria  
• Number of adverse events due to apheresis 
• Type of adverse events due to apheresis 
• Number of complications  
• Type of complications 





• Number of adverse events due to apheresis 
• Type of adverse events due to apheresis 
• Number of complications  
• Type of complications 
Babesiosis 
• Number of adverse events due to apheresis 
• Type of adverse events due to apheresis 
• Number of complications  
• Type of complications 
Pertussis 
• Number of adverse events due to apheresis 
• Type of adverse events due to apheresis 
• Number of complications  
• Type of complications 
Types of studies 
Literature searches will not be restricted to a type of study; however, it is anticipated 
that most (or all) of the relevant studies will be case reports.  
Search strategy 
The search strategy aims to find both published and unpublished studies. A two-step 
search strategy will be utilized in this review. An initial limited search (see below) of 
MEDLINE, PUBMED, EMBASE and CINAHL will be undertaken followed by an 
analysis of the text words contained in the title and abstract, and of the index terms 
used to describe article. Secondly, the reference list of all identified reports and 
articles will be searched for additional studies. Studies published in all languages 
will be considered for inclusion in this review. Papers not written in English and 
identified as potentially relevant (based on their title and/or abstract) will be 
translated as required. Because apheresis was introduced in the 1970s, searches will 
be restricted to studies published from 1 January 1969 to current. Animal studies will 
be excluded. 




The indexes of the following journals will be hand searched: Journal of Clinical 
Apheresis, Transfusion and Apheresis Science, Therapeutic Apheresis and Dialysis,  
The databases to be searched include: MEDLINE, EMBASE, PUBMED, 
COCHRANE and CINAHL. 
The search for unpublished studies will include American society for apheresis. 
Data extraction 
Data from papers will be extracted into four Excel spreadsheets (1 spreadsheet per 
condition). The data extracted will include specific details about the apheresis 
intervention, populations, study methods and outcomes of relevance to the review 
questions and objectives.  
Data synthesis 
Quantitative data will, where possible be pooled in statistical meta-analysis using 
JBI-MAStARI. All results will be subject to double data entry. Effect sizes 
expressed as odds ratio (for categorical data) and weighted mean differences (for 
continuous data) and their 95% confidence intervals will be calculated for analysis 
#modify text as appropriate#. Heterogeneity will be assessed statistically using the 
standard Chi-square and explored using subgroup analyses based on the different 
study designs included in this review. Where statistical pooling is not possible the 
findings will be presented in narrative form including tables and figures to aid in data 
presentation where appropriate. However, going into the review, we expect that the 
data will only allow for descriptive analysis. 






Initial World Health Organization criteria from 1990 
Cerebral malaria Unarousable coma not attributable to any other 
cause, with a Glasgow Coma Scale score ≤ 9. Coma 
should persist for at least 30 min after a generalized 
convulsion 
Severe anemia Haematocrit <15% or haemoglobin < 50 g/L in the 
presence of parasite count >10 000/μL 
Renal failure Urine output <400 ml/24 hours in adults (<12 
mL/kg/24 hours in children) and a serum 
creatinine>265 μmol/L (>3.0 mg/dl) despite 
adequate volume repletion 
Pulmonary edema and acute 
respiratory distress syndrome 
The acute lung injury score is calculated on the basis 
of radiographic densities, severity of hypoxemia, 
and positive end-expiratory pressure  
Hypoglycemia Whole blood glucose concentration <2.2 mmol/l 
(<40 mg/dL) 
Circulatory collapse (algid 
malaria) 
Systolic blood pressure <70 mmHg in patients >5 
years of age (<50 mmHg in children aged 1–5 
years), with cold clammy skin or a core-skin 
temperature difference >10°C 
Abnormal bleeding and/or 
disseminated intravascular 
coagulation 
Spontaneous bleeding from gums, nose, 
gastrointestinal tract, or laboratory evidence of 
disseminated intravascular coagulation 
Repeated generalized 
convulsions 
≥3 convulsions observed within 24 hours 





Acidemia/acidosis Arterial pH <7.25 or acidosis (plasma bicarbonate 
<15 mmol/L) 
Macroscopic haemoglobinuria Haemolysis not secondary to glucose-6-phosphate 
dehydrogenase deficiency 
Added World Health Organization criteria from 2000 
Impaired consciousness Rousable mental condition 
Prostration or weakness 
 
Hyperparasitaemia >5% parasitized erythrocytes or >250000 
parasites/μL (in nonimmune individuals) 
Hyperpyrexia Core body temperature >40°C 
Hyperbilirubinemia Total bilirubin >43 μmol/L (>2.5 mg/dL) 
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STATEMENT OF COMPLIANCE  
Investigator declaration  
I have read the protocol and agree that it contains all necessary details for carrying out the 
study as described. I will conduct this protocol as outlined herein and will make a reasonable 
effort to complete the study within the time designated.  
I agree to personally conduct or supervise the described study.  
The study will be conducted in accordance with the following:  
• World Medical Association Declaration of Helsinki – Ethical Principles for Medical 
Research Involving Human Subjects (Fortaleza, Brazil 2013).  
• NHMRC National Statement on Ethical Conduct in Human Research (2007, updated 
May 2015).   
• Notes for Guidance on Good Clinical Practice – Annotated with TGA Comments 
(CPMP/ICH/135/95), as adopted by the Australian Therapeutic Goods Administration 
(July 2000).  
• Current ethics approved Clinical Trial Protocol.  
I agree to inform all subjects that the study drug is being used for investigational purposes and I 
will ensure that the requirements related to obtaining informed consent are in accordance 
with ICH Guidelines for Good Clinical Practice (GCP) section 4.8 and local requirements.  
I agree to report adverse events that occur in the course of the study to the Sponsor in 
accordance with ICH Guidelines for GCP section 4.11 and local requirements.  
I have read and understand the information in the Investigator’s Brochure, including the 
potential risks and side effects of the study drug.  
I agree to promptly report to the Human Research Ethics Committee (HREC) all changes in the 
research activity and all unanticipated problems involving risk to subjects. I will not make any 
changes to the conduct of the study without HREC and Sponsor approval, except when 
necessary to eliminate apparent immediate harm to subjects.  
I agree to maintain adequate and accurate records and make those records available in 
accordance with ICH Guidelines for GCP section 4.11 and local requirements.  
I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the 
study are informed about their obligations in meeting the above commitments.  
I understand that the study may be terminated or enrolment suspended at any time by the 
Sponsor, with or without cause, or by me if it becomes necessary to protect the best interest of 
the subjects.  
______________________________                            Date: _____________________________ 
Prof. James McCarthy, Principal Investigator  





The undersigned agrees that the protocol was written in accordance with the World Medical 
Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human  
Subjects (Fortaleza, Brazil 2013), the National Statement on Ethical Conduct in Human 
Research  
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PROTOCOL SUMMARY  
Title:  Apheresis of subjects with induced blood stage Plasmodium vivax  
Précis:  
This is a Phase 1 exploratory study  designed to determine the 
safety and feasibility of using apheresis as a method for 
extracting all lifecycle stages of malaria parasites from the blood 
of healthy subjects experimentally infected with blood stage P. 
vivax. This study will be conducted in up to 8 subjects (8 cohorts 
of 1 subject each).   
Subjects will be inoculated intravenously on Day 0 with 
approximately 1100 viable P. vivax HMPBS02-Pv parasite-infected 
erythrocytes. On an outpatient basis, subjects will be monitored 




daily via phone and then will attend the clinical unit daily from 4 
days post-inoculation for blood sampling to measure parasitaemia 
via qPCR targeting the P. vivax 18S rRNA gene (referred to as 
malaria 18S qPCR), to monitor symptoms and signs of malaria, and 
to record AEs.   
The threshold for the commencement of apheresis and 
subsequent antimalarial rescue treatment with 
artemether/lumefantrine will occur when parasitaemia is 
>20,000 parasites/mL or the Malaria Clinical Score is  >6 (within 
24 hours of notification) or at the Investigator’s discretion. On the 
day that this threshold is reached (expected to occur on Day 10, 
11 or 12), the subject will be admitted to the clinical unit for 
initial safety assessments before undergoing apheresis whilst 
being supervised by the apheresis specialist nurse.  
The subject will then be administered the first dose of 
artemether/lumefantrine and will remain confined within the 
clinical unit for 72 hours (or less -48h minimum- at the discretion 
of the investigator if the subject is deemed clinically well and the 
subject is happy for early release) to monitor for safety and 
tolerability of apheresis and rescue therapy, and to ensure 
adequate clinical and parasitological response to treatment. In 
the unlikely event that artemether/lumefantrine fails to clear 
parasitaemia, subjects will be treated with chloroquine. If oral 
administration of either artemether/lumefantrine or chloroquine 
is not possible (e.g. the subject is vomiting), the subject will 
receive intravenous treatment with artesunate. After discharge 
from the clinical unit, subjects will be followed up on an out-
patient basis for monitoring of safety and parasite clearance. 
Follow-up for safety assessments will be performed on Day 28±3, 
Day 56±7 (phone call only), and Day 90±7 (End of Study).  
Subjects will also be evaluated for the presence of sexual parasite 
stages (gametocytes) and other parasite lifecycle stages in the 
blood during the study using reverse transcriptase qPCR (qRT-
PCR). Parasite lifecycle stage qRT-PCR may also be used at the  
Investigator’s discretion to determine the timing of direct feeding 
assays (DFAs) and/or membrane feeding assays (MFAs) which may 
occur at up to 2 time-points prior to apheresis and rescue 
treatment initiation.   
Objectives:  




  Primary objectives  
• To further assess the safety of the P. vivax induced blood 
stage malaria (IBSM) model following inoculation of 
healthy subjects with P. vivax isolate HMPBS02-Pv.  
• To assess the safety of apheresis in the P. vivax IBSM 
model following inoculation of healthy subjects with P. 
vivax isolate  
HMPBS02-Pv.  
Secondary objectives  
• To assess the feasibility of apheresis as a method of 
extracting and concentrating all stages of malaria parasites 
following inoculation of healthy subjects with P. vivax 
isolate  
HMPBS02-Pv.  
• To evaluate the success of cryopreservation of all stages of 
P. vivax parasites from blood products extracted via 




• To explore the potential for apheresis to be used as a 
method for producing a P. vivax Human Malaria Parasite 
(HMP) bank to be used for future IBSM studies.  
• To evaluate the transmission of P. vivax gametocytes to 
mosquitoes.  
  




Exploratory optional  
• To collect and store plasma and peripheral blood 
mononuclear cells (PBMCs) harvested using apheresis for 
future research on the immunology and pathophysiology 
of P. vivax.    
• To assess development and/or functionality of antibodies 
to asexual stage parasites and/or gametocytes.  
Endpoints:  
Primary endpoint  
The primary objectives will be assessed by adverse events (AE) 
recording, safety laboratory parameters, vital signs recording, 
electrocardiograms (ECGs), physical examination findings and 
Malaria Clinical Score recording.   
Secondary endpoints  
The secondary objectives will be assessed as follows:  
• The feasibility of apheresis as a method of extracting and 
concentrating all stages of malaria parasites will be 
determined by qPCR, qRT-PCR, microscopy, and flow 
cytometry on blood products extracted using apheresis, 
and expressed as a percentage of baseline parasitaemia 
(pre-apheresis).   
• The success of cryopreservation of gametocytes will be 
determined by measuring their infectivity to mosquitoes 
using a membrane feeding assay, reported as prevalence 
of infection (percentage of oocyst positive mosquitoes). 
The success of cryopreservation of asexual parasites will 
be determined based on their viability tested using in 
vitro re-invasion assay.    
Exploratory endpoints  
The exploratory objectives will be assessed as follows:  
• The potential for apheresis to be used as a method for 
producing a P. vivax HMP bank will be determined based 
on the efficiency of extraction and concentration of 
parasites, the viability of extracted parasites, the 
successful leukodepletion of the sample, and the 




confirmation that the donor subject is free from blood-
borne infections.   
• Transmission of P. vivax gametocytes to mosquitoes will 
be determined using a direct feeding assay and/or 
membrane feeding assay, and reported as prevalence of 
infection (percentage of oocyst positive mosquitoes).  
Optional exploratory endpoints  
The optional exploratory objectives will be assessed as follows:  
• The successful collection of PBMCs will be determined, if 
considered appropriate, by cell counts and cell viability 
tested using trypan blue staining.  
• Detection and evaluation of anti-blood-stage or anti-
gametocyte specific antibodies using immunological 
assays (including but not limited to enzyme-linked 
immunosorbent assays and indirect immunofluorescence 
assays).  
  
Population:  A maximum of 8 subjects will be enrolled in this study (8 cohorts of 1 
subject each). Subjects will be malaria naïve healthy adults (male), aged 
between 18-55 years old, who meet all of the inclusion criteria and none 
of the exclusion criteria.   
Phase:  Phase 1 (exploratory study)  
Number of Sites enrolling 
subjects:  
Single Centre  
Q-Pharm Pty Ltd  
Level 5, 300C Herston Rd and   
Level 6, Block 8, Royal Brisbane and Women’s Hospital Herston, QLD 
4006, Australia  
  
Description of Study 
Agent(s):  
Malaria challenge agent:  
The P .vivax HMPBS02-Pv Master Cell Bank (MCB) was produced from 
blood donated from a returned traveller from India who presented with 
clinical manifestations of malaria. Each inoculum dose will be prepared 
aseptically from an aliquot of the P. vivax HMPBS02-Pv MCB. Each subject 
will be inoculated intravenously with a dose of approximately 1100 viable 
parasite-infected erythrocytes in 2 mL saline for injection.  
  
Antimalarial rescue medication:  
  





Riamet® (20 mg Artemether and 120 mg Lumefantrine) will be 
administered to all subjects post apheresis or earlier if apheresis 
cannot performed for safety reasons. A course of treatment 
comprises 6 doses of 4 tablets administered orally over a period of 
60 hours (total course of 24 tablets). Each dose of tablets should 
be taken with food or drinks rich in fat (e.g., milk).   
Chloroquine (if required)   
Subjects will be administered Chloroquine if 
artemether/lumefantrine fails to clear the malaria parasites. 
Chloroquine tablets each containing 250 mg chloroquine 
phosphate (equivalent to 155 mg chloroquine base) will be 
administered orally. An initial dose of chloroquine will be 
administered as 4 tablets, followed by a dose of 2 tablets each at 
6, 24 and 48 hours (i.e. a total dose of 2.5 g chloroquine 
phosphate [1.550 g base]).   
Artesunate (if required)  
Treatment of subjects with intravenous artesunate will only occur 
in the event that subjects are unable to complete oral treatment 
with either artemether/lumefantrine or chloroquine (e.g. the 
subject is vomiting). This would be done at the recommended 
dose regime of 2.4 mg/kg at approximately 0, 12, 24 hours and 
then daily for up to 7 days or until able to take oral drugs.   
Study Duration:  Approximately 12 months.  
Subject Duration:  
  
Approximately 4 months.  
    




SCHEMATIC OF STUDY DESIGN  
  
1  KEY ROLES  
  
Principal Investigator  Prof. James McCarthy, MBBS  
Q-Pharm Pty Ltd (visiting Medical Officer) and   
QIMR Berghofer Medical Research Institute  
Level 5, 300C Herston Rd   
Herston, QLD 4006, Australia  
Tel: +61(0)7 3845 3647 or +61 (0)7 3845 3636  
Email: j.mccarthy@uq.edu.au  
Co-Principal Investigator  Dr Anand Odedra, MBBS  
Q-Pharm Pty Ltd (visiting Medical Officer) and   
QIMR Berghofer Medical Research Institute  
Level 5, 300C Herston Rd   
Herston, QLD 4006, Australia  
Tel: +61(0)7 3845 3647 or +61 (0)411041391  
Email: anand.odedra@qimrberghofer.edu.au  




Co-Principal Investigator  Bridget Barber, MD  
Q-Pharm Pty Limited (Visiting Medical Officer) and  
QIMR Berghofer Medical Research Institute   
Level 5, 300C Herston Rd  
Herston, QLD 4006, AUSTRALIA  
Tel: +61 (0)4 24 73 71 53  
Email: Bridget.Barber@qimrberghofer.edu.au  
Co-Principal Investigator  Professor David Lalloo, MBBS MD FRCP MRCP  
Liverpool School of Tropical Medicine   
Pembroke Place Liverpool   
L3 5QA UK   
Tel: +44 (0)151 705 3218  
Email: david.lalloo@lstmed.ac.uk   
Collaborating Principal 
Investigator  
A/Prof. Glen Kennedy, MBBS  
Acting Executive Director  
Cancer Care Services  
Metro North HHS  





Dr Paul Griffin, MBBS, FRACP, FRCPA  
Manager of Medical Services and Principal Investigator,   
Q-Pharm Pty Ltd  
Level 5, 300C Herston Rd  
Herston, QLD 4006, Australia  
Tel: +61  (0)7 3845 3636 or +61 (0)402077302  
Email: p.griffin@qpharm.com.au  
Trial Sponsor  QIMR Berghofer Medical Research Institute   
300 Herston Road  
Herston QLD 4006, Australia  
Tel: +61 (0)7 3362 0222  
Sponsor Signatory  Prof. David Whiteman, MBBS, PhD, FAFPHM  
Deputy Director  
QIMR Berghofer Medical Research Institute  
300 Herston Rd,   
Herston, QLD 4006, Australia                                        
Tel: +61 (0)7 3362 0222  
David.Whiteman@qimrberghofer.edu.au  
Independent Medical Monitor  Professor Dennis Shanks  
Australian Army Malaria Institute  
Gallipoli Barracks  
Enoggera Qld 4051   
Ph +61 (0)7 3332 4931  
Dennis.SHANKS@defence.gov.au  




Institutional Ethics Committee  QIMR Berghofer Medical Research Institute Human Research 
Ethics Committee (QIMR Berghofer-HREC; EC00278) Locked 
Bag 2000, Royal Brisbane and Women’s Hospital,  
Brisbane, QLD 4029, Australia  
Tel: +61 (0)7 3362 0117  
Sponsor’s Monitors  Clinical Network Services (CNS) Pty Ltd  
Level 4, 88 Jephson St  
Toowong QLD 4066, Australia  
Tel: +61 (0)7 3719 6000  
Clinical Study Centre  Q-Pharm Pty Ltd  
Level 5, 300C Herston Rd and   
Level 6, Block 8, Royal Brisbane and Women’s Hospital  
Herston, QLD 4006, Australia  
Tel: +61  (0)7 3845 3636  
Clinical Laboratories  Clinical laboratory measurements  
Sullivan Nicolaides Pathology Central Laboratory (SNP)  
24 Hurworth Street   
Bowen Hills, QLD  4006, Australia  
Tel: +61 (0)7 3377 8782  
  
Parasite quantification in blood samples  
Queensland Paediatric Infectious Diseases Laboratory (QPID), 
SASVRC, Level 8, Centre for Children’s Health Research  
62 Graham Street,   
South Brisbane, QLD 4101, Australia  
Tel: +61 (0)7 3069 7464  
    
2   INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE   
  
2.1  BACKGROUND INFORMATION   
Despite the decrease in malaria incidence achieved in the last 17 years, this parasitic disease 
still threatens almost half of the world’s population. In 2015, there were 214 million cases of 
malaria and 438,000 deaths (1). Most malaria cases occurred in sub-Saharan Africa. However, 
Asia, Latin America, the Middle East and parts of Europe are also at risk (1).  
Whilst Plasmodium falciparum  (P. falciparum) is the most prevalent malaria parasite in Africa, 
Plasmodium vivax (P. vivax) has a wider geographical distribution. In 2015, 41% of the malaria 
cases that occurred outside the African continent were caused by P. vivax resulting in an 
estimated 3,100 deaths (1). Moreover, 70 to 80 million cases per year of relapsing malaria 
occur due to infection with P. vivax.   
The World Health Organization (WHO) has declared that the response to malaria is a global 
development priority and has changed their recommendation from control to eradication 




programs. A robust development pipeline of potential drug candidates is required in order to 
meet this target and the screening process for determining safety and clinical efficacy of 
potential antimalarials requires fast, efficient test systems.    
Controlled human malaria infection (CHMI) is increasingly being used to evaluate antimalarial 
drug candidates (2-4, 14-24). CHMI studies with P. falciparum  and P. vivax use the induced 
blood stage malaria (IBSM) model, whereby subjects are infected with blood stage malaria 
parasites. The availability of the IBSM model offers a pathway to test the efficacy of P. 
falciparum  and/or P. vivax vaccines and drugs in non-immune subjects, in a rapid and cost 
effective manner. One of the advantages of the blood stage challenge model is its ability to 
allow analysis of antimalarial efficacy, by providing opportunities to monitor parasite growth 
after challenge. This serves as a robust surrogate for the activity of a test compound/vaccine. 
Validation studies have shown a high correlation between natural and experimental infections, 
which further justifies the use of CHMI for testing new vaccines or drugs (2, 4).  The safety and 
utility of this approach for assessment of antimalarial efficacy has been augmented by the 
implementation of a rapid, sensitive and robust real-time PCR assay for quantification of 
parasitaemia (5). A significant benefit of the IBSM model for P. vivax studies is the exclusion of 
the liver stage of the parasite that is the source of relapses, thus removing risk of recurring P. 
vivax infection from occult hypnozoites.   
In the absence of a method of in vitro culture of P. vivax, the only way to source parasites is ex 
vivo. This hampers all aspects of development of tools to eliminate this parasite. For example, 
to test and develop candidate hypnozoiticidal drugs, a reliable source of P. vivax sporozoites is 
required. Currently this entails an expensive, logistically complex and unreliable process of 
sourcing P. vivax-infected mosquitoes from endemic areas of Asia. In addition to the logistic 
issues, the parasites are not genetically homogenous.  
Recently we have been successful in transmitting P. vivax to mosquitoes and harvesting 
sporozoites. In a recent study we pooled 75 mL blood from 6 subjects, concentrated parasites 
by density gradient centrifugation and fed the concentrate to 6 pots of 100 Anopheles 
Stephensi mosquitoes (ANZCTR reference ID: ACTRN12616000174482). Approximately 95% of 
fed mosquitoes were infected; an average yield of approximately 4,000 sporozoites per salivary 
gland was obtained when mosquitoes were dissected 14 days later. Although this system offers 
great potential to study transmission biology, ethical and logistic issues will preclude it from 
becoming a source of sporozoites for downstream work.   
Apheresis is the removal of a specific component of an individual’s blood with the remainder of 
the blood being returned to the individual. Apheresis may involve the removal of red cells 
(erythrocytapheresis), white cells (leukocytapheresis), plasma (plasmapheresis) or platelets 
(thrombocytapheresis). Currently centrifugal apheresis is the preferred method whereby blood 
components can be separated based on buoyancy. Centrifugal machines use citrate to prevent 
clotting of extracorporeal blood, thereby minimising the bleeding risk; they pack red cells to a 
haematocrit of ≥80%, therefore requiring smaller blood volumes to achieve extraction and 
enable peripheral veins to be used (6).   




Since its introduction in the 1970s, apheresis has been used to treat a wide array of conditions, 
including essential thrombocythaemia, familial hypercholesterolaemia, graft versus host 
disease and babesiosis. Parasite apheresis has also been used to reduce Loa parasitemia, to 
prevent post-treatment encephalopathy (7-9). Until now apheresis in malaria has been limited 
to the context of exchange blood transfusion and red cell exchange as adjuncts to intravenous 
quinine therapy for severe P. falciparum  malaria (parasitemia >5%), as per WHO 
recommendations prior to the availability of IV artesunate (10). The rapid parasite clearance 
resulting from artesunate therapy has resulted in exchange transfusion and red cell exchange 
falling out of favour as a treatment for malaria.   
2.2  RATIONALE   
  
We propose to carry out a exploratory study to assess the use of apheresis as a means to 
harvest and concentrate all stages of P. vivax including gametocytes from up to 8 human 
subjects infected with blood stage P. vivax malaria. The harvested parasites would then be 
cryopreserved; the asexual parasites could then be used to produce a human malaria parasite 
(HMP) bank for use in future IBSM model studies, while the gametocytes could be used to 
infect Anopheles mosquitoes. Previous work has established that cryopreserved P. vivax 
gametocytes are infectious to mosquitoes (11). These infected mosquitoes, or sporozoites 
derived from them, could be used to infect healthy subjects in radical cure challenge models. 
Additionally, these sporozoites could be used in in vitro microfluidic devices that sustain 
human hepatocyte culture (12), as well as in humanised mouse models such as the severe 
combined immunodeficiency (SCID) mouse model which has shown the potential of acting as a 
model for the hepatic stage of malaria infection (13). Furthermore, it would transform P. vivax 
mosquito membrane feeding assays, obviating the need for a gametocytaemic test subject. We 
estimate that in collecting the entire parasite population from up to 5L of a subject’s blood by 
apheresis there would be sufficient gametocytes to feed ~400 pots of 100 mosquitoes. From a 
total of ~40,000 mosquitoes the theoretical yield would be ~3.2 x107 sporozoites.   
This explorative study has been designed to establish for the first time apheresis as a method 
of acquiring purified P. vivax parasites from healthy human subjects infected with IBSM. 
Venesection (whole blood removal using large bore cannula) cannot be used to select a specific 
haematocrit and therefore purified parasites cannot be sourced as efficiently as through 
apheresis, hence our decision to use apheresis.  
Hypotheses:  
• The apheresis procedure is safe in healthy subjects experimentally infected with blood 
stage P. vivax.  
• Apheresis can be used to extract and concentrate all stages of P. vivax parasites at 
numbers greater than can be attained by simple blood draws.   
• Parasites harvested via apheresis can be successfully cryopreserved.  
• Cryopreserved gametocytes can successfully be used to infect Anopheles mosquitoes.  




• Asexual parasites extracted by apheresis can be used to produce a HMP bank for future 
IBSM model studies.   
• Peripheral blood mononuclear cells (PBMCs) can be collected using apheresis.   
  
2.3  POTENTIAL RISKS AND BENEFITS   
  
2.3.1 KNOWN POTENTIAL RISKS   
Apheresis  
Apheresis is generally considered to be a safe and well tolerated method of treatment as well 
as a  method for collecting blood component donations from healthy volunteers. Apheresis in 
the form of automated red blood cell exchange has been used as an adjunct to anti-malarial 
treatment, particularly during the quinine era to remove P. falciparum  infected red cells. 
During review of the literature, we identified 42 patients treated with red cell exchange as 
adjunct therapy, the only significant adverse effect experienced as a result of automated red 
cell exchange was transient hypotension (blood pressure 70/40) which resulted in halting of 
apheresis for 10 minutes before starting again once the hypotension had resolved (25-39). In 
the current study, subjects will have far lower parasitaemia than that seen in severe malaria. 
Furthermore, subjects will be infected with blood stage P. vivax which is generally considered 
one of the benign malarias. There is no documented use of apheresis in P. vivax infection, but 
the good safety profile evident in subjects with severe P. falciparum infection suggests that 
this procedure should be well tolerated by healthy subjects with subclinical P. vivax infection. 
However, it is important to note that we will be carrying out either a Continuous Mononuclear 
Cell (CMNC) procedure on our subjects (this is the procedure typically performed to collect 
stem cells and lymphocytes) or  a double red cell collection, although both procedures fall 
under the umbrella of apheresis. Double red cell collection involves removal of haemoglobin 
containing red bloods cells thus the haemoglobin count could drop. The haemoglobin count 
will recover with time but may result in a mild transient iron deficiency anaemia. As 
participants will have normal haemoglobin counts going into the study, the expected drop in 
haemoglobin is not expected to be high enough to result in more than mild anaemia. In 
addition, as a result of the drop in haemoglobin, the subjects may experience a period of 
relative fatigue while the haemoglobin count recovers over a few weeks. The level of fatigue is 
not anticipated to affect the participants daily activities or work.  
Leukapheresis has been used successfully to acquire PBMCs from subjects immunised with 
radiation-attenuated P. falciparum sporozoites via mosquito bite prior to malaria challenge 
(40). PBMCs have been extracted via leukapheresis from healthy volunteers in order to study 
differences in immune responses to P. vivax between Duffy positive and Duffy negative 
individuals and were subsequently cryopreserved (41).   
The potential for minor transient complications is documented below.   




The Australian haemovigilance report published in 2016 states that during 2013-2014 they 
recorded over 518,000 apheresis donations (plasmapheresis and plateletpheresis), the total 
rate of adverse events was 212 per 10,000 apheresis procedures (42). There were no 
associated deaths. The most common adverse events associated with plasmapheresis were 
vasovagal (65/10,000), haematoma and bruising (13/10,000). The vast majority of these 
adverse events were mild in severity. Adverse events requiring hospitalisation were 2/10,000 
and 4/10,000 for plasmapheresis and plateletpheresis respectively. Plateletpheresis is 
generally considered to have greater complication rates due to the greater need for anti-
coagulation and longer duration of the procedure. The vast majority of these hospital 
attendances were brief and uneventful requiring no treatment. With the exception of citrate 
reactions which are known to be more common in CMNC procedures, other adverse events are 
thought to be similar to other forms of apheresis.  
Risk management of citrate reactions  
Citrate reactions are probably the most likely adverse events that may occur during the 
apheresis procedure. They are a result of low blood calcium levels caused by the anticoagulant 
citrate commonly used instead of heparin for apheresis due to its lower tendency to cause 
bleeding and its short half-life. Citrate reactions can occur in around 48% (43) of CMNC 
produces, the vast majority of which present as mild tingling around the mouth, nose, ears, 
fingers and toes (44). Other symptoms of mild citrate reactions include sneezing, headache, 
shivers, and mild drops in blood pressure. Very occasionally citrate reactions can cause anxiety, 
irritability, abdominal discomfort, nausea and vomiting, spasms of muscles of the hands and 
feet and more significant drops in blood pressure. Very rarely citrate reactions may be severe 
and can manifest with seizures and abnormal heart rhythms. Subjects will be supervised during 
the apheresis procedure by nursing staff experienced in the delivery of apheresis, and if any of 
the above symptoms occur the subject will be given calcium replacement which usually results 
in a rapid resolution of symptoms and halting of further progression. To reduce the chances of 
citrate reactions we will only include subjects in the trial who have no history of low blood 
calcium levels and with normal calcium levels on screening blood tests. If the subject develops 
signs or symptoms of low calcium levels during apheresis they may be advised verbally to 
commence a high calcium diet for 24 hours post apheresis. This is in line with routine 
management of citrate reactions within the apheresis unit. The decision to commence a high 
calcium diet will be made by the apheresis specialist staff and the exact nature of that high 
calcium diet will also be determined by the apheresis specialist staff in conjunction with the 
subject (e.g. avoid milk if lactose intolerant).   
Risk management of fainting and pre-fainting  
Apheresis is an isovolaemic procedure hence there is thought to be little if any physiological 
challenge to the donor as a result of the procedure (45) hence syncope and presyncope is less 
common. Evidence from the United States suggests that double red cell and platelet donation 
have reduced instances of syncope compared with whole blood donation (46).  Vasovagal 
reactions causing fainting can occur during or after donation sometimes up to 8 hours after 




donation. Events that occur in the donation center are termed immediate whereas those that 
occur after donation are termed delayed. A specialist apheresis nurse will be present 
throughout the procedure and in the event of pre-faint or faint they will act according to their 
standard protocols (see Appendix 3) e.g. by halting the apheresis procedure temporarily or 
permanently. Patients most commonly experience fainting and pre-fainting during venous 
cannulation often because of difficult venous access. We will reduce the likelihood of this by 
only including subjects with no previous history of syncope as a result of venous cannulation or 
blood taking and good venous access. Furthermore, we will avoid blood draws from veins 
located in the ante-cubital fossa in the lead up to apheresis in order to preserve the veins. 
Venous cannulation will be carried out by experienced staff. Delayed events are much less 
common than immediate reactions. In the unlikely event of a delayed event, the subject will be 
under medical supervision in confinement and thus will be managed appropriately. We will be 
initiating apheresis 8-12 days after inoculation of P. vivax at which point the subject is likely to 
have symptoms similar to a mild/moderate “flu like” illness. The symptoms tend to be well 
controlled by simple analgesia such as acetaminophen (the use of ibuprofen immediately prior 
to apheresis is not recommended due to potential for altered platelet function). In general 
these subjects will be far more healthy than those with severe P. falciparum  malaria requiring 
therapeutic apheresis, which evidence suggests is generally well tolerated.   
Risk management of bruising and haematoma during venous cannulation  
The risk of bruising and haematoma is approximately 13/10,000 procedures, the vast majority 
of these are mild in nature and require no intervention. Low platelet counts commonly occur in 
malaria and may increase the risk of bleeding and haematoma. However, apheresis procedures 
have been done successfully with very low platelet counts. We will be using peripheral venous 
access as it is less invasive thus safer and the more commonly used method of access.  We will 
reduce the chances of bruising and haematoma by only including subjects with good venous 
access and we plan to avoid blood draws from the veins in the ante-cubital fossa in the lead up 
to apheresis in order to preserve the veins. Venous cannulation will be carried out by 
experienced staff. The subject will not be permitted to take ibuprofen 48 hours before 
apheresis.  
Risk management of haemoglobin drop  
Statistical analysis of the trends in haemoglobin during P. vivax IBSM studies at QIMR 
Berghofer have shown on average the haemoglobin drop by 10 days post inoculation is 3 g/L 
and the average maximum fall in haemoglobin at any point during the study is 13 g/L with a 
standard deviation of 7 g/L. We estimate a maximum drop of 20% in haemoglobin from the 
double red cell collection apheresis, this approximates to 30 g/L. Thus, the maximum 
anticipated fall of around 43 g/L will leave a haemoglobin of 92 g/L, a level well above the cut-
off for transfusion (70 g/L).   




General risk management procedures  
There have been cases of air emboli (air bubbles in the blood) occurring as a result of 
apheresis. However, modern machines have a built in alarm that can detect air emboli. There is 
also the possibility of machine malfunction although this is rare, but if it occurred it may mean 
that some of the blood that was removed may not be returned. This is unlikely to cause any 
significant problems to the subject.  
The apheresis procedure will be supervised by experienced and trained staff in the delivery of 
apheresis. A specialist apheresis nurse will be present throughout the procedure. In addition 
one of our trial doctors experienced in malaria management will be present during the 
procedure or contactable by phone and available at the site of apheresis within 10 minutes in 
case of any concerns. Furthermore, the apheresis unit will have a haematology 
doctor/consultant within easy access in the event of any other issues. The haematology staff 
will retain the right to stop the apheresis procedure at any time as per their discretion. Time on 
the apheresis machine will be approximately 2-4 hours. The subject may have to remain in the 
apheresis unit slightly longer to allow connection to the apheresis apparatus.    
Induced blood stage malaria  
In this study, a cryopreserved inoculum containing P. vivax isolate HMPBS02-Pv  will be used.  
The P. vivax parasite HMPBS02-Pv bank has been previously used to inoculate 34 malaria  
study subjects using the IBSM model (24). No SAEs related to the challenge inoculum were 
reported in the subjects exposed to date.   
Risk management of blood borne infections  
Overall, the risk of infection from a possible blood borne virus from the blood transfused in 
this study would be expected to be very low for a number of reasons. First, the donor was 
screened and tested negative for presence of acute blood borne infections. Furthermore, the 
volume of blood used in the IBSM model for transmitting malaria is significantly lower than in 
a transfused unit, thus reducing the risk for transfusion reaction. The white cells are removed 
from the master cell bank during the production process, which lowers the risk of Epstein-
Barr virus (EBV) and Cytomegalovirus (CMV) infection due to transfusion. The bank tested PCR 
negative for both CMV and EBV viruses even though the donor of the bank was antibody 
positive for both CMV and EBV.     
As part of the safety monitoring, all study subjects will have serum stored for testing of 
bloodborne virus infections before entry and after the completion of the study.    




Risk management of reaction to the blood sample  
The malaria inoculum contains a small number of red cells from the original donor. The risk for 
development of red cell antibodies in this study is considered extremely low. The donor of the 
malaria cell bank used in this study was confirmed to be blood group O, Rh (D) positive; 
people with blood group O are generally considered “universal donors”, as recipients of their 
blood have minimal risk of developing red cell alloantibodies when given much larger volumes 
of blood than is envisaged for the process routinely used in the IBSM model. However, it is 
possible that subjects could suffer a transfusion reaction after they receive the inoculum, or 
develop antibodies to the donor red blood cells that may make blood transfusion more 
difficult in the future. Subjects will also be monitored for signs and symptoms in the period 
immediately after the administration of the malaria parasite dose and screened at the end of 
the study for occurrence of red cell alloantibodies as part of the safety monitoring.    
Risk management of malaria infection  
The number of blood stage parasites used to infect the study subjects in this study is much 
lower than that which reaches the blood after the bite of a single malaria-infected mosquito, 
where approximately 30,000 parasites are released into the blood when they break out of a 
single infected liver cell. For this study, following administration of the challenge inoculum, 
the growth of the parasites as well as any symptoms in the subjects will be closely monitored. 
The threshold for commencement of treatment will be when parasitaemia is ≥ 20,000 
parasites/mL or the clinical symptom score is >6 (then treatment will begin within a 24 h 
period from notification) or at the Investigator’s discretion. This treatment threshold has been 
selected because it is below the point at which advanced and severe clinical symptoms of 
malaria infection are likely to occur.  Furthermore, treatment may be started before the 
threshold is met by the Investigator at their discretion.   
The parasites used in the challenge inoculum for this study are known to be sensitive to the 
standard anti-malarial drugs artemether/lumefantrine  and Chloroquine. As such, there is no 
serious risk of clinical malaria providing that the inoculated subjects comply with the curative 
anti-malarial regimen as directed by the Investigator.   
  
Risk management of liver function derangements  
Transient, asymptomatic liver function test (LFT) derangements have been reported in several 
subjects in IBSM studies (19, 23, 47,48). These LFT derangements which consisted of ALT/AST 
elevation with no change in bilirubin did not require treatment, and resolved by the end of the 
studies. Following an independent review involving drug-induced liver injury experts, it was 
found that these LFT elevations, are most likely a direct consequence of the malaria infection 
rather than reflecting a direct drug-induced liver injury caused by an investigational 
antimalarial drug. As a precaution all subjects in this study will undergo regular safety 




monitoring to assess for asymptomatic LFT abnormalities. Subjects are required to reduce 
intake of possibly hepatotoxic substances during the course of the study including alcohol and 
acetaminophen (acetaminophen can be used as second line symptom control after ibuprofen 
and will not exceed 4g/day in the study).  
Antimalarial rescue medications  
Artemether/lumefantrine, chloroquine, and artesunate risks are detailed in their respective 
approved manufacturer’s prescribing information (Appendix 4).  
Mosquito feeding  
Subjects will be continuously monitored during the direct feeding of mosquitoes. If a 
participant develops severe skin sensitivity or experiences discomfort through the mosquito 
feed process, they will be given the option to withdraw from this process. Treatment for the 
skin irritation will be provided.  
In summary, the risk to subjects in this study will be minimised as follows:  
• Adherence to the inclusion/exclusion criteria, specific contraception rules for subjects.  
• Close clinical and laboratory monitoring to ensure the safety and wellbeing of the 
healthy subjects.  
• Monitoring and management by specialist staff trained in the delivery of apheresis, 
haematology team can stop apheresis at any point at their discretion.  
• Only subjects without a history of low blood calcium and with normal calcium levels on 
screening blood tests will be included.  
• Subjects will be advised to have a high calcium diet in the 24 hours prior to apheresis.   
• Subjects will not be allowed to utilise ibuprofen in the 48 hours prior to apheresis.  
• Acetaminophen ≤ 4g/day   
• Subjects with good venous access will be selected and ante cubital fossa veins will not 
be used for blood sampling prior to apheresis.   
• Admission to clinical unit for at least 48 h following the apheresis procedure and 
initiation of anti-malarial treatment.  
• If subject requires hospitalisation this will be done at the Infectious Diseases Unit, 
Royal Brisbane and Women’s Hospital.  
• A Safety Review Team will meet approximately 4 weeks after the inoculation of each 
subject to review safety data before proceeding with the inoculation of a subsequent 
subject.  




2.3.2 KNOWN POTENTIAL BENEFITS   
There are no known direct benefits to the subjects in this study. There may be a benefit to the 
subjects from the results of the screening tests and procedures (blood tests, physical 
examination and electrocardiogram).  
3  OBJECTIVES AND PURPOSE  
Primary objectives  
• To further assess the safety of the P. vivax induced blood stage malaria (IBSM) model 
following inoculation of healthy subjects with P. vivax isolate HMPBS02-Pv.  
• To assess the safety of apheresis in the P. vivax IBSM model following inoculation of 
healthy subjects with P. vivax isolate HMPBS02-Pv.  
Secondary objectives  
• To assess the feasibility of apheresis as a method of extracting and concentrating all 
stages of malaria parasites following inoculation of healthy subjects with P. vivax 
isolate  
HMPBS02-Pv.  
• To evaluate the success of cryopreservation of all stages of P. vivax parasites from 




• To explore the potential for apheresis to be used as a method for producing a P. vivax 
Human Malaria Parasite (HMP) bank to be used for future IBSM studies.   
• To evaluate the transmission of P. vivax gametocytes to mosquitoes.  
Exploratory optional  
• To collect and store plasma and peripheral blood mononuclear cells (PBMCs) 
harvested using apheresis for future research on the immunology and pathophysiology 
of P. vivax.  
• To assess development and/or functionality of antibodies to asexual stage parasites 
and/or gametocytes.      
  
4  STUDY DESIGN AND ENDPOINTS  
   
4.1  DESCRIPTION OF THE STUDY DESIGN  




This is a Phase 1 exploratory study designed to determine the safety and feasibility of using 
apheresis as a method for extracting all lifecycle stages of malaria parasites from the blood of 
healthy subjects experimentally infected with blood stage P. vivax. This study will be 
conducted in up to 8 subjects (8 cohorts of 1 subject each). Approximately 4 weeks after the 
inoculation of each subject, the safety review team (SRT) will meet to review the progress of 
the subject before going forward with the inoculation of a subsequent subject.   
Subjects will be consenting and eligible healthy adults males, aged between 18-55 years old. 
Subjects will be inoculated intravenously on Day 0 with approximately 1100 viable P. vivax 
HMPBS02-Pv parasite-infected erythrocytes.   
On an outpatient basis, subjects will be monitored daily via phone and then will attend the 
clinical unit daily from 4 days post-inoculation for blood sampling to measure parasitaemia via 
qPCR targeting the P. vivax 18S rRNA gene (referred to as malaria 18S qPCR), to monitor 
symptoms and signs of malaria, and to record AEs.   
The threshold for the commencement of apheresis and subsequent antimalarial rescue 
treatment with artemether/lumefantrine will occur when parasitaemia is >20,000 parasites/mL 
or the Malaria Clinical Score is  >6 (within 24 hours of notification) or at the Investigator’s 
discretion. Within 24h of the  day that this threshold is reached (expected to occur on Day 9, 
10 or 11), subjects will be admitted to the clinical unit (expected on day 10, 11 or 12) for initial 
safety assessments before being escorted to the apheresis unit in the Cancer Care Services by 
Q-pharm staff. The subject will then undergo the apheresis procedure as per the Standard 
Operating Procedure (SOP) (see Appendix 3) whilst being supervised by the apheresis specialist 
nurse (the apheresis procedure is expected to take 2-4 hours). The subject will then be 
escorted back to the clinical site and administered the first dose of artemether/lumefantrine. 
The subject will remain confined within the clinical unit for 72 hours (or less - 48h minimum- at 
the discretion of the investigator if the subject is deemed clinically well and the subject is 
happy for early release) to monitor for safety and tolerability of apheresis and rescue therapy, 
and to ensure adequate clinical and parasitological response to treatment. In the unlikely event 
that artemether/lumefantrine fails to clear parasitaemia, subjects will be treated with 
chloroquine. If oral administration of either artemether/lumefantrine or chloroquine is not 
possible (e.g. the subject is vomiting), the subject will receive intravenous treatment with 
artesunate. After discharge from the clinical unit, subjects will be followed up on an out-
patient basis for monitoring of safety and parasite clearance. Follow-up for safety assessments 
will be performed on Day 28±3, Day 56±7 (phone call only), and Day 90±7(End of Study).  
Subjects will also be evaluated for the presence of sexual parasite stages (gametocytes) and 
other parasite lifecycle stages in the blood during the study using reverse transcriptase qPCR 
(qRTPCR). Parasite lifecycle stage qRT-PCR will also be used at the Investigator’s discretion to 
determine the timing of malaria transmission experiments; direct feeding assays (DFAs) and/or 
membrane feeding assays (MFAs) which may occur at up to 2 time-points prior to apheresis 
and rescue treatment initiation.  




4.2  STUDY ENDPOINTS  
  
 
The primary objectives will be assessed by adverse events (AE) recording, safety laboratory 
parameters, vital signs recording, electrocardiograms (ECGs), physical examination findings and 
Malaria Clinical Score recording.   
4.2.2 SECONDARY ENDPOINTS  
The secondary objectives will be assessed as follows:  
• The feasibility of apheresis as a method of extracting and concentrating all stages of 
malaria parasites will be determined by qPCR, qRT-PCR, microscopy and flow 
cytometry on blood products extracted using apheresis, and expressed as a percentage 
of baseline parasitaemia (pre-apheresis).   
• The success of cryopreservation of gametocytes will be determined by measuring their 
infectivity to mosquitoes using a membrane feeding assay, reported as prevalence of 
infection (percentage of oocyst positive mosquitoes). The success of cryopreservation 
of asexual parasites will be determined based on their viability tested using in vitro 
reinvasion assay.    
4.2.3 EXPLORATORY ENDPOINTS  
 The exploratory objectives will be assessed as follows:  
• The potential for apheresis to be used as a method for producing a P. vivax HMP bank 
will be determined based on the efficiency of extraction and concentration of 
parasites, the viability of extracted parasites, the successful leukodepletion of the 
sample, and the confirmation that the donor subject is free from blood-borne viruses.   
• Transmission of P. vivax gametocytes to mosquitoes will be determined using a direct 
feeding assay and/or membrane feeding assay, and reported as prevalence of infection 
(percentage of oocyst positive mosquitoes).  
  
4.2.4 OPTIONAL EXPLORATORY ENDPOINTS  
 The optional exploratory objectives will be assessed as follows:  
• The successful collection of PBMCs will be determined by cell counts and cell viability 
tested using trypan blue staining.  
4. 2 .1   PRIMARY ENDPOINT   




• Detection and evaluation of anti-blood-stage or anti-gametocyte specific antibodies 
using immunological assays (including but not limited to enzyme-linked 
immunosorbent assays and indirect immunofluorescence assays).  
5  STUDY ENROLLMENT AND WITHDRAWAL  
   
5.1  SUBJECT INCLUSION CRITERIA  
Subjects eligible for inclusion in this study must fulfil all of the following criteria:  
Demography  
I01. Adult male subjects between 18 and 55 years of age, inclusive who do not live alone (from 
Day 0 until at least the end of the anti-malarial drug treatment) and will be contactable 
and available for the duration of the trial and up to 2 weeks following end of study visit.   
I02.  Body mass index between 18.0 and 32.0 kg/m2, inclusive and a minimum body weight of 
50 kg.  
Health status  
I03. Certified as healthy by a comprehensive clinical assessment (detailed medical history and 
complete physical examination).  
I04. Vital signs after 5 minutes resting in supine position:  
• 90 mmHg ≤ systolic blood pressure (SBP) ≤ 140 mmHg,  
• 50 mmHg ≤ diastolic blood pressure (DBP) ≤ 90 mmHg,  
• 50 bpm ≤ heart rate (HR) ≤ 100 bpm.  
I05. Normal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine 
position, QTcF≤450 ms with absence of second or third degree atrioventricular block or 
abnormal T wave morphology.  
I06. Laboratory parameters within the normal range, unless the Investigator considers an 
abnormality to be clinically irrelevant for healthy subjects enrolled in this clinical 
investigation in accordance with approved clinically acceptable laboratory ranges 
documented prior to study start. More specifically for serum corrected calcium, 
creatinine, hepatic transaminase enzymes (aspartate aminotransferase, alanine 
aminotransferase), and total bilirubin (unless the participant has documented Gilbert 
syndrome) should not exceed the approved acceptable ranges and haemoglobin must be 
equal or higher than the lower limit of normal.   
I07. As there is the risk of adverse effects with artemether/lumefantrine and chloroquine in 
pregnancy, it is important that any subjects involved in this study do not get pregnant.  




I08. All subjects must be Duffy Blood group positive and have blood type O.   
Contraception  
Male subjects must agree to use a double method of contraception including condom plus 
diaphragm or condom plus stable oral/transdermal/injectable hormonal contraceptive by 
female partner during the study.   
Abstinent heterosexual male subjects must agree to start a double method if they start a 
sexual relationship during the study.   
Adequate contraception does not apply to male subjects with same sex partners, provided 
they agree to start a double barrier method if they start a sexual relationship with a female 
during the study.  
Adequate contraception rules do not apply to males who have undergone a vasectomy and 
had testing to confirm the success of the vasectomy.  
Adequate contraception rules do not apply to males with female partners who are not of child 
bearing potential (e.g. due to total hysterectomy) and this female is the sole partner for that 
participant.  
Adequate contraception does not apply to subjects of childbearing potential with same sex 
partners (abstinence from penile-vaginal intercourse), when this is their preferred and usual 
lifestyle.   
Regulations  
I010. Having given written informed consent prior to undertaking any study-related procedure.  
5.2  SUBJECT EXCLUSION CRITERIA  
Subjects fulfilling any of the following criteria will not be eligible for inclusion in this study:  
Medical history and clinical status  
E01. Any history of malaria or participation in a previous malaria challenge study.  
E02. Any history of retinal abnormalities, disease of the retina or macula of the eye, visual field 
defects, hearing disorders (e.g. reduced hearing, tinnitus).   
E03. Must not have travelled to or lived (>2 weeks) in a malaria-endemic region during the past 
12 months or planned travel to a malaria-endemic region during the course of the study 
(for endemic regions see http://www.map.ox.ac.uk/browse-resources/).  
E04. Has evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk for 
those greater than 35 years of age, as determined by the Australian Absolute 
Cardiovascular Disease Risk Calculator (http://www.cvdcheck.org.au/). Risk factors include 




sex, age, systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol 
(mmol/L), and reported diabetes status.  
E05. History of splenectomy.  
E06. Presence or history of drug hypersensitivity, or allergic disease diagnosed by an 
allergist/immunologist and/or treated by a physician for allergy or history of a severe 
allergic reaction, anaphylaxis or convulsions following any vaccination or infusion.  
E07. Presence of current or suspected serious chronic diseases such as cardiac or autoimmune 
disease (HIV or other immuno-deficiencies), insulin-dependent and non-insulin dependent 
diabetes, progressive neurological disease, severe malnutrition, acute or progressive 
hepatic disease, acute or progressive renal disease, porphyria, psoriasis, rheumatoid 
arthritis, asthma, epilepsy, or obsessive compulsive disorder.  
E08. History of malignancy of any organ system (other than localised basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within 5 years of screening, 
regardless of whether there is evidence of local recurrence or metastases.  
E09. Subjects with history of schizophrenia, bi-polar disease, or other severe (disabling) chronic 
psychiatric diagnosis including depression or receiving psychiatric drugs or who has been 
hospitalised within the past 5 years prior to enrolment for psychiatric illness, history of 
suicide attempt, or confinement for danger to self or others.  
E10. History of serious psychiatric condition that may affect participation in the study or 
preclude compliance with the protocol, including but not limited to past or present 
psychoses, disorders requiring lithium, a history of attempted or planned suicide, more 
than one previous episode of major depression, any previous single episode of major 
depression lasting for or requiring treatment for more than 6 months, or any episode of 
major depression during the 5 years preceding screening.   
The Beck Depression Inventory (Appendix 5) will be used as an objective tool for the 
assessment of depression at screening. In addition to the conditions listed above, subjects 
with a score of 20 or more on the Beck Depression Inventory and/or a response of 1, 2 or 
3 for item 9 of this inventory (related to suicidal ideation) will not be eligible for 
participation. These subjects will be referred to a general practitioner or medical specialist 
as appropriate. Subjects with a Beck score of 17 to 19 may be enrolled at the discretion of 
the Investigator if they do not have a history of the psychiatric conditions mentioned in 
this criterion and their mental state is not considered to pose additional risk to the health 
of the volunteer or to the execution of the study and interpretation of the data gathered.  
E11. Frequent headaches and/or migraines, recurrent nausea, and/or vomiting (more than 
twice a month).  
E12. Presence of acute infectious disease or fever (e.g., sub-lingual temperature ≥38.5°C) 
within the 5 days  prior to inoculation with malaria parasites.  




E13. Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems 
may compromise participant safety.  
E14. Significant inter-current disease of any type, in particular liver, renal, cardiac, pulmonary, 
neurologic, rheumatologic, or autoimmune disease by history, physical examination, 
and/or laboratory studies including urinalysis.  
E15. Participant has a clinically significant disease or any condition or disease that might affect 
drug absorption, distribution or excretion (e.g. gastrectomy, diarrhoea).  
E16. Participation in any investigational product study within the 12 weeks preceding the 
study.  
E17. Blood donation, any volume, within 1 month before inclusion, or participation in any 
research study involving blood sampling (more than 450 mL/unit of blood), or blood 
donation to the Australian Red Cross Blood Service (Blood Service) or other blood bank 
during the 8 weeks preceding the treatment drug dose in the study.  
E18. Participant unwilling to defer blood donations to the Blood Service for at least 6 months.  
E19. Medical requirement for intravenous immunoglobulin or blood transfusions.  
E20. Participant who has ever received a blood transfusion.  
E21. Symptomatic postural hypotension at screening, irrespective of the decrease in blood 
pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood 
pressure ≥20 mmHg within 2-3 minutes when changing from supine to standing position. 
In the event of a single asymptomatic postural hypotension reading the Investigator may 
repeat the reading once only at their discretion.  
E22. Previous history of syncope or presyncope during blood donation or blood taking.  
E23. History or presence of alcohol abuse (alcohol consumption more than 4 units per day) or 
drug habituation, or any prior intravenous usage of an illicit substance.  
E24. Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the 
duration of confinement. Subjects may smoke up to 5 cigarettes or equivalent per day for 
the rest of the study.  
E25. Ingestion of any poppy seeds within the 24 hours prior to the screening blood test 
(subjects will be advised by phone not to consume any poppy seeds in this time period).  
E26. Excessive consumption of beverages or food containing xanthine bases, including Red Bull, 
chocolate etc., more than 400 mg caffeine per day (equivalent to more than 4 cups per 
day).  




Interfering substance  
E27. Any vaccination within the last 28 days.  
E28. Any corticosteroids, anti-inflammatory drugs, immunomodulators or anticoagulants. Any 
participant currently receiving or having previously received immunosuppressive therapy, 
including systemic steroids including adrenocorticotrophic hormone (ACTH) or inhaled 
steroids in dosages which are associated with hypothalamic-pituitary-adrenal axis 
suppression such as 1 mg/kg/day of prednisone or its equivalent or chronic use of inhaled 
high potency corticosteroids (budesonide 800 μg per day or fluticasone 750 μg).  
E29. Any recent (<6 weeks) or current systemic therapy with an antibiotic or drug with 
potential anti-malarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, 
fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.).  
General conditions  
E30. Any participant who, in the judgment of the Investigator, is likely to be noncompliant 
during the study, or is unable to cooperate because of a language or mental deficit.  
E31. Any participant in the exclusion period of a previous study according to applicable 
regulations.  
E32. Any participant who is the Investigator or any sub-investigator, research assistant, 
pharmacist, study coordinator, or other staff thereof, directly involved in conducting the 
study.  
E33. Any participant without a good peripheral venous access.  
Biological status  
E34. Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, 
antihepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, 
antihuman immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab), 
syphilis (EIA).  
E35. Positive urine drug test for any drug listed in Section 7.2.1 (Drug Screening) unless there is 
an explanation acceptable to the Investigator (e.g., the participant has stated in advance 
that they consumed a prescription or over-the-counter product which contained the 
detected drug) and/or the participant has a negative urine drug screen on retest by the 
pathology laboratory. Any participant testing positive for acetaminophen 
(acetaminophen) at screening may still be eligible for study participation, at the 
Investigator’s discretion.  
E36.  Positive alcohol breath test.  




Specific to the study  
E37. Cardiac/QT risk:  
• Family history of sudden death or of congenital prolongation of the QTc interval or 
known congenital prolongation of the QTc interval or any clinical condition known to 
prolong the QTc interval.    
• History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.   
• History of electrolyte disturbances, particularly hypokalaemia, hypocalcaemia, or 
hypomagnesaemia.  
• Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) 
which in the opinion of the Investigator is clinically relevant or will interfere with the 
ECG analyses on study.  
E38. Known hypersensitivity to artemether/lumefantrine or chloroquine or any of their 
excipients, or 4-aminoquinolines, artemether or other artemisinin derivatives, 
lumefantrine, piperaquine.  
E39. Known severe reaction to mosquito bites other than local itching and redness.  
E40. Unwillingness to abstain from consumption of grapefruit or Seville orange from initiation 
of the study (Day 0 until completion of antimalarial treatment).   
E41. Unwillingness to abstain from consumption of quinine containing foods/beverages such as 
tonic water, lemon bitter, from inoculation (Day 0) to the end of the antimalarial 
treatment.  
E42. Use of prescription drugs or non-prescription drugs and herbal supplements (such as St  
John’s Wort), within 14 days or 5 half-lives (whichever is longer) prior to the inoculation 
administration. (Note: diazepam interferes with the analysis of blood levels of chloroquine 
and thus should not have been used for at least 8 weeks prior to administration of the 
study drug). If needed (i.e. an incidental and limited need) ibuprofen up to 1.2 g/day or 
acetaminophen is acceptable up to 4 g/day. The subject must inform the investigator of 
any ibuprofen or acetaminophen use at the next convenient time. Limited use of other 
non-prescription medications or dietary supplements not believed to affect subject safety 
or the overall results of the study, may be permitted on a case-by-case basis following 
approval by the Sponsor in consultation with the Investigator. Subjects are requested to 
refrain from taking non-approved concomitant medications from recruitment until the 
conclusion of the study.  
E43. History of coagulopathy or bleeding diasthesis.  




Subjects who are excluded from participation on study days for any of the above reasons may 
be eligible to participate on a postponed schedule if the Investigator considers this 
appropriate.  
5.3  STRATEGIES FOR RECRUITMENT AND RETENTION  
A maximum of 8 subjects are planned to be enrolled. It is estimated that up to 20 subjects may 
need to be screened to complete enrolment.  
No restrictions will apply for ethnic or racial categories. The expected population may include 
all Australian racial categories. Subjects will be recruited from the QIMR Berghofer Human 
Research Ethics Committee (QIMR Berghofer HREC) approved database of healthy subjects 
maintained by Q-Pharm, or by a general or study specific advertisement via print, radio or 
poster media to students of Queensland universities or to the general community, as approved 
by the QIMR Berghofer HREC.   
Subjects who complete the study up to Day 90±7/EOS will be paid $2750 compensation for 
their participation. Subjects who withdraw or are withdrawn from the study will be 
compensated on a fractional basis for their involvement unless they are withdrawn as a 
consequence of their misconduct. Reserve subjects who do not participate in the study will be 
paid $150 compensation for the inconvenience associated with their attendance for screening 
and for their attendance on the inoculation day, in case they are required to participate. 
Subjects who are screened but are ineligible for the study will be paid up to $75 compensation 
for the inconvenience associated with their attendance for screening (unless there is evidence 
that the subject knowingly omitted information about their eligibility before screening e.g. 
positive urine drug screen or positive alcohol breath test etc.).  
5.4  SUBJECT WITHDRAWAL OR TERMINATION  
  
5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION  
Subjects are free to withdraw from the study at any time. A subject may be considered 
withdrawn if he/she states an intention to withdraw, fails to return for scheduled protocol 
visits for any reason, or becomes lost to follow-up. Subjects may also be withdrawn by the 
Investigator. Possible reasons for withdrawal by the Investigator include the occurrence of a 
serious adverse event (SAE), failure by the subject to comply with the requirements of the 
protocol, or for any other reason at the Investigator’s discretion.  
5.4.2 HANDLING OF SUBJECT WITHDRAWALS OR TERMINATION  
The Investigator will make every effort to determine the primary reason for a subject’s 
withdrawal from the study and record this information in the Case Report Form (CRF). For 
subjects who are lost to follow-up, the Investigator will demonstrate "due diligence" by 
documenting all steps taken to contact the subject (e.g. dates of telephone calls, home visit, 
etc.) in the source documents.  
  




If the subject is withdrawn from the study procedures or follow-up for any reason, with the 
subject’s permission, medical care will be provided for any SAEs that occurred during 
participation in the study until the symptoms of any SAEs are resolved and the subject’s 
condition becomes stable. Follow-up for AEs is described in Section 8.3.   
If earlier withdrawal from further study procedures occurs, the subject will be asked to 
complete the antimalarial treatment. The subjects will also be asked to complete the early 
termination evaluation as described in Section 7.3.5.   
5.5  PREMATURE TERMINATION OR SUSPENSION OF STUDY  
The Sponsor, Principal Investigator, HREC and Regulatory Authorities independently reserve 
the right to discontinue the study at any time for safety or other reasons. This will be done in 
consultation with the Sponsor where practical. In the event of premature trial termination or 
suspension, the above-mentioned parties will be notified in writing by the 
terminator/suspender stating the reasons for early termination or suspension (with the 
exception of the Sponsor’s responsibility for notifying the Regulatory Authorities). After such a 
decision, the Sponsor and the  
Investigator will ensure that adequate consideration is given to the protection of the subjects’ 
interest and safety. The Investigator must review all subjects as soon as practical and complete 
all required records.  
In addition to the classic assessment of SAEs and the occurrence/severity of other AEs by the 
Sponsor and the Investigator, after exploring potential confounding factors, the following 
criteria should be considered as guidance for the decision to stop inoculation of further 
subjects:   
• A subject experiences an SAE that is related to the inoculum.   
• The haematology team or apheresis specialist may decide to stop apheresis based on 
safety, at their discretion.  
• The Investigator and Sponsor may decide to stop inoculation based on other safety 
signals not described in the above criteria.   
  
6  STUDY AGENT  
   
6.1  STUDY AGENT(S) AND CONTROL DESCRIPTION  
  
6.1.1 ACQUISITION  
P. vivax HMPBS02-Pv challenge agent  
The P. vivax HMPBS02-Pv MCB was derived from blood group O rhesus positive blood donated 
from a returned traveller from India who presented with clinical manifestations of malaria. The 
P. vivax HMPBS02-Pv MCB was cryopreserved, aliquoted into cryovials and stored under liquid 




nitrogen under controlled conditions. Refer to the P. vivax HMPBS02-Pv Investigator’s 
Brochure for more details. A  P. vivax HMPBS02-Pv MCB cryovial will be retrieved from 
storage, thawed, and used to aseptically prepare the  inoculum at Q-Gen.  
Rescue medications  
Artemether/lumefantrine (Riamet®) distributed by Novartis Pharmaceuticals Australia Pty Ltd, 
and chloroquine distributed by Alliance Pharmaceuticals Ltd will be acquired by Q-Pharm. 
Artesunate is the recommended parenteral treatment for malaria in Australia. Currently, it is a  
Special Access Scheme drug, and has been sourced from Guilin Pharmaceutical (Shanghai) Co., 
Ltd. Import was facilitated by Medicines for Malaria Venture. The manufacture of intravenous 
artesunate is undertaken in a WHO Pre-Qualified GMP facility  
(http://www.mmv.org/access/access-portfolio/artesun-injectable-artesunate).  
6.1.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
P. vivax HMPBS02-Pv challenge agent  
Each inoculum dose will contain parasitised and unparasitised RBCs, resuspended in 0.9% 
Sodium Chloride Intravenous Infusion, in a total volume of 2 mL in syringes. The syringes will 
be double contained following preparation and labelled in accordance with GCP guidelines, the 
Australian Clinical Trial Handbook (Guidance in conducting clinical trials in Australia using 
“unapproved” therapeutic goods), v2.0, March 2018 and PIC/S Guide to Good Manufacturing 
Practice for Medicinal Products Annex 13 (January 2017).    
Rescue medications  
Artemether/lumefantrine tablets are pale yellow, flat, round, uncoated tablets with bevelled 
edges, marked with N/C and a score line on one side and CG on the other, supplied in blister 
packs containing 16, 24, or 400 tablets. Chloroquine tablets are round, flat, white, uncoated  
tablets with a break line on one side, supplied in a bottle containing 100 tablets. Artesunate for 
i.v administration is presented as a powder for reconstitution (60 mg artesunic acid) in a vial.   
All rescue drugs will be labelled according to identity, brand or source, and batch number. The 
contents of the label for drug to be administered to the subjects will be in accordance with all 
applicable regulatory requirements.  
6.1.3 PRODUCT STORAGE AND STABILITY  
P. vivax HMPBS02-Pv challenge agent  
The malaria challenge agent is prepared at Q-Gen on inoculation day (Day 0). The time 
between preparation of the inoculum and administration to each subject will be a maximum of 




1.5 hours, during which time the syringes will be kept at the required temperature as recorded 
on the label.  
Rescue medications  
• Artemether/lumefantrine: store below 30°C protected from moisture.   
• Chloroquine: store below 30°C.  
• Artesunate: store in tightly closed containers, protected from light.  
All drugs will be held in appropriate locked storage conditions at the clinical unit until required.  
6.1.4 PREPARATION  
P. vivax HMPBS02-Pv challenge agent  
The inocula will be prepared aseptically at Q-Gen (QIMR Berghofer) from a frozen cryovial of 
the P. vivax HMPBS02-Pv MCB by nominated QIMR Berghofer staff under the guidance of the 
Investigator. The infected erythrocytes will be thawed, washed, re-suspended in normal saline, 
diluted in a final volume of 2 mL of clinical grade saline, and dispensed into syringes. Any 
remaining unused infected RBCs will be discarded as per approved standard operating 
procedures.  
Rescue medications  
Artemether/lumefantrine, chloroquine are available as tablets and no preparation is required.  
Artesunate powder for reconstitution will be dissolved in 1 mL sodium bicarbonate (5%), 
then 5 mL sodium chloride (0.9%) will be added to create a 10 mg/mL solution (total volume 
6 mL).   
6.1.5 DOSING AND ADMINISTRATION  
P. vivax HMPBS02-Pv challenge agent  
An inoculum dose, containing an estimated ~1100 viable P. vivax-infected erythrocytes in a 
volume of 2 mL, will be administered intravenously to each participant on the morning of Day 
0. The actual number of parasites inoculated will take into account the loss of viability resulting 
from cryopreservation, storage and thawing. On inoculation day, subjects may have food until 
at least half an hour prior to inoculation. Subjects will undergo intravenous cannulation with an 
appropriate gauge cannula. Placement and patency will be checked by flushing the vein with 
510 mL of clinical grade saline. The inoculum will be injected, and the cannula again flushed 
with 5-10 mL of clinical grade saline. The cannula will then be removed, and haemostasis 
ensured by use of an appropriate dressing. Following inoculation of the subjects, the parasite 
count of the inocula will be quantified by malaria 18S qPCR.  
Rescue medications  





All subjects will receive compulsory treatment with artemether/lumefantrine following 
apheresis directly after returning to Q-Pharm. The threshold for treatment will occur when 
parasitaemia is  
>20,000 parasites/mL or the Malaria Clinical Score is  >6 or at the Investigator’s discretion. 
Artemether/lumefantrine tablets containing 20 mg artemether and 120 mg lumefantrine will 
be administered as  6 doses of 4 tablets (total course of 24 tablets) given over a period of 60 
hours (total dose of 480 mg artemether and 2.88 g lumefantrine). Each dose of tablets 
administered orally should be taken with food or drinks rich in fat (e.g., milk). Subjects will be 
reminded of the potential side effects of artemether/lumefantrine (Riamet®) and given the 
Consumer Medicine Information for Riamet® (Appendix 4).  
Chloroquine (only if required)  
Subjects will only be administered chloroquine if artemether/lumefantrine fails to clear the 
malaria parasites. For example, if qPCR results indicate unsatisfactory clearance of the 
parasitaemia, defined as 2 consecutive qPCR time-points showing less than 20% of baseline 
(i.e. the parasitaemia before drug treatment) by 72 hours, subjects may be administered 
chloroquine. The decision to institute early curative treatment will be made in consultation 
with the Local Independent Medical Monitor (IMM), who is an external malaria expert, to 
advise on the safety of continuing observation without rescue versus administration of curative 
treatment. Chloroquine tablets containing 250 mg chloroquine phosphate (equivalent to 155 
mg chloroquine base) will be administered as an initial oral dose of 4 tablets, followed by 2 
tablets at 6, 24, and 48 hours (total dose of 2.5 g chloroquine phosphate [1.550 g base]).  
Artesunate (only if required)  
Treatment of subjects with i.v. artesunate will only occur in the event that subjects are unable 
to complete oral treatment with either artemether/lumefantrine or chloroquine (e.g. the 
subject is vomiting). This would be done at the recommended dose regime of 2.4 mg/kg at 
approximately 0, 12, 24, hours and then daily for up to 7 days or until able to take oral drugs.   
6.1.6 ROUTE OF ADMINISTRATION  
Inoculum  
Intravenous.  
Rescue medications  
• Artemether/lumefantrine: oral.  
• Chloroquine (if required): oral.  
• Artesunate (if required): intravenous.  




6.1.7 STARTING DOSE AND DOSE ESCALATION SCHEDULE  
Dosing with the malaria challenge agent and rescue drugs is presented in Section 6.1.5. No 
dose escalation will be performed.   
6.1.8 DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS  
Not applicable.  
6.1.9 DURATION OF THERAPY  
• Inoculum: single dose.  
• Artemether/lumefantrine: 3 days.  
• Chloroquine (if required): 3 days.  
• Artesunate (if required): maximum of 7 days.   
 
The P. vivax challenge inocula, artemether/lumefantrine, chloroquine (if required) and 
artesunate (if required) will be administered at the clinical research Unit (CRU) in the 
presence of clinic staff.   
6.2  STUDY AGENT ACCOUNTABILITY PROCEDURES  
The Q-Pharm pharmacist or designee, as nominated by the Investigator, is responsible for 
maintaining accurate study agent accountability records throughout the study. Study agents 
include the malaria challenge agent and the rescue medication. Dispensing, accountability and 
documentation will be in accordance with Q-Pharm standard procedures. All products will be 
inventoried upon receipt by the Q-Pharm pharmacist. The condition of the products at the time 
of receipt by the pharmacist will be documented, as will the time restrictions of use for the 
syringes containing the malaria challenge agent. The lot numbers and expiry dates of the 
inoculum and antimalarial drugs will be documented. The Q-Pharm pharmacist or delegate will 
ensure that the received products are the specified formulation.  
The storage, handling and the disposal of the challenge agents will be in accordance with 
approved procedures. All dosages prescribed and dispensed to the subjects and all dose 
changes during the study must be recorded in the CRFs. All drug supplies are to be used only in 
accordance with this protocol, and not for any other purpose. All used medications will be fully 
documented. Used and unused drug containers must be destroyed at the site once drug 
accountability is final and has been checked by the Sponsor or its delegate, and written 
permission for destruction has been obtained from the Sponsor.  
Study products and study accountability logs will be available to the Sponsor or their 
representative as part of the study monitoring procedures. Upon completion of the study, 
copies of all study drug management records will be provided to the Sponsor. Original records 
will be maintained at the clinical site with the rest of the study records.  
6.1.10   TRACKING OF DOSE   




7  STUDY PROCEDURES AND SCHEDULE  
   
7.1  STUDY PROCEDURES/EVALUATIONS  
  
7.1.1 STUDY SPECIFIC PROCEDURES   
Medical history  
Past Medical/Surgical History Includes:   
History of all known allergies   
Current medications, including over-the-counter and herbal preparations   
History of substance abuse and recreational drug use   
History of depression, anxiety, mental illness, emotional problems, use of psychiatric 
medications and  
Surgical procedures and results   
  
Physical examination  
Complete Physical Examination Includes:  
 
Weight (Screening only)  
Height  (Screening only)   
Review of systems excluding genitourinary examination and including the following:   
Head, neck (including thyroid), ears, eyes, nose and throat   
Heart/circulation   
Chest   
Lungs   
Abdomen   
Skin   
Neurological exam   
Symptom-Directed Physical Examination: physical examinations will be symptom-directed at 
specified time-points (i.e. systems will be reviewed only if clinically indicated at the discretion 
of the Investigator).   
Beck Depression Inventory  
All subjects will be required to complete the Beck Depression Inventory at screening. This is a 
validated questionnaire used as an objective tool for the assessment of depression (See 
Appendix  
5).   




Vital signs  
Vital signs (temperature, heart rate, respiratory rate and blood pressure) will be measured at 
screening after the subject has rested in the supine position for at least 5 minutes and in the 
standing position within 2-3 minutes when changing from the supine to standing position 
(blood pressure and heart rate only). At all other time-points, vital signs will be measured after 
the subject has rested in the seated position for at least 5 minutes. Tympanic temperature will 
be taken at the clinical unit, and sublingual temperature will be taken by subjects at home for 
practical reasons.  
Electrocardiograms  
A single 12-lead ECG will be recorded after resting supine for at least 5 minutes.   
Apheresis  
Apheresis will be performed according to the SOP included in Appendix 3. This procedure is 
similar to the double red blood cell donation procedure used by the Council of Europe and the 
American Red Cross (49). 386 mL of red blood cells can be collected safely in subjects with 
normal haemoglobin and haematocrit levels according to this well-recognised procedure.   
Blood sampling  
Blood will be collected for clinical laboratory evaluations including haematology, clinical 
chemistry, serology and pregnancy testing (see section 7.2.1). Blood samples will also be 
collected to monitor malaria parasitaemia and for immunology/pathophysiology research (see 
section 7.2.2). The estimated blood volume required for the these tests is listed in Appendix 1. 
The total volume of whole blood drawn from each adult male subject in addition to the red 
blood cells collected during the apheresis procedure will not exceed 200 mL in any given 30-
day period. This volume includes allowance for unscheduled safety laboratory assessments 
that may be required at the discretion of the Principal Investigator or the Sponsor to ensure 
subject safety. The subject haemoglobin count will be checked regularly during the study. 
Subjects with haemoglobin levels below 120 g/L will not undergo apheresis. Subjects with 
haemoglobin count below 135 g/L will be excluded from the study at screening.   
Urine sample collection  
Urine will be collected for urinalysis and drug screening (see section 7.2.1).   
Adverse event recording  
Adverse events will be recorded as described in section 8 and follow the CTCAE V4.03 gradings.  
Malaria Clinical Score  
The following 14 signs/symptoms frequently associated with malaria will be graded using a 
4point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total 




Malaria Clinical Score (maximum score possible is 42). Individual scores for each symptom as 
well as the total score will be recorded.  
Headache  Anorexia  
Myalgia (muscle ache)  Nausea  
Arthralgia (joint ache)  Vomiting  
Fatigue/lethargy  Abdominal discomfort  
Malaise (general discomfort/uneasiness)  Fever  
Chills/Shivering/Rigors  Tachycardia  
Sweating/hot spells  Hypotension  
7.1.2 STANDARD OF CARE STUDY PROCEDURES   
Not applicable.   
7.2  LABORATORY PROCEDURES/EVALUATIONS  
  
7.2.1 CLINICAL LABORATORY EVALUATIONS   
Haematology   
Full blood count (FBC) with differential   
White blood cell count (WBC)   
WBC differential (diff)   
A manual blood smear should be reviewed if there are immature/abnormal cells detected on 
the automated differential or if an automated differential was not able to be performed.   
neutrophils (NEUT)  
lymphocytes (LYM)  
monocytes  (MON)  
eosinophils (EOS)  
basophils (BAS)  
Red blood cell count (RBC)  
Haemoglobin (HGB)   
Haematocrit (HCT)   
Platelet count (PLAT)   
Reticulocyte count (RETI) (Day -3 to -1 eligibility confirmation visit or at screening if between 
Day -3 to -1, and Day 28±3 or early termination visit only)   
Blood Group and Rh(D) (Screening only)  
Duffy antigen (Screening only)  
Biochemistry  
Sodium (SODIUM)    Alkaline phosphatase (ALP)  




Potassium (K)  Alanine aminotransferase (ALT, SGPT)  
Chloride (CL)  Aspartate aminotransferase (AST, SGOT)  
Bicarbonate (BICARB)  Corrected calcium (CA) (Screening and 1-3 days 
Pre apheresis and immediately post apheresis)   
Glucose (GLUC)  Phosphate (PHOS)  
Urea   Lactate dehydrogenase (LDH)  
Creatinine (CREAT)  Magnesium  (Screening and 1-3 days Pre apheresis 
and immediately post apheresis )  
Estimated glomerular filtration rate 
(eGFR)  
Cholesterol  (Screening only)  
Albumin (ALB)  Triglycerides (Screening only)  
Globulin   HDL (Screening only)  
Total protein   Urate  
Total bilirubin (BILI)     
Direct bilirubin (BILDIR)    
Urinalysis  
Urine will be tested by dipstick at the clinical unit. If there are any abnormalities considered 
clinically significant in blood, leucocytes or protein, the urine will be sent for formal laboratory 
urinalysis per the clinical unit standard procedure.  
Glucose (GLUC)  
Bilirubin (BILI)  
Ketone (KETONES)  
Specific gravity (SPGRAV)  
Blood   
pH   
Protein (PROT)  
Urobilinogen (UROBIL)  
Nitrite   
Leukocytes (WBC)   
Formal laboratory analysis (if required)   
Urine drug screens and alcohol breath tests  
If the results of the urine drug screens or alcohol breath tests are positive, subjects may be 
allowed to continue, or may be delayed or withdrawn according to site-specific instructions.   
  




All subjects will be questioned about concomitant medications and use of recreational drugs. 
The urine drug screen may be repeated if the potential subject denies usage of any of these 
agents and the test result is believed to be a false positive.   
Subjects testing positive for acetaminophen at screening and/or inoculation day may still be 
eligible for study participation, at the Investigator’s discretion. Subjects requiring 
acetaminophen on a daily basis would not be eligible to enrol in the study, as the use of any 
over-the-counter medication during the study is restricted and potential subjects should not 
discontinue their usual medications in order to participate in the study.  
Urine Testing:   
Amphetamines  Opiates  
Methamphetamines  Phencyclidine  
Barbiturates  Tetrahydrocannabinol (cannabis)  
Benzodiazepines  Tricyclic antidepressants  
Cocaine   Paracetamol (acetaminophen)  
Methadone    
Alcohol breath test   
Serology  
HIV-1/HIV-2  antigen/antibody   
Hepatitis B (HBsAg, anti-HBc (IgG + IgM if IgG is positive))  
Hepatitis C (anti-HCV)  
Syphilis EIA  
Hepatitis A (anti-HAV)  (IgM) - performed off stored sample for testing, at Investigator’s 
discretion  
Hepatitis E (anti-HEV)  (IgM) - performed off stored sample for testing, at Investigator’s 
discretion  
EBV - performed off stored sample for testing, at Investigator’s discretion  
CMV - performed off stored sample for testing, at Investigator’s discretion  
  
  
Assessment of blood for HMP bank (at screening or 1-3 days pre inoculation and again at Day 
28 or Day 90; all timepoints at discretion of Investigator)  
The HMP bank questionnaire may be presented to the subject at the Investigator’s discretion at 
screening or the Day -3 to Day -1 visit, in order to assess eligibility to act as a donor for creation 
of a HMP bank (Appendix 6). If the subject is deemed suitable as a donor, additional blood (55 
mL, Appendix 7) may be collected at screening or Day -3 to Day -1 and again at either Day 28±7 
or Day 90±7 at the Investigator’s discretion for the tests listed below and if the whole blood 
volume does not exceed the 200 mL per 30 day period maximum.   
Barmah Forest Virus IgG  Flavivirus IgM  
Barmah Forest Virus IgM  Dengue PCR  
River Ross Virus IgG  EBV PCR  




River Ross Virus IgM  CMV PCR  
Human T cell Lymphotropic Virus 1/2  Parvo B19 PCR  
Human Herpes Virus 6  Human Herpes Virus 7  
If the flavivirus IgM test is positive, tests may be performed at the Investigator’s discretion for 
confirmation and identification of the specific flavivirus. This may include tests for Japanese 
encephalitis virus, West Nile virus, Dengue virus (may include typing of 4 Dengue serotypes), 
and Murray Valley encephalitis virus.  
Other laboratory tests  
• RBC alloantibodies (Screening and Day 28±3 or Day 90±7  or early termination visit only 
– see 7.3.3  Follow-up).  
• Glucose-6-phosphate dehydrogenase (G6PD) (Screening only).  
Safety serum storage  
Blood for serum storage as safety retention samples will be collected at Day 0 and at the final 
study visit.  
  
7.2.2 OTHER ASSAYS OR PROCEDURES  
Malaria monitoring   
Blood will be collected to monitor malaria parasite numbers using qPCR targeting the 18S rRNA 
gene. Additional blood (up to approximately 2 mL per time-point) may be collected for parasite 
lifecycle stage qRT-PCR at the Investigator’s discretion. This is to evaluate for the presence of 
sexual parasite stages (gametocytes) and other parasite lifecycle stages in the blood. This blood 
may also be used for research into various aspects of parasite biology e.g. gametocytes, 
parasite lifecycle stages, recrudescence, commitment etc. The qRT-PCR may target genes 
including but not limited to: the female gametocyte-specific transcript pvs25, the male 
gametocyte-specific transcript pfMGET, and the ring-stage transcript pfSBP-1 as appropriate. 
This testing will occur between inoculation and day 28.  
Microscopic examination for evidence of parasitaemia or gametocytaemia may be conducted 
at the Investigator’s discretion. Thick films may be prepared from blood collected at time-
points coinciding with MFA.   
Malaria transmission and mosquito infectivity assays  
Transmission of gametocytes to Anopheles mosquitoes may be determined using direct skin 
feeding assays (DFA) and/or membrane feeding assays (MFA). Mosquitoes will be maintained 
in a controlled environment in the PC3 QIMR Berghofer insectary.  




DFA: Subjects will be escorted to the insectary and asked to allow mosquitoes to feed on them 
at up to 2 time-points. Approximately 30 mosquitoes will be distributed into containers with 
gauze lids and starved prior to feeding assays. Mosquitoes will be allowed to bite on the volar 
surface of the forearms, thighs or calves of subjects to directly feed for approximately 15±5 
minutes until fully engorged.   
MFA: Up to approximately 80 mL blood (total) may be collected if maximum whole blood 
volume is not exceeded over either 1 or 2 time-points and transported at ~37°C. Mosquitoes 
(approximately 100) will be distributed into containers with gauze lids and starved prior to 
feeding assays. Mosquitoes will be allowed to feed for approximately 30 minutes on the blood 
through bovine caecum or parafilm membranes on water jacketed glass feeders attached to a 
37°C water bath.  
For both the DFA and MFA, after feeding, the number of non-engorged mosquitoes will be 
recorded. Following the feeds, the mosquitoes will be maintained in a controlled environment 
and will be provided with a sugar solution supplemented with 0.05% para-amino benzoic acid 
to promote the sporogonic cycle. Seven to ten days after blood feeding, mosquitoes will be 
dissected to quantify oocysts in midgut preparations using either malaria 18S qPCR, microscopy 
(oocysts will be stained with 0.1% mercurochrome) or CS ELISA.   
A subset of fed mosquitoes may be kept for up to 24 days in order to investigate for 
development of salivary gland sporozoites. The prevalence and/or intensity of oocyst infection 
will be determined in the blood fed mosquitoes. The number of mosquitoes dying prior to 
dissection will be recorded.  
Detection and evaluation of anti-blood-stage or anti-gametocyte specific antibodies  
Plasma from blood samples taken for other purposes, e.g. membrane feeding assays, 
immunology samples etc., may be used at the Investigator’s discretion for the detection and 
evaluation of anti-blood stage or anti-gametocyte specific antibodies. The plasma may be used 
for immunological assays including, but not limited to, enzyme-linked immunosorbent assays 
and indirect immunofluorescence assays.  
Plasma samples and peripheral blood mononuclear cells for research on the 
immunology and pathophysiology of P. vivax  
Plasma and PBMCs harvested using apheresis may be collected and stored for research on the  
immunology and pathophysiology of P. vivax, at the Investigator’s discretion. A baseline 
sample (20 mL) for plasma and PBMCs may also be collected on Day 0 pre-inoculation, at the 
Investigator’s discretion if the maximum whole blood volume is not exceeded.   




7.2.3 SPECIMEN PREPARATION, HANDLING, AND STORAGE  
Biological samples will be retained for the time required for assessment for analysis, and may 
then be discarded. Safety serum samples will be stored indefinitely with the permission of the 
subjects for any retrospective safety assessments.  
 
Samples collected will be shipped to nominated local or international laboratories for 
assessment. The site staff will be responsible for shipment of samples to analytical laboratories 
for testing. Samples must be packed securely together with completed shipment forms in 
shipping containers together with sufficient dry ice as per Shipper procedures.  
7.3  STUDY SCHEDULE  
  
 
A screening visit will be scheduled after an initial telephone interview conducted by clinical unit 
staff has occurred to review background information. For the screening visit, potential subjects 
will be told to come to the clinical unit after an overnight fast of ≥8 hours. During this initial 
screening visit, the potential subject will read the Participant Information Sheet and be 
encouraged to ask questions. Individuals willing to be considered for inclusion may sign the 
screening consent form during the screening visit, or return to the clinical unit after further 
consideration. The subject will be given a copy of the Participant Information Sheet and signed 
consent form for their records. The signed and dated originals will be held on file by the CRU. 
Participation consent must be obtained from all eligible subjects prior to screening tests.  
After providing written consent to participate, the subject will be examined by a medical officer 
and physical examinations, vital signs and ECG testing will be done together with collection of 
blood and urine samples for safety assessment. The subjects will be fully informed of the 
nature of the study at this time, and advised of the requirement to repeat some screening tests 
during the  
Day -3 to Day -1 safety visit (if required) and/or on the day of malaria challenge inoculum 
administration to determine their continuing eligibility. Subjects must confirm that they will 
not be living alone from Day 0 until completion of antimalarial treatment.  
The pre-study screening will be conducted within 4 weeks prior to the Day 0 malaria challenge 
day and will include:  
1. Provide the Main Participation Information Sheet and Informed Consent form and 
apheresis specific Participation Information Sheet and Informed Consent form and give the 
subject sufficient time to review the contents.  
2. Explain the study via the main Participation Information Sheet and gain Informed Consent 
from the subject.   
7 .2.4   SPECIMEN SHIPMENT   
7.3.1   SCREENING   




3. Ensure the subject has signed the main Participant Information Sheet and Informed 
Consent and received a signed copy.   
4. The subject will then be escorted to the apheresis unit in the Cancer Care Services 
department at RBWH by a Q-pharm staff. A specialist in apheresis will explain the 
apheresis component of the study via the apheresis specific Participation Information 
Sheet and gain Informed Consent from the subject. The subject will also be provided with a 
leaflet explaining the apheresis procedure (lymphocyte collection leaflet).   
5. A specialist in apheresis will ensure the subject has signed the apheresis specific 
Participant Information Sheet and Informed Consent and received a signed copy.   
6. The subject will then be escorted back to the apheresis unit at the RBWH by Q-pharm staff.  
7. A screening number will be assigned to each subject.  
8. Elicit a complete medical history and use of medications.   
9. Elicit a social history including alcohol and tobacco use.   
10. Undertake a full physical examination.  
11. Ask subject to complete the Beck Depression Inventory.   
12. Ask subject to complete the HMP bank questionnaire and collect blood samples for HMP 
bank assessment (at Investigator’s discretion if the maximum whole blood volume is not 
exceeded) (Section 7.2.1).   
13. Assessment of the cardiovascular disease risk (defined as >10%, 5 year risk when greater 
than 35 years of age) as determined by the Australian Absolute Cardiovascular Disease Risk 
Calculator (http://www.cvdcheck.org.au/). Risk factors include sex, age, systolic blood 
pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported 
diabetes status.   
14. Perform alcohol breath test.  
15. Record vital signs.  
16. Obtain a single 12-lead ECG.   
17. Collect urine for urinalysis and urine drug screen.   
18. Collect blood samples for haematology, biochemistry, RBC alloantibodies, G6PD testing, 
Duffy antigen, and serology (syphilis, viral hepatitis B and C and HIV).  
Blood samples must not be taken from veins located in the ante-cubital fossa.  
19. Verify subject meets inclusion/exclusion criteria.  
Subjects who complete all screening procedures and satisfy all entry criteria will be considered 
eligible to participate in this study. To be eligible for study entry, laboratory values at screening 
must not be outside the range of the normal values at a level deemed to be clinically 
significant. For eligibility parameters a repeat may be requested to exclude laboratory error.    
If screening laboratory results are abnormal, e.g. HIV testing, the volunteer will be referred for 
appropriate counselling. If any clinically significant abnormalities are detected during 
screening, the subject will be referred for follow-up tests to a general practitioner or medical 
specialist as appropriate.  




7.3.2 ENROLLMENT/BASELINE  
Day -3 to Day -1 eligibility confirmation visit  
Subjects (including reserve subjects) will report to the CRU between Day -3 to Day -1 for the 
following baseline assessments, unless screening laboratory assessments were conducted 
within this period, in which case repeat sampling will not be required.   
1. Ask subject to complete the HMP bank questionnaire and collect blood samples for 
HMP bank assessment (at Investigator’s discretion if the maximum whole blood 
volume is not exceeded).   
2. Collect blood samples for haematology and biochemistry analysis.  
Blood samples must not be taken from veins located in the ante-cubital fossa.  
3. Collect urine for urinalysis.     
The timing of these assessments is to ensure that results are available for review by the 
Investigator prior to inoculation on Day 0. Subjects with clinically significant laboratory findings 
at this stage will not be eligible for malaria parasite inoculation.  
Administration of Malaria Challenge Inoculum (Day 0)  
Each subject (and up to 3 reserve subjects) will report to the CRU on the morning of Day 0. The 
Investigator will review the subjects’ screening results prior to their enrolment into the study. 
The Investigator will emphasise the requirement to return for malaria drug treatment after the 
malaria inoculation. Subjects will be reviewed by the Investigator to confirm their continued 
eligibility for the study, including confirmation that they will not be living alone from Day 0 until 
the end of antimalarial treatment by checking housemates contact details recorded at 
screening visit.   
On admission to the study centre, subjects will be required to undertake further screening 
procedures to determine whether they remain eligible to be enrolled. Subjects may have food 
until at least half an hour prior to inoculation. A reserve subject may be asked to replace a 
subject who does not continue to meet eligibility. These reserves will be compensated for the 
study visit even if not inoculated, as described in the Participant Information Sheet and 
Consent Form.   
The procedures that will be undertaken prior to inoculation include:  
1. Verify that all applicable eligibility criteria have been met.   
2. Elicit information regarding any new medical conditions or illnesses since screening.  
3. Perform alcohol breath test and urine drug screen.  
4. Conduct symptom-directed physical examination.   
5. Record vital signs.   
6. Obtain a single 12-lead ECG.   




7. Cannulate subjects with an indwelling intravenous cannula for the malaria inoculum, and 
record which arm is utilised.   
Cannulation must not be performed in veins located in the ante-cubital fossa.  
8. Collect blood samples for malaria 18S qPCR (parasitaemia baseline sample), parasite 
lifecycle stage qRT-PCR (parasite lifecycle stage baseline sample), immunology/ 
pathophysiology (baseline sample), and safety serum storage.  
Blood samples must not be taken from veins located in the ante-cubital fossa.  
Administration of the malaria inoculum:  
1. Administer the malaria inoculum of ~1100 viable P. vivax infected human RBCs 
intravenously.   
2. Observe for a minimum of 60 minutes after administration of the inoculum to evaluate for 
immediate adverse reactions.   
3. Educate subjects on signs and symptoms of malaria (Appendix 2).   
4. Emphasise to subjects the importance of returning on the nominated day for antimalarial 
treatment.   
5. Provide subjects with diary cards and thermometers to record any temperature readings 
during the study in the event of symptoms of fever. Subjects will also record symptoms 
and concomitant medications on the diary cards during the study.  
6. Record adverse events and concomitant medications.   
7. Record vital signs prior to leaving the clinic (approximately 60 minutes after inoculation).  
8. Record malaria clinical score prior to leaving the clinical unit (malaria clinical score 
baseline sample; see Section 7.1.1).  
 
Malaria monitoring via phone (Day 1 to Day 3)  
During this period, subjects are expected to be asymptomatic. A daily phone call or text 
message will be made to the subjects by clinic staff to monitor subject well-being and to solicit 
any adverse events.  
Daily visits for malaria monitoring (Day 4 until treatment day)  
Follow-up from Day 4 until the day of apheresis and rescue treatment initiation will be 
undertaken through daily visits (approximately 8:00 AM) to the clinical site. It may be required 
to increase the frequency of the visits to 3 times a day from day 9 until treatment to allow 
collection of blood samples for parasitaemia determination. The study investigator reserves 
the right to confine subjects earlier than planned for symptoms relief and observation prior to 
apheresis and treatment.   
The following procedures will occur during these visits:  
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1. Perform symptom-directed physical examination when signs and symptoms of malaria are 
identified and it is clinically indicated at the Investigator’s discretion.  
2. Record vital signs.  
3. Collect blood samples for malaria 18S qPCR and parasite lifecycle stage qRT-PCR (if 
required). Sample may be collected up to 3 times per day from Day 9 until treatment day 
(at the discretion of the investigator and if maximum whole blood volume is not 
exceeded).   Blood samples must not be taken from veins located in the ante-cubital 
fossa.  
4. Record malaria clinical score.   
5. Record AEs and use of concomitant medications.   
6. Advise subject that ibuprofen cannot be taken within 48 hours of apheresis.   
7. Haematology and biochemistry (including calcium and magnesium) will be performed on 
Day 9.  
  
Study days for malaria transmission assays  
The transmission of parasites to mosquitoes may be measured using DFAs and/or MFAs at up 
to 2 time-points prior to apheresis and rescue treatment. Parasite lifecycle stage qRT-PCR will 
be used at the Investigator’s discretion to determine the timing of DFAs and/or MFAs. At these 
transmission assay time-points, vital signs will be recorded and a symptom-directed physical 
examination will be performed if symptoms or signs of malaria are identified and it is clinically 
indicated. Blood may also be collected for malaria 18S qPCR and parasite lifecycle stage 
qRTPCR. Thick films may also be performed at the Investigator’s discretion.  
In-patient observation, apheresis and antimalarial treatment phase (confinement)  
Subjects will be admitted to the clinical unit for 72 hours (or less - 48h minimum - at the 
discretion of the investigator if the subject is deemed clinically well and the subject is happy for 
early release) when parasitaemia is >20,000 parasites/mL or the Malaria Clinical Score is  >6 
(within 24 hours of notification) or at the Investigator’s discretion.   
Admission  
The following procedures will occur at admission to the clinical unit (or just prior to the 
apheresis procedure for the blood sample collection):  
1. Perform symptom-directed physical examination.  
2. Record vital signs.  
3. Perform alcohol breath test.  
4. Collect urine for urinalysis and drug screen.  




5. Collect blood samples for haematology, biochemistry, malaria 18S qPCR (pre-apheresis), 
and parasite lifecycle stage qRT-PCR. In the case where apheresis is not performed soon 
after admission but later in the day, blood samples collection will be postponed and 
performed just prior to the apheresis procedure.   
Blood samples must not be taken from veins located in the ante-cubital fossa.  
6. Record Malaria Clinical Score.  
7. Record AEs and use of concomitant medications.   
Apheresis, rescue treatment and observation  
The following procedures will occur during the apheresis, rescue treatment and observation 
period:  
1. The subject will be escorted to the apheresis unit in the Cancer Care Services department 
at RBWH by a staff member. The subject will then undergo the apheresis procedure as per 
the (SOP) (see Appendix 3) whilst being supervised by the apheresis specialist nurse. Time 
on the apheresis machine will be approximately 2-4 hours. The subject may have to 
remain in the apheresis unit slightly longer to allow connection to the apheresis 
apparatus.  Once the procedure is over the subject will be escorted back to the clinical site 
(Q-Pharm). A QPharm study doctor will be available by phone for the duration of the 
apheresis and be able to attend the subject within 10 minutes if needed. If the subject 
develops signs or symptoms of low calcium levels the apheresis specialist may advise the 
subject verbally to commence a high calcium diet.  
2. Cannulate subjects with an indwelling intravenous cannula.   
3. Collect blood samples for haematology, biochemistry (including calcium and magnesium) 
and malaria 18S qPCR (post-apheresis). A blood sample can also be collected for parasite 
lifecycle stage qRT-PCR (at the discretion of the investigator and if the maximum whole 
blood volume is not exceeded).  
4. Obtain a single 12-lead ECG.  
5. Administer artemether/lumefantrine treatment under direct observation.   
6. Follow-up subjects as in-patients for 72 hours (or shorter - 48h minimum - at the 
discretion of the investigator if the subject is deemed clinically well and the subject is 
happy for early release) to ensure tolerance of the therapy and adequate clinical 
response.   
7. Perform symptom-directed physical examination when signs or symptoms of malaria are 
identified and it is clinically indicated at the Investigator’s discretion.  
8. Record vital signs 3 times a day whilst confined.   
9. Record Malaria Clinical Score 3 times a day whilst confined.   
10. Collect blood samples for malaria 18S qPCR at 12, , 24, 36, and 48 (if the subject remains 
in confinement for 72 h), hours following artemether/lumefantrine treatment initiation. 
Additional blood samples can be collected at the discretion of the investigator if required 
to ensure the safety of the subject.  




11. Record AEs and use of concomitant medications.   
Prior to exit from clinical unit  
Subjects will be allowed to leave the unit 48 to 72 hours after initiation of 
artemether/lumefantrine treatment at the Investigator’s discretion if they are asymptomatic 
and have a normal examination and no clinically significant laboratory abnormalities. Subjects 
may be requested to stay in confinement longer than 72 hours at the Investigator’s discretion if 
deemed in their clinical interest.  
The following procedures will occur prior to discharge from the clinical unit:  
1. Perform symptom-directed physical examination.  
2. Record vital signs.  
3. Obtain a single 12-lead ECG.  
4. Collect blood samples for haematology, biochemistry, malaria 18S qPCR if the subject is 
released around 48 or 72h. A blood sample can also be collected for parasite lifecycle 
stage qRT-PCR (at the discretion of the investigator and if the maximum whole blood 
volume is not exceeded).   
5. Record AEs and use of concomitant medications.   
Chloroquine phosphate rescue treatment (if required)  
It is hypothesised that artemether/lumefantrine treatment will be curative considering that it 
is a registered drug used for treatment of P. vivax malaria infection. However, there is a 
possibility that resistance to artemether/lumefantrine by the P. vivax isolate HMPBS02-Pv may 
occur. In this case subjects will receive a standard course of therapy with chloroquine 
phosphate within 72 hours of administration of the first dose of artemether/lumefantrine 
treatment, at the discretion of the Investigator. Full details on the decision process to 
commence chloroquine treatment are presented in Section 6.1.5. If Chloroquine dosing is 
required, safety bloods (haematology and biochemistry) will be collected and assessed if not 
already scheduled prior to first dose and after last dose (or within 1 day of last dose). 
Monitoring of subjects post-chloroquine treatment will occur as presented above for 
artemether/lumefantrine treatment.  
Artesunate rescue treatment (if required)  
Treatment of subjects with i.v. artesunate will only occur in the event that subjects are unable 
to complete oral treatment with either artemether/lumefantrine or chloroquine (e.g. the 
subject is vomiting). Details on artesunate dosing are presented in Section 6.1.5. Subjects will 
be administered i.v artesunate on site and monitored as described above.   




Out-patient monitoring post-artemether/lumefantrine treatment (post confinement 
until safety visit)  
If the subject is released from confinement before 72h post Riamet® treatment, a follow-up 
visit will be undertaken at 72h for clinical evaluation and blood sampling.  If the 18S PCR result 
is positive, the subject will be followed up until a minimum of one negative qPCR is detected.   
The following procedures will take place during these visits:  
1. Collect blood samples for malaria 18S qPCR monitoring. Blood sampling for malaria 
monitoring will occur at the investigator‘s discretion if there is concern regarding the 
possible recrudescence of parasitaemia.   
2. Collect blood samples for parasite lifecycle stage qRT-PCR at the Investigator’s discretion.   
3. Collect blood samples for haematology and biochemistry, and urine for urinalysis at the  
Investigator’s discretion.   
4. Perform symptom-directed physical examination when signs and symptoms of malaria are 
identified and it is clinically indicated at the Investigator’s discretion.  
5. Record vital signs.    
6. Record Malaria Clinical Score if vital signs are abnormal or at the Investigator’s discretion.  
7. Record AEs and use of concomitant medications.   
Day 28±3  
The following procedures will occur on Day 28±3:  
1. Perform full physical examination.  
2. Record vital signs.  
3. Obtain a single 12-lead ECG.  
4. Collect urine for urinalysis.   
5. At the discretion of the investigator and if required for safety reasons, collect blood 
samples for haematology, biochemistry, malaria 18S qPCR and parasite lifecycle stage 
qRT-PCR (if required), RBC alloantibodies, and serology. If not required at Day 28±3, 
these samples will be collected at Day 90±7 to limit the volume of whole blood 
collected within 30 days of the apheresis procedure.  
6. Collect blood samples for HMP bank assessment (at Investigator’s discretion and if the 
maximum whole blood volume is not exceeded).  
7. Record AEs and use of concomitant medications.  




Follow-up phone call (Day 56±7)  
A phone call will be made on Day 56±7 to the participants by clinic staff to monitor participant 
well-being and to solicit any adverse events.  
7.3.4 FINAL STUDY VISIT  
The following procedures will occur at the EOS visit (Day 90±7):  
1. Perform symptom-directed physical examination.  
2. Record vital signs.  
3. If not already done on day 28±3, collect blood samples for haematology, biochemistry, 
malaria 18S qPCR and parasite lifecycle stage qRT-PCR (if required), RBC alloantibodies, 
and serology.  
4. Collect blood samples for safety serum storage.   
5. Collect blood samples for HMP bank assessment (at Investigator’s discretion and if 
the maximum whole blood volume is not exceeded).  
6. Record adverse events and use of concomitant medications.  
7.3.5 EARLY TERMINATION VISIT  
If withdrawal occurs at any stage of the study, the subject will be asked to complete an EOS 
evaluation. In addition, subjects are informed on the essential requirement to complete the 
antimalarial drug treatment for their safety, via the Participant Information Sheet.  
Participation in an EOS evaluation by each subject is voluntary. Procedures during the early 
termination visit will include the following if withdrawal occurs prior to Day 28 visit:   
1. Perform full physical examination.  
2. Record vital signs.  
3. Obtain a 12-lead ECG.  
4. Collect urine sample for urinalysis.  
5. Obtain blood for haematology, biochemistry, malaria qPCR and parasite lifecycle stage 
qRT-PCR, RBC alloantibodies and safety serum storage.  
6. Record AEs and use of concomitant medications.  
If withdrawal occurs after the Day 28 visit, the procedures outlined for the final study visit will 
be performed.   
 
Unscheduled visits for malaria 18S qPCR or safety monitoring may be required at the  
Investigator’s discretion based on parasitaemia, clinical symptoms or laboratory results. 
Subjects will be contacted by phone to arrange these visits. Where possible, visits will be 
7.3.6   UNSCHEDULED VISIT   




arranged at a time that is both convenient for the subject and meets any clinical urgency as 
determined by the Investigator. Unscheduled visits will be documented in the source 
documents and CRF.  
7.3.7 SCHEDULE OF EVENTS TABLE  
  
The Schedule of Events Table summarises the procedures to be conducted as per this protocol 
during screening, confinement and post-confinement. Section 7.1 and 7.2 provide detailed 
information on the procedures.  
  




Table 1  Schedule of Events  

















  D-28 to D-1  D-3 to D-1  D0  D1 to D3  D4 to 
apheresis  
Apheresis to 




to Safety visitt  
D28±3  D90±7  
Eligibility and safety assessments    
Informed consent  X                  
Beck Depression Inventory  X                  
Medical history, eligibility & 
prior medications  
X    X              
Drug & alcohol screen  X    X      Xd        
Full physical examination  X              X    
Symptom-directed physical 
examinatione  
    X    X  X  Xt    X  
Vital signs assessment  X    X    X  X  Xt  X  X  
ECG  X    X      Xf    X    
Urinalysis  X  X        Xd  Xt  X    
Haematology & biochemistry  X  X      Xo  Xf  Xt  Xu  Xv  
G6PD test & Duffy antigen  X                  
Assessment for HMP banki    Xq  Xq            Xr  Xr  
Serology & RBC alloantibody  
X              Xu  Xv  
Safety serum storage      X            X  
AEs & concomitant 
medications  
    X  X  X  X  Xt  X  X  
Malaria clinical score      X    X  X  Xht      
Malaria monitoring and apheresis    
Malaria 18S qPCR blood 
sampling  
    X    Xg  X  Xt  Xu  Xv  
Parasite lifecycle stage 
qRTPCR blood samplingi  
    X    X  X  Xt  Xu    




Malaria transmission assays 
(DFA and/or MFA)  
        Xj  Xj        
Apheresis            Xk        
Immunology/pathophysiology 
    Xs      Xs        
Rescue drug treatment     
Riamet® treatment            Xk        
Chloroquine treatment            Xm        
Artesunate treatment            Xn        
ECG: Electrocardiogram; G6PD: Glucose 6-phosphate dehydrogenase; RBC: Red blood cell; AEs: Adverse events; qPCR: quantitative polymerase 
chain reaction; qRT-PCR: quantitative reverse-transcriptase polymerase chain reaction; HMP: human malaria parasite; DFA: direct feed assay; 
MFA: membrane feed assay; EOS: End of study.   
  
a This visit is not required in the event that the screening visit is conducted within this period. b Daily visits until Day 9. Up to 3 visits per day may 
be required, at the discretion of the investigator, between day 9 and treatment day.  c Confinement is expected to start on day 9, 10, 11 or 12 
and last between 48 to 72h. d At time of admission to clinical unit only. e Physical examinations should be performed prior to inoculation, upon 
admission to the clinical unit for apheresis and rescue treatment, and at Day 90±14/EOS. At all other times, symptom-directed physical 
examinations will only be performed when signs or symptoms of malaria are identified and it is clinically indicated at the Investigator’s 
discretion. Before exit from confinement, nursing staff must confirm with the study doctor or investigator if any subject requires symptom-
driven examination pre discharge. f On day of admission (just prior to the apheresis procedure) and exit from clinical unit only. Haematology and 
biochemistry (including calcium and magnesium) will be taken upon return to Q-pharm immediately post apheresis. g Blood sampling for malaria 
may be done up to 3 times a day from Day 9 to treatment day (at the discretion of the investigator) h Only if vital signs are abnormal, or at the 
Investigator’s discretion. i At the Investigator’s discretion, if in doubt contact Investigator. j Transmission assays may be performed at up to 2 
time points prior to apheresis and rescue treatment, at the discretion of the Investigator.  k Apheresis and initiation of rescue treatment with 
artemether/lumefantrine will be performed on the first day of admission to the clinical unit (expected to occur on Day 10, 11 or 12).  m 
Chloroquine will only be administered to subjects in the case of failure of artemether/lumefantrine therapy.  n Intravenous artesunate treatment 
will only occur in the event that a subject is unable to complete oral treatment with either artemether/lumefantrine or chloroquine (e.g. the 
subject is vomiting). o Haematology and biochemistry (including calcium and magnesium) will be performed on the day before apheresis.  p A 
phone call will also be made on Day 56±7 to monitor participant well-being and to solicit any adverse events. q Assessment for HMP bank at 
screening or Day -3 to -1 eligibility confirmation visit will include a questionnaire to be completed by each subject.   




r  Blood for HMP bank may be taken at the Investigator’s discretion on day 28 or day 90 but not both and if the maximum whole blood volume is 
not exceeded.  s At the Investigator’s discretion and if the maximum whole blood volume is not exceeded. If in doubt contact Investigator. t If 
subject is released from confinement before 72h post Riamet® treatment.  
u At the discretion of the investigator and if required for safety reasons. Otherwise, blood sample will be collected on day 90±7 to limit the 
volume of whole blood collected within 30 days of the apheresis procedure. v If not performed on day 28 ±3.  
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7.4  JUSTIFICATION FOR SENSITIVE PROCEDURES  
Not applicable.   
7.5  CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES   
Concomitant medications, treatments and procedures are those occurring from administration of the 
malaria inoculum until the end of the study (last visit). Those occurring prior to administration of the 
inoculum are classified as prior medications, treatments and procedures. Medications taken within 28 
days before the malaria inoculation will be recorded as prior medication. Prior and concomitant 
medications, treatments and procedures permitted in this study are outlined in the inclusion/exclusion 
criteria (section 5.1 and 5.2).   
On inoculation day, subjects will be questioned in relation to relevant aspects of compliance with the 
study protocol, including drug intake since their screening clinic visit. Details of all other drugs taken 
(prescription and over-the-counter, systemic and topical administration) will be recorded at this time 
and appropriate action taken. The Investigator may permit the use of ibuprofen up to 1.2 g/day (except 
during the 48 hour period prior to apheresis) or acetaminophen up to 4 g/day, for treatment of 
headache or other pain if required. Any medication taken during the study for treatment of a medical 
condition or adverse event is to be recorded in the concomitant medication pages in the CRF (exact dose 
and timing of each dose to be specified).  
7.5.1 PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDURES  
Ibuprofen should not be taken in the 48 hour period prior to apheresis.   
7.6  PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES   
All concomitant medications other than those routinely used for symptom relief in IBSM trials (i.e. 
acetaminophen, ibuprofen, ondansetron) or routine medications approved at screening (e.g. oral 
contraceptive) should be discussed with the Investigator before being approved unless deemed 
medically urgent. If the medication has already been taken it should be reviewed by the Investigator at 
the next opportunity and a decision should be made to continue, to stop, to switch to an alternative, or 
to withdraw the subject from the trial.   
Subjects should not eat any poppy seeds in the 24 hours before the following time-points:  
screening, inoculation day, and day of admission for antimalarial treatment.   
  
Subjects should not eat or drink any food or beverages that contain alcohol (e.g. beer, wine, and mixed 
drinks) from 24 hours prior to each alcohol breath test and from inoculation until the end of antimalarial 
treatment.  
  
Subjects should not consume more than 400 mg caffeine per day, equivalent to more than 4 cups of 
coffee, from inoculation until the end of the antimalarial  treatment.   
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7.7  PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES   
Not applicable.   
7.8  RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES   
Rescue medications used in this study are defined in section 6 and details on their administration are 
given in section 7.3.   
7.9  SUBJECT ACCESS TO STUDY AGENT AT STUDY CLOSURE   
Not applicable.   
8  ASSESSMENT OF SAFETY  
   
8.1  SPECIFICATION OF SAFETY PARAMETERS  
Safety assessments to be performed in this study include recording of AEs, clinical laboratory 
measurements (haematology, biochemistry, urinalysis), physical examinations, vital signs recording, 
ECGs, and Malaria Clinical Score recording.   
8.1.1 DEFINITION OF ADVERSE EVENTS (AE)  
An AE is any adverse change, i.e., any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom or disease that occurs in a subject during the course of the study, whether 
or not considered by the Investigator as related to study treatment.  
AEs include:  
• A new symptom, sign or medical condition.  
• A disease or medical condition detected or diagnosed during the course of the study even 
though it may have been present prior to the start of the study.  
• An exacerbation of a pre-existing medical condition or disease.  
• An increase in frequency or intensity of a pre-existing episodic disease or medical condition.  
• Continuous persistent disease or symptoms present at study start that worsen following the 
start of the study.  
• An abnormal assessment (e.g. change on physical examination, ECG findings) if it represents a 
clinically significant finding that was not present at study start or worsened during the course of 
the study.  
• An abnormal laboratory test result if it represents a clinically significant finding, symptomatic or 
not, which was not present at study start or worsened during the course of the study or led to 
dose reduction, interruption or permanent discontinuation of study treatment.  
Mosquito bite reactions (if DFA are performed) regardless of clinical significance.  
Borderline abnormal laboratory findings and other objective assessments should NOT be routinely 
captured and reported as AEs, as they will be collected and analysed separately. However, abnormal 
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laboratory findings or other objective measurements that meet the following criteria should be captured 
and reported in the AE section of the CRF:  
• The result meets the criteria for reporting as an SAE  
• The test result is associated with accompanying symptoms, and/or  
• It requires additional diagnostic testing or medical/surgical intervention, and/or  
• It leads to a change in trial dosing outside of protocol-stipulated dose adjustments, or 
discontinuation from the trial, significant additional concomitant drug treatment, or other 
therapy, and/or  
• It is considered by the Investigator or Sponsor to be clinically significant or represent a clinically 
significant change from baseline.  
Merely repeating an abnormal test, in the absence of any of the above conditions, does not constitute 
an AE. Any abnormal test result that is determined to be an error does not require reporting as an AE.  
If a clinical diagnosis is associated with an abnormal laboratory finding, the relevant adverse event 
should be recorded as the diagnosis rather than the incidental laboratory finding (e.g. “hepatitis” should 
be recorded rather than “elevated transaminases”).  
Surgical procedures themselves are not AEs; they are therapeutic measures for conditions which may, or 
may not, be AEs.   
  
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
A serious adverse event (SAE) is defined as an AE which fulfils at least one of the following criteria:  
• Results in death  
• Is life-threatening  o The term "life-threatening" in the definition of "serious" refers to an event 
in which the subject was at immediate risk of death at the time of the event; it does not refer to 
an event which hypothetically might have caused death if it was more severe.  
• Requires inpatient hospitalisation or prolongs existing hospitalisation, unless this is for:  
o Elective or pre-planned treatment or standard monitoring for a pre-existing condition that 
is unrelated to the study and has not worsened since the start of the study. o Cosmetic 
surgery or for social reasons or respite care in the absence of any deterioration in the 
subject’s general condition.  
• Results in persistent or significant disability/incapacity  
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Is a congenital abnormality/birth defect  
• Is considered medically important  o Medical and scientific judgement should be exercised in 
deciding whether other AEs are to be considered serious, such as important medical events that 
may not be immediately life-threatening but may jeopardise the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above. Examples of 
such events are: intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias; convulsions that do not result in hospitalisation; development 
of drug dependency or drug abuse.  
• Constitutes a possible Hy’s Law case o Hy’s Law case is defined as a subject with any value of 
alanine or aspartate aminotransferase greater than 3 × ULN together with an increase in total 
bilirubin to a value greater than 2 × ULN and not associated to an alkaline phosphatase value 
greater than 2 × ULN (FDA Guidance on Drug Induced Liver Injury: Premarketing Clinical 
Evaluation [2009]).  
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is any SAE where a causal relationship 
with the malaria challenge agent (P. vivax HMPBS02-Pv) or the antimalarial rescue drugs 
(artemether/lumefantrine, Chloroquine, or artesunate) is at least a reasonable possibility, but the event 
is not listed in the Investigator Brochure(s) and/or Summary of Product Characteristics.  
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP)  
Not applicable.   
8.2  CLASSIFICATION OF AN ADVERSE EVENT  
  
 
In addition to determining whether an AE fulfils the criteria for a SAE or not, the severity of AEs 
experienced by study subjects will be graded according to the Common Terminology Criteria for Adverse 
Events v4.03 published 14 June 2010 (CTCAE v4.03). This guidance provides a common language to 
describe levels of severity, to analyse and interpret data, to scale the aggregate AE score, and to 
articulate the clinical significance of all AEs.  
The severity of adverse events will be graded as follows:   
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2: Moderate; minimal, local or non-invasive intervention indicated; limiting age 
appropriate instrumental activities of daily living.  
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalisation or 
prolongation of hospitalisation indicated; disabling; limiting self-care activities of daily living.  
8 .2.1   SEVERITY OF EVENT   
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• Grade 4: Life-threatening consequences; urgent intervention indicated.  Grade 5: Death 
related to AE.  
A mild, moderate, or severe AE may or may not be serious (see Section 8.1.2). These terms are used to 
describe the intensity of a specific event. Medical judgment should be used on a case-by case basis.   
Seriousness, rather than severity assessment, determines the regulatory reporting obligations.  
8.2.2 RELATIONSHIP TO STUDY AGENT  
The Investigator will decide if AEs are related to any of the study agents or procedures. Where possible, 
a distinction should be made between events considered related to the malaria challenge agents or the 
apheresis procedure and those related to protocol-mandated procedure (including mosquito feeding, 
and rescue medication).   
The assessment of causality will be made using the following definitions:   
Unrelated   
This category is applicable to those AEs which are judged to be clearly and incontrovertibly due to 
extraneous causes (disease, environment, etc.) and do not meet the criteria for the relationship listed 
under unlikely, possible or probable.   
  
Unlikely   
In general, this category is applicable to an AE which meets the following criteria (must have the first 
two):   
  
1. It does not follow a reasonable temporal sequence from administration of any of the study 
agents.   
2. It may readily have been produced by the subject’s clinical state, environment or toxic factors, 
or other modes of therapy administered to the subject.   
3. It does not follow a known pattern of response to the study agents.   
4. It does not reappear or worsen when any of the study agents are re-administered.   
  
Possible   
This category applies to those AEs in which the connection with any of the study agents appears unlikely 
but cannot be ruled out with certainty. An adverse event may be considered possible if or when (must 
have the first two):   
  
1. It follows a reasonable temporal sequence from administration of any of the study agents.   
2. It may have been produced by the subject’s clinical state, environment or toxic factors, or other 
modes of therapy administered to the subject.   
3. It follows a known pattern of response to any of the study agents.   




Probable   
This category applies to those adverse events which are considered, with a high degree of certainty, to 
be related to the study agents. An adverse event may be considered probable if (must have the first 
three):   
  
1. It follows a reasonable temporal sequence from administration of any of the study agents.   
2. It cannot be reasonably explained by the known characteristics of the subject’s clinical state, 
environment or toxic factors, or other modes of therapy administered to the subject.  
3. It disappears or decreases on cessation or reduction in dose.   
4. It follows a known pattern of response to any of the study agents.   
5. It reappears on re-administration.  
 
An AE is regarded as an unexpected event if its nature or severity is not consistent with the applicable 
reference safety information (Investigator’s Brochures or approved manufacturer’s prescribing 
information for marketed drugs). Events that add significant information on the specificity, severity or 
frequency of previously described reactions, are also regarded as unexpected.  
Expected AEs from the malaria infection are listed in Appendix 2 and the Investigator’s Brochure for the 
P. vivax HMPBS02-Pv challenge agent. Expected AEs from the antimalarial drugs used are listed in the 
artemether/lumefantrine and Chloroquine Consumer Medicine Information  (see Appendix 4) and 
artesunate product insert.   
8.3  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP  
All AEs must be documented and followed up by the Investigator until:  
• the event is resolved, or  
• no further medically relevant information in relation to the event can be expected, and  
• the Investigator considers it justifiable to terminate the follow-up.  
Events that are unresolved at the time of the subject’s last follow-up visit should continue to be followed 
up by the Investigator for as long as medically indicated. The Sponsor retains the right to request 
additional information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if judged 
necessary.  
8 .2.3   EXPECTEDNESS    




All AEs should be treated appropriately. The Investigator will decide upon the appropriate 
action to be taken in response to an AE, which may include one or more of the following:  
• no action taken (i.e. further observation only)  
• apheresis is withheld and the subject withdrawn from the study  
• administration of a concomitant medication  
• hospitalisation or prolongation of current hospitalisation (event to be reported as an 
SAE)  
• other.  
In a case of occurrence of SAEs, regardless of whether or not it is judged to be challenge agent- 
or antimalarial drug-related, the subject will receive appropriate care under clinical supervision 
until all the symptoms of the SAEs have diminished or resolved and the subject’s condition 
improved.  
For ongoing AEs, care will be provided for a period of time as specified in the clinical site work 
instruction protocols. However, if the nature of the ongoing AE is determined by the 
Investigator as not being inoculum-, apheresis-, or antimalarial drug-associated, the subject will 
be advised to visit his/her own general practitioner for further clinical care that he might 
require.  
8.4  REPORTING PROCEDURES  
  
8.4.1 ADVERSE EVENT REPORTING   
It is the Investigator’s responsibility to document and report all AEs occurring in the clinical trial 
whether spontaneously reported by the subject, observed by the Investigator (either directly 
or by laboratory or other assessments), or elicited by general questioning. The period of 
observation for collection of AEs extends from the time of  inoculation up to the end of the 
study. Events reported prior to this will be recorded as medical history, unless the symptoms 
worsen during the study.  
The following information should be recorded for all AEs:  
• a description of the AE  
• the dates and times of onset and resolution of the event  
• the duration of the event in hours  
• the time of onset relative to the administration of the inoculum and/or apheresis  
• the seriousness and severity of the event  
• the action take in response to the event (including treatment required)  
• the outcome of the event  




• the relationship of the event to the study agents (causality assessment), including 
inoculum, apheresis, mosquito feeding, rescue medication, or any other treatment or 
procedure conducted during the study.   
Changes in the severity of an AE will be documented to allow assessment of the duration of the 
event at each level of severity. AEs changing severity will be documented as separate AEs; 
those worsening in severity will be considered unresolved and those reducing in severity will be 
considered resolving. AEs characterised as intermittent require documentation of onset and 
duration at each episode.   
  
All malaria-specific AEs will be tabulated and results graded according to a purpose-designed 
Malaria Clinical Score (Section 7.1.1).  
  
8.4.2 SERIOUS ADVERSE EVENT REPORTING   
The Investigator will take immediate appropriate action in response to SAEs to ensure subject 
safety and in an attempt to identify the causes of the event. Review and reporting of SAEs will 
be in accordance with the Sponsor’s and QPharm’s SAE reporting procedures. The Investigator 
will notify the Sponsor representative (QIMR Berghofer Regulatory Affairs), the QIMR 
Berghofer HREC, and the IMM of the occurrence of any SAE within 24 hours of becoming aware 
of the event. The notification should be in writing by email or fax, and documented on a 
standard SAE reporting form.  
  
Sponsor Representative  
QIMR Berghofer Regulatory Affairs  
Email: clinical.trials@qimrberghofer.edu.au  
QIMR Berghofer-HREC Contact  
QIMR Berghofer HREC Secretary  
E-mail: HREC.Secretariat@qimrberghofer.edu.au 
Phone: +61 7 3362 0117  
Independent Medical Monitor:  
Professor Dennis Shanks  
E-mail: Dennis.SHANKS@defence.gov.au  
Phone: +61 7 3332 493  
The Investigator will complete a follow-up SAE report within 14 days of the SAE, unless no 
further information is available in which case the follow-up report will be provided as soon as 
new information becomes available. The follow-up SAE report will be sent to QIMR Berghofer 




Regulatory Affairs, the QIMR Berghofer HREC, and the IMM. Other supporting documents may 
be requested by these parties and will be provided by the Investigator or a delegate as soon as 
possible.  
Any SAE that meets the criteria of a SUSAR (Section 8.1.2) will be reported to the TGA by  
QIMR Berghofer Regulatory Affairs in accordance with the Sponsor’s reporting procedures.  
8.4.3 UNANTICIPATED PROBLEM REPORTING   
Not applicable.   
8.4.4 EVENTS OF SPECIAL INTEREST   
Not applicable.  
  
8.4.5 REPORTING OF PREGNANCY   
Not applicable.  
8.5  STUDY HALTING RULES   
See Section 5.5.  
8.6  SAFETY OVERSIGHT  
Safety oversight will be undertaken by the Principal Investigator , the collaborating PI, and the 
IMM who will serve as an independent expert to advise on clinical safety specifically in the 
situation where expert external advice is required regarding the need for administration of 
alternative/rescue antimalarial treatment in the circumstance of suboptimal response.  
The Safety Review Team (SRT) will be responsible for decisions related to the safety of subjects 
and the continuation of the study. The role and composition of the SRT is outlined in the study 
specific SRT Charter. The SRT will meet approximately 4 weeks after the inoculation of each 
subject to review safety data before proceeding with the inoculation of a subsequent subject. 
A final SRT will also take place at completion of the study which will review safety parameters 
for all the subjects involved. The SRT will be composed of the Principal Investigator, the 
collaborating PI, the IMM, and a physician with expertise in clinical trials or infectious diseases. 
The SRT will review the clinical and laboratory safety data as well as the recorded AEs and 
SAEs. The SRT makes recommendations to the Sponsor. These recommendations are approved 
by the SRT Chair who signs a letter of recommendation that is sent to the Principal Investigator 
and the Sponsor.  
Additionally, the SRT may meet to assess any events that trigger the stopping rules (Section 
5.5) or as needed to provide a recommendation and findings to QIMR Berghofer HREC and the 
Principal Investigator, in accordance with the approved SRT Charter.  




Whether at a scheduled or unscheduled meeting, the SRT will consider safety signals to 
determine whether or not they can recommend that the study continue.  
9  CLINICAL MONITORING  
It will be the Sponsor’s responsibility to ensure that the study is monitored in accordance with 
the requirements of GCP. The conduct of the study will be reviewed internally by the clinical 
unit (QPharm) in accordance with their standard procedures and work instructions, and GCP 
guidelines. The study will be monitored according to the Sponsor’s SOPs and all protocol 
deviations will be reported to the Sponsor (see Section 14.3 for more detail). Protocol 
deviations that impact subject safety or data integrity will also be reported to the QIMR 
Berghofer HREC.  
During the study, appointed study monitor(s) (on behalf of the Sponsor) will visit the site to 
check completeness of subject records, accuracy of CRF entries, adherence to the protocol and 
to GCP, progress of enrolment, and to ensure that study agents were stored, dispensed, and 
accounted for according to specifications. Key study personnel are required to be available to 
assist the study monitor during these visits.  
The Investigator will be required to give the monitor access to all relevant source documents to 
confirm their consistency with the CRF entries. The Sponsor will require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and the recording of data that is used for all primary and safety variables. Additional 
checks of the consistency of the source data with the CRFs will be performed according to the 
study specific monitoring plan. No information in source documents about the identity of the 
subjects will be disclosed.  
  
10  STATISTICAL CONSIDERATIONS   
   
10.1  STATISTICAL AND ANALYTICAL PLANS  
This study is a Phase I exploratory study to investigate the safety and plausibility of apheresis as 
a method for harvesting parasites from healthy subjects experimentally infected with blood 
stage malaria. As such, no formal statistical analysis plan will be generated.  
10.2  STATISTICAL HYPOTHESES  
Not applicable.   
10.3  ANALYSIS DATASETS  
The safety analysis dataset will include all subjects who receive the malaria inoculum. This 
population will be used to analyse all safety data as well as demographic and baseline data.   
  
  
10.4  DESCRIPTION OF STATISTICAL METHODS  
  





All measured variables and derived values will be listed. Continuous data will be summarised 
using descriptive statistics (mean and standard deviation, or median and interquartile range).  
Categorical data will be presented using N and % (using the number of subjects without 
missing data in the calculation).  
10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
Not applicable.   
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)  
No formal statistical analysis of the secondary endpoints will be performed, see Section 10.4.1.   
 
The overall number and percentage of subjects with at least one AE (and SAE) will be tabulated 
over the entire study period. All AE data will be summarised by MedDRA system organ class 
and preferred term, and maximum severity. Vital signs, routine safety laboratory data and ECG 
parameters will be summarised descriptively by time-point. Both absolute values and change 
from baseline (inoculation) will be presented.  
10.4.5 ADHERENCE AND RETENTION ANALYSES  
Not applicable.  
10.4.6   BASELINE DESCRIPTIVE STATISTICS  
Demographic data will be summarised by descriptive statistics and will include total number of 
observations (n), mean, standard deviation (SD) and range for continuous variables and 
number and percentages with characteristics for dichotomous variables.   
The subject disposition will be summarised. Study completion, study withdrawals, exclusions 
and violations will be summarised and the reasons for withdrawal, exclusions and violations 
will be listed.   
Medical history, current medical conditions, previous and concomitant medications, results of 
laboratory screening tests, drug tests and any other relevant baseline information will be listed 
by subject.   
  
 
1 0 .4.1   GENERAL APPROACH   
1 0 .4.4   SAFETY ANALYSES   
1 0 .4.7   PLANNED INTERIM ANALYSES     
  
1 0 .4.7.1   SAFETY REVIEW   




There will be an SRT meeting approximately 4 weeks after the inoculation of each subject  to 
review safety data before proceeding with the inoculation of a subsequent subject. There will 
also be a final SRT after the last subject which will review any SAEs, AEs, blood tests, vital signs 
or other investigations of concern. The SRT members must agree on the safety of the trial 
before going forward with the inoculation of the subsequent subject.  
 
The SRT meeting undertaken approximately 4 weeks after the inoculation of the each subject 
will also assess the progress of the each subject in relation to the success or failure in 
extracting and concentrating all stages of malaria parasites by apheresis. The SRT may decide 
not to proceed with inoculating further subjects if they deem it futile and highly unlikely to be 
successful.  
10.4.8 ADDITIONAL SUB-GROUP ANALYSES  
Not applicable.  
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY  
Not applicable.   
10.4.10 TABULATION OF INDIVIDUAL RESPONSE DATA  
All individual subject data will be listed by measure and time point.   
10.4.11  EXPLORATORY ANALYSES  
Not applicable.  
10.5  SAMPLE SIZE  
This study is a exploratory study to investigate the safety and plausibility of apheresis as a 
method for extracting and concentrating parasites from healthy subjects experimentally 
infected with blood stage P. vivax. Therefore, statistical considerations regarding sample size 
do not apply. We estimate that a total of up to 8 subjects inoculated in a sequential manner 
will be sufficient to meet the objectives of this study. Approximately 4 weeks after the 
inoculation of each subject an assessment of all data collected will be performed. If it is 
deemed by the PI that there is no need to proceed further as all objectives of the study have 
been met, the study may be considered complete with fewer than 8 subjects enrolled.   
10.6  MEASURES TO MINIMIZE BIAS  
  
1 0 .4.7.2   EFFICACY REVIEW   




10.6.1 ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES  
Treatment numbers will be allocated prior to inoculation and will serve as subject identifiers 
and for the purpose of distinction between cohorts, and will not correspond to a 
randomisation schedule.  
Treatment numbers will be defined according to the CRU standard operating procedures 
(SOPs) and noted in a work instruction prior to study start. These numbers will be assigned to 
subjects on the morning of the dose administration after confirmation of their continued 
eligibility, in ascending, sequential order corresponding to the sequence of screening numbers 
for the subject in the admitted cohort. A log will be maintained at the site cross-referencing 
each subject’s screening number to the treatment number assigned.  
After allocation, treatment numbers will be recorded in the CRFs and displayed behind each 
subject’s bed and on a wrist band at all times during the admission period.  
10.6.2 EVALUATION OF SUCCESS OF BLINDING   
Not applicable.   
10.6.3 BREAKING THE STUDY BLIND/SUBJECT CODE  
Not applicable.  
11  SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
  
The Investigator will maintain source documents for each subject in the study. Information 
entered into CRFs will be traceable to these source documents in the subject's file. The 
Investigator must certify that the data entered into the CRFs are complete and accurate. 
Documentation of the apheresis procedure will occur as normal in the specialist centre (see 
Appendix 3) and will be retained as a source document in the subject’s file. After database lock, 
the Investigator will retain copies of the subject data for archiving at the investigational site.  
  
Upon request, the Investigator(s)/institution(s) will permit direct access to source 
data/documents for trial-related monitoring, audits, Ethics Committee review, and regulatory 
inspection(s) by the Sponsor (or their appropriately qualified delegate) and Regulatory 
Authorities. Direct access includes examination, analysis, verification and reproduction of 
records and reports that are important to the evaluation of the trial.  
  
12  QUALITY ASSURANCE AND QUALITY CONTROL  
Data management will be performed in accordance with regulatory requirements. The data 
entered into the CRFs by investigational staff will be reviewed for completeness and accuracy. 




The site personnel will clarify any apparent erroneous entries or inconsistencies and additional 
information will be requested from the site as required.  
Medical history/current medical conditions and adverse events will be coded using the Medical 
dictionary for regulatory activities (MedDRA) terminology (version 19.0 or later).  
After all data have been captured and reviewed, all queries have been resolved with the site 
and any protocol non-compliances that were identified during the data management processes 
have been confirmed by the site, the database will be declared to be complete and accurate, it 
will be locked and made available for data analysis. Any changes to the database after that 
time may only be made by the data manager, in consultation with the Sponsor and in 
accordance with documented database unlock and relock procedures.  
Clinical monitoring will be conducted as described in Section 9.  
Audits may be carried out by Sponsor quality assurance representatives, local authorities or 
authorities to whom information on this study has been submitted. All documents pertinent to 
this study must be made available for such inspections after adequate notice of intention to 
audit.  
13  ETHICS/PROTECTION OF HUMAN SUBJECTS   
   
13.1  ETHICAL STANDARD   
The study will be conducted in accordance with the protocol approved by QIMR Berghofer 
HREC and the Royal Brisbane and Women’s Hospital HREC, the principles of the Declaration of 
Helsinki (Recommendations guiding Medical Doctors in Biomedical Research Involving Human 
Subjects, Fortaleza, Brazil 2013), the NHMRC National Statement on Ethical Conduct in Human 
Research (2007) and the Notes for Guidance on Good Clinical Practice (GCP) 
(CPMP/ICH/135/95), as adopted by the Australian Therapeutic Goods Administration (2000).  
The Investigator will minimise any discomfort experienced by subjects during the study. The 
only invasive procedures will be the intravenous inoculation of the malaria inoculum and the 
blood collection by cannulation/venepuncture and apheresis.   
The maximum amount of blood to be collected from an individual in the study would be up to 
approximately 286 mL if HMP bank production is not performed (i.e. a volume which will not 
be more than the equivalent to a standard blood bank donation and it will be taken over at 
least a 4-8 week interval). See Appendix 1.   
The total volume of blood drawn from each subject will not exceed 450 mL in any given 30 day 
period. This volume includes allowance for unscheduled safety and qPCR assessments that may 
be required at the discretion of the Principal Investigator or the Sponsor to ensure subject 
safety.   
  
13.2  ETHICAL REVIEW   
The protocol, consent forms and participant information sheets will be reviewed by the QIMR  




Berghofer-HREC and the Royal Brisbane and Women’s Hospital HREC. No study activities will be 
initiated prior to the approval of these documents by those committees. All amendments and 
addenda to the protocol will similarly be submitted to the QIMR Berghofer-HREC and the Royal 
Brisbane and Women’s Hospital HREC for approval prior to their implementation.  
Changes to the final study protocol can only be made with the prior consent of the Principal 
Investigator, the Sponsor and the HREC. All such changes must be attached to, or incorporated 
into, the final protocol, and communicated to all relevant members of Q-Pharm staff and, if 
appropriate, to study subjects. All deviations from this study protocol will be included in the 
trial master file and included in the CSR. An assessment of the significance of each protocol 
deviation will be given in the CSR. All deviations/amendments will be reported to the Sponsor. 
The different types of amendments are discussed below.  
Non-substantial amendment  
Administrative or logistical minor changes require a non-substantial amendment. Such changes 
include but are not limited to changes in study staff or contact details (e.g., Sponsor instead of 
CRO monitors) or minor changes in the packaging or labelling of study drug. An amendment 
deemed to be non-substantial must have no ethical implications.  
The implementation of a non-substantial amendment may be done without notification to the 
HREC. It does not require their approval or to be signed by the Investigator. The HREC will be 
notified for these non-substantial changes in the next submission round, with the annual study 
report or study close out report which ever comes sooner that will be submitted to HREC.  
Substantial amendment  
Significant changes require a substantial amendment. Significant changes include but are not 
limited to: new data affecting the safety of subjects, change of the objectives/endpoints of the 
study, eligibility criteria, dose regimen, study assessments/procedures, treatment or study 
duration, with or without the need to modify the Participant Information Sheet and Informed 
Consent.  
Substantial amendments are to be approved by the HREC. The implementation of a substantial 
amendment can only occur after formal approval by the HREC and must be signed by the 
Investigator.  
Urgent amendment  
An urgent amendment might become necessary to preserve the safety of the subjects included 
in the study. The requirements for approval should in no way prevent any immediate action 
being taken by the Investigator or the Sponsor in the best interests of the subjects. Therefore, 
if deemed necessary, an Investigator can implement an immediate change to the protocol for 
safety reasons. This means that, exceptionally, the implementation of urgent amendments will 
occur before submission to and approval by the HREC.  




In such cases, the Investigator must notify the Sponsor within 24 hours. A related substantial 
amendment will be written within 10 working days and submitted to the HREC, together with a 
description of the steps that have already been taken in regard to implementation of this 
amendment.  
HREC approval of future research  
In the event that the Principal Investigator or the Sponsor want to perform testing on the 
samples that is not described in the protocol, additional HREC approval will be sought. This 
may be done if a subject consents to blood storage for use in future research (Section 13.3.1).   
13.3  INFORMED CONSENT PROCESS   
  
13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS 
PROVIDED TO SUBJECTS  
Subjects will be fully informed of the nature of the study, the properties and adverse effects of 
the inoculum, apheresis procedure, Chloroquine treatment and potential rescue treatment 
with artemether/lumefantrine and all relevant aspects of study procedures in the ‘Participant 
Information Sheet’.  
The Participant Information Sheet and informed Consent Form describes in detail the study 
agents, study procedures, and risks. Subjects will also receive an Informed Consent for Blood 
Storage and an option to grant permission to be contacted about future studies involvement.  
Subjects will also receive the Consumer Medicine Information for artemether/lumefantrine. 
Subjects may also receive the Consumer Medicine Information for chloroquine (Appendix 4), 
and the product insert for artesunate if required.  
  
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION  
  
During the initial screening visit/recruitment, potential subjects will read the Participant 
Information Sheet. The Investigator or clinical unit staff will explain the study via the 
Participant Information Sheet and the potential subjects will be encouraged to ask questions. 
Individuals willing to be considered for inclusion in the study will sign and date the informed 
Consent Form in the presence of an Investigator. Subjects will be given a copy of their signed 
informed Consent Form. Once the subject has consented to the study, the trial-specific 
screening activities may commence. See Section 7.3.1 for further details.  
13.4  SUBJECT AND DATA CONFIDENTIALITY   
Subjects will be informed that their data will be held on file by Q-Pharm and that these data 
may be viewed by staff of Q-Pharm (including, where necessary, staff of Q-Pharm other than 
the named Investigators).   




Upon request, the Investigator(s)/institution(s) will permit direct access to source 
data/documents for trial-related monitoring, audits, Ethics Committee review, and regulatory 
inspection(s) by the Sponsor (or their appropriately qualified delegates) and Regulatory 
Authorities (see Section 11).   
Subjects will be informed  that a report of the study will be submitted to the Sponsor and may 
also be submitted to government agencies and perhaps for publication, but that they will only 
be identified in such reports by their study identification number, and their gender and age. 
The Investigators undertake to hold all personal information in confidence.  
Subjects will be informed that samples collected for the purposes described in the protocol will 
be sent to Sponsor’s nominated national or international laboratory for assessment.  
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES,SPECIMENS OR DATA  
Samples and data collected during this study will be used to achieve the study objectives. 
Samples and data will be stored according to Q-Pharm and QIMR Berghofer SOPs, and access 
will be limited to authorised personnel. Biological samples will be retained for the time 
required for assessment for analysis, and may then be discarded.  
13.5  FUTURE USE OF STORED SPECIMENS   
As part of the study, safety serum samples will be stored indefinitely at Q-Pharm/QIMR 
Berghofer for retrospective safety assessments that may later be indicated. Subjects consent to 
this storage and the use of the sample for safety assessments, when they sign the informed 
Consent Form for the study.  
For all other samples, consent must be obtained from the subjects to store and use their 
samples for future research. This is done via the Informed Consent for Blood Storage that 
subjects receive during recruitment/screening. Subjects can decide if they want their samples 
to be used for future research or have their samples destroyed at the EOS. A subject’s decision 
can be changed at any time prior to the EOS by notifying the study doctors or nurses in writing. 
However, if a subject consents to future use and some of their blood has already been used for 
research purposes, the information from that research may still be used.  
Any future research using the stored samples that is beyond the current study will be reviewed 
by the QIMR Berghofer HREC (Section 13.2). All samples will be stored at QIMR Berghofer in 
accordance with the laboratory SOPs. The Investigator will ensure that confidentiality will be 
maintained continuously in all future research that involves use of these samples. The vials 
containing the samples of the consented subjects will be coded and the identifying information 
will not be released to any unauthorised third party. The subjects can also choose (via the 
Informed Consent for Blood Storage Form) for the samples to be re-labelled with only the 
study number, malaria strain and visit. No genetic testing will be performed on the stored 
samples without obtaining consent from the subjects. The stored samples will not be sold or 
used directly for production of any commercial product. There are no benefits to subjects in 
the collection, storage and subsequent research use of their samples. Reports about future 




research done with subject samples will NOT be kept in their health records, but a subject’s 
samples may be kept with the study records or in other secure areas.  
14  DATA HANDLING AND RECORD KEEPING   
   
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES   
Each subject will have a clinical file (source data) and case report form (CRF, for protocol 
specific data) into which relevant data will be recorded. All recording will be done only in black 
ink. Corrections will only be made by drawing a single line through the incorrect entry, writing 
the correction in the nearest practicable space, and initialling and dating the correction. 
Correction fluids are not allowed.  
A log of names, signatures and initials of all staff authorised to enter data into a subject’s Clinic 
File and CRF will be kept. Upon completion of each study visit, all CRFs will be reviewed 
internally by the clinic for omissions or apparent errors so that these can be corrected without 
delay. Any corrections made after the review and signature of the Principal Investigator will be 
noted in the audit trail and will required reauthorisation (electronic sign off) by the Principal 
Investigator.   
14.2  STUDY RECORDS RETENTION   
All source data, clinical records and laboratory data relating to the study will be retained in the 
archive of the clinical unit (Q-Pharm) for a minimum of 15 years after the completion of the 
study. Data will be available for retrospective review or audit by arrangement with the Chief 
Executive Officer of the clinical unit (Q-Pharm). Written agreement from the Sponsor must 
precede destruction of the same.  
14.3  PROTOCOL DEVIATIONS   
A protocol deviation is any change, divergence or departure from the study design or 
procedures defined in the protocol.   
All protocol deviations will be documented in the trial master file and included in the CSR. An 
assessment of the significance of each protocol deviation will be discussed in the CSR.   
All protocol deviations will be reported to the Sponsor. Protocol deviations that are not 
approved by the Sponsor and QIMR Berghofer HREC prior to implementation should be 
reported to the Sponsor by the clinical unit. Protocol deviations should be recorded on a 
protocol deviation log by the clinical unit staff. Protocol deviation logs should be submitted to 
the Sponsor and QIMR Berghofer HREC via inclusion with the annual report.   
Protocol deviations that impact subject safety or data integrity will be reported to both the 
Sponsor and the QIMR Berghofer HREC in a timely manner. A protocol deviation report form 
will be used for this purpose.  
14.4  PUBLICATION AND DATA SHARING POLICY  
The data management, statistical and medical writing team appointed by the Sponsor will 
collaborate to provide a detailed CSR upon conclusion of the study. This will include appendices 




of all tables and listings generated during the analyses of data. The Sponsor undertakes to 
ensure that all safety observations made during the conduct of the trial are documented in this 
report.  
Publication and reporting of results and outcomes of this trial will be accurate and honest, 
undertaken with integrity and transparency and in accordance with the relevant clauses 
outlined in the QIMR Berghofer Policy on Criteria for Authorship. QIMR Berghofer and the 
Principal Investigator have a responsibility to ensure that results of scientific interest arising 
from the clinical trials are appropriately published and disseminated. Publication of results will 
be subjected to fair peer-review. Authorship will be given to all persons providing significant 
input into the conception, design, and execution or reporting of the research according to the 
QIMR Berghofer Policy on Criteria of Authorship. No person who is an author, consistent with 
this definition, will be excluded as an author without his/her permission in writing. Authorship 
will be discussed between researchers prior to study commencement (or as soon as possible 
thereafter) and reviewed whenever there are changes in participation. Joint publications 
between QIMR Berghofer and the Royal Brisbane & Women’s Hospital are envisaged. 
Acknowledgment will be given to collaborating institutions and hospitals and other individuals 
and organisations providing finance or facilities. All conflicts arising through disputes about 
authorship will be reviewed by the QIMR Berghofer Director.  
Data will not be released publicly until the manuscript is accepted for publication. In the case of 
no publication, information will only be released to the public and media in accordance with 
the QIMR Berghofer Corporate Media Strategy Policy. However, the Investigator undertakes 
not to make any publication or release pertaining to the study and/or results of the study 
without the  
Sponsor’s prior written consent, being understood that the Sponsor will not unreasonably 
withhold its approval. The Sponsor has the right to publish the results of the study at any time.  
The Investigator shall not use the name(s) of the Sponsor and/or of its employees in advertising 
or promotional material or publication without the prior written consent of the Sponsor. The 
Sponsor shall not use the name(s) of the Investigator and/or the collaborators in advertising or 
promotional material or publication without having received his/her and/or their prior written 
consent(s).  
QIMR Berghofer will ensure that the key design elements of this protocol are posted in a 
publicly accessible database such as Australian New Zealand Clinical Trials Registry (ANZCTR) or 
Clinicaltrials.gov. In addition, upon study completion and finalisation of the study report the 
results of this trial will be either submitted for publication in an open access journal and/or 
posted in a publicly accessible database of clinical trial results.  
15  STUDY ADMINISTRATION  
   
15.1  STUDY LEADERSHIP  
See Section 1 for key roles.   
15.2  LIABILITY/INDEMNITY/INSURANCE  




The study Sponsor will ensure sufficient insurance is available to enable it to indemnify and 
hold the investigator(s) and relevant staff as well as any hospital, institution, Ethics Committee 
or the like, harmless from any claims for damages for unexpected injuries, including death, that 
may be caused by the participant’s participation in the study but only to the extent that the 
claim is not caused by the fault or negligence of the subjects or investigator(s). The Sponsor 
adheres to the guidelines of Medicines Australia for injury resulting from participation in a 
company sponsored trial, including the provision of ‘No-fault clinical trial insurance’.  
16  CONFLICT OF INTEREST POLICY  
No conflicts of interest are applicable in this study.   
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Appendix 1: Total whole blood volume in addition to Apheresis procedure  





No. samples per 
subject for the first 
30 days  
Total volume per 
subject (mL) for 





(including G6PD)  
2  4  8  
4  1  4  
Biochemistry  








Serology   3.5  0  0  
Safety Serum storage  
5  1  5  
Cannulation  Discard  2  8 (+2 if required)  
16 (+4 if required)  
Malaria  
Monitoring  
Malaria qPCR (18S)  2  15 (+5 if required)  
30 (+10 if required)  
Microscopy  2  0  0  
Parasite life-cycle 
stage qRT-PCR  
2  5 (+3 if required)  
10 (+6 if required)  
Malaria Research  Immunology/ 
pathophysiology 
sample  
20  0  0  
MFA (in selected 
subjects but not  
those selected for 
HMP bank 
production)  
  Up to 80  Up to 1  
80 (total over 
either 1 or 2 
timepoints)  
HMP bank  
blood borne 
infection testing  
(Appendix 7)  
  55  Up to 1  55  
(in selected 
subjects but not  
those selected for 
MFA)  
    
Study Total (mL) no MFA no HMP 
Bank 
  
98 (+20 if 
required)  
Study Total (mL) MFA no HMP Bank   
178 (+20  if 
required)  
Study Total (mL) HMP Bank no MFA   
up to - 153 (+20  
if required)  




Most subjects (not involved into membrane feeding or HMP bank procedures) will have 118 mL 
or less of whole blood taken during the first 30 days of the study (post screening)  in addition 
to the 386 mL of red blood cells collected during the Apheresis procedure. An additional 20 mL 
may be collected on day 90±7.   
Subjects involved in membrane feeding or HMP bank procedure will have 200 mL or less of 
whole blood taken during the first 30 days of the study (post screening) in addition to the 386 
mL of red blood cells collected during the Apheresis procedure. An additional 75 mL may be 













Appendix 2: Symptoms and Signs of Malaria  
  
Following challenge via the intravenous malaria challenge inoculation and during the post 
challenge period, the following signs and symptoms of malaria will be monitored:  
  
Signs of Malaria  
  
Fever (≥38°C)  




Symptoms of Malaria  
  
Headache  
Myalgia (muscle ache)  
Arthralgia (joint ache)  
Fatigue/lethargy  
Malaise (general discomfort/uneasiness)  





Appendix 4: Antimalarial Rescue drugs approved manufacturer’s prescribing information  
Riamet® TGA July 2012   
• Product Information   
• Consumer Medicine Information  




Appendix 5: Tubes for HMP bank blood borne infection testing  
   
Tube Type and 






and Date  
Operator  
initials  
   5 x 4 mL EDTA          
   3 x 5 mL SST  
        
   3 x 5 mL SST     
   4 x 5 mL PPT          
  




Appendix 6: Version History  
  
Version  Date  Author(s)/Reviewer(s)  Significant Revisions   
1.0  29 Aug 2017  A. Odedra  Initial version  
1.1  17 Oct 2017  R. Watts/A. Odedra  Changed Principal 
Investigator to Prof. James 
McCarthy. Made changes 
in response to the  
RBWH HREC comments. 
See summary of changes 
document for more 
details.  
2.0  1 Nov 2017  R. Watts/A. Odedra  Added an additional 
exploratory objective for 
antibody research. Added 
a baseline blood sample at 
Day 0 for immunology and 
pathophysiology malaria 
research. Changed blood 
volume for membrane 
feeding assays to 80 mL 
total over 1-2 time-points. 
See summary of changes 
document for more 
details.  
2.1  22 March  
2018  
E. Rossignol/ A. Odedra  Addition of an additional 
coprincipal investigator  




3.0  15 May 2018  E. Rossignol/ A. Odedra  - Added the 
possibility to reduce 
confinement to 48h if the 
subjects are deemed 
clinically well by the 
investigator and are happy 
to be released early.  
- Clarified that 
apheresis may occur on a 
day other than day 10. 
Earlier cohorts results have 
shown that, 24h before 
day 10, parasite levels may 
be much below the 20,000 
parasites/mL threshold 
and the malaria score 
much below 6.   
- Added the 
possibility to collect 
samples more frequently 
for 18s PCR analysis from 
Day 9 to treatment day.  
- Added the 
possibility to confine 
subjects from day 9 until 
treatment day.  
- Clarified that the 
duration of stay at the 
apheresis unit may be 
longer than 4h (to allow 
preparation for the 
procedure).   




Version  Date  Author(s)/Reviewer(s)  Significant Revisions   
   - Clarified that 
immunology exploratory 
endpoints are optional.  
- Modified the inclusion 
criteria to exclude females. A 
very good venous access is 
required for the apheresis 
procedure and females often fail 
this criteria. It is deemed 
inappropriate to invite females 
for screening, considering the 
low likelihood that they may be 
included in the study.   
-Corrected the intravenous 
artesunate treatment 
duration. - Clarified that, 
before exit from confinement, 
nursing staff must confirm 
with the study doctor or 
investigator if any subject 
requires symptom-driven 
examination pre discharge.  
  
3.1  9 July 2018  E. Rossignol/ A. Odedra  Addition of an additional 
coprincipal investigator  
4.0  22 October  
2018  
E. Rossignol/ A. Odedra  Modification of the apheresis 
procedure and increase of the 
volume of red blood cells 
collected. Reduction of the 
volume of whole blood collected 
in compensation.  
4.1  15 
November  
2018  
E. Rossignol/ A. Odedra  Correct typos as per HREC 
request.   
Added the risk of low iron levels 
and fatigue in relation with the 
double red cell collection 
apheresis.  
   




APPENDIX 3. MALARIA CLINICAL SCORE. 
The malaria clinical score was calculated to quantify the clinical symptoms of 
malaria experienced by the subject. The following symptoms were scored as either 
absent (0), mild (1), moderate (2), or severe (3) at each specified timepoint to 
generate a total score (maximum score possible = 42). 
•  Headache 
•  Myalgia (muscle ache) 
•  Arthralgia (joint ache) 
•  Fatigue/lethargy 
•  Malaise (general discomfort/uneasiness) 
•  Chills/Shivering/Rigors 
•  Sweating/hot spells 
•  Anorexia 
•  Nausea 
•  Vomiting 
•  Abdominal discomfort 
•  Fever 
•  Tachycardia 
•  Hypotension 
 
  




APPENDIX 4. APHERESIS COHORT 1 CLINICAL STANDARD OPERATING 
PROCEDURE.  
1. Purpose  
1.1. This SOP describes how to perform a continuous mononuclear cell (CMNC) 
procedure. It is intended to be used in conjunction with:  
1.1.1. Spectra Optia Essentials  
1.1.2. Spectra Optia Continuous Mononuclear Cell Collection (CMNC) 
Procedure Guide 
2. Scope  
2.1. The target audience for this resource are the registered nurses and medical 
officers who care for patients in the Apheresis Unit, Royal Brisbane & 
Women’s Hospital (RBWH), who are involved and trained in apheresis.  
2.2. Patient safety takes priority during a CMNC collection, therefore only 
competent nurses can perform this procedure.   
2.3. All apheresis procedures will comply with 05009/WUG: Apheresis   
2.4. All deviations and associated corrective actions shall be documented in the 
patient medical record.  
3. Principle / Background  
3.1. Apheresis refers to a number of procedures involving the removal of whole 
blood, separating it into the various blood components through 
centrifugation, removing a desired component (white/red cells, platelets 
and plasma with or without replacement fluids) and returning the rest of the 
components. Access to the intravascular compartment is required and 
efficacy of the treatment will depend on the volume of blood processed. 
3.2. All patients requiring a CMNC collection are under the direct care of a 
Haematologist. 
3.3. The RBWH Apheresis Unit is accredited by:  
3.3.1. Australian Bone Marrow Donor Registry (ABMDR)  




3.3.2. National Association of Testing Authorities (NATA)   
3.3.3. Foundation for the Accreditation of Cellular Therapies (FACT)  
3.4. The Royal Brisbane & Women’s Hospital (RBWH) is accredited by the 
Australian Council on Healthcare Standards (ACHS)  
3.5. The Disaster Plan (Section 11) addresses those elements most considered to 
be at risk and provides guidelines to cover some of the potential serious 
emergencies that may arise. All staff involved in apheresis procedures are 
responsible for following this plan as directed by senior personnel.  
4. Objectives / Endpoints  
4.1. All apheresis procedures shall be performed safely and appropriately. 
5. Documentation  
5.1. Policy and Standard/s  
5.1.1. ACHS EQUiP National  
5.1.2. Blood and Blood Products, Management of PROC103 Doc 110/15 
(MNHHS)  
5.1.3. Clinical Incident and Disclosure Management PROC007 Document 
13/14 (MNHHS)  
5.2. Procedures, Guidelines, Protocols  
5.2.1. Australian Guidelines for the Prevention and Control of Infection in 
Healthcare (2010)  
5.2.2. COLGDE001: RBWH Guidelines in the Management of Potential 
Adverse Events in Apheresis  
5.2.3. 02002/Proc: Medications Management  
5.2.4. 21605/Proc: Blood collection (Adult)  
5.2.5. 05009/Proc: Apheresis  
5.2.6. 05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics  




5.2.7. 74100/Proc: Documentation in the Patient Record  
5.2.8. 81000/Proc: Aseptic Non Touch Technique  
5.2.9. 000342/Proc: Standard Precautions  
5.2.10. 003139/Proc: Cleaning and Decontamination – patient environment 
and clinical equipment  
5.3. Forms and Templates  
5.3.1. CLIFRM013: RBWH Donor Consent for Bone Marrow Harvest or 
Apheresis Procedure  
5.3.2. COLFRM009: RBWH Apheresis Patient Checklist label  
5.3.3. COLFRM028: RBWH Apheresis Service Request  
5.3.4. COLFRM030: RBWH Apheresis Product Collection Form  
5.3.5. COLFRM053: RBWH Apheresis Procedure Run Sheet: Spectra Optia  
6. Definitions and Abbreviations  
 6.1.  AIM    Automated interface management  
 6.2.  ABMDR   Australian Bone Marrow Donor Registry  
 6.3.  ACD-A    Acid citrate dextrose - solution A  
 6.4.  BTS    Biomedical Technical Services  
 6.5.  CMNC    Continuous mononuclear cell  
 6.6.  CMV    Cytomegalovirus  
 6.7.  CP    Collection preference  
 6.8.  ELFT    Electrolyte & liver function tests  
 6.9.  FBC    Full blood count  
 6.10. Hb    Haemoglobin  
 6.11. HBV    Hepatitis B virus  
 6.12. HCV    Hepatitis C virus  
 6.13. HIV    Human immunodeficiency virus  




 6.14. HTLV    Human T-lymphotropic virus  
 6.15. IDM    Infectious disease marker  
 6.16. IV     Intravenous  
 6.17. MNC    Mononuclear cell  
 6.18. MNHHS   Metro North Hospital and Health Service  
 6.19. NUM    Nurse Unit Manager  
 6.20. ODTU    Oncology Day Therapy Unit  
 6.21. RBWH    Royal Brisbane & Women’s Hospital  
 6.22. RN    Registered nurse  
 6.23. SOP    Standard operating procedure  
 6.24. TBV    Total blood volume  
7. Materials  
7.1. Equipment  
7.1.1. Spectra Optia Apheresis System (version 11.3) – CMNC Collection.  
7.1.2. IDL filler  
7.1.3. Electronic blood pressure monitor  
7.1.4. Volumetric infusion pump  
7.1.5. Heat sealer  
7.2. Disposables and Reagents  
7.2.1. Spectra Optia IDL Set (Ref: 10310).  
7.2.2. ACD-A anticoagulant (750ml)  
7.2.3. 0.9% normal saline (1000ml)  
7.2.4. Alcohol swab  
7.2.5. 3 way taps (2)  




7.2.6. IV cannulation or central line equipment. Refer to procedures: 
05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics; 05501/Proc: Cannulation of 
Haemodialysis Access; 05600/Proc: Central Venous Access Devices 
(CVADs), Management – Adult. Ensure use of sufficient gauge 
cannulas (backeye needles are preferable for inlet venous access) to 
allow for adequate flow required for the procedure (preferably at least 
16G for inlet and 18G for return)  
7.2.7. Blood collection tubes  
7.2.8. Intravenous giving set  
7.2.9. Burette  
8. Special Considerations  
8.1. This procedure describes how to perform a CMNC procedure.   
8.2. Ensure haematocrit is accurate, as this is used to calculate:  
8.2.1. The limit for collect volumes  
8.2.2. The plasma pump flow rate before the AIM system manages the 
concentration of cells in the collect port  
8.2.3. Changing the haematocrit after the interface has been established will 
not change the interface position   
8.3. The packing factor whilst collecting MNC defaults to 4.5  
8.4. No plasma is to be collected  
8.5. There MUST be FBC and ELFT blood test results available (taken within the 
previous 24hrs) PRIOR to commencement of procedure.  
8.6. The minimum FBC criteria required in order to proceed with the procedure is 
described below.   
  
QIMR volunteer  
  
Platelet     > 100 × 109/L  





Hb            > 100G/L  
8.7. There is a risk of deranged electrolytes due to the effects of the procedure. 
This effect is usually transient and resolves quickly upon cessation of 
CMNC collection. Electrolyte replacement may be required. Calcium 
gluconate is the most frequently required electrolyte replacement and the 
amount and rate is dependent on symptoms of hypocalcaemia during the 
procedure. Magnesium and potassium replacement can also be required, 
below is a guide for when supplementation may be required:  
  
Pre-Procedure Electrolyte  Replacement guide  
Magnesium  < 60 mmol/L  10 – 20 mmols IV magnesium sulphate 
may be required during procedure  
Potassium between 3.0 – 3.5 mmol/L  Oral potassium may be required e.g. 1-2 
chlorvescent tablets   
Potassium < 3.0 mmol  IV potassium chloride 20 mmols may 
be required during the procedure and / 
or 3 oral chlorvescent   
9. Procedure  
9.1. Confirm the following forms are current and valid:  
9.1.1. CLIFRM013: RBWH Donor Consent for Bone Marrow harvest or 
Apheresis Procedure  
9.1.2. COLFRM028: RBWH Apheresis Service Request  
9.2. Prior to commencement of procedure, ensure patient has had appropriate 
IDMs taken.   
9.2.1. HIV serology   
9.2.2. Hepatitis B serology   
9.2.3. Hepatitis C serology   
9.2.4. Syphilis  




9.3. All stock used to collect the product must be visually examined prior to use 
for signs of damage and contamination, as per COLSOP004: Apheresis 
Inventory Control Procedure. Record expiry date and lot number of all 
stock used on COLFRM030: RBWH Apheresis Product Collection form. 
Check expiry dates and lot numbers of procedure kit and intravenous fluid 
bags with 2nd RN and record on  
COLFRM053: RBWH Apheresis Procedure Run Sheet: Spectra Optia   
9.3.1. Confirm that all consumables and reagents used during the procedure 
are satisfactory for use; inspect for damage or evidence of 
contamination and mark the appropriate check box on COLFRM030: 
RBWH Apheresis Product Collection form  
9.4. Set up, load and prime Spectra Optia IDL Set (Ref: 10310) as per on screen 
instructions  
9.5. Follow machine prompts and enter patient data.  
9.6. Educate patient of signs and symptoms of potential adverse reactions, 
emphasising importance of informing nursing staff if he/she experiences 
any such reactions  
9.7. Perform baseline observations (temperature, pulse, respirations and blood 
pressure) and record on run sheet  
9.8. Ensure COLFRM009: RBWH Apheresis Patient Checklist has been 
completed   
9.9. Perform Cannulation according to 05450/Proc: Peripheral Intravenous 
Cannulation, Venepuncture and Infusions – Adult and Paediatrics  
9.10. Collect blood samples if required.   
9.11. Follow machine prompts to commence procedure  
9.12. Review run screen to ensure pump flow rates are appropriate for the 
procedure. Monitor the AC infusion rate, ensuring that it does not exceed 
0.9 ml/min  




9.13. The Spectra Optia system will attempt to establish the interface at 
commencement of the procedure, during this time, the collect valve will 
remain closed.   
9.14. The AIM system monitors the collect port and changes the plasma pump 
flow rate to manage the concentration of cells that flow through the collect 
port. When the AIM system detects cells in the collect port, the collect 
valve opens and starts collecting. Ensure the collect flow rate is set at 
3ml/min  
9.15. The CP defaults to 50 at commencement of procedure. The apheresis nurse 
can set the CP to collect lighter or darker from the buffy coat. Use the 
collection preference tool as a guide for the appropriate CP.  
9.15.1. See appendix 1 for the appropriate CP, using the collection preference 
tool.  
9.15.2. A higher CP results in collecting lighter in the buffy coat  
9.15.3. A lower CP results in collecting darker in the buffy coat  
9.16. Monitor and record patient’s vital signs and run parameters q30 minutes or 
as clinically indicated. Monitor for signs of adverse reactions and record on 
procedure run sheet, reporting adverse events on PRIME.  
9.17. Ensure patient comfort and safety throughout the procedure.  
9.18. Apply a patient ID label to the collection bag. THE LABELS MUST BE 
APPLIED TO THE COLLECT BAG BEFORE THE PATIENT OR THE 
COLLECT BAG ARE DISCONNECTED FROMTHE PROCEDURE 
KIT.  
9.19. At the end of the procedure, follow the system prompts to rinse back  
9.20. Seal the collection bags using a heat sealer prior to disconnection of the 
patient. Ensure that there is approximately 20cm of sterile dockable tubing 
remaining after heat sealing.   




9.21. The RN performing the collections shall record the date, time of completion 
and sign the collection bag label. Verify the identity of the patient with the 
patient ID label.  
9.22. Contact QIMR to collect the cells. The time of collection completion shall 
be recorded on COLFRM030: RBWH Apheresis Product Collection form. 
The collection bags must be placed in a sealed plastic bag for transport to 
QIMR.  
9.23. Release of the product from the Apheresis nurse to the QIMR scientist is 
recorded on COLFRM030: RBWH Apheresis Product Collection form. 
The Apheresis nurse releasing the collected product, must sign (stating 
time and date) that the product has been released, the QIMR scientist 
accepting the collected product must sign (stating date and time) that they 
have accepted product quarantine. Glove must be worn by all staff handling 
the product.   
9.24. On completion of rinseback, collect routine blood samples (usually FBC 
and ELFT).  
9.25. Perform final set of observations and record on procedure run sheet  
9.26. Remove venous access as appropriate  
9.27. Record final values on COLFRM053: RBWH Apheresis Procedure Run 
Sheet and complete COLFRM030: RBWH Apheresis Product Collection 
form.  
9.28. Once paperwork is complete, scan / photocopy all procedural paperwork 
and send to QIMR.  
9.29. Unload set and dispose of waste appropriately   
9.30. Decontaminate Spectra Optia as per protocol (see COLSOP005: RBWH 
Apheresis Equipment Cleaning Procedure). Decontaminate all other 
equipment involved in performing the procedure, in accordance with 
003139/Proc: Cleaning and Decontamination – patient environment and 
clinical equipment. Once all equipment used during the procedure has been 




cleaned, tick appropriate area at the end of the run sheet, confirming 
completion of cleaning tasks.  
9.31. Document all care given in patient medical notes. Include all completed 
paperwork with patient’s medical notes.  
9.32. Record relevant statistical information in: G:\Oncology\Apheresis\Log and  
Statistics  
10. End Points  
10.1. A maximum of 500mls is to be collected, unless clinically indicated  
11.  Disaster Plan  
11.1. This section describes the actions to be taken in the event of serious 
problems which may arise in the Apheresis Unit which may impact on 
either:   
11.1.1. The ability to perform the CMNC collection to the required 
specification 11.1.2. The quality of the collected product  
11.2. Air-Conditioning System Failure – in the event that the air-conditioning 
system malfunctions, contact hospital maintenance and arrange for urgent 
repairs (ext. 67963).  
11.3. Loss of Power – All critical equipment used to perform apheresis 
procedures should be connected to red emergency power points. These 
power points are supplied with the electricity from the emergency backup 
power generators, and in the event of a power failure, are automatically 
activated.  
 11.3.1.  Critical equipment used within the apheresis unit includes:  
 11.3.1.1.   Cell separators  
 11.3.1.2.  Blood warmers  
 11.3.1.3.  Electronic blood pressure monitors  
 11.3.1.4.  Intravenous volumetric pumps  
 11.3.1.5.  Heat sealers   




11.3.2. In the event of an interruption to normal power supply, there may be a 
temporary loss of power before the emergency generator is 
activated. If there is an interruption of the power supply:  
 11.3.2.1.  Close clamps on collect line immediately  
11.3.2.2. If the emergency power supply is activated, power will 
resume, and the Spectra Optia system will reset. After 
system resets, a screen will appear with instructions for 
how to proceed.   
 11.3.2.3.  To restart the procedure, follow onscreen instructions  
11.3.2.4. To abort procedure, press RINSEBACK (if appropriate) or 
DISCONNECT and follow on screen instructions  
11.3.3.  In the event of a complete loss of power with no emergency 
power supply:  
11.3.3.1. The Spectra Optia cell separator will shut down completely. 
Close clamps on collect line immediately. Seal the 
collection bags using a heat sealer (these should still be 
functional if battery charged)  
11.3.3.2. Contact the patient physician and inform him of events and 
that the procedure may be aborted  
 11.3.3.3.  Consult with the Director of the Haematology & BMT   
 11.3.3.4.  The extracorporeal volume in the kit will be 297ml  
11.3.3.5.  The  patient  may  be  disconnected  without 
 performing RINSEBACK or perform MANUAL 
RINSEBACK as per instructions in Spectra Optia 
Essentials Guide, pp.73-76 (in the event that a blood 
prime was performed, RINSEBACK is not necessary)  
11.4. Immediate evacuation – in the event that an immediate evacuation is 
required:  




11.4.1.  Close clamps on collect line if possible. NURSE AND PATIENT 
SAFETY IS PARAMOUNT, therefore do not complete this 
step if completion may endanger the health and safety of the 
nurse or the patient  
11.4.2. Disconnect patient immediately and evacuate as per RBWH Code 
Orange Evacuation procedure. N.B. since RINSEBACK has not 
been performed, the patient will have a 297ml fluid deficit and 
may become hypotensive, monitor patient accordingly  
11.5. Structural damage (e.g. fire, water / flood damage) – in the event of 
structural damage, relocate product, material and patient files as required, 
to another area of ODTU if possible. Depending on the scale of the 
problem, a final decision on a temporary location may need to be 
determined on a case-by-case assessment by a structural engineer and the 
Director of the BMT program  
11.5.1. All critical equipment and/or consumables which may have incurred 
damage should be discarded and replaced as soon as possible  
11.5.2. Contact hospital maintenance (ext. 67963) and organise for them to 
inspect critical equipment as soon as possible  
11.5.3. Suspend all operational activities until repairs are complete and the 
facility is signed off as safe to reoccupy  
11.6. Critical equipment failure – Perform troubleshooting as per relevant 
equipment manuals. If unable to resolve problem, contact BTS or 
manufacturer representative.  
11.7. Critical consumable shortage – if a critical consumable shortage occurs, 
contact the following Apheresis Units to source consumables:  
 11.7.1.  Greenslopes Private Hospital (Speed dial *2521).  
11.7.2. Lady Cilento Childrens’ Hospital (Jo Ritchie – 3068 5686, or Jill 
Shergold – 3068 5767)  
 11.7.3.  Once alternative supply has been sourced, organise transport of the  




required consumables. Liaise with the NUM, ODTU to 
organise payment of delivery e.g. courier service  
11.8. Critical staff shortage – The Apheresis Nurse Practitioner shall liaise with 
the NUM, ODTU regularly to ensure staffing requirements of the apheresis 
unit are met. In the event that key personnel are unavailable to perform 
critical procedures:  
11.8.1. Contact Apheresis Nurse Practitioner (pager# 26299) and NUM, 
ODTU (ext. 68754 / 73991) informing them of the situation  
11.8.2. The NUM / Apheresis Nurse Practitioner will attempt to adequately 
staff the Apheresis Unit   
11.8.3. If appropriate, the situation can be escalated to the Director of the 
BMT program and the Nursing Director, CCS  
11.8.4. If adequate staffing cannot be accomplished, the Apheresis Nurse 
Practitioner shall liaise with the Director of the BMT Program 
to discuss requesting the assistance of other apheresis units in 
the area. Alternative units may be affiliated with the RBWH 
e.g. Greenslopes Private Hospital, or other similarly accredited 
Apheresis Units e.g. Princess Alexandra Hospital or the Mater 
Public Hospital  













  X  X  X  X  
Medical 
Director  
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Nursing Staff          X  




13.  Occupational Health and Safety  
13.1. Standard precautions shall be maintained throughout the procedure. Refer to 
000342/Proc: Standard Precautions.  
14. Risk  
14.1. Low to Medium (case dependant).  
15.  Consultation   
15.1. Director Bone Marrow Transplant Glen Kennedy  
15.2. Apheresis Nurse Practitioner Kari Mudie  
    


















APPENDIX 5. APHERESIS COHORT 2 CLINICAL STANDARD OPERATING 
PROCEDURE. 
1. Purpose  
1.1. This SOP describes how to perform a continuous mononuclear cell (CMNC) 
procedure. It is intended to be used in conjunction with:  
1.1.1. Spectra Optia Essentials  
1.1.2. Spectra Optia Continuous Mononuclear Cell Collection (CMNC) 
Procedure Guide  
2. Scope  
2.1. The target audience for this resource are the registered nurses and medical 
officers who care for patients in the Apheresis Unit, Royal Brisbane & 
Women’s Hospital (RBWH), who are involved and trained in apheresis.  
2.2. Patient safety takes priority during a CMNC collection, therefore only 
competent nurses can perform this procedure.   
2.3. All apheresis procedures will comply with 05009/WUG: Apheresis   
2.4. All deviations and associated corrective actions shall be documented in the 
patient medical record.  
3. Principle / Background  
3.1. Apheresis refers to a number of procedures involving the removal of whole 
blood, separating it into the various blood components through 
centrifugation, removing a desired component (white/red cells, platelets 
and plasma with or without replacement fluids) and returning the rest of the 
components. Access to the intravascular compartment is required and 
efficacy of the treatment will depend on the volume of blood processed.   
3.2. All patients requiring a CMNC collection are under the direct care of a 
Haematologist.   
3.3. The RBWH Apheresis Unit is accredited by:  
3.3.1. Australian Bone Marrow Donor Registry (ABMDR)  




3.3.2. National Association of Testing Authorities (NATA)  
  
  
3.3.3. Foundation for the Accreditation of Cellular Therapies (FACT)  
3.4. The Royal Brisbane & Women’s Hospital (RBWH) is accredited by the 
Australian Council on Healthcare Standards (ACHS)  
3.5. The Disaster Plan (Section 11) addresses those elements most considered to 
be at risk and provides guidelines to cover some of the potential serious 
emergencies that may arise. All staff involved in apheresis procedures are 
responsible for following this plan as directed by senior personnel.  
  
4. Objectives / Endpoints  
4.1. All apheresis procedures shall be performed safely and appropriately.   
5. Documentation  
5.1. Policy and Standard/s  
5.1.1. ACHS EQUiP National  
5.1.2. Blood and Blood Products, Management of PROC103 Doc 110/15 
(MNHHS)  
5.1.3. Clinical Incident and Disclosure Management PROC007 Document 
13/14 (MNHHS)  
5.2. Procedures, Guidelines, Protocols  
5.2.1. Australian Guidelines for the Prevention and Control of Infection in 
Healthcare (2010)  
5.2.2. COLGDE001: RBWH Guidelines in the Management of Potential 
Adverse Events in Apheresis  
5.2.3. 02002/Proc: Medications Management  
5.2.4. 21605/Proc: Blood collection (Adult)  




5.2.5. 05009/Proc: Apheresis  
5.2.6. 05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics  
5.2.7. 74100/Proc: Documentation in the Patient Record  
5.2.8. 81000/Proc: Aseptic Non Touch Technique  
5.2.9. 000342/Proc: Standard Precautions  
5.2.10. 003139/Proc: Cleaning and Decontamination – patient environment 
and clinical equipment  
    
5.3. Forms and Templates  
5.3.1. CLIFRM013: RBWH Donor Consent for Bone Marrow Harvest or 
Apheresis Procedure  
5.3.2. COLFRM009: RBWH Apheresis Patient Checklist label  
5.3.3. COLFRM028: RBWH Apheresis Service Request  
5.3.4. COLFRM030: RBWH Apheresis Product Collection Form  
5.3.5. COLFRM053: RBWH Apheresis Procedure Run Sheet: Spectra Optia  
6. Definitions and Abbreviations  
 6.1.  AIM    Automated interface management  
 6.2.  ABMDR   Australian Bone Marrow Donor Registry  
 6.3.  ACD-A    Acid citrate dextrose - solution A  
 6.4.  BTS    Biomedical Technical Services  
 6.5.  CMNC    Continuous mononuclear cell  
 6.6.  CMV    Cytomegalovirus  
 6.7.  CP    Collection preference  
 6.8.  ELFT    Electrolyte & liver function tests  
 6.9.  FBC    Full blood count  




 6.10. Hb    Haemoglobin  
 6.11. HBV    Hepatitis B virus  
 6.12. HCV    Hepatitis C virus  
 6.13. HIV    Human immunodeficiency virus  
 6.14. IDM    Infectious disease marker  
 6.15. IV     Intravenous  
 6.16. MNC    Mononuclear cell  
 6.17. MNHHS   Metro North Hospital and Health Service  
 6.18. NUM    Nurse Unit Manager  
 6.19. ODTU    Oncology Day Therapy Unit  
 6.20. QIMR    Queensland Institute of Medical Research  
 6.21. RBWH    Royal Brisbane & Women’s Hospital  
 6.22. RN    Registered nurse  
 6.23. SOP    Standard operating procedure  
 6.24. TBV    Total blood volume  
7. Materials  
7.1. Equipment  
7.1.1. Spectra Optia Apheresis System (version 11.3) – CMNC Collection.  
7.1.2. IDL filler  
7.1.3. Electronic blood pressure monitor  
7.1.4. Volumetric infusion pump  
7.1.5. Heat sealer  
7.2. Disposables and Reagents  
7.2.1. Spectra Optia IDL Set (Ref: 10310).  
7.2.2. ACD-A anticoagulant (750ml)  




7.2.3. 0.9% normal saline (1000ml)  
7.2.4. Alcohol swab  
7.2.5. 3 way taps (2)  
7.2.6. IV cannulation or central line equipment. Refer to procedures: 
05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics; 05501/Proc: Cannulation of 
Haemodialysis Access; 05600/Proc: Central Venous Access Devices 
(CVADs), Management – Adult. Ensure use of sufficient gauge 
cannulas (backeye needles are preferable for inlet venous access) to 
allow for adequate flow required for the procedure (preferably at least 
16G for inlet and 18G for return)  
7.2.7. Blood collection tubes  
7.2.8. Intravenous giving set  
7.2.9. Burette  
8. Special Considerations  
8.1. This procedure describes how to perform a CMNC procedure.   
8.2. Ensure haematocrit is accurate, as this is used to calculate:  
8.2.1. The limit for collect volumes  
8.2.2. The plasma pump flow rate before the AIM system manages the 
concentration of cells in the collect port  
8.2.3. Changing the haematocrit after the interface has been established will 
not change the interface position   
8.3. The packing factor whilst collecting MNC defaults to 4.5  
8.4. No plasma is to be collected  
8.5. There MUST be FBC and ELFT blood test results available (taken within the 
previous 24hrs) PRIOR to commencement of procedure.  




8.6. The minimum FBC criteria required in order to proceed with the procedure is 
described below.   
  
QIMR volunteer  
  
Platelet     > 100 × 109/L  
  
Hb            > 100G/L  
8.7. There is a risk of deranged electrolytes due to the effects of the procedure. 
This effect is usually transient and resolves quickly upon cessation of 
CMNC collection. Electrolyte replacement may be required. Calcium 
gluconate is the most frequently required electrolyte replacement and the 
amount and rate is dependent on symptoms of hypocalcaemia during the 
procedure. Magnesium and potassium replacement can also be required, 
below is a guide for when supplementation may be required:  
  
Pre-Procedure Electrolyte  Replacement guide  
Magnesium  < 60 mmol/L  10 – 20 mmols IV magnesium sulphate 
may be required during procedure  
Potassium between 3.0 – 3.5 mmol/L  Oral potassium may be required e.g. 1-2 
chlorvescent tablets   
Potassium < 3.0 mmol  IV potassium chloride 20 mmols may be 
required during the procedure and / or 3 
oral chlorvescent   
9. Procedure  
9.1. Confirm the following forms are current and valid:  
9.1.1. CLIFRM013: RBWH Donor Consent for Bone Marrow harvest or 
Apheresis Procedure  
9.1.2. COLFRM028: RBWH Apheresis Service Request  
9.2. Prior to commencement of procedure, ensure patient has had appropriate 
IDMs taken. 




9.2.1. HIV serology   
9.2.2. Hepatitis B serology   
9.2.3. Hepatitis C serology   
9.2.4. Syphilis  
9.3. All stock used to collect the product must be visually examined prior to use 
for signs of damage and contamination, as per COLSOP004: Apheresis 
Inventory Control Procedure. Record expiry date and lot number of all 
stock used on COLFRM030: RBWH Apheresis Product Collection form. 
Check expiry dates and lot numbers of procedure kit and intravenous fluid 
bags with 2nd RN and record on  
COLFRM053: RBWH Apheresis Procedure Run Sheet: Spectra Optia   
9.3.1. Confirm that all consumables and reagents used during the procedure 
are satisfactory for use; inspect for damage or evidence of 
contamination and mark the appropriate check box on COLFRM030: 
RBWH Apheresis Product Collection form  
9.4. Set up, load and prime Spectra Optia IDL Set (Ref: 10310) as per on screen 
instructions  
9.5. Follow machine prompts and enter patient data.  
9.6. Educate patient of signs and symptoms of potential adverse reactions, 
emphasising importance of informing nursing staff if he/she experiences 
any such reactions  
9.7. Perform baseline observations (temperature, pulse, respirations and blood 
pressure) and record on run sheet  
9.8. Ensure COLFRM009: RBWH Apheresis Patient Checklist has been 
completed   
9.9. Perform Cannulation according to 05450/Proc: Peripheral Intravenous 
Cannulation, Venepuncture and Infusions – Adult and Paediatrics  
9.10. Collect blood samples if required.   




9.11. Follow machine prompts to commence procedure  
9.12. Review run screen to ensure pump flow rates are appropriate for the 
procedure. Monitor the AC infusion rate, ensuring that it does not exceed 
0.9 ml/min  
9.13. The Spectra Optia system will attempt to establish the interface at 
commencement of the procedure, during this time, the collect valve will 
remain closed. 
9.14. The AIM system monitors the collect port and changes the plasma pump 
flow rate to manage the concentration of cells that flow through the collect 
port. When the AIM system detects cells in the collect port, the collect 
valve opens and starts collecting. Ensure the collect flow rate is set at 
3ml/min  
9.15. The CP defaults to 50 at commencement of procedure. The apheresis nurse 
can set the CP to collect lighter or darker from the buffy coat. Use the 
collection preference tool as a guide for the appropriate CP.  
9.15.1. See appendix 1 for the appropriate CP, using the collection preference 
tool.  
9.15.2. A higher CP results in collecting lighter in the buffy coat  
9.15.3. A lower CP results in collecting darker in the buffy coat  
9.16. Monitor and record patient’s vital signs and run parameters q30 minutes or 
as clinically indicated. Monitor for signs of adverse reactions and record on 
procedure run sheet, reporting adverse events on PRIME.  
9.17. Ensure patient comfort and safety throughout the procedure.  
9.18. Apply a patient ID label to the collection bag. THE LABELS MUST BE 
APPLIED TO THE COLLECT BAG BEFORE THE PATIENT OR THE 
COLLECT BAG ARE DISCONNECTED FROMTHE PROCEDURE 
KIT.  
9.19. At the end of the procedure, follow the system prompts to rinseback  




9.20. Seal the collection bags using a heat sealer prior to disconnection of the 
patient. Ensure that there is approximately 20cm of sterile dockable tubing 
remaining after heat sealing.   
9.21. The RN performing the collections shall record the date, time of completion 
and sign the collection bag label. Verify the identity of the patient with the 
patient ID label.  
9.22. Contact QIMR to collect the cells. The time of collection completion shall 
be recorded on COLFRM030: RBWH Apheresis Product Collection form. 
The collection bags must be placed in a sealed plastic bag for transport to 
QIMR.  
9.23. Release of the product from the Apheresis nurse to the QIMR scientist is 
recorded on COLFRM030: RBWH Apheresis Product Collection form. 
The Apheresis nurse releasing the collected product, must sign (stating 
time and date) that the product has been released, the QIMR scientist 
accepting the collected product must sign (stating date and time) that they 
have accepted product quarantine. Glove must be worn by all staff handling 
the product.   
9.24. On completion of rinseback, collect routine blood samples (usually FBC 
and ELFT).  
9.25. Perform final set of observations and record on procedure run sheet  
9.26. Remove venous access as appropriate  
9.27. Record final values on COLFRM053: RBWH Apheresis Procedure Run 
Sheet and complete COLFRM030: RBWH Apheresis Product Collection 
form.  
9.28. Once paperwork is complete, scan / photocopy all procedural paperwork 
and send to QIMR.  
9.29. Unload set and dispose of waste appropriately   
9.30. Decontaminate Spectra Optia as per protocol (see COLSOP005: RBWH 
Apheresis Equipment Cleaning Procedure). Decontaminate all other 
equipment involved in performing the procedure, in accordance with 




003139/Proc: Cleaning and Decontamination – patient environment and 
clinical equipment. Once all equipment used during the procedure has been 
cleaned, tick appropriate area at the end of the run sheet, confirming 
completion of cleaning tasks.  
9.31. Document all care given in patient medical notes. Include all completed 
paperwork with patient’s medical notes.  
9.32. Record relevant statistical information in: G:\Oncology\Apheresis\Log and  
Statistics  
10.  End Points  
10.1. QIMR will inform the apheresis nursing staff of the target collect volume 
which will not exceed 450ml   
10.1.1. QIMR may request a specified volume of red cells be added to 
collection at end of procedure. The volume of red cells collected must 
not be more than 162ml and must be included in the maximum target 
collect volume of 450ml  
 10.1.1.1.  The total collect volume must not exceed 450ml  
11.  Disaster Plan  
11.1. This section describes the actions to be taken in the event of serious 
problems which may arise in the Apheresis Unit which may impact on 
either:   
11.1.1. The ability to perform the CMNC collection to the required 
specification 11.1.2. The quality of the collected product  
11.2. Air-Conditioning System Failure – in the event that the air-conditioning 
system malfunctions, contact hospital maintenance and arrange for urgent 
repairs (ext. 67963).  
11.3. Loss of Power – All critical equipment used to perform apheresis 
procedures should be connected to red emergency power points. These 
power points are supplied with the electricity from the emergency backup 
power generators, and in the event of a power failure, are automatically 
activated.  




 11.3.1.  Critical equipment used within the apheresis unit includes:  
 11.3.1.1.   Cell separators  
 11.3.1.2.  Blood warmers  
 11.3.1.3.  Electronic blood pressure monitors  
 11.3.1.4.  Intravenous volumetric pumps  
 11.3.1.5.  Heat sealers   
11.3.2. In the event of an interruption to normal power supply, there may be a 
temporary loss of power before the emergency generator is 
activated. If there is an interruption of the power supply:  
 11.3.2.1.  Close clamps on collect line immediately  
11.3.2.2. If the emergency power supply is activated, power will 
resume, and the Spectra Optia system will reset. After 
system resets, a screen will appear with instructions for 
how to proceed.   
 11.3.2.3.  To restart the procedure, follow onscreen instructions  
 11.3.2.4.  To abort procedure, press RINSEBACK (if appropriate) or  
DISCONNECT and follow on screen instructions  
11.3.3.  In the event of a complete loss of power with no emergency 
power supply:  
11.3.3.1. The Spectra Optia cell separator will shut down completely. 
Close clamps on collect line immediately. Seal the 
collection bags using a heat sealer (these should still be 
functional if battery charged)  
11.3.3.2. Contact the patient physician and inform him of events and 
that the procedure may be aborted  
 11.3.3.3.  Consult with the Director of the Haematology & BMT   
 11.3.3.4.  The extracorporeal volume in the kit will be 297ml  




11.3.3.5.  The  patient  may  be  disconnected  without 
 performing RINSEBACK or perform MANUAL 
RINSEBACK as per instructions in Spectra Optia 
Essentials Guide, pp.73-76 (in the event that a blood 
prime was performed, RINSEBACK is not necessary)  
11.4. Immediate evacuation – in the event that an immediate evacuation is 
required:  
11.4.1.  Close clamps on collect line if possible. NURSE AND PATIENT 
SAFETY IS PARAMOUNT, therefore do not complete this 
step if completion may endanger the health and safety of the 
nurse or the patient  
11.4.2. Disconnect patient immediately and evacuate as per RBWH Code 
Orange Evacuation procedure. N.B. since RINSEBACK has not 
been performed, the patient will have a 297ml fluid deficit and 
may become hypotensive, monitor patient accordingly  
11.5. Structural damage (e.g. fire, water / flood damage) – in the event of 
structural damage, relocate product, material and patient files as required, 
to another area of ODTU if possible. Depending on the scale of the 
problem, a final decision on a temporary location may need to be 
determined on a case-by-case assessment by a structural engineer and the 
Director of the BMT program  
11.5.1. All critical equipment and/or consumables which may have incurred 
damage should be discarded and replaced as soon as possible  
11.5.2. Contact hospital maintenance (ext. 67963) and organise for them to 
inspect critical equipment as soon as possible  
11.5.3. Suspend all operational activities until repairs are complete and the 
facility is signed off as safe to reoccupy  
11.6. Critical equipment failure – Perform troubleshooting as per relevant 
equipment manuals. If unable to resolve problem, contact BTS or 
manufacturer representative.  




11.7. Critical consumable shortage – if a critical consumable shortage occurs, 
contact the following Apheresis Units to source consumables:  
 11.7.1.  Greenslopes Private Hospital (Speed dial *2521).  
11.7.2. Lady Cilento Childrens’ Hospital (Jo Ritchie – 3068 5686, or Jill 
Shergold – 3068 5767)  
 11.7.3.  Once alternative supply has been sourced, organise transport of the  
required consumables. Liaise with the NUM, ODTU to 
organise payment of delivery e.g. courier service  
11.8. Critical staff shortage – The Apheresis Nurse Practitioner shall liaise with 
the NUM, ODTU regularly to ensure staffing requirements of the apheresis 
unit are met. In the event that key personnel are unavailable to perform 
critical procedures:  
11.8.1. Contact Apheresis Nurse Practitioner (pager# 26299) and NUM, 
ODTU (ext. 68754 / 73991) informing them of the situation  
11.8.2. The NUM / Apheresis Nurse Practitioner will attempt to adequately 
staff the Apheresis Unit   
11.8.3. If appropriate, the situation can be escalated to the Director of the 
BMT program and the Nursing Director, CCS  
11.8.4. If adequate staffing cannot be accomplished, the Apheresis Nurse 
Practitioner shall liaise with the Director of the BMT Program 
to discuss requesting the assistance of other apheresis units in 
the area. Alternative units may be affiliated with the RBWH 
e.g. Greenslopes Private Hospital, or other similarly accredited 
Apheresis Units e.g. Princess Alexandra Hospital or the Mater 
Public Hospital  
  




12.  Responsibility  
  
Final 
Approval  Implement  
Quality 






  X  X  X  X  
Medical 
Director  
X  X        
Nursing Staff          X  
13.  Occupational Health and Safety  
13.1. Standard precautions shall be maintained throughout the procedure. Refer to 
000342/Proc: Standard Precautions.  
14. Risk  
14.1. Low to Medium (case dependant).  
15.  Consultation   
15.1. Director Bone Marrow Transplant Glen Kennedy  
15.2. Apheresis Nurse Practitioner Kari Mudie  






















APPENDIX 6. APHERESIS COHORT 3 CLINICAL STANDARD OPERATING 
PROCEDURE. 
1. Purpose  
1.1. This SOP describes the apheresis procedures used for this study. It is 
intended to be used in conjunction with:  
1.1.1. Spectra Optia Essentials  
2. Scope  
2.1. The target audience for this resource are the registered nurses and medical 
officers who care for patients in the Apheresis Unit, Royal Brisbane & 
Women’s Hospital (RBWH), who are involved and trained in apheresis.  
2.2. Patient safety takes priority during all apheresis procedures, therefore only 
competent nurses can perform this procedure.   
2.3. All apheresis procedures will comply with 05009/WUG: Apheresis   
2.4. All deviations and associated corrective actions shall be documented in the 
patient medical record.  
3. Principle / Background  
3.1. Apheresis refers to a number of procedures involving the removal of whole 
blood, separating it into the various blood components through 
centrifugation, removing a desired component (white/red cells, platelets 
and plasma with or without replacement fluids) and returning the rest of the 
components. Access to the intravascular compartment is required and 
efficacy of the treatment will depend on the volume of blood processed.   
3.2. This apheresis procedure will consist of 2 stages:  
3.2.1. Stage 1: RBC Depletion of QIMR volunteer  
3.2.2. Stage 2: PMN procedure of concentrated red blood cell product  




3.3. During a red cell depletion, red blood cells are removed from the patient until 
the target haematocrit has been attained, and replaced with desired 
replacement fluid  
3.4. All patients requiring an apheresis procedure are under the direct care of a 
Haematologist.  
3.5. The RBWH Apheresis Unit is accredited by:  
3.5.1. Australian Bone Marrow Donor Registry (ABMDR)  
3.5.2. National Association of Testing Authorities (NATA)  
3.5.3. Foundation for the Accreditation of Cellular Therapies (FACT)  
3.6. The Royal Brisbane & Women’s Hospital (RBWH) is accredited by the 
Australian Council on Healthcare Standards (ACHS)  
3.7. The Disaster Plan (Section 11) addresses those elements most considered to 
be at risk and provides guidelines to cover some of the potential serious 
emergencies that may arise. All staff involved in apheresis procedures are 
responsible for following this plan as directed by senior personnel.  
4. Objectives / Endpoints  
4.1. All apheresis procedures shall be performed safely and appropriately.   
5. Documentation  
5.1. Policy and Standard/s  
5.1.1. ACHS EQUiP National  
5.1.2. Blood and Blood Products, Management of PROC103 Doc 110/15 
(MNHHS)  
5.1.3. Clinical Incident and Disclosure Management PROC007 Document 
13/14 (MNHHS)  
5.2. Procedures, Guidelines, Protocols  
5.2.1. Australian Guidelines for the Prevention and Control of Infection in 
Healthcare (2010)  




5.2.2. COLGDE001: RBWH Guidelines in the Management of Potential 
Adverse Events in Apheresis  
5.2.3. 02002/Proc: Medications Management  
5.2.4. 21605/Proc: Blood collection (Adult)  
5.2.5. 05009/Proc: Apheresis  
5.2.6. 05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics  
5.2.7. 74100/Proc: Documentation in the Patient Record  
5.2.8. 81000/Proc: Aseptic Non Touch Technique  
5.2.9. 000342/Proc: Standard Precautions  
5.2.10. 003139/Proc: Cleaning and Decontamination – patient environment 
and clinical equipment  
5.3. Forms and Templates  
5.3.1. CLIFRM013: RBWH Donor Consent for Bone Marrow Harvest or 
Apheresis Procedure  
5.3.2. COLFRM009: RBWH Apheresis Patient Checklist label  
5.3.3. COLFRM028: RBWH Apheresis Service Request  
5.3.4. COLFRM030: RBWH Apheresis Product Collection Form  
5.3.5. COLFRM053: RBWH Apheresis Procedure Run Sheet: Spectra Optia  
  
6. Definitions and Abbreviations  
 6.1.  AIM    Automated interface management  
 6.2.  ABMDR   Australian Bone Marrow Donor Registry  
 6.3.  ACD-A    Acid citrate dextrose - solution A  
 6.4.  BMP    Bone Marrow Processing  
 6.5.  BTS    Biomedical Technical Services  




 6.6.  ELFT    Electrolyte & liver function tests  
 6.7.  FBC    Full blood count  
 6.8.  Hb    Haemoglobin  
 6.9.  HBV    Hepatitis B virus  
 6.10. HCV    Hepatitis C virus  
 6.11. HIV    Human immunodeficiency virus  
 6.12. IDM    Infectious disease marker  
 6.13. IV     Intravenous  
 6.14. MNHHS   Metro North Hospital and Health Service  
 6.15. NUM    Nurse Unit Manager  
 6.16. ODTU    Oncology Day Therapy Unit  
 6.17. PMN    Polymorphonuclear (abbreviation used for granulocytes)  
 6.18. QIMR    Queensland Institute of Medical Research  
 6.19. RBC    Red blood cell  
 6.20. RBCX    Red blood cell exchange  
 6.21. RBWH    Royal Brisbane & Women’s Hospital  
 6.22. RN    Registered nurse  
 6.23. SOP    Standard operating procedure  
 6.24. TBV    Total blood volume  
7. Materials  
7.1. Equipment  
7.1.1. Spectra Optia Apheresis System (version 11.3)  
 7.1.1.1.  RBCX (Depletion)  
 7.1.1.2.  PMN procedure  
7.1.2. IDL filler  




7.1.3. Standard filler  
7.1.4. Electronic blood pressure monitor  
7.1.5. Volumetric infusion pump  
7.1.6. Heat sealer  
7.2. Disposables and Reagents  
7.2.1. Spectra Optia IDL Set (Ref: 10310).  
7.2.2. Spectra Optia Exchange Set (Ref: 12220)  
7.2.3. BMP Accessory Set (Ref: 11300)  
7.2.4. ACD-A anticoagulant (750ml)  
7.2.5. 0.9% normal saline (1000ml)  
7.2.6. Alcohol swab  
7.2.7. 3 way taps   
7.2.8. IV cannulation or central line equipment. Refer to procedures: 
05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics; 05501/Proc: Cannulation of 
Haemodialysis Access; 05600/Proc: Central Venous Access Devices 
(CVADs), Management – Adult. Ensure use of sufficient gauge 
cannulas (backeye needles are preferable for inlet venous access) to 
allow for adequate flow required for the procedure (preferably at least 
16G for inlet and 18G for return)  
7.2.9. Blood collection tubes  
7.2.10. Intravenous giving set  
7.2.11. Burette  
8. Special Considerations  
8.1. This procedure describes how to perform:  
8.1.1. Stage 1 - Red cell depletion procedure.   




8.1.2. Stage 2 - PMN procedure  
8.2. Ensure haematocrit is accurate, as this is used to calculate:  
8.2.1. The limit for collect volumes  
8.2.2. The plasma pump flow rate before the AIM system manages the 
concentration of cells in the collect port  
8.2.3. Changing the haematocrit after the interface has been established will 
not change the interface position   
8.3. The packing factor during a red cell depletion defaults to 20  
8.4. The packing factor during a PMN procedure defaults to 4.5  
8.5. The Inlet:AC ratio defaults to 13:1 during a RBC depletion procedure  
8.6. There MUST be FBC and ELFT blood test results available (taken within the 
previous 24hrs) PRIOR to commencement of procedure.  
8.7. The minimum FBC criteria required in order to proceed with the procedure is 
described below.   
  
QIMR volunteer  
  
Platelet     > 100 × 109/L  
  
Hb            > 100G/L  
8.8. There is a risk of deranged electrolytes due to the effects of the procedure. 
This effect is usually transient and resolves quickly upon cessation of 
CMNC collection. Electrolyte replacement may be required. Calcium 
gluconate is the most frequently required electrolyte replacement and the 
amount and rate is dependent on symptoms of hypocalcaemia during the 
procedure. Magnesium and potassium replacement can also be required, 
below is a guide for when supplementation may be required:  
  
Pre-Procedure Electrolyte  Replacement guide  
Magnesium  < 60 mmol/L  10 – 20 mmols IV magnesium sulphate 




may be required during procedure  
Potassium between 3.0 – 3.5 mmol/L  Oral potassium may be required e.g 1-2 
chlorvescent tablets   
Potassium < 3.0 mmol  IV potassium chloride 20 mmols may be 
required during the procedure and / or 3 
oral chlorvescent   
 
9. Stage 1 - Red Cell Depletion Procedure  
9.1. Confirm the following forms are current and valid:  
9.1.1. CLIFRM013: RBWH Donor Consent for Bone Marrow harvest or 
Apheresis Procedure  
9.1.2. COLFRM028: RBWH Apheresis Service Request  
9.2. Prior to commencement of procedure, ensure patient has had appropriate 
IDMs taken.   
9.2.1. HIV serology   
9.2.2. Hepatitis B serology   
9.2.3. Hepatitis C serology   
9.2.4. Syphilis  
9.3. All stock used to collect the product must be visually examined prior to use 
for signs of damage and contamination, as per COLSOP004: Apheresis 
Inventory Control Procedure. Record expiry date and lot number of all 
stock used on COLFRM030: RBWH Apheresis Product Collection form. 
Check expiry dates and lot numbers of procedure kit and intravenous fluid 
bags with 2nd RN and record on COLFRM053: RBWH Apheresis 
Procedure Run Sheet: Spectra Optia   
9.3.1. Confirm that all consumables and reagents used during the procedure 
are satisfactory for use; inspect for damage or evidence of 




contamination and mark the appropriate check box on COLFRM030: 
RBWH Apheresis Product Collection form  
9.4. On initial set up screen, choose RBCX procedure  
9.5. Set up, load and prime Spectra Optia Exchange Set (Ref: 12220) as per on 
screen instructions  
9.6. Follow machine prompts and enter patient data.  
9.7. Exchange type - Depletion  
9.8. Depletion fluid type – Saline / Albumin  
9.9. Fluid balance – 100%  
9.10. The default end point is target hct  
9.11. Enter target hct required to collect 450ml of concentrated red cell product  
9.11.1. Collect volume should not exceed 500ml  
9.11.2. Target hct shall not exceed 10% drop from pre procedure hct  
9.12. Educate patient of signs and symptoms of potential adverse reactions, 
emphasising importance of informing nursing staff if he/she experiences 
any such reactions  
9.13. Perform baseline observations (temperature, pulse, respirations and blood 
pressure) and record on run sheet  
9.14. Ensure COLFRM009: RBWH Apheresis Patient Checklist has been 
completed   
9.15. Perform Cannulation according to 05450/Proc: Peripheral Intravenous 
Cannulation, Venepuncture and Infusions – Adult and Paediatrics  
9.16. Collect blood samples if required.   
9.17. Follow machine prompts to commence procedure  
9.18. Review run screen to ensure pump flow rates are appropriate for the 
procedure. Monitor the AC infusion rate, ensuring that it does not exceed 
0.9 ml/min  




9.19. The Spectra Optia system will attempt to establish the interface at 
commencement of the procedure, during this time, the collect valve will 
remain closed.   
9.20. The AIM system monitors for RBC spill over.  
9.21. The replace pump pumps replacement fluid into the reservoir where it 
combines with the plasma for return to the patient  
9.22. Monitor and record patient’s vital signs and run parameters q15 minutes or 
as clinically indicated. Monitor for signs of adverse reactions and record on 
procedure run sheet, reporting adverse events on Riskman.  
9.23. Ensure patient comfort and safety throughout the procedure.  
9.24. During a RBC depletion procedure, RBC are removed until the target Hct 
has been attained.  
9.25. At the end of the procedure, follow the system prompts to rinseback  
9.26. Seal the collection bag prior to disconnection of the patient, in preparation 
for transfer to BMP Accessory Set  
9.27. The time of collection completion shall be recorded on COLFRM030: 
RBWH Apheresis Product Collection form.   
9.28. On completion of rinseback, collect routine blood samples (usually FBC 
and ELFT).  
9.29. Perform final set of observations and record on procedure run sheet  
9.30. Remove venous access as appropriate  
9.31. Record final values on COLFRM053: RBWH Apheresis Procedure Run 
Sheet and complete COLFRM030: RBWH Apheresis Product Collection 
form.  
9.32. Unload set and dispose of waste appropriately   
9.33. Document all care given in patient medical notes. Include all completed 
paperwork with patient’s medical notes.  




9.34. Record relevant statistical information in: G:\Oncology\Apheresis\Log and  
Statistics  
10.  Stage 2 - PMN Procedure  
10.1. Transfer collected red cell concentrate into BMP Accessory Set (Ref: 
12220)  
10.2. All stock used to collect the product must be visually examined prior to use 
for signs of damage and contamination, as per COLSOP004: Apheresis 
Inventory Control Procedure. Check expiry dates and lot numbers of 
consumables with 2nd  
RN and record on COLFRM053: RBWH Apheresis Procedure Run Sheet: 
Spectra Optia  
10.3. Set up, load and prime Spectra Optia IDL Set (Ref: 10310) as per on screen 
instructions for PMN procedure  
10.3.1. If custom prime is required, use Albumin 4% to complete  
10.4. This procedure is intended for patients, not a bag of concentrated red cells, 
therefore requires patient data to be entered into program in order to 
proceed with procedure.   
10.4.1. Follow machine prompts and enter patient data.  
10.4.2. When prompted, enter 60% for patient hct   
10.5. Follow machine prompts to commence procedure  
10.6. The Spectra Optia system will attempt to establish the interface at 
commencement of procedure, during this time, the collect valve will 
remain closed  
10.7. The AIM system monitors the collect port and changes the plasma pump 
flow rate to manage the concentration of cells that flow through he collect 
port. When the AIM system detects cells in the collect port, the collect 
valve opens. Ensure the collect flow rate is set at 2ml/min.   
10.8. Ensure the main run screen accurately displays that no HES is being used  




10.9. Review AC infusion rate regularly, ensuring that it does not exceed 
0.9mls/min  
10.10. The CP defaults to 60 at commencement of procedure. The apheresis nurse 
can set the CP to collect lighter or darker from the buffy coat. Use the 
collection preference tool for the appropriate CP  
10.10.1. See Appendix  1 for the appropriate CP, using the collection 
preference tool, for PMN collections  
10.10.2. A higher CP results in collecting lighter in the buffy coat  
10.10.3. A lower CP results in collecting darker in the buffy coat  
10.11. If the interface is lost during the procedure, the collect flow rate can be 
reduced to 1ml/min until interface has been regained. Ensure the collect 
flow rate is then returned to 2ml/min  
10.12. QIMR staff are responsible for labelling of collection bags.    
10.13. Seal the collection bag using heat sealer - QIMR staff will indicate the 
most appropriate point to heat seal line.   
10.14. On completion of procedure select DISCONNECT when prompted  
10.15. Record final procedural values on run sheet  
10.16. QIMR staff are responsible for transporting collected product to QIMR for 
further testing.    
10.17. Record relevant statistical information located in: 
G:\Oncology\Apheresis\Log and Statistics  
10.18. Unload set and dispose of waste appropriately   
10.19. Decontaminate Spectra Optia as per protocol (see COLSOP005: RBWH 
Apheresis Equipment Cleaning Procedure). Decontaminate all other 
equipment involved in performing the procedure, in accordance with 
003139/Proc: Cleaning and Decontamination – patient environment and 
clinical equipment. Once all equipment used during the procedure has 




been cleaned, tick appropriate area at the end of the run sheet, confirming 
completion of cleaning tasks.  
10.20. Once paperwork is complete, scan / photocopy all procedural paperwork 
and send to QIMR.  
11.  End Points  
11.1. The total collect volume of red cell depletion will be approximately 450ml  
11.1.1. Total collect volume shall not exceed 500ml  
11.1.2. Discuss with QIMR staff if total collect volume is expected to exceed 
500ml. QIMR staff will advise apheresis nursing staff of most 
appropriate action  
11.2. Target hct shall not exceed 10% drop from pre procedure hct  
11.3. RBC depletion procedure time should not exceed 180 minutes  
11.3.1. Discuss with QIMR staff if total procedure time is expected to exceed 
180 minutes. QIMR staff will advise apheresis nursing staff of most 
appropriate action  
12.  Disaster Plan  
12.1. This section describes the actions to be taken in the event of serious 
problems which may arise in the Apheresis Unit which may impact on 
either:   
12.1.1. The ability to perform the CMNC collection to the required 
specification  
12.1.2. The quality of the collected product  
12.2. Air-Conditioning System Failure – in the event that the air-conditioning 
system malfunctions, contact hospital maintenance and arrange for urgent 
repairs (ext. 67963).  
12.3. Loss of Power – All critical equipment used to perform apheresis 
procedures should be connected to red emergency power points. These 
power points are supplied with the electricity from the emergency backup 




power generators, and in the event of a power failure, are automatically 
activated.  
12.3.1. Critical equipment used within the apheresis unit includes:  
12.3.1.1.  Cell separators  
12.3.1.2. Blood warmers  
12.3.1.3. Electronic blood pressure monitors  
12.3.1.4. Intravenous volumetric pumps  
12.3.1.5. Heat sealers   
12.3.2. In the event of an interruption to normal power supply, there may be a 
temporary loss of power before the emergency generator is activated. 
If there is an interruption of the power supply:  
12.3.2.1. Close clamps on collect line immediately  
12.3.2.2. If the emergency power supply is activated, power will resume, 
and the Spectra Optia system will reset. After system resets, a 
screen will appear with instructions for how to proceed.   
12.3.2.3. To restart the procedure, follow onscreen instructions  
12.3.2.4. To  abort  procedure,  press RINSEBACK  (if 
appropriate) or DISCONNECT and follow on screen 
instructions  
12.3.3. In the event of a complete loss of power with no emergency power 
supply:  
12.3.3.1. The Spectra Optia cell separator will shut down completely. 
Close clamps on collect line immediately. Seal the collection 
bags using a heat sealer (these should still be functional if 
battery charged)  
12.3.3.2. Contact the patient physician and inform him of events and that 
the procedure may be aborted  




12.3.3.3. Consult with the Director of the Haematology & BMT   
12.3.3.4. The extracorporeal volume in the kit will be 297ml  
12.3.3.5. The patient may be disconnected without performing 
RINSEBACK or perform MANUAL RINSEBACK as per 
instructions in Spectra Optia Essentials Guide, pp.73-76 (in the 
event that a blood prime was performed, RINSEBACK is not 
necessary)  
12.4. Immediate evacuation – in the event that an immediate evacuation is 
required:  
12.4.1.  Close clamps on collect line if possible. NURSE AND PATIENT 
SAFETY IS PARAMOUNT, therefore do not complete this step if 
completion may endanger the health and safety of the nurse or the 
patient  
12.4.2. Disconnect patient immediately and evacuate as per RBWH Code 
Orange Evacuation procedure. N.B. since RINSEBACK has not been 
performed, the patient will have a 297ml fluid deficit and may 
become hypotensive, monitor patient accordingly  
12.5. Structural damage (e.g. fire, water / flood damage) – in the event of 
structural damage, relocate product, material and patient files as required, 
to another area of ODTU if possible. Depending on the scale of the 
problem, a final decision on a temporary location may need to be 
determined on a case-by-case assessment by a structural engineer and the 
Director of the BMT program  
12.5.1. All critical equipment and/or consumables which may have incurred 
damage should be discarded and replaced as soon as possible  
12.5.2. Contact hospital maintenance (ext. 67963) and organise for them to 
inspect critical equipment as soon as possible  
12.5.3. Suspend all operational activities until repairs are complete and the 
facility is signed off as safe to reoccupy  




12.6. Critical equipment failure – Perform troubleshooting as per relevant 
equipment manuals. If unable to resolve problem, contact BTS or 
manufacturer representative.  
12.7. Critical consumable shortage – if a critical consumable shortage occurs, 
contact the following Apheresis Units to source consumables:  
12.7.1. Greenslopes Private Hospital (Speed dial *2521).  
12.7.2. Lady Cilento Childrens’ Hospital (Jo Ritchie – 3068 5686, or Jill 
Shergold – 3068 5767)  
12.7.3. Once alternative supply has been sourced, organise transport of the 
required consumables. Liaise with the NUM, ODTU to organise 
payment of delivery e.g. courier service  
12.8. Critical staff shortage – The Apheresis Nurse Practitioner shall liaise with 
the NUM, ODTU regularly to ensure staffing requirements of the apheresis 
unit are met. In the event that key personnel are unavailable to perform 
critical procedures:  
12.8.1. Contact Apheresis Nurse Practitioner (pager# 26299) and NUM, 
ODTU (ext. 68754 / 73991) informing them of the situation  
12.8.2. The NUM / Apheresis Nurse Practitioner will attempt to adequately 
staff the Apheresis Unit   
12.8.3. If appropriate, the situation can be escalated to the Director of the 
BMT program and the Nursing Director, CCS  
12.8.4. If adequate staffing cannot be accomplished, the Apheresis Nurse 
Practitioner shall liaise with the Director of the BMT Program to 
discuss requesting the assistance of other apheresis units in the area. 
Alternative units may be affiliated with the RBWH e.g. Greenslopes 
Private Hospital, or other similarly accredited Apheresis Units e.g. 
Princess Alexandra Hospital or the Mater Public Hospital   

















  X  X  X  X  
Medical 
Director  
X  X        
QIMR staff        X    
Nursing Staff          X  
 
14.  Occupational Health and Safety  
14.1. Standard precautions shall be maintained throughout the procedure. Refer to 
000342/Proc: Standard Precautions.  
15. Risk  
15.1. Low to Medium (case dependant).  
16.  Consultation   
 16.1. Director Haematology & Bone Marrow Transplant   Glen Kennedy  
 16.2. Apheresis Nurse Practitioner          Kari Mudie  
 16.3. QIMR Registrar             Anand Odedra















      




APPENDIX 7. APHERESIS COHORT 4 CLINICAL STANDARD OPERATING 
PROCEDURE. 
1. Purpose  
1.1. This SOP describes the apheresis procedures used for this study. It is 
intended to be used in conjunction with:  
1.1.1. Spectra Optia Essentials  
2. Scope  
2.1. The target audience for this resource are the registered nurses and medical 
officers who care for patients in the Apheresis Unit, Royal Brisbane & 
Women’s Hospital (RBWH), who are involved and trained in apheresis.  
2.2. Patient safety takes priority during all apheresis procedures, therefore only 
competent nurses can perform this procedure.   
2.3. All apheresis procedures will comply with 05009/WUG: Apheresis   
2.4. All deviations and associated corrective actions shall be documented in the 
patient medical record.  
3. Principle / Background  
3.1. Apheresis refers to a number of procedures involving the removal of whole 
blood, separating it into the various blood components through 
centrifugation, removing a desired component (white/red cells, platelets 
and plasma with or without replacement fluids) and returning the rest of the 
components. Access to the intravascular compartment is required and 
efficacy of the treatment will depend on the volume of blood processed.   
3.2. This apheresis procedure will consist of 2 stages:  
3.2.1. Stage 1: RBC Depletion of QIMR volunteer  
3.2.2. Stage 2: PMN procedure of concentrated red blood cell product  
3.3. During a red cell depletion, red blood cells are removed from the patient until 
the target haematocrit has been attained, and replaced with desired 
replacement fluid  




3.4. All patients requiring an apheresis procedure are under the direct care of a 
Haematologist. 
3.5. The RBWH Apheresis Unit is accredited by:  
3.5.1. Australian Bone Marrow Donor Registry (ABMDR)  
3.5.2. National Association of Testing Authorities (NATA)  
3.5.3. Foundation for the Accreditation of Cellular Therapies (FACT)  
3.6. The Royal Brisbane & Women’s Hospital (RBWH) is accredited by the 
Australian Council on Healthcare Standards (ACHS)  
3.7. The Disaster Plan (Section 11) addresses those elements most considered to 
be at risk and provides guidelines to cover some of the potential serious 
emergencies that may arise. All staff involved in apheresis procedures are 
responsible for following this plan as directed by senior personnel.  
4. Objectives / Endpoints  
4.1. All apheresis procedures shall be performed safely and appropriately. 
5. Documentation  
5.1. Policy and Standard/s  
5.1.1. ACHS EQUiP National  
5.1.2. Blood and Blood Products, Management of PROC103 Doc 110/15 
(MNHHS)  
5.1.3. Clinical Incident and Disclosure Management PROC007 Document 
13/14 (MNHHS)  
5.2. Procedures, Guidelines, Protocols  
5.2.1. Australian Guidelines for the Prevention and Control of Infection in 
Healthcare (2010)  
5.2.2. COLGDE001: RBWH Guidelines in the Management of Potential 
Adverse Events in Apheresis  
5.2.3. 02002/Proc: Medications Management  




5.2.4. 21605/Proc: Blood collection (Adult)  
5.2.5. 05009/Proc: Apheresis  
5.2.6. 05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics  
5.2.7. 74100/Proc: Documentation in the Patient Record  
5.2.8. 81000/Proc: Aseptic Non Touch Technique  
5.2.9. 000342/Proc: Standard Precautions  
5.2.10. 003139/Proc: Cleaning and Decontamination – patient environment 
and clinical equipment  
5.3. Forms and Templates  
5.3.1. CLIFRM013: RBWH Donor Consent for Bone Marrow Harvest or 
Apheresis Procedure  
5.3.2. COLFRM009: RBWH Apheresis Patient Checklist label  
5.3.3. COLFRM028: RBWH Apheresis Service Request  
5.3.4. COLFRM030: RBWH Apheresis Product Collection Form  
5.3.5. COLFRM053: RBWH Apheresis Procedure Run Sheet: Spectra Optia  
6. Definitions and Abbreviations  
 6.1.  AIM    Automated interface management  
 6.2.  ABMDR   Australian Bone Marrow Donor Registry  
 6.3.  ACD-A    Acid citrate dextrose - solution A  
 6.4.  BMP    Bone Marrow Processing  
 6.5.  BTS    Biomedical Technical Services  
 6.6.  ELFT    Electrolyte & liver function tests  
 6.7.  FBC    Full blood count  
 6.8.  Hb    Haemoglobin  
 6.9.  HBV    Hepatitis B virus  




 6.10. HCV    Hepatitis C virus  
 6.11. HIV    Human immunodeficiency virus  
 6.12. IDM    Infectious disease marker  
 6.13. IV     Intravenous  
 6.14. MNHHS   Metro North Hospital and Health Service  
 6.15. NUM    Nurse Unit Manager  
 6.16. ODTU    Oncology Day Therapy Unit  
 6.17. PMN    Polymorphonuclear (abbreviation used for granulocytes)  
 6.18. QIMR    Queensland Institute of Medical Research  
 6.19. RBC    Red blood cell  
 6.20. RBCX    Red blood cell exchange  
 6.21. RBWH    Royal Brisbane & Women’s Hospital  
 6.22. RN    Registered nurse  
 6.23. SOP    Standard operating procedure  
 6.24. TBV    Total blood volume  
7. Materials  
7.1. Equipment  
7.1.1. Spectra Optia Apheresis System (version 11.3)  
 7.1.1.1.  RBCX (Depletion)  
 7.1.1.2.  PMN procedure  
7.1.2. IDL filler  
7.1.3. Standard filler  
7.1.4. Electronic blood pressure monitor  
7.1.5. Volumetric infusion pump  
7.1.6. Heat sealer  




7.2. Disposables and Reagents  
7.2.1. Spectra Optia IDL Set (Ref: 10310).  
7.2.2. Spectra Optia Exchange Set (Ref: 12220)  
7.2.3. BMP Accessory Set (Ref: 11300)  
7.2.4. ACD-A anticoagulant (750ml)  
7.2.5. 0.9% normal saline (1000ml)  
7.2.6. Alcohol swab  
7.2.7. 3 way taps   
7.2.8. IV cannulation or central line equipment. Refer to procedures: 
05450/Proc: Peripheral Intravenous Cannulation, Venepuncture and 
Infusions – Adult and Paediatrics; 05501/Proc: Cannulation of 
Haemodialysis Access; 05600/Proc: Central Venous Access Devices 
(CVADs), Management – Adult. Ensure use of sufficient gauge 
cannulas (backeye needles are preferable for inlet venous access) to 
allow for adequate flow required for the procedure (preferably at least 
16G for inlet and 18G for return)  
7.2.9. Blood collection tubes  
7.2.10. Intravenous giving set  
7.2.11. Burette  
8. Special Considerations  
8.1. This procedure describes how to perform:  
8.1.1. Stage 1 - Red cell depletion procedure.   
8.1.2. Stage 2 - PMN procedure  
8.2. Ensure haematocrit is accurate, as this is used to calculate:  
8.2.1. The limit for collect volumes  
8.2.2. The plasma pump flow rate before the AIM system manages the 
concentration of cells in the collect port  




8.2.3. Changing the haematocrit after the interface has been established will 
not change the interface position   
8.3. The packing factor during a red cell depletion defaults to 20  
8.4. The packing factor during a PMN procedure defaults to 4.5  
8.5. The Inlet:AC ratio defaults to 13:1 during a RBC depletion procedure  
8.6. There MUST be FBC and ELFT blood test results available (taken within the 
previous 24hrs) PRIOR to commencement of procedure.  
8.7. The minimum FBC criteria required in order to proceed with the procedure is 
described below.   
  
QIMR volunteer  
  
Platelet     > 100 × 109/L  
  
Hb            > 100G/L  
8.8. There is a risk of deranged electrolytes due to the effects of the procedure. 
This effect is usually transient and resolves quickly upon cessation of 
CMNC collection. Electrolyte replacement may be required. Calcium 
gluconate is the most frequently required electrolyte replacement and the 
amount and rate is dependent on symptoms of hypocalcaemia during the 
procedure. Magnesium and potassium replacement can also be required, 
below is a guide for when supplementation may be required:  
  
Pre-Procedure Electrolyte  Replacement guide  
Magnesium  < 60 mmol/L  10 – 20 mmols IV magnesium sulphate 
may be required during procedure  
Potassium between 3.0 – 3.5 mmol/L  Oral potassium may be required e.g 1-2 
chlorvescent tablets   
Potassium < 3.0 mmol  IV potassium chloride 20 mmols may 
be required during the procedure and / 
or 3 oral chlorvescent   





9. Stage 1 - Red Cell Depletion Procedure  
9.1. Confirm the following forms are current and valid:  
9.1.1. CLIFRM013: RBWH Donor Consent for Bone Marrow harvest or 
Apheresis Procedure  
9.1.2. COLFRM028: RBWH Apheresis Service Request  
9.2. Prior to commencement of procedure, ensure patient has had appropriate 
IDMs taken.   
9.2.1. HIV serology   
9.2.2. Hepatitis B serology   
9.2.3. Hepatitis C serology   
9.2.4. Syphilis  
9.3. All stock used to collect the product must be visually examined prior to use 
for signs of damage and contamination, as per COLSOP004: Apheresis 
Inventory Control Procedure. Record expiry date and lot number of all 
stock used on COLFRM030: RBWH Apheresis Product Collection form. 
Check expiry dates and lot numbers of procedure kit and intravenous fluid 
bags with 2nd RN and record on COLFRM053: RBWH Apheresis 
Procedure Run Sheet: Spectra Optia   
9.3.1. Confirm that all consumables and reagents used during the procedure 
are satisfactory for use; inspect for damage or evidence of 
contamination and mark the appropriate check box on COLFRM030: 
RBWH Apheresis Product Collection form  
9.4. On initial set up screen, choose RBCX procedure  
9.5. Set up, load and prime Spectra Optia Exchange Set (Ref: 12220) as per on 
screen instructions  
9.6. Follow machine prompts and enter patient data.  
9.7. Exchange type - Depletion  




9.8. Depletion fluid type – Saline / Albumin  
9.9. Fluid balance – 100%  
9.10. The default end point is target hct  
9.11. Enter target hct required to collect 450ml of concentrated red cell product  
9.11.1. Collect volume should not exceed 500ml  
9.11.2. Target hct shall not exceed 10% drop from pre procedure hct  
9.12. Educate patient of signs and symptoms of potential adverse reactions, 
emphasising importance of informing nursing staff if he/she experiences 
any such reactions  
9.13. Perform baseline observations (temperature, pulse, respirations and blood 
pressure) and record on run sheet  
9.14. Ensure COLFRM009: RBWH Apheresis Patient Checklist has been 
completed   
9.15. Perform Cannulation according to 05450/Proc: Peripheral Intravenous 
Cannulation, Venepuncture and Infusions – Adult and Paediatrics  
9.16. Collect blood samples if required.   
9.17. Follow machine prompts to commence procedure  
9.18. Review run screen to ensure pump flow rates are appropriate for the 
procedure. Monitor the AC infusion rate, ensuring that it does not exceed 
0.9 ml/min  
9.19. The Spectra Optia system will attempt to establish the interface at 
commencement of the procedure, during this time, the collect valve will 
remain closed.   
9.20. The AIM system monitors for RBC spillover.  
9.21. The replace pump pumps replacement fluid into the reservoir where it 
combines with the plasma for return to the patient  




9.22. Monitor and record patient’s vital signs and run parameters q15 minutes or 
as clinically indicated. Monitor for signs of adverse reactions and record on 
procedure run sheet, reporting adverse events on Riskman.  
9.23. Ensure patient comfort and safety throughout the procedure.  
9.24. During a RBC depletion procedure, RBC are removed until the target Hct 
has been attained.  
9.25. At the end of the procedure, follow the system prompts to rinseback  
9.26. Seal the collection bag prior to disconnection of the patient, in preparation 
for transfer to BMP Accessory Set  
9.27. The time of collection completion shall be recorded on COLFRM030: 
RBWH Apheresis Product Collection form.   
9.28. On completion of rinseback, collect routine blood samples (usually FBC 
and ELFT).  
9.29. Perform final set of observations and record on procedure run sheet  
9.30. Remove venous access as appropriate  
9.31. Record final values on COLFRM053: RBWH Apheresis Procedure Run 
Sheet and complete COLFRM030: RBWH Apheresis Product Collection 
form.  
9.32. Unload set and dispose of waste appropriately   
9.33. Document all care given in patient medical notes. Include all completed 
paperwork with patient’s medical notes.  
9.34. Record relevant statistical information in: G:\Oncology\Apheresis\Log and  
Statistics   
10.  Stage 2 - PMN Procedure  
10.1. Transfer collected red cell concentrate into BMP Accessory Set (Ref: 
12220)  
10.2. All stock used to collect the product must be visually examined prior to use 
for signs of damage and contamination, as per COLSOP004: Apheresis 




Inventory Control Procedure. Check expiry dates and lot numbers of 
consumables with 2nd  
RN and record on COLFRM053: RBWH Apheresis Procedure Run Sheet: 
Spectra Optia  
10.3. Set up, load and prime Spectra Optia IDL Set (Ref: 10310) as per on screen 
instructions for PMN procedure  
10.3.1. If custom prime is required, use Albumin 4% to complete  
10.4. This procedure is intended for patients, not a bag of concentrated red cells, 
therefore requires patient data to be entered into program in order to 
proceed with procedure.   
10.4.1. Follow machine prompts and enter patient data.  
10.4.2. When prompted, enter 60% for patient hct   
10.5. Follow machine prompts to commence procedure  
10.6. The Spectra Optia system will attempt to establish the interface at 
commencement of procedure, during this time, the collect valve will 
remain closed  
10.7. The AIM system monitors the collect port and changes the plasma pump 
flow rate to manage the concentration of cells that flow through he collect 
port. When the AIM system detects cells in the collect port, the collect 
valve opens. Ensure the collect flow rate is set at 2ml/min.   
10.8. Ensure the main run screen accurately displays that no HES is being used  
10.9. Review AC infusion rate regularly, ensuring that it does not exceed 
0.9mls/min  
10.10. The CP defaults to 60 at commencement of procedure. The apheresis nurse 
can set the CP to collect lighter or darker from the buffy coat. Use the 
collection preference tool for the appropriate CP  
10.10.1. See Appendix  1 for the appropriate CP, using the collection 
preference tool, for PMN collections  




10.10.2. A higher CP results in collecting lighter in the buffy coat  
10.10.3. A lower CP results in collecting darker in the buffy coat  
10.11. If the interface is lost during the procedure, the collect flow rate can be 
reduced to 1ml/min until interface has been regained. Ensure the collect 
flow rate is then returned to 2ml/min  
10.12. QIMR staff are responsible for labelling of collection bags.    
10.13. Seal the collection bag using heat sealer - QIMR staff will indicate the 
most appropriate point to heat seal line.   
10.14. On completion of procedure select DISCONNECT when prompted  
10.15. Record final procedural values on run sheet  
10.16. QIMR staff are responsible for transporting collected product to QIMR for 
further testing.    
10.17. Record relevant statistical information located in: 
G:\Oncology\Apheresis\Log and Statistics  
10.18. Unload set and dispose of waste appropriately   
10.19. Decontaminate Spectra Optia as per protocol (see COLSOP005: RBWH 
Apheresis Equipment Cleaning Procedure). Decontaminate all other 
equipment involved in performing the procedure, in accordance with 
003139/Proc: Cleaning and Decontamination – patient environment and 
clinical equipment. Once all equipment used during the procedure has 
been cleaned, tick appropriate area at the end of the run sheet, confirming 
completion of cleaning tasks.  
10.20. Once paperwork is complete, scan / photocopy all procedural paperwork 
and send to QIMR.  
11.  End Points  
11.1. The total collect volume of red cell depletion will be approximately 450ml  
11.1.1. Total collect volume shall not exceed 500ml  




11.1.2. Discuss with QIMR staff if total collect volume is expected to exceed 
500ml. QIMR staff will advise apheresis nursing staff of most 
appropriate action  
11.2. Target hct shall not exceed 10% drop from pre procedure hct  
11.3. RBC depletion procedure time should not exceed 180 minutes  
11.3.1. Discuss with QIMR staff if total procedure time is expected to exceed 
180 minutes. QIMR staff will advise apheresis nursing staff of most 
appropriate action  
12.  Disaster Plan  
12.1. This section describes the actions to be taken in the event of serious 
problems which may arise in the Apheresis Unit which may impact on 
either:   
12.1.1. The ability to perform the CMNC collection to the required 
specification  
12.1.2. The quality of the collected product  
12.2. Air-Conditioning System Failure – in the event that the air-conditioning 
system malfunctions, contact hospital maintenance and arrange for urgent 
repairs (ext. 67963).  
12.3. Loss of Power – All critical equipment used to perform apheresis 
procedures should be connected to red emergency power points. These 
power points are supplied with the electricity from the emergency backup 
power generators, and in the event of a power failure, are automatically 
activated.  
12.3.1. Critical equipment used within the apheresis unit includes:  
12.3.1.1.  Cell separators  
12.3.1.2. Blood warmers  
12.3.1.3. Electronic blood pressure monitors  
12.3.1.4. Intravenous volumetric pumps  




12.3.1.5. Heat sealers   
12.3.2. In the event of an interruption to normal power supply, there may be a 
temporary loss of power before the emergency generator is activated. 
If there is an interruption of the power supply:  
12.3.2.1. Close clamps on collect line immediately  
12.3.2.2. If the emergency power supply is activated, power will resume, 
and the Spectra Optia system will reset. After system resets, a 
screen will appear with instructions for how to proceed.   
12.3.2.3. To restart the procedure, follow onscreen instructions  
12.3.2.4. To  abort  procedure,  press RINSEBACK  (if 
appropriate) or DISCONNECT and follow on screen 
instructions  
12.3.3. In the event of a complete loss of power with no emergency power 
supply:  
12.3.3.1. The Spectra Optia cell separator will shut down completely. 
Close clamps on collect line immediately. Seal the collection 
bags using a heat sealer (these should still be functional if 
battery charged)  
12.3.3.2. Contact the patient physician and inform him of events and that 
the procedure may be aborted  
12.3.3.3. Consult with the Director of the Haematology & BMT   
12.3.3.4. The extracorporeal volume in the kit will be 297ml  
12.3.3.5. The patient may be disconnected without performing 
RINSEBACK or perform MANUAL RINSEBACK as per 
instructions in Spectra Optia Essentials Guide, pp.73-76 (in the 
event that a blood prime was performed, RINSEBACK is not 
necessary)  




12.4. Immediate evacuation – in the event that an immediate evacuation is 
required:  
12.4.1.  Close clamps on collect line if possible. NURSE AND PATIENT 
SAFETY IS PARAMOUNT, therefore do not complete this step if 
completion may endanger the health and safety of the nurse or the 
patient  
12.4.2. Disconnect patient immediately and evacuate as per RBWH Code 
Orange Evacuation procedure. N.B. since RINSEBACK has not been 
performed, the patient will have a 297ml fluid deficit and may 
become hypotensive, monitor patient accordingly  
12.5. Structural damage (e.g. fire, water / flood damage) – in the event of 
structural damage, relocate product, material and patient files as required, 
to another area of ODTU if possible. Depending on the scale of the 
problem, a final decision on a temporary location may need to be 
determined on a case-by-case assessment by a structural engineer and the 
Director of the BMT program  
12.5.1. All critical equipment and/or consumables which may have incurred 
damage should be discarded and replaced as soon as possible  
12.5.2. Contact hospital maintenance (ext. 67963) and organise for them to 
inspect critical equipment as soon as possible  
12.5.3. Suspend all operational activities until repairs are complete and the 
facility is signed off as safe to reoccupy  
12.6. Critical equipment failure – Perform troubleshooting as per relevant 
equipment manuals. If unable to resolve problem, contact BTS or 
manufacturer representative.  
12.7. Critical consumable shortage – if a critical consumable shortage occurs, 
contact the following Apheresis Units to source consumables:  
12.7.1. Greenslopes Private Hospital (Speed dial *2521).  




12.7.2. Lady Cilento Childrens’ Hospital (Jo Ritchie – 3068 5686, or Jill 
Shergold – 3068 5767)  
12.7.3. Once alternative supply has been sourced, organise transport of the 
required consumables. Liaise with the NUM, ODTU to organise 
payment of delivery e.g. courier service  
12.8. Critical staff shortage – The Apheresis Nurse Practitioner shall liaise with 
the NUM, ODTU regularly to ensure staffing requirements of the apheresis 
unit are met. In the event that key personnel are unavailable to perform 
critical procedures:  
12.8.1. Contact Apheresis Nurse Practitioner (pager# 26299) and NUM, 
ODTU (ext. 68754 / 73991) informing them of the situation  
12.8.2. The NUM / Apheresis Nurse Practitioner will attempt to adequately 
staff the Apheresis Unit   
12.8.3. If appropriate, the situation can be escalated to the Director of the 
BMT program and the Nursing Director, CCS  
12.8.4. If adequate staffing cannot be accomplished, the Apheresis Nurse 
Practitioner shall liaise with the Director of the BMT Program to 
discuss requesting the assistance of other apheresis units in the area. 
Alternative units may be affiliated with the RBWH e.g. Greenslopes 
Private Hospital, or other similarly accredited Apheresis Units e.g. 
Princess Alexandra Hospital or the Mater Public Hospital  










Apheresis Nurse  
Practitioner  
  X  X  X  X  
Medical 
Director  
X  X        
QIMR staff        X    




Nursing Staff          X  
 
14.  Occupational Health and Safety  
14.1. Standard precautions shall be maintained throughout the procedure. Refer to 
000342/Proc: Standard Precautions.  
  
15. Risk  
15.1. Low to Medium (case dependant).  
16.  Consultation   
 16.1. Director Haematology & Bone Marrow Transplant   Glen Kennedy  
 16.2. Apheresis Nurse Practitioner          Kari Mudie  
 16.3. QIMR Registrar             Anand Odedra  
   























      




APPENDIX 8. APHERESIS COHORT 1 LABORATORY STANDARD 
OPERATING PROCEDURE. 
Clinical Tropical Medicine, QIMR  
CTM QIMR   Malarial  Enrichment via 
Apheresis - Form 
  Date Effective:  
Version: 
Status: 
Review Date: Two years 
after review date 
 
Apheresis laboratory master SOP: Cohort 1 
 
1. NB Ensure the corresponding form is filled out in conjunction with the 
below method  
2. Ensure centrifuge is preheated using program 9 – 4500rpmr/HOLD/40°C 
3. Once blood bag has been transported to the waterbath in CTM and process is 
ready to continue, fill two large silver thermos’ with preheated water. Refer 
to “Appendix 1 – Table of Correct Water Volumes” for volume of water to 
add. Prepare one thermos for holding the blood bag and one thermos for 
holding 50ml falcons at temperature. 
4. Check temperature of water and replace if below 38°C. 
5. Place blood bag into thermos and move into BSC. 
6. Move 50/250ml (for 1 and 2% HCT) collection tube into BSC and hold in 
thermos. 
7. Use spike adaptor on sterile port of blood bag. 
7.1.Note: Do not remove blood bag from thermos or lift above water 
level. 
8. Grab a 30/50ml preheated syringe from prewarming incubator. 
9. Unscrew white cap of spike adaptor and place to the side. 
10. Connect syringe to leur lock of spike adaptor. 
11. Carefully syringe blood out of blood bag and dispense into 50ml/250ml 
collection tube.  
12. Repeat process as necessary until all blood has been removed from blood 
bag. 
13. Prepare a labelled 50ml falcon for sampling into a 50ml tube rack. 




14. Mix collection tube well, either by gentle swirling or aspiration using a 25ml 
strippette. 
15. Measure volume of HCT fraction received. 
16. Aspirate 3.5 ml of whole blood using a 5ml strippette into sampling tube. 
Sampling tube can be moved into another BSC for aliquoting during process.  
17. Spin 50ml/250ml collection tube in a preheated centrifuge at 530g/5-
15min/40°C 
18. Replace water in thermos just before centrifuge stops spinning. 
19. Collect collection tube from centrifuge with thermos and set centrifuge to 
preheat. (Program 9 – 4500rpm, HOLD, 40°C) 
20. Place thermos back into BSC. 
21. Use a strippette to remove supernatant and place into a waste tube.  
22. Resuspend pellet and measure. 
22.1. For 1%, 2% or 3% HCT: Resuspend pellet in equal volume of 
prewarmed AB serum.  
22.1.1. Take 600ul for Feed mix. Remainder is transferred for 
subsampling and cryopreservation  
22.1.2. Calculate volume of packed RBCs to add to prepare 
Feed Mix. Add equal volume of prewarmed AB serum. 
22.1.3. Aliquot 1.25ml of Feed Mix into prewarmed 
eppendorf. 
22.1.4. Prepare small thermos for transportation. 
22.1.5. Place FM into floatie and transport in small thermos to 
PC3. 
22.1.6. Conduct Membrane Feed as per CTM QIMR SOP 15 –
Infection of Mosquitoes’ with plasmodium by membrane 
feeding 




1. Use remaining Feed Mix for slides & flow sampling. 
2. For 5% and 7% HCT: Resuspend pellet in equal volume of RPMI and prepare 
thin and thick films. 
3. PREEPARING CELL PELLETS FOR STORAGE PRIOR TO 
CRYOPRESERVATION (PER HCT FRACTION) 
3.1. Transfer remaining pellet to prepared 25mL aliquots of pre-warmed (37°C) 
AB complete media.  
3.2. Add additional media until total volume is 30mL. 
3.3. Store at 37°C until shortly prior to cryopreservation. 
3.4. Record details on Apheresis Fraction Processing CTM QIMR QF 75A 
4. PRECHILLNG OF CELL SOLUTIONS FOR CRYOPRESERVATION (PER 
HCT FRACTION) 
4.1. Immediately before pre chilling solutions, prepare a dry ice/ethanol slurry in 
a plastic beaker 
4.2. Whilst rapidly mixing, prechill a dummy tube of WFI for a period of 50 
seconds within slurry 
4.3. Measure temperature of dummy tube. 
4.4. If within 3-8°C, proceed with chilling of HCT Fraction cell suspension in 
the same manner as the dummy tube. 
4.5. If not alter slurry until desired specifications can be rechecked using fresh 
dummy tubes prior to proceeding with rapid chilling 
4.6. Wipe chilled cell suspension thoroughly with 80% v/v ethanol and transfer 
to ice slurry within clean biohazard hood. 
4.7. Evenly split cell suspension into two labelled tubes and transfer to fridge for 
storage at 2-8°C 
4.8. Record details on Apheresis Fraction Processing CTM QIMR QF 75A 
 




5. ADDITION OF GLYCEROLYTE TO RBCS/WBCS FOR 
CRYOPRESERVATION  (PER HCT FRACTION) 
5.1. Calculate the total volume of glycerolyte needed (the pooled volume of the 
parasitised RBCs multiplied by 2.2).  
5.2. Record glycerolyte lot number expiry date and volume required on Section  
5.3. Centrifuge cell suspension at 530g/5-15min/ 2-8°C 
5.4. Remove and discard supernatant 
5.5. Agitate pellet (or gently pipette) to resuspend pellet. 
5.6. Slowly add dropwise 1/5 of the total volume of glycerolyte to the pooled 
volume RBCs, whilst gently shaking the tubes to mix the content. 
5.7. Note: Rapid introduction of glycerolyte can cause damage to RBCs. 
therefore glycerolyte should be added slowly and should be mixed well after 
addition. 
5.8. Incubate at room temperature (18-24°C) for 5 minutes. 
5.9. Add dropwise the remaining volume of glycerolyte. 
5.10. Add 1ml volumes to prechilled labelled nunc tubes. 
5.11. On completion of aliquoting, ensure tubes are tightly sealed and 
transfer to a preconditioned Mr Frosty. 
5.12. Carefully transfer Mr Frosty to -80°C freezer for a minimum of 
twelve hours 
5.13. Record details on Apheresis Fraction Processing CTM QIMR QF 
75A 
6. ADDITION OF CRYOSTOR CS2 TO WBC/RBC FOR 
CRYOPRESERVATION  (PER HCT FRACTION) 
6.1. Remove a 50µL sample from the cell suspension tube stored at 2-8°C 
6.2. Perform total cell count (Refer to CTM QIMR SOP 38 – RBC Counting 
using a Haemocytometer) and record details of CTM QIMR QF 38A – RBC 
Calculation Form. 




6.3. Calculate the volume of Cryostor CS2 that the pellet would have to be 
resuspended in to give a concentration of 106c/mL. 
6.4. Centrifuge cell suspension at 530g/5-15min/ 2-8°C 
6.5. Remove and discard supernatant 
6.6. Agitate pellet (or gently pipette) to resuspend pellet. 
6.7. Slowly add required volume of prechilled Cryostor CS2 
6.8. Add 1ml volumes to prechilled labelled nunc tubes. 
6.9. On completion of aliquoting, ensure tubes are tightly sealed and transfer to a 
preconditioned Mr Frosty. 
6.10. Carefully transfer Mr Frosty to -80°C freezer for a minimum of 
twelve hours 








APPENDIX 9. APHERESIS COHORT 2 LABORATORY STANDARD 
OPERATING PROCEDURE. 
Clinical Tropical Medicine, QIMR  
CTM QIMR   Malarial  Enrichment via 
Apheresis - Form 
  Date Effective:  
Version: 
Status: 
Review Date: Two years 
after review date 
 




23. Record all lot and catalogue numbers on QIMR- QF-75-B Malaria Parasite 
Isolation from Apheresis Product for volumes. 
 
24. Spray or wipe labelled transfer bags, exchange couplers, CPDA-1 blood bags and 
necessary consumables into the hood using 80% v/v Ethanol. 
25. Insert exchange coupler into CPDA-1 blood bag and aliquot citrate into labelled 
50mL tubes. 
26. Using an exchange coupler and pipette prefill labelled transferred bags with the 
correct citrate volumes. 
26.1. Refer to QIMR- QF-75-B Malaria Parasite Isolation from Apheresis 
Product for volumes. 
27. Record times on QIMR-QF-75-B of when transfer bags containing citrate are 
prewarmed. 
 
Collection and Waterbath setup for maintaining temperature of transfer 
bags at Apheresis unit 
1. Refer to “Waterbath setup for blood bags”. 
1.1. Refer to and ensure to QIMR- QF-75-B Malaria Parasite Isolation from 
Apheresis Product for volumes is filled out for all fractions being collected. 
 
Transfer of transfer bags from Apheresis unit to CTM 




1. “Refer to Apheresis Thermos Blood Collection Method”. 
2. Ensure “Apheresis_Thermos_Transport_Form” is filled out for each transfer of 
fraction of blood collected. 
 
Processing of Apheresis Blood Fractions 
 
1. NB Ensure QIMR-QF-75-A Apheresis Fraction Processing is filled in . 
2. Ensure centrifuge is preheated using program 9 – 4500rpmr/HOLD/40°C. 
3. Once blood bag has been transported to the waterbath in CTM and process is 
ready to continue, fill two large silver thermos’ with preheated water. Prepare 
one thermos for holding the blood bag and one thermos for holding 50ml falcons 
at temperature. 
4. Check temperature of water and replace if below 38°C. 
5. Place blood bag into thermos and move into BSC. 
6. Move 50/250ml (for 1 and 2% HCT) collection tube into BSC and hold in 
thermos. 
7. Use spike adaptor on sterile port of blood bag. 
7.1. Note: Do not remove blood bag from thermos or lift above water level. 
8. Grab a 30/50ml preheated syringe from prewarming incubator. 
9. Unscrew white cap of spike adaptor and place to the side. 
10. Connect syringe to leur lock of spike adaptor. 
11. Carefully syringe blood out of blood bag and dispense into 50ml/250ml 
collection tube.  
12. Repeat process as necessary until all blood has been removed from blood bag. 
13. Prepare a labelled 50ml falcon for sampling into a 50ml tube rack. 
14. Mix collection tube well, either by gentle swirling or aspiration using a 25ml 
strippette. 
15. Measure volume of HCT fraction received. 
16. Aspirate an appropriate volume of sample into sampling tube. Sampling tube can 
be moved into another BSC for aliquoting during process.  
16.1. Refer to Master Sample list for details regarding subsampling 
17. Spin 50ml/250ml collection tube in a preheated centrifuge at 1455g/5-
15min/40°C 




18. Replace water in thermos just before centrifuge stops spinning. 
19. Collect collection tube from centrifuge with thermos and set centrifuge to 
preheat. (Program 9 – 4500rpm, HOLD, 40°C) 
20. Place thermos back into BSC. 
21. Use a strippette to remove plasma and place into a labelled collection tube.  
22. Resuspend pellet and measure. 
22.1. For 1%, 2% or 3% HCT: Resuspend 650uL of pellet in 650uL of 
prewarmed AB serum for “Feed Mix”. Remainder is to be used for 
subsampling. 
22.1.1.1. Refer Master Sample list for details regarding subsampling. 
22.1.2. Prepare small thermos for transportation. 
22.1.3. Place FM into floatie and transport in small thermos to PC3. 
22.1.4. Conduct Membrane Feed as per CTM QIMR SOP 15 –Infection of 
Mosquitoes’ with plasmodium by membrane feeding 
22.2. For 5% and 7% HCT: Resuspend pellet in equal volume of RPMI and 
prepare thin and thick films. 
 
Volume of Water to Add to Thermos: 
PREEPARING CELL PELLETS FOR STORAGE PRIOR TO 
CRYOPRESERVATION (PER HCT FRACTION) 




6.12. Transfer remaining pellet to prepared 25mL aliquots of pre-warmed 
(37°C) AB complete media.  
6.13. Add additional media until total volume is 30mL. 
6.14. Store at 37°C until shortly prior to cryopreservation. 
6.15. Record details on Apheresis Fraction Processing CTM QIMR QF 
75A 
7. PRECHILLNG OF CELL SOLUTIONS FOR CRYOPRESERVATION (PER 
HCT FRACTION) 
7.1. Immediately before pre chilling solutions, prepare a dry ice/ethanol slurry in 
a plastic beaker 
7.2. Whilst rapidly mixing, prechill a dummy tube of WFI for a period of 50 
seconds within slurry 
7.3. Measure temperature of dummy tube. 
7.4. If within 3-8°C, proceed with chilling of HCT Fraction cell suspension in 
the same manner as the dummy tube. 
7.5. If not alter slurry until desired specifications can be rechecked using fresh 
dummy tubes prior to proceeding with rapid chilling 
7.6. Wipe chilled cell suspension thoroughly with 80% v/v ethanol and transfer 
to ice slurry within clean biohazard hood. 
7.7. Evenly split cell suspension into two labelled tubes and transfer to fridge for 
storage at 2-8°C 
7.8. Record details on Apheresis Fraction Processing CTM QIMR QF 75A 
 
8. ADDITION OF GLYCEROLYTE TO RBCS/WBCS FOR 
CRYOPRESERVATION (PER HCT FRACTION) 
8.1. Calculate the total volume of glycerolyte needed (the pooled volume of the 
parasitised RBCs multiplied by 2.2).  




8.2. Record glycerolyte lot number expiry date and volume required on Section  
8.3. Centrifuge cell suspension at 530g/5-15min/ 2-8°C 
8.4. Remove and discard supernatant 
8.5. Agitate pellet (or gently pipette) to resuspend pellet. 
8.6. Slowly add dropwise 1/5 of the total volume of glycerolyte to the pooled 
volume RBCs, whilst gently shaking the tubes to mix the content. 
8.7. Note: Rapid introduction of glycerolyte can cause damage to RBCs. 
therefore glycerolyte should be added slowly and should be mixed well after 
addition. 
8.8. Incubate at room temperature (18-24°C) for 5 minutes. 
8.9. Add dropwise the remaining volume of glycerolyte. 
8.10. Add 1ml volumes to prechilled labelled nunc tubes. 
8.11. On completion of aliquoting, ensure tubes are tightly sealed and 
transfer to a preconditioned Mr Frosty. 
8.12. Carefully transfer Mr Frosty to -80°C freezer for a minimum of 
twelve hours 
8.13. Record details on Apheresis Fraction Processing CTM QIMR QF 
75A 
9. ADDITION OF CRYOSTOR CS2 TO WBC/RBC FOR 
CRYOPRESERVATION (PER HCT FRACTION) 
9.1. Remove a 50µL sample from the cell suspension tube stored at 2-8°C 
9.2. Perform total cell count (Refer to CTM QIMR SOP 38 – RBC Counting 
using a Haemocytometer) and record details of CTM QIMR QF 38A – RBC 
Calculation Form. 
9.3. Calculate the volume of Cryostor CS2 that the pellet would have to be 
resuspended in to give a concentration of 106c/mL. 
9.4. Centrifuge cell suspension at 530g/5-15min/ 2-8°C 
9.5. Remove and discard supernatant 




9.6. Agitate pellet (or gently pipette) to resuspend pellet. 
9.7. Slowly add required volume of prechilled Cryostor CS2 
9.8. Add 1ml volumes to prechilled labelled nunc tubes. 
9.9. On completion of aliquoting, ensure tubes are tightly sealed and transfer to a 
preconditioned Mr Frosty. 
9.10. Carefully transfer Mr Frosty to -80°C freezer for a minimum of 
twelve hours 








APPENDIX 10. APHERESIS COHORT 3 LABORATORY STANDARD 
OPERATING PROCEDURE. 
Clinical Tropical Medicine, QIMR  
CTM QIMR   Malarial  Enrichment via 
Apheresis - Form 
  Date Effective:  
Version: 
Status: 
Review Date: Two years 
after review date 
 
Apheresis laboratory master SOP: Cohort 3 
Pre-processing 
 
28. Record all lot and catalogue numbers on QIMR- QF-75-B Malaria Parasite 
Isolation from Apheresis Product for volumes. 
 
29. Spray or wipe labelled transfer bags, exchange couplers, CPDA-1 blood bags and 
necessary consumables into the hood using 80% v/v Ethanol. 
30. Insert exchange coupler into CPDA-1 blood bag and aliquot citrate into labelled 
50mL tubes. 
31. Using an exchange coupler and pipette prefill labelled transferred bags with the 
correct citrate volumes. 
31.1. Refer to QIMR- QF-75-B Malaria Parasite Isolation from Apheresis 
Product for volumes. 
32. Record times on QIMR-QF-75-B of when transfer bags containing citrate are 
prewarmed. 
 
Processing of Apheresis Blood Fractions – Above 1%, 1%, 2%, 3%, 5% 7%, 
below 7% -20mL volumes 
 
23. NB Ensure QIMR-QF-75-A Apheresis Fraction Processing is filled in . 
24. Ensure centrifuge is preheated using program 9 – 4500rpmr/HOLD/40°C. 
25. Following wiping down with 80% v/v Ethanol, place blood bag into  BSC. 
26. Move 50mL collection tube into BSC.  
27. Use spike adaptor on sterile port of blood bag. 




28. Unscrew white cap of spike adaptor and place to the side. 
29. Dispense fractions into 50ml collection tube.  
30. Repeat process as necessary until all blood has been removed from blood bag. 
31. Prepare a labelled 50ml falcon for sampling into a 50ml tube rack. 
32. Mix collection tube well, either by gentle swirling or aspiration using a 25ml 
strippette. 
33. Measure volume of HCT fraction received. 
34. Aspirate an appropriate volume of sample into sampling tube. Sampling tube can 
be moved into another BSC for aliquoting during process.  
34.1. Refer to Master Sample list for details regarding subsampling 
35. Spin 50ml collection tube in a preheated centrifuge at 1455g/5-15min/RT 
36. Use a strippette to remove plasma and place into a labelled collection tube 
36.1. Refer to Master Sample list for details regarding subsampling and 
slide manufacture 
 
Pooling fractions for  sampling– Above 1%, 1%, 2%, 3%, 5% 7%, below 7%: 2 
mL volumes 
2%,3% Pool – 5mL each, 5%,7% Pool – 5mL each 
 
1. From each of the fractions, sample the appropriate volumes and pool into 50mL 
tubes 








APPENDIX 11. APHERESIS COHORT 4 LABORATORY STANDARD 
OPERATING PROCEDURE. 
Clinical Tropical Medicine, QIMR  
CTM QIMR   Malarial Enrichment via 
Apheresis - Form 
  Date Effective:  
Version: 
Status: 
Review Date: Two years 
after review date 
 




APHERESIS DAY 1 
TIME POINTS AND TASKS 
PRE-APHERESIS T=0hr 
• Blood collection (Q-Pharm; 1 x 6 mL EDTA, 2 x 10mL LiHep tubes) 
• Pre-aliquot 19,600 µL and 39,200 µL of McCoy media into 12 x PRE-
APHERESIS T75 (T=8hr, T=16hr, T=32hr, T=40hr and T=48hr (=/- NAG) 
and 3 x PRE-APHERESIS T225 flasks (T=4hr, T=24hr, T=48hr) 
respectively. 
• 1 x 6mL EDTA TUBE 
o Aliquot samples for testing (18S SAF, pvs25, Sysmex) 
o Aliquot samples for and prepare thick/thin films  
o Aliquot sample for FLOW cytometry, laser capture microdissection 
slide (LCS) 
• 1 x 10mL LIHEP TUBE:  
o Prepare feed mix and perform MFA 
o Set up 3 x T225 MFA culture flasks (T=4hr, T=24hr, T=48hr) 
• 1x10mL LiHEP TUBE: 
o Set up 12 x T75 asexual/sexual culture flasks (+/- NAG) (T=8hr, 
T=16hr, T=24hr, T=32hr, T=40hr, T=48hr) 
o Aliquot sample for pLDH 
 




INTERMEDIATE T=0hr, FINAL T=0hr, SPARE T=0hr (optional), WASTE 
T=0hr  
• Intermediate, Final, Spare (optional)and Waste sample collection (Apheresis 
Unit) 
• Aliquot samples for testing (18S SAF, pvs25, Sysmex) 
• Aliquot samples for and prepare thick/thin films  
• Aliquot sample for FLOW cytometry 
• Prepare feed mix and perform MFA 
• Set up 3 x T225 MFA cultures (T=4hr, T=24hr, T=48hr) 
• Set up 4 x T75 Asexual/Sexual cultures (+/- NAG) (T=24hr, T=48hr) 
• Aliquot sample for pLDH 
PRE-APHERESIS T=4hr 
• Prepare feed mix from 1 x T=4hr T225 flask and perform MFA  
• Aliquot sample for and prepare thin films from T=4hr T225 flask 
• Aliquot sample for DNA, RNA, FLOW cytometry from T=4hr T225 flask 
 
INTERMEDIATE T=4hr 
• Prepare feed mix from 1 x T=4hr T225 flask and perform MFA  
• Aliquot sample for and prepare thin film from T=4hr T225 flask 
• Aliquot sample for DNA, RNA, FLOW cytometry from T=4hr T225 flask 
 
PRE-APHERESIS T=8hr 
• Aliquot samples for pLDH from 2 x T=8hr T75 flasks (+/- NAG) 
• Aliquot samples for and prepare thin film from 2 x T=8hr T75 flasks (+/- 
NAG) 
• Aliquot samples for DNA, RNA, FLOW cytometry from 2 x T=8hr T75 
flasks (+/- NAG) 
PRE-APHERESIS T=16hr 
• Aliquot samples for pLDH from 2 xT=16hr T75 flasks (+/- NAG) 
• Aliquot sample for and prepare thin films from 2x T=16hr T75 flasks (+/- 
NAG) 




• Aliquot sample for DNA, RNA, FLOW cytometry from 2 x T=16hr T75 
flasks (+/- NAG) 
APHERESIS DAY 2 
TIME POINTS AND TASKS 
PRE-APHERESIS T=24hr; INTERMEDIATE T=24hr; FINAL T=24hr; 
WASTE T=24hr 
For each time point sample type: 
• Prepare feed mix from T=24hr T225 flask and perform MFA  
• Aliquot sample for and prepare thin film from T=24hr T225 flask 
• Aliquot sample for DNA, RNA from T=24hr T225 flask 
• Aliquot sample for pLDH from 2 x T=24hr T75 flasks (+/- NAG) 
• Aliquot sample for and prepare thin films from 2 x T=24hr T75 flasks (+/- 
NAG) 
• Aliquot sample for DNA, RNA, FLOW cytometry from 2 x T=24hr T75 
flasks (+/- NAG) 
 
PRE-APHERESIS T=32hr 
• Aliquot sample for pLDH from 2 x T=32hr T75 flasks (+/- NAG) 
• Aliquot sample for and prepare thin film from 2 x T=32hr T75 flasks (+/- 
NAG) 
• Aliquot sample for DNA, RNA, FLOW cytometry from 2 x T=32hr T75 
flasks (+/- NAG) 
 
PRE-APHERESIS T=40hr 
• Aliquot sample for pLDH from 2 x T=40hr T75 flasks (+/- NAG) 
• Aliquot sample for and prepare thin film from 2 x T=40hr T75 flasks (+/- 
NAG) 
• Aliquot sample for DNA, RNA, FLOW cytometry from 2 x T=40hr T75 
flasks (+/- NAG) 
 
MEDIA CHANGES 
• Perform 50% media change on remaining T=48hr T225 flasks 




• Perform 50% media change on remaining T=32hr; T=40hr; T=48hr T75 
flasks 
 
APHERESIS DAY 3 
TIME POINTS AND TASKS 
PRE-APHERESIS T=48hr; INTERMEDIATE T=48hr; FINAL T=24hr; 
SPARE (optional) T=24hr; WASTE T=24hr 
For each time point sample type: 
• Prepare feed mix from T=48hr T225 flask and perform MFA  
• Aliquot sample for and prepare thin/thick films from T=48hr T225 flask 
• Aliquot sample for DNA, RNA, FLOW cytometry from T=48hr T225 flask 
• Aliquot sample for pLDH from 2 x T=48hr T75 flasks (+/- NAG) 
• Aliquot sample for and prepare thin film from 2 x T=48hr T75 flasks (+/- 
NAG) 
• Aliquot sample for DNA, RNA, FLOW cytometry from 2 x T=48hr T75 
flask (+/- NAG) 
  





APHERESIS DAY 1 
PRE-APHERESIS T=0hr BLOOD COLLECTION (Q-Pharm; 1 x 6mL EDTA 
tube, 2 x10mL LiHep tubes) 
PRE-BLOOD COLLECTION PROCESS 
1. Turn on water baths in the CTM general lab (set 38.5C) and PC3 (set 40C). 
2. Turn on heat blocks in TC (set 40C). 
3. Configure Mediheat unit for sample transport. 
4. Collect apheresis sampling labels, Mediheat unit, esky, APH kit and take 
over to Apheresis Ward. 
5. Once at the ward, set up the Mediheat unit as per SOP and label collection 
bags. 
6. Return to CTM lab and prepare for pre-apheresis blood sample transport 
from Q-Pharm. 
7. Clean BSC with 80% ethanol. 
8. Pre-aliquot 19,600 L and 39,200 L of McCoy media into pre-labelled 12 x 
PRE-APHERESIS T75 (T=8hr, T=16hr, T=32hr, T=40hr and T=48hr (+/- 
NAG) and 3 x PRE-APHERESIS T225 flasks (T=4hr, T=24hr, T=48hr) 
respectively. 
9. Following phone call from Q-Pharm, prepare for blood collection. 
10. Fill required number of thermos flasks with a pre-measured volume (650mL) 
of pre-heated water. Ensure a spare thermos flask is also filled. 
11. Place no more than 2 thermos flasks per esky. Bring a spare esky for 
collection of blood tubes and beakers. 
12. Head to Q-Pharm, Level 5 CBCRC and gain entry from reception. Collect 
pre-heated blood tubes and beakers. Transport to Level 5 CBCRC. 
13. Place a maximum of 4 x 10mL tubes per thermos flask. Place a maximum of 
5 x 6mL tubes per thermos flask. 
14. Note: Tubes will need to be inverted upon collection from Q-Pharm staff. 
Invert tubes 3-4 times. 
15. Record blood draw and collection time on transport form QIMRB CTM 
QF-15-C.  




16. Transport tubes to Tissue Culture lab on level 13 Bancroft and place blood 
tubes in waterbath set to 38.5°C. 
ALIQUOT PRE-APHERESIS T=0hr SAMPLES FROM EDTA TUBE 
1. Wipe blood tube into BSC with 80% ethanol. 
2. Invert blood collection tubes to mix, then transfer the contents of the EDTA 
blood collection tube into a 50mL tube and the contents of the two LiHep 
blood collection tubes into two separate 50mL tubes. 
3. Aliquot samples for 18S, pvs25, Sysmex, thin/thick films, laser capture 
(LCS) and FLOW from EDTA 50 mL tube according to Table 1, mixing 
well between aliquots. Record, Initial and date. 
 
4. Store samples as per Table 2. Record time stored, initial/date. 
5. Prepare 3 x thick and 3 x thin blood films from EDTA sub-sample tube. 





































































6. Store films as per Table 2. Record time stored, initial/date. 
7. Prepare blood films for LCS according to Experimental Plan (GR). 










































































PRE-APHERESIS T=0hr MEMBRAME FEED ASSAY (MFA)  9:30AM 
Note: Keep sample heated throughout process. 
 
1. Centrifuge 1 x 50mL LiHep tube at 530xg for 5 mins at 40°C in a pre-heated 
centrifuge. 
2. While sample is spinning, aliquot 1.3mLof AB serum into labelled 2mL 
eppendorf tube. 
3. Remove supernatant from sample and discard. 




4. Aliquot 650µl of packed infected red blood cells (RBCs) into eppendorf tube 
and mix. 
5. Fill small thermos flask with pre-heated water. 
6. Place feed mix tube in blue floaty and transport to PC3 in thermos flask. 
7. Perform MFA as per CTM QIMR SOP 15. 
Day 1 NF54 CONTROL MFA 
Note: Prepare NF54 feed-mix at the same time as PRE-APHERESIS MFA process 
above. 
1. Remove 15mL of culture from gametocyte plate into pre-warmed 50mL tube. 
2. Centrifuge at 530xg for 5 mins at 40°C in a pre-warmed centrifuge. 
3. Aliquot 1.3mL of AB serum into a 2mL Eppendorf tube. 
4. Fill small thermos flask to 1/2 - 2/3 total volume with pre-heated water. 
5. Once sample has been centrifuged, remove supernatant. 
6. Add 650µL of packed infected red blood cells into 2mL tube and mix well. 
7. Place 2mL eppendorf tube into blue floaty and then into small thermos flask. 
 
PRE-APHERESIS T=0hr T225 MFA CULTURE SET-UP 
1. After the feed-mix is prepared, set up 3 x Pre-Apheresis T225 MFA Culture 
flasks (T=4hr, T=24hr and T=48hr).  
2. Mix the RBC pellet in the same 50mL tube used to prepare the feed mix and 
transfer 800µL packed RBCs into each of the T225 flasks (Pre-Apheresis 
T225 MFA Culture flask T=4hr, T=24hr and T=48hr).  
3. Gas each flask for 1 min at ≥ 10L/min. 
4. Wipe flasks with 80% ethanol before placing in the incubator. 
5. Place the T=48hr flask in the vertical position. 
6. Record the volume of packed red cells and the actual culture set-up 
time/date. 
 
PRE-APHERESIS T=0hr T75 ASEXUAL/SEXUAL PARASITE CULTURE 
SET-UP 
1. Set up 12 x PRE-APHERESIS T75 (T=8hr, T=16hr, T=32hr, T=40hr and 
T=48hr (+/- NAG). 




2. Centrifuge the second 50mL LiHep tube at 530xg for 5 mins at 40°C in a pre-
heated centrifuge. 
3. Remove supernatant from sample and discard. 
4. Mix pellet and transfer 400µL of packed red blood cells into each of the 
twelve T75 flasks pre-filled with media (T=8hr, T=16hr, T=24hr, T=32hr, 
T=40hr, T=48hr +/- NAG).  
5. Gas each flask for 30sec at 7-10L/min. 
6. Wipe flasks with 80% ethanol before placing in the incubator. 
7. Place T=32hr, T=40hr and T=48hr flask +/- NAG in vertical position (6 
T75 flasks in total). 
7. Record the volume of packed red cells and the actual culture set-up 
time/date. 
8. Aliquot sample for pLDH. 
 
INTERMEDIATE T=0hr SUB-SAMPLE COLLECTION (Apheresis Ward) 
Note: A Red Cell Depletion process will be run by the Apheresis Nurse on 
an apheresis unit (RBWH; Apheresis Ward). A sub-sample 
(INTERMEDIATE sample; 20-25mL) will be harvested from the collection 
bag. Lab staff from CTM Bancroft 13 lab will be called to retrieve the 
sample. 
1. Using pre-heated water, fill a thermos flask of appropriate size with 
appropriate insert and place in an esky. Transport the esky to the Apheresis 
ward. 
2. Transport the INTERMEDIATE sub-sample to CTM Bancroft Level 13 lab 
in the thermos flask within the esky. 
Note: Citrate may be sterilely injected into bag after process if concerns of 
clotting arise. The Apheresis Nurse will transfer Red Blood Cell 
Depletion to a Bone Marrow Processing accessory set for the PMN 
apheresis process (i.e. for collection of FINAL AND WASTE samples).  
 
DETERMINE SAMPLE VOLUME AND THE HAEMATOCRIT OF THE 
INTERMEDIATE T=0hr SUB-SAMPLE 
1. Following wiping down with 80% Ethanol, place sample into BSC. 




2. Prepare a labelled 50mL falcon tube for sampling into a 50mL tube rack. 
3. Move labelled 50mL collection tube into BSC.  
4. Mix sample tube well, either by gentle swirling or aspiration using a 
strippette. 
5. Measure volume of sample received using a strippette and record in Table 5. 
6. Dispense the sample aseptically into 50mL collection tube. 
 





Total volume of 
sample (mL) 
Date Initials 
Intermediate     
Final     
Spare     
Waste     
 
7. Mix collection tube well, either by gentle swirling or aspiration using a 
strippette. 
8. Aliquot 100µL of sample into 1.5mL eppendorf tube for Coulter Counter 
sampling. 
9. Perform Coulter Counter analysis on Level 9 CBCRC. 
10. Once haematocrit is determined, contact either Anand (0411 041 391) or Kari 
(0438 736 371) to inform of the result. 
 
ALIQUOT INTERMEDIATE T=0hr SAMPLES FOR TESTING 
1. Aliquot samples for 18S, pvs25, Sysmex, thin/thick films, FLOW 
cytometry, MFA/T225 MFA culture set up, T75 Asexual/Sexual culture 













Initial & Date 





QPID 3 250 18S_SAF 400 
 
Intermediate 
QPID 3 250 pvs25 1250 
 
Intermediate 
Sysmex 1 1000 Blood count - 
 
Intermediate 
Thin Film 1 50 Parasitemia - 
 
Intermediate 
Thick Film 1 50 Parasitemia - 
 
Intermediate 




1 10,000 Growth - 
 
Intermediate 




2. Store samples as per Table 7. 
3. Prepare 3 x thick and 3 x thin blood films. Refer to SOP-MBE-1. 
4. Store blood films as per Table 7. 
 
 













Intermediate QPID -80°C -80°C freezer   
Intermediate QPID -80°C -80°C freezer   
Intermediate Sysmex 






















INTERMEDIATE T=0hr MFA  12:00PM 
Note: Keep sample heated throughout process. 
1. Centrifuge 10mL of INTERMEDIATE sub-sample (in 50mL tube) at 530xg 
for 5 mins at 40°C in a pre-heated centrifuge. 
2. While sample is spinning, aliquot 1.3mLof AB serum into labelled 2mL 
eppendorf tube. 
3. Remove supernatant from sample and discard. 
4. Aliquot 650µl of packed infected red blood cells into eppendorf tube and 
mix. 
5. Fill small thermos flask with pre-heated water. 
6. Place feed mix tube in blue floaty and transport to PC3 in thermos flask. 
7. Perform MFA as per CTM QIMR SOP 15. 
 
INTERMEDIATE T=0hr T225 MFA CULTURE SET-UP 
1. After the feed-mix is prepared, aliquot 39,200 µL McCoy media into 3 x 
INTERMEDIATE T225 MFA Culture flasks (T=4hr, T=24hr and T=48hr).  
2. Mix the RBC pellet in the same 50mL tube used to prepare the feed mix and 
transfer 800µL packed RBCs into each of the 3 x INTERMEDIATE T225 
flasks (T=4hr, T=24hr and T=48hr).  
3. Gas each flask for 1 min at ≥ 10L/min. 
4. Wipe flasks with 80% ethanol before placing in the incubator. 
5. Place the T=48hr flask in the vertical position. 
6. Record the volume of packed red cells and the actual culture set-up 
time/date. 
 
INTERMEDIATE T=0hr T75 ASEXUAL/SEXUAL PARASITE CULTURE 
SET-UP 
1. Aliquot 19,600 µL McCoy media (+/- NAG) into 4 x INTERMEDIATE T75 
flasks (T=24hr, T=48hr +/- NAG). 
2. Centrifuge 10mL of INTERMEDIATE sub-sample at 530xg for 5 mins at 
40°C in a pre-heated centrifuge. 
3. Remove supernatant from sample and discard. 




4. Mix pellet and transfer 400µL of packed red blood cells into 4 xT75 flasks 
pre-filled with media (T=24hr, T=48hr +/- NAG).  
5. Gas each flask for 30 sec at 7-10L/min. 
6. Wipe flasks with 80% ethanol before placing in the incubator. 
6. Record the volume of packed RBCs and the actual culture set-up 
time/date. 
7. Place the T=48hr flasks (+/- NAG) in the vertical position (2 T75 flasks in 
total). 
8. Aliquot sample for pLDH. 
 
PRE-APHERESIS T=4hr MFA AND SAMPLING (T225 FLASK)  1:30PM 
 
Note: One hour prior to preparing feed mix, pre-warm the centrifuge, thaw 
an aliquot of AB serum, rack up pre-labelled tubes for sampling (DNA, RNA, 
pLDH, FLOW cytometry) and have slides available for preparing blood films 
in the work station. 
 
1. Remove the PRE-APHERESIS T225 T=4hr flask from incubator. 
2. Wipe all the surfaces with 80% ethanol. 
3. Transfer the entire contents of the flask into a 50 mL tube. 
4. Centrifuge at 530xg for 5 mins at 40°C in a pre-warmed centrifuge. 
5. While sample is spinning, aliquot 1.3mL of AB serum into labelled 2mL 
eppendorf tube. 
6. Remove 90% of the supernatant from sample and discard. 
7. Aliquot 650µl of packed infected red blood cells into eppendorf tube and 
mix. 
8. Fill a small thermos flask with pre-heated water. 
9. Place feed mix tube in blue floaty and transport to PC3 in thermos flask. 
10. Perform membrane feed assay as per CTM QIMR SOP 15. 
11. Aliquot the remaining packed RBC transferring 100µL in DNA tubes 
(containing 400 µL lysis buffer) and 100µL in RNA tubes (containing 1000 
µL RNACell protect) and 50µL for FLOW cytometry. 
12. Store samples 




13. Aliquot 10µL for preparing thin blood film. 
14. Prepare thin blood film. Store blood film. 
15. Record pRBC volume, actual date and time. 
 
FINAL, SPARE (optional) & WASTE T=0hr SAMPLE COLLECTION 
(Apheresis Ward) 
1. Label BMP accessories set bag with “WASTE” label, ensure label is over 
existing label. 
2. Place collection bags in Mediheat transport unit.  
Note: While collecting sample, make sure to frequently mix the bag. The 
Apheresis Nurse will run PMN collection process on apheresis machine and 
collect 100mL of first fraction based on collection colour into a bag labelled 
“FINAL”. A decision will be made to collect a further 100mL if possible, into 
a bag labelled “SPARE”. Bags will be heat sealed prior to removal from 
Apheresis Ward.  
3. Place all bags including BMP accessories set/WASTE bag in Mediheat for 
transport to CTM Bancroft Level 13.  
 
FINAL, SPARE (optional) & WASTE T=0hr SUB-SAMPLING FOR TESTING 
1. Following wiping down with 80% v/v Ethanol, place bags into BSC. 
2. Prepare a labelled 50mL falcon tubes for sampling into a 50mL tube rack. 
3. Move labelled 50mL tubes into BSC.  
4. Mix sample bag well. 
5. Dispense sample aseptically into 250mL tube using a sterile spike adaptor.  
6. Measure volume of sample received using a strippette/pipette and record in 
Table 8. 
 





Total volume of 
sample (mL) 
Date Initials 
Intermediate     
Final     
Spare     




Waste     
 
7. For each sample source, aliquot samples for 18S, pvs25, Sysmex, thin/thick 
films, FLOW cytometry, MFA/T225 MFA culture set up, T75 
Asexual/Sexual culture set up according to Table 9, mixing well between 
aliquots. Initial and date. 
  


























Final QPID 3 250 18S_SAF 400  
Final QPID 3 250 pvs25 1250  





























Spare QPID 3 250 18S_SAF 400  
Spare QPID 3 250 pvs25 1250  




















Waste QPID 3 250 18S_SAF 400  
Waste QPID 3 250 pvs25 1250  






























8. Store samples as per Table 10. 
9. For each sample source, prepare 3 x thick and 3 x thin blood films. Refer to 
SOP-MBE-1. 
10. Store films as per Table 10. Record time stored, initial/date. 

















-80°C -80°C freezer   




Final QPID pvs25 -80°C -80°C freezer   
Final Sysmex 4-8°C 
TC blood 
fridge   
Final Flow 4-8°C 
Flow room 
fridge   












-80°C -80°C freezer   
Waste QPID pvs25     




















-80°C -80°C freezer   
Spare QPID pvs25 -80°C -80°C freezer   
Spare Sysmex 4-8°C 
TC blood 
fridge   





FINAL & WASTE T=0hr MFA  2:00PM 
Note: Keep sample heated throughout process. 
1. Centrifuge 10mL of FINAL, SPARE (optional) and WASTE sub-sample at 
530xg for 5 mins at 40°C in a pre-heated centrifuge. 
2. While sample is spinning, aliquot 1.3mL of AB serum into labelled 2mL 
eppendorf tube. 
3. Remove supernatant from sample and discard. 
4. Aliquot 650µl of packed infected RBCs into eppendorf tubes and mix. 
5. Fill small thermos flask with pre-heated water. 
6. Place feed mix tubes in blue floaty and transport to PC3 in thermos flask. 
7. Perform MFA as per CTM QIMR SOP 15. 
 
FINAL & WASTE T=0hr T225 MFA CULTURE SET-UP 
1. After the feed-mix is prepared, aliquot 39,200 µL McCoy media into 4 x 
FINAL and WASTE T225 MFA Culture flasks (T=24hr and T=48hr).  
2. Mix the RBC pellet in the same 50mL tube used to prepare the feed mix and 
transfer 800µL packed RBCs into each of the T225 flasks (FINAL and 
WASTE T225 MFA Culture flask T=24hr and T=48hr).  
3. Gas each flask for 1 min at 10L/min. 
4. Wipe flasks with 80% ethanol before placing in the incubator. 
5. Place the T=48hr flask in the vertical position. 
6. Record the volume of packed red cells and the actual culture set-up 
time/date. 
 
















FINAL, SPARE (optional) & WASTE T=0hr T75 ASEXUAL/SEXUAL 
PARASITE CULTURE SET-UP 
1. Aliquot 19,600 µL McCoy media (+/- NAG) into 8 x FINAL and WASTE 
T75 Asexual/Sexual Culture flasks (T=24hr, T=48hr +/- NAG). 
2. Centrifuge 10mL of FINAL and WASTE sub-sample and centrifuge at 530xg 
for 5 mins at 40°C in a pre-heated centrifuge. 
3. Remove supernatant from sample and discard. 
4. Mix pellet and transfer 400µL of packed red blood cells into each of the 8 x 
T75 flasks pre-filled with media (T=24hr, T=48hr +/- NAG).  
5. Gas each flask for 30 sec at 7-10L/min. 
6. Wipe flasks with 80% ethanol before placing in the incubator. 
7. Record the volume of packed RBCs and the actual culture set-up 
time/date. 
8. Place the T=48hr flasks (+/- NAG) in the vertical position (2 T75 flasks 
in total). 
9. Aliquot sample for pLDH.  
 
DELIVER SYSMEX SAMPLES TO PATHOLOGY QUEENSLAND 
1. Once all samples are collected for SYSMEX analysis, place relevant samples 
(with completed sample request form) in a bag in an esky and deliver to 
Pathology QLD no later than 4:00pm. 
 
INTERMEDIATE T=4hr MFA (T225 FLASK)  4:00PM 
Note: One hour prior to preparing feed mix, pre-warm the centrifuge, thaw 
an aliquot of AB serum, rack up pre-labelled tubes for sampling (DNA, RNA, 
pLDH, FLOW cytometry) and have slides available for preparing blood films 
in the work station. 
 
1. Remove the INTERMEDIATE T225 T=4hr MFA flask from incubator. 
2. Wipe all the surfaces with 80% ethanol. 
3. Transfer the entire contents of the flask into a 50 mL tube. 
4. Centrifuge at 530xg for 5 mins at 40°C in a pre-warmed centrifuge. 




5. While sample is spinning, aliquot 1.3mL of AB serum into labelled 2mL 
eppendorf tube. 
6. Remove 90% of the supernatant from sample and discard. 
7. Aliquot 650µl of packed infected red blood cells into eppendorf tube and 
mix. 
8. Fill a small thermos flask with pre-heated water. 
9. Place feed mix tube in blue floaty and transport to PC3 in thermos flask. 
10. Perform membrane feed assay as per CTM QIMR SOP 15. 
11. Aliquot the remaining packed RBC transferring 100µL in DNA tubes 
(containing 400 µL lysis buffer) and 100µL in RNA tubes (containing 1000 
µL RNAcell protect).  
12. Store samples. 
13. Aliquot 10µL for preparing blood films. 
14. Prepare thin blood slide. 
 
PRE-APHERESIS T=8hr T75 SAMPLING  5:30PM 
Note: Sampling will be performed every 8 hours after culture set up (T=8hr, 
T=16hr, T=24hr, T=32hr, T=40hr and T=48hr). Table 13 will be generated 
with actual times to harvest at the end of APHERESIS DAY 1 after all 
samples have been received. 
 
1. Ten minutes before the set-up time, prepare/rack up sampling tubes (DNA, 
RNA, Flow and pLDH) and have slides available for preparing blood films in 
the workstation. 
2. Verify time-point and the type of media in the label of the 2 X T75 flasks. 
3. Remove the 2 x PRE-APHERESIS T=8hr T75 flasks (+/- NAG) from 
incubator. 
4. Wipe all the surfaces with 80% ethanol. 
1. Transfer the entire contents of each flask into a pre-labelled 50mL tube. 
2. Centrifuge tubes at 530xg for 5 mins at 40°C and remove and discard 90% of 
supernatant 
15. For each flask, aliquot packed RBCs transferring 150µL in pLDH tubes (O-
Ring tubes empty) 100µL in DNA tubes (containing 400 µL lysis buffer) and 




100µL in RNA tubes (containing 1000 µL RNAcell protect) and 50µL for 
FLOW cytometry. 
16. Store samples. 
17. Aliquot 10µL for preparing blood films. 
18. Prepare 2 x thin blood films. 
19. Record pRBC volume, actual date and time. 
PRE-APHERESIS T=16hr T75 SAMPLING  1:30AM 
1. Ten minutes before the set-up time, prepare/rack up sampling tubes (DNA, 
RNA, flow and pLDH) and have slides available for preparing blood films in 
the workstation. 
2. Verify time-point and the type of media in the label of the 2 X T75 flasks. 
3. Remove the 2 x PRE-APHERESIS T=16hr T75 flasks (+/- NAG) from 
incubator. 
4. Wipe all the surfaces with 80% ethanol. 
3. Transfer the entire contents of each flask into a pre-labelled 50mL tube. 
4. Centrifuge tubes at 530xg for 5 mins at 40°C and remove and discard 90% of 
supernatant 
20. For each flask, aliquot packed RBCs transferring 150µL in pLDH tubes (O-
Ring tubes empty) 100µL in DNA tubes (containing 400 µL lysis buffer) and 
100µL in RNA tubes (containing 1000 µL RNAcell protect) and 50µL for 
FLOW cytometry.  
21. Store samples as per  
22. Aliquot 10µL for preparing blood films. 
23. Prepare 2 x thin blood films.  
 
  




APPENDIX 12. SUPPLEMENTARY MATERIAL. 
Table 1. Asexual parasites/mL and asexual parasites/RBC apheresis clinical 
study 




















4.35E+09 2.64E-06 1.00 
1% HCT 27,394 
2.38 
1.40E+08 1.96E-04 74.03 
2% HCT 37,064 
3.22 
1.90E+08 1.95E-04 73.81 
3% HCT 41,945 
3.65 
3.00E+08 1.40E-04 52.90 
5% HCT 46,105 
4.01 
4.30E+08 1.07E-04 40.57 
7% HCT 56,180 
4.89 




4.81E+09 5.01E-06 1.00 
1% HCT 21,409 
0.89 
2.00E+08 1.07E-04 21.36 
2% HCT 27,022 
1.12 
3.50E+08 7.72E-05 15.41 
3%HCT 34,406 
1.43 
2.60E+08 1.32E-04 26.41 
5% HCT 38,646 
1.6 
4.30E+08 8.99E-05 17.94 
7% HCT 43,480 
1.8 
5.00E+08 8.70E-05 17.36 
3 
Pre-apheresis 25,475 1 5.34E+09 4.77E-06 1.00 
0.5% HCT 46,009 
1.81 
7.00E+07 6.57E-04 137.77 
1% HCT 46,212 
1.81 
1.40E+08 3.30E-04 69.19 
2% HCT 50,077 
1.97 
1.50E+08 3.34E-04 69.98 
3% HCT 68,441 
2.69 
3.50E+08 1.96E-04 40.99 
5% HCT 51,600 
2.03 
4.40E+08 1.17E-04 24.58 
7% HCT 80,024 
3.14 
7.70E+08 1.04E-04 21.78 
11% HCT 100,951 
3.96 
1.23E+09 8.21E-05 17.20 
2/3% HCT 90,662 
3.56 
2.60E+08 3.49E-04 73.09 
5/7% HCT 95,699 
3.76 
6.10E+08 1.57E-04 32.89 
0.5-11%  HCT 94,785 
3.72 




5.22E+09 1.82E-05 1.00 
Intermediate 108,041 1.15 7.18E+09 1.50E-05 0.83 
Final 107,251 
1.14 
2.90E+08 3.70E-04 20.33 
Spare 74,149 
0.79 
4.80E+08 1.54E-04 8.49 
Waste 36,059 
0.38 
3.94E+09 9.15E-06 0.50 




Asexual parasites/mL and asexual parasites/RBC apheresis clinical study data from 





























Table 2. Gametocytes/mL and gametocytes/RBC apheresis clinical study 


















apheresis 26,458 1.00 4.35E+09 6.08E-06 1.00 
1% HCT 
454 0.02 1.40E+08 3.24E-06 0.53 
2% HCT 
952 0.04 1.90E+08 5.01E-06 0.82 
3% HCT 
1,186 0.04 3.00E+08 3.95E-06 0.65 
5% HCT 
1,388 0.05 4.30E+08 3.22E-06 0.53 
7% HCT 
1,146 0.04 5.90E+08 1.94E-06 0.32 
Percoll 
9,396 0.36 N/A N/A N/A 
2 
Pre-
apheresis 88,670 1.00 4.81E+09 1.84E-05 1.00 
1% HCT 
3,216 0.04 2.00E+08 1.61E-05 0.87 
2% HCT 
2,871 0.03 3.50E+08 8.20E-06 0.44 
3%HCT 
2,246 0.03 2.60E+08 8.64E-06 0.47 
5% HCT 
2,429 0.03 4.30E+08 5.65E-06 0.31 
7% HCT 
3,907 0.04 5.00E+08 7.81E-06 0.42 
Percoll 





1.00 5.34E+09 2.14E-05 1.00 
0.5% HCT 
9,283 0.08 7.00E+07 1.33E-04 6.19 
1% HCT 
12,573 0.11 1.40E+08 8.98E-05 4.19 
2% HCT 
10,983 0.10 1.50E+08 7.32E-05 3.42 
3% HCT 
9,390 0.08 3.50E+08 2.68E-05 1.25 
5% HCT 
8,100 0.07 4.40E+08 1.84E-05 0.86 
7% HCT 
10,999 0.10 7.70E+08 1.43E-05 0.67 
11% HCT 
13,472 0.12 1.23E+09 1.10E-05 0.51 
2/3% HCT 
11,035 
0.10 2.60E+08 4.24E-05 1.98 
5/7% HCT 
9,097 




0.13 4.50E+08 3.35E-05 1.56 
Percoll 
3,618,500 
44.8 N/A N/A N/A 
4 
Pre-
apheresis 547,975 1.00 5.22E+09 1.05E-04 1.00 
Intermediate 
794,329 1.45 7.18E+09 1.11E-04 1.05 
Final 
102,192 0.19 2.90E+08 3.52E-04 3.36 
Spare 
304,977 0.56 4.80E+08 6.35E-04 6.05 
Waste 
90,743 0.17 3.94E+09 2.30E-05 0.22 




Gametocytes/mL and gametocytes/RBC apheresis clinical study data from subjects 1 
to 4 including fold enrichments as measured by pvS25 qPCR. 
Human malaria parasite bank formation calculations 
The maximum level of asexual parasite enrichment per mL of sample compared to 
pre-apheresis was 4.9-fold. Percoll concentration increases the theoretical level of 
enrichment to 15.5-fold compared to pre-apheresis.  
The HMP013 P. vivax parasite bank produces vials each of which contains 2.08 × 
106 parasites. The following formulas were used to calculate the viability of 
apheresis as a method to concentrate parasites. Maximum enrichment values were 
used as the purpose was to assess the possibility of producing a HMP bank using 
apheresis rather than the practicality. 
Parasites/mL of enriched blood = Pre-apheresis whole blood 18S qPCR/mL × Fold 
enrichment derived from percoll × Maximum fold enrichment from apheresis 
Parasites/mL of packed blood (based on bank HCT of 0.39) = Parasites/mL of 
enriched blood/0.39 
Number of parasites/vial compared based on 248 µL = (Parasites/mL of packed 
blood/1000) × 248 
Parasites/mL of enriched blood = 25,475 × 3.17 × 4.89 = 3.95 × 105 
Parasites/mL of packed blood (based on bank HCT of 0.39) = 3.95 × 105/0.39 = 1.01 
× 106 
Number of parasites/vial based on 248 μL = (1.01 × 106/1000) × 248 = 2.51 × 105 
Hence apheresis and percoll cannot concentrate parasites enough to create HMP 
bank vials equivalent to those used to infect subjects in this study (2.51 × 105 
compared to 2.08 × 106). If only apheresis is used to concentrate parasites the vials 
would contain a maximum of 7.92 × 104 parasites.   
 
  














































ALT: alanine transaminase,; AST: aspartate transaminase; ULN: upper limit of 
normal; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; LDH: 
Lactate dehydrogenase; CRP: C-reactive protein.   
Graphical representations of parasitaemia (log10 scale), clinical score, ALT (× ULN), 
CRP (× ULN), LDH (U/L) and temperature from screening to end of study for all 
IBSM subjects. Scales have been manipulated in order to make sure the data could 
fit on a single graph. ALP, GGT and albumin, were not included as there were no 
significant rises in any of these parameters. Bilirubin was rarely raised above the 
ULN, with only two subjects having a bilirubin result at ULN or higher. As such, 
bilirubin is not included in the graphs. AST behaved similarly to ALT, and is nearly 
always the lower of the two, hence it was not included. The graphs also include 
parasitemia on a logarithmic scale as well as documented peak parasitemia. Clinical 
markers associated with malaria infection such as temperature clinical score and 
CRP have been included to provide a measure of the level of inflammation from 
malaria infection. Ethnicity was indicated in those who were non-white. 
Subjects with significant ALT abnormalities tended to have a greater number and 
severity of other malaria related measures and vice versa.  
Table 3. Correlation with peak ALT  
 Clinical measure Correlation  p-value 
Peak AST 0.99 <0.001 
Peak Bilirubin  -0.10 0.57 
Peak LDH 0.58 <0.001 




Overall Peak parasitemia 0.39 0.027 
Burden 0.58 <0.001 
Nadir Neutrophils -0.09 0.62 
Nadir Platelets -0.26 0.15 
Nadir Lymphocytes -0.41 0.018 
Nadir White cell count -0.03 0.87 
Peak Clinical Score 0.42 0.017 
Maximum Temperature 0.29 0.11 
Peak CRP 0.44 0.012 
ALT: alanine transaminase; AST: aspartate transaminase; LDH: lactate 
dehydrogenase; CRP: C-reactive protein; LDH: lactate dehydrogenase. LFT and 




haematology results are in units of overall peak/minimum times ULN or LLN. 
Significant effects and associations with Pearson’s correlation (p<0.05) are 
highlighted in bold. 
Table 4. Results of backwards stepwise logistic regression for the risk of 
elevated peak ALT in induced blood stage malaria with PCT1/2 included in all 
steps of the models  
Model Measure OR (95% CI) p 
Including 
cohort effect 
PCT1/2 1.81 (0.57-5.69) 0.31 
Nadir Platelets × LLN^ 2.79 (1.12-6.93) 0.027 
Cohort – ref Artefenomel Cohort 
A2 
1  
Chloroquine Cohort C1 0.16 (0.006-3.89) 0.26 
Chloroquine Cohort C2 0.04 (0.001-1.36) 0.075 
Chloroquine Cohort C3 0.03 (<0.001-1.15) 0.059 
No cohort 
effect 
PCT1/2 0.95 (0.39-2.33) 0.92 
Peak CRP (relative to baseline)  1.06 (1.01-1.12) 0.013 
CRP: C-reactive Protein; LLN: lower limit of normal; PCT1/2 parasite clearance half-
life; OR: odds ratio. ^Effect size (OR and 95% CI) are converted to per 0.1 unit 
decrease in × LLN. The order of variables removed in the model including cohort 
effect were parasite clearance burden, white cell count, and then peak CRP relative 
to baseline. The order of variables removed in the model did not include cohort 
effect were platelets, parasite clearance burden, and then white cell count. 
  




Table 5. Results of backwards stepwise logistic regression for the risk of 
elevated peak ALT in induced blood stage malaria with parasite clearance 
burden included in all steps of the models  




PCB (log10 scale) 3.60 (0.19-68.81) 0.40 
Peak CRP (relative to 
baseline)  
1.06 (1.00-1.13) 0.044 




Chloroquine Cohort C1 8.63 (0.026-2889) 0.47 
Chloroquine Cohort C2 2.89 (0.05-153) 0.60 
Chloroquine Cohort C3 1.77 (0.03-114) 0.79 
No cohort 
effect 
PCB (log10 scale) 1.86 (0.42-8.17) 0.41 
PCB: parasite clearance burden; CRP: C-reactive protein; OR: odds ratio. ^Effect 
size (OR and 95% CI) are converted to per 0.1 unit decrease in × LLN. The order of 
variables removed in the model including cohort effect were PCT1/2, platelets and 
then white cell count. The order of variables removed in the model did not include 
cohort effect was white cell count, PCT1/2 and then platelets.  
Table 6. Pharmacokinetic parameters per cohort in induced blood stage 
malaria 
Identifier  Antimalarial 
Cohort Statistical 
measure 
Cmax (μg/mL) AUC96 (μg/mL × h) 
Artefenomel Median (IQR)  0.60 (0.43-0.72) 3.86 (3.08-4.66) 
Chloroquine C1 Median (IQR)  1.24 (1.11-1.46) 66.28 (59.56-79.36) 
Chloroquine C2 Median (IQR)  0.88 (0.73-1.02) 52.88 (41.48-60.37) 
Chloroquine C3  Median (IQR)  0.99 (0.82-1.09) 58.24 (48.24-64.48) 
Cmax: maximum concentration of drug; AUC96: area under the curve for drug dose 96 
hour after drug administration; IQR: interquartile range.  
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